ondansetron has been researched along with Emesis in 1054 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postoperative nausea and vomiting (PONV) is still a common perioperative complication and ondansetron has proved to be an effective antiemetic substance in its prevention." | 10.18 | [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms]. ( Buhre, W; Kazmaier, S; Mühr, C; Neumann, P; Saur, P, 1996) |
| "Twenty patients receiving cisplatin (greater than or equal to 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5-HT3) antagonist, in controlling delayed emesis." | 10.17 | Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1992) |
| "Ondansetron is a 5-HT3 receptor antagonist which is effective and well tolerated as an antiemetic for emesis induced by cancer chemotherapy and radiation therapy, and in the prevention and treatment of postoperative nausea and vomiting." | 10.17 | Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ( Baber, N; Frazer, NM; Palmer, JL; Pritchard, JF, 1992) |
| "We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC)." | 9.69 | Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. ( Eom, YA; Jin, JY; Kang, JH; Kim, HK; Ko, YH; Park, SY; Sun, S; Woo, IS, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 9.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 9.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "To compare effectiveness of maropitant and ondansetron in preventing preoperative vomiting and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate." | 9.41 | Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate. ( Burke, JE; Hess, RS; Silverstein, DC, 2021) |
| " PONV incidence, complete response, 80 mg aprepitant combined with dexamethasone and ondansetron, vomiting, nausea, and analgesic dose-response were the main outcomes measured." | 9.41 | The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. ( Chen, X; He, H; Hu, W; Liao, Y; Liu, W; Liu, Y; Pan, Z; Wang, X; Zheng, F; Zhong, H, 2023) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 9.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| " Interestingly, none of the patients aged under 7 years, receiving divided dosing ondansetron, presented nausea symptoms compared with those receiving single daily dosing (p-value ." | 9.41 | Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. ( Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021) |
| "To determine the cost-effectiveness of adding oral ondansetron to care as usual (CAU) for children with acute gastroenteritis presenting to out-of-hours primary care (OOH-PC)." | 9.41 | Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Holtman, GA; Kollen, BJ; Vermeulen, KM; Weghorst, AA; Wolters, PI, 2021) |
| " In secondary care, ondansetron was found to be effective at reducing vomiting." | 9.41 | Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Fickweiler, F; Holtman, GA; Kollen, BJ; Russchen, HA; Verkade, HJ; Weghorst, AA, 2021) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC)." | 9.34 | The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Angspatt, P; Chenaksara, P; Parinyanitikun, N; Poovorawan, N; Sakdejayont, S; Sriuranpong, V; Sukprakun, S; Tanasanvimon, S; Thawinwisan, W; Vimolchalao, V; Vinayanuwatikun, C; Wongchanapai, P, 2020) |
| "This study was conducted to determine the effect of intramuscular ondansetron on ketamine-associated vomiting in children undergoing procedural sedation." | 9.34 | Does intramuscular ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomized, double blind, controlled study. ( Akbari, H; Davarani, SS; Hossein, F; Nejati, A; Talebian, MT, 2020) |
| "Oral ondansetron does not significantly reduce vomiting during or shortly after procedural sedation with combined intranasal fentanyl and inhaled nitrous oxide." | 9.34 | Oral Ondansetron to Reduce Vomiting in Children Receiving Intranasal Fentanyl and Inhaled Nitrous Oxide for Procedural Sedation and Analgesia: A Randomized Controlled Trial. ( Babl, FE; Davidson, A; Fauteux-Lamarre, E; Hopper, SM; Lee, KJ; Legge, D; McCarthy, M; Palmer, GM; Quinn, N, 2020) |
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 9.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| " In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit." | 9.34 | Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. ( Beer, D; Dixon, A; Finkelstein, Y; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Pechlivanoglou, P; Plint, AC; Williamson-Urquhart, S, 2020) |
| "To evaluate the incidence of tranexamic acid (TXA)-induced nausea and vomiting after the prophylactic use of 2 antiemetics, ondansetron and maropitant, compared with saline." | 9.34 | Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis. ( Bettschart-Wolfensberger, R; Hartnack, S; Kantyka, ME; Kutter, APN; Meira, C, 2020) |
| "The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo." | 9.34 | A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. ( Beer, D; Dixon, A; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Offringa, M; Pechlivanoglou, P; Plint, AC; Rios, JD; Williamson-Urquhart, S, 2020) |
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 9.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration." | 9.30 | Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. ( Avarello, J; Fathi, R; Hahn, B; House, SL; Kalfus, IN; Lovato, LM; Meltzer, AC; Miller, JB; Plasse, TF; Raday, G; Silverman, RA; Yan, EC, 2019) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay." | 9.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 9.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 9.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 9.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV)." | 9.24 | Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. ( Abbas, N; Abdel-Malek, R; Fawzy, R; Ismail, M; Safwat, E; Salem, DS; Shohdy, KS, 2017) |
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 9.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 9.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "The aim of the study was to evaluate the efficiencies of selected anti-emetic drugs (metoclopramide, ondansetron and maropitant) in preventing vomiting in the treatment of canine parvoviral enteritis." | 9.24 | Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs. ( Keser, GO; Yalcin, E, 2017) |
| "To describe the use of ketamine in an adult patient in aborting a cyclic vomiting syndrome (CVS) episode." | 9.22 | Ketamine in Refractory Cyclic Vomiting Syndrome: A Case Report and Review of Literature. ( Cheung, F; Doherty, SM; Tatara, AW, 2022) |
| "To evaluate the role of oral ondansetron in facilitating successful rehydration of under-5-year-old children suffering from acute diarrhea with vomiting and some dehydration." | 9.22 | Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial. ( Batra, P; Bhattacharya, SK; Danewa, AS; Gupta, P; Shah, D, 2016) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 9.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 9.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 9.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 9.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 9.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 9.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| "Regardless of age, gender, or region, the aprepitant regimen provided better control for the no-vomiting and complete-response (no vomiting, no rescue therapy) endpoints." | 9.19 | Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. ( Rapoport, BL, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 9.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 9.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| "Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1." | 9.16 | Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ( Dube, P; Hesketh, PJ; Kopp, M; Lane, S; Levin, J; Makhson, A; Moiseyenko, V; Rosati, G; Russo, M; Wright, O, 2012) |
| "To observe the therapeutic efficacy of Hewei Zhiou Recipe (HZR) combined ondansetron hydrochloride (OH) in treating vomiting in children patients with solid tumor." | 9.16 | [Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride]. ( Liu, ZM; Shi, X; Zhu, XD, 2012) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 9.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 9.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| "Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours)." | 9.15 | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. ( Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A, 2011) |
| "To determine the effect of ondansetron on the incidence of vomiting in cats pre-medicated with dexmedetomidine and buprenorphine." | 9.15 | A randomized, blinded, controlled trial of the antiemetic effect of ondansetron on dexmedetomidine-induced emesis in cats. ( Basher, KL; Erb, HN; Kirch, P; Ludders, JW; Martin-Flores, M; Santos, LC, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 9.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 9.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 9.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 9.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 9.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis." | 9.14 | Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. ( Sertdemir, Y; Yildizdas, RD; Yilmaz, HL, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with ondansetron/dexamethasone (ond/dex) for the prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera ( Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J, 2009) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 9.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 9.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 9.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 9.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "We hypothesize that ondansetron will facilitate oral rehydration therapy in children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy." | 9.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea." | 9.13 | Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. ( Braude, D; Crandall, C, 2008) |
| " We evaluated the effects of oral ondansetron disintegrating tablets (ODT) on the incidence of at-home emesis in children undergoing tonsillectomy with and without adenoidectomy and with and without bilateral myringotomy and tube insertion." | 9.13 | The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery. ( Boretsky, KR; Davis, PJ; Fedel, GM; Fertal, KM; Gurnaney, H; Hoffmann, PC; Ingram, MD; Woelfel, SK; Young, MC, 2008) |
| "We investigate the effect of ondansetron on the incidence of vomiting in children who receive intravenous (IV) ketamine for procedural sedation and analgesia in the emergency department (ED)." | 9.13 | Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. ( Bajaj, L; Langston, WT; Roback, MG; Wathen, JE, 2008) |
| "To compare the efficacy of prophylactic ondansetron and tropisetron for postoperative nausea and vomiting (PONV)." | 9.12 | Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: A meta-analysis of randomized controlled trials. ( Chen, Y; Song, X; Wang, J; Wang, N; Wang, R, 2021) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 9.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| "In children with gastroenteritis and dehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department." | 9.12 | Oral ondansetron for gastroenteritis in a pediatric emergency department. ( Adler, M; Freedman, SB; Powell, EC; Seshadri, R, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 9.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "This pivotal phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)." | 9.12 | A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F, 2006) |
| "In children with dehydration secondary to vomiting from acute viral gastritis, ondansetron with intravenous rehydration improves tolerance of oral fluids after two hours and reduces the hospital admission rate when compared with intravenous rehydration with or without dexamethasone." | 9.12 | Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. ( Brown, KM; Brown, LH; Reilly, TH; Secreti, L; Stork, CM, 2006) |
| "We compared the efficacy of inhaled isopropyl alcohol (IPA) with ondansetron for the control of postoperative nausea and vomiting (PONV) during a 24-hour period in 100 ASA class I-III women undergoing laparoscopic surgery." | 9.12 | A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. ( Cotton, JW; Hood, RR; Pellegrini, JE; Rowell, LR, 2007) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 9.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "All consecutive chemotherapy-naive patients enrolled onto study were randomly assigned to receive for the prevention of acute emesis, during the first 24 hours, one of the following dexamethasone regimens, in combination with ondansetron 8 mg intravenously (i." | 9.11 | Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. ( , 2004) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 9.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "This study in volunteers has shown that betamethasone does not prevent nausea and vomiting induced by oral intake of ipecacuanha syrup." | 9.11 | Betamethasone does not prevent nausea and vomiting induced by ipecacuanha. ( Axelsson, P; Thörn, SE; Wattwil, M, 2004) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 9.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 9.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| " Overall nausea and vomiting were significantly lower in the ondansetron prophylaxis group than in the group without prophylaxis (52." | 9.11 | Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis. ( Baublys, A; Ivaskevicius, J; Kontrimaviciute, E, 2005) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 9.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "To study the enhancement by dexamethasone of the effect of ondansetron and tropiesetron against postoperative nausea and vomiting (PONV) in patients receiving patient-controlled analgesia (PCA) and observe the effect of dexamethasone on wound healing." | 9.10 | [Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia]. ( Liu, HF; Lu, ZH; Sheng, PT; Wang, C; Wang, LY; Xiong, LZ; Xu, N; Yang, XY, 2002) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 9.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| "In this study, the efficacy and safety of intravenous administration of droperidol followed by oral use of dimenhydrinate did not differ from that of intravenous followed by oral use of ondansetron in children undergoing strabismus surgery." | 9.10 | Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery. ( Bussières, JF; Caron, E; Jacob, JL; Lebel, D; Lortie, L; Mathews, S; Milot, J; Moride, Y, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 9.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 9.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 9.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 9.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "Although combination antiemetics prevent vomiting during the initial 24 h after high-dose (> or =100 mg/m2) cisplatin, many patients experience delayed emesis 24-120 h afterwards despite receiving prophylactic dexamethasone and metoclopramide during this time." | 9.09 | Oral cisapride for the control of delayed vomiting following high-dose cisplatin. ( Baltzer, L; Grant, SC; Hinckley, L; Kris, MG; Miller, VA; Pisters, KM; Pizzo, BA, 1999) |
| "This randomized, double-masked, placebo-controlled, multicenter trial was conducted in 9 countries to assess the safety and efficacy of 2 doses of intravenous ondansetron (8 and 16 mg) for the control of opioid-induced nausea and vomiting." | 9.09 | Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. ( Allegra, J; Ames, M; Creed, MR; Ducharme, J; Ferrer-Brechner, T; Foster, E; Grafstein, E; Larsen, LS; Montgomery, R; Noll, D; Ortenwall, P; Patel, V; Ramalanjaona, G; Schreck, D; Shurman, J; Sussman, G, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 9.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "To assess the efficacy and safety of intravenous ondansetron (4 mg) for the prevention of nausea and vomiting after middle ear surgery under local anesthesia." | 9.09 | Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia. ( Ku, PK; Lo, P; Tong, MC; van Hasselt, CA, 2000) |
| "The purpose of this study was to compare the antiemetic efficacy of three 5-HT3 antagonists (granisetron, ondansetron, tropisetron) plus dexamethasone for the prevention of acute emesis induced by high-dose cisplatin chemotherapy." | 9.09 | Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. ( Chan, R; Chua, DT; Foo, YC; Kwok, CC; Kwong, DL; Sham, JS; Yue, A, 2000) |
| " All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy (acute emesis)." | 9.09 | Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. ( , 2000) |
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 9.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 9.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 9.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| " dexamethasone had comparable antiemetic efficacy for the prevention of nausea in the first 24-hour period after initiation of chemotherapy compared with intravenous ondansetron plus i." | 9.09 | Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. ( Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tzeng, WF; Wang, WS; Yen, CC, 2000) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| " There was a statistically significant decrease in the chance of vomiting with increasing dose of ondansetron (P=0." | 9.09 | A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children. ( Booker, PD; Bowhay, AR; May, HA; Rudnicka, AR, 2001) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 9.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 9.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "A prospective double-blind study was conducted to compare the anti-emetic efficacy of ondansetron and droperidol in preventing postoperative emesis following strabismus surgery." | 9.08 | A double-blind randomized prospective study comparing ondansetron with droperidol in the prevention of emesis following strabismus surgery. ( Davis, A; Krige, S; Moyes, D, 1995) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 9.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Ondansetron and droperidol are both effective in the prevention of postoperative nausea and vomiting (PONV)." | 9.08 | Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery. ( Altrock, K; Diefenbach, C; Grond, S; Lehmann, KA; Lynch, J, 1995) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 9.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To investigate the efficacy and safety of oral ondansetron in the control of cisplatin-induced delayed emesis in patients who do not require rescue antiemetic therapy for acute emesis." | 9.08 | Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. ( Anderson, N; Beck, TM; Caldwell, KC; Chang, AY; Garewal, H; Greenberg, B; Madajewicz, S; Navari, RM; Tchekmedyian, NS; Whaley, W, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 9.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "To compare the effectiveness of ondansetron with droperidol in preventing postoperative emesis in children after strabismus repair." | 9.08 | Prevention of emesis after strabismus repair in children: a prospective, double-blinded, randomized comparison of droperidol versus ondansetron. ( Griswold, JD; Lee, A; Litman, RS; Marshall, C; Voisine, R; Wu, CL, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 9.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 9.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " Effective prophylaxis for postoperative nausea and vomiting can be achieved in adults with lower doses of ondansetron, a 5-hydroxytryptamine subtype 3 receptor antagonist, compared with chemotherapy-induced emesis." | 9.08 | The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. ( Bras, PJ; Cieslak, GD; Pennant, JH; Watcha, MF, 1995) |
| "In a randomised, placebo-controlled trial we have compared the efficacy of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia after orthopaedic surgery." | 9.08 | Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. ( Alexander, R; Jones, RM; Lovell, AT; Seingry, D, 1995) |
| "Ondansetron 8mg and granisetron 3 mg, both combined with dexamethasone, showed similar efficacy and tolerability in the prevention of cisplatin-induced emesis." | 9.08 | Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. ( , 1995) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 9.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "We performed a prospective, single arm, observational study examining the effectiveness of the 5HT3 receptor antagonist ondansetron in the management if nausea and vomiting associated with acetaminophen poisoning." | 9.08 | The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. ( Chen, R; Clark, RF; Harchelroad, F; Johnson, CL; Williams, SR, 1996) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 9.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 9.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "The aim of this study was to compare the efficacy and safety of ondansetron plus droperidol with each drug alone or placebo in the prevention of postoperative nausea and vomiting (PONV)." | 9.08 | Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. ( Carrascosa, F; García-Pedrajas, F; Iribarren, MJ; Lopez, L; Pueyo, FJ; Saez, A, 1996) |
| " Patients received one of four regimens for the prevention of postoperative nausea and vomiting (PONV): ondansetron 4 mg (n = 25), dexamethasone 8 mg (n = 25), ondansetron with dexamethasone (4 mg and 8 mg, respectively, n = 25) or placebo (saline, n = 25) There were no differences in background factors or factors related to operation and anaesthesia, morphine consumption, pain or side effects between groups." | 9.08 | Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. ( Busto, N; Carrascosa, F; López-Olaondo, L; Monedero, P; Pueyo, FJ; Sáez, A, 1996) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 9.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 9.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| " This randomized, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of ondansetron in the control of established postoperative emesis in outpatients aged 2-12 yr." | 9.08 | Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group. ( Creed, M; Ginsberg, B; Grunwald, Z; Kaye, R; Khalil, S; Lawhorn, CD; Otto, A; Prillaman, BA; Rodarte, A; Weinstein, M; Weldon, BC; Wheeler, M, 1996) |
| "The efficacy of ondansetron 4 mg and 8 mg was compared with placebo in the reduction of postoperative nausea, retching and vomiting (PONV) after middle ear surgery during general anaesthesia, in 75 patients, in a double-blind and randomized study." | 9.08 | Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. ( Honkavaara, P, 1996) |
| "This study has compared the incidences of nausea, vomiting and headache after ondansetron 0." | 9.08 | Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. ( van den Berg, AA, 1996) |
| "The new antiemetic ondansetron is effective for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), but has been subject to limited comparative evaluation in surgical inpatients." | 9.08 | Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. ( Evans, SF; Paech, MJ; Pavy, TJ, 1995) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 9.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 9.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 9.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "To compare the antimetic efficacy of prophylactic ondansetron, metoclopramide, and placebo for prevention of postoperative vomiting in pediatric tonsillectomy or adenotonsillectomy patients." | 9.08 | Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. ( Bohnsack, LE; Bostrom, BC; Seay, RE; Stene, FN; Young, LA, 1996) |
| "Propofol administered to induce and maintain anesthesia is more effective than ondansetron (with thiopental-isoflurane anesthesia) in preventing postoperative vomiting and is associated with fewer requests for rescue antiemetic and sedation in the early phase of recovery." | 9.08 | Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. ( Gan, TJ; Ginsberg, B; Glass, PS; Grant, AP, 1996) |
| "To determine (1) the efficacy and safety of ondansetron in the prevention of postoperative nausea and vomiting (PONV) in male outpatients; (2) prognostic factors for PONV in male outpatients; and (3) patients' perceptions of the debilitating effects of PONV in the ambulatory surgery setting." | 9.08 | Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group. ( Cox, F; Joslyn, AF; Khalil, SN; Kovac, AL; Pearman, MH; Prillaman, BA; Scuderi, PE, 1996) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 9.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 9.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "The hypothesis that the addition of dexamethasone to the propofolondansetron combination would significantly reduce postoperative nausea and vomiting (PONV) was not confirmed." | 9.08 | Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. ( Hamilton, DL; McKenzie, R; Riley, TJ; Tantisira, B, 1997) |
| "To assess the efficacy of 4 mg of intravenous ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV) in cholecystectomy, a type of surgery that is highly emetic." | 9.08 | [Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy]. ( Cabrera, JC; Castaño, J; Castillo, J; Escolano, F; Matute, E; Santiveri, X, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 9.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "Twenty-nine patients with gynecologic malignancies were treated with a fixed low dose of intravenous ondansetron (8 mg) plus dexamethasone (20 mg) in an effort to develop an effective and less expensive antiemetic regimen for the control of carboplatin-induced emesis." | 9.08 | Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 9.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "To compare the efficacy in the treatment of post-operative nausea and/or vomiting (PONV), 75 patients undergoing gynaecological procedures under general anaesthesia using N2O/enflurane who suffered from PONV in the first hour after surgery were randomly allocated to three groups containing 25 patients each to receive either alizapride 100 mg, droperidol 1 mg or ondansetron 8 mg (i." | 9.08 | Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea. ( Bovill, JG; de Bont, LE; el-Mofty, M; Samhan, YM; Stienstra, R, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 9.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 9.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 9.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 9.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "In this study the antiemetic effects of droperidol, ondansetron and their combination were evaluated in 160 ASA Grade I and II children undergoing surgery for strabismus, who were randomly assigned to one of four groups: Group D received droperidol 75 micrograms kg-1, group O ondansetron 0." | 9.08 | Ondansetron, droperidol and their combination for the prevention of post-operative vomiting in children. ( Braun, U; Klockgether-Radke, A; Mühlendyck, H; Neumann, P; Neumann, S, 1997) |
| "To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to evaluate the efficacy when dexamethasone is added to either drug in the first 24 hours; and to extend these comparisons over 7 days in patients receiving moderately emetogenic chemotherapy." | 9.08 | Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. ( Chin, C; Dempsey, E; Guevin, RM; Hainsworth, J; Hoskins, P; Krook, JE; Lofters, WS; Moquin, JP; Navari, R; Palmer, M; Pater, JL; Verma, S; Walde, D; Wilson, K; Zee, B, 1997) |
| "Intravenous dolasetron mesilate has shown efficacy in the prevention of postoperative nausea and vomiting (PONV) when administered as a single dose prior to emergence from anesthesia." | 9.08 | Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. ( Brown, R; Clergue, F; Feiss, P; Hahne, W; Korttila, K; Leeser, J; Nave, S; Olthoff, D; Payeur-Michel, C; Wessel, P, 1997) |
| "To compare the prophylactic administration of ondansetron with droperidol or placebo to determine its effectiveness in reducing postoperative nausea and vomiting after middle ear procedures." | 9.08 | Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. ( Fluter, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1997) |
| "1 mg/kg to 4 mg intravenously) compared with placebo in the prevention of postoperative vomiting in 429 ASA status I-III children 1-12 yr old undergoing outpatient surgery under nitrous oxide- and halothane-based general anesthesia." | 9.08 | Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. ( Cohen, IT; Colingo, K; Creed, MR; Davis, PJ; Donlon, JV; Ferrari, LR; Haberkern, CM; Hannallah, RS; McGowan, FX; Orr, RJ; Parasuraman, TV; Patel, RI; Prillaman, BA; Rimar, S, 1997) |
| "To investigate the incidence of postoperative nausea and vomiting (PONV) depending on the administration time of ondansetron." | 9.08 | [Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients]. ( Kainzwaldner, A; Ploner, F, 1997) |
| "To compare the efficacy of ondansetron, droperidol, or metoclopramide with placebo in preventing postoperative vomiting following strabismus surgery." | 9.08 | A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children. ( Elliott, WG; James, RL; Mims, G; Scuderi, PE; Weaver, RG; Weeks, DB, 1997) |
| "Patient functional status after administration of either granisetron or ondansetron to prevent acute chemotherapy-induced nausea and vomiting (CINV) was studied." | 9.08 | Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. ( Bernstein, G; Colgan, K; Dempsey, CL; Farley, PA; Kulis-Robitaille, C; Shillington, AA, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 9.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "The proportion of patients with nausea was 48%, 50% and 67% in the ondansetron, droperidol and placebo groups, respectively; with a significant difference when both ondansetron (P=0." | 9.08 | Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. ( Alahuhta, S; Koivuranta, M; Läärä, E; Ranta, P; Ravaska, P, 1997) |
| "Low-dose ondansetron plus dexamethasone is an effective prophylactic antiemetic combination for children undergoing strabismus surgery." | 9.08 | Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron. ( Rhine, EJ; Splinter, WM, 1998) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 9.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 9.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| " bolus dose of ondansetron 4 mg were evaluated in the prevention of postoperative nausea and vomiting (PONV), which remains one of the most unpleasant side effects experienced by patients postoperatively." | 9.08 | Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis. ( De Guchteneere, E; Hendrickx, P; Levarlet, M; Moens, P, 1997) |
| "To investigate the hypothesis that the combination of ondansetron and droperidol would be more effective than droperidol alone in reducing nausea and vomiting." | 9.08 | Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy. ( Hamilton, DL; McKenzie, R; Riley, TJ; Trantisira, BR, 1998) |
| "We have compared the effects of ondansetron and perphenazine on vomiting after tonsillectomy in 216 healthy children, aged 2-12 yr." | 9.08 | Prophylaxis for vomiting by children after tonsillectomy: ondansetron compared with perphenazine. ( Rhine, EJ; Splinter, WM, 1998) |
| "This study compares the preoperative administration of ondansetron with that of droperidol or saline solution for the prevention of nausea and vomiting in otologic surgery patients." | 9.08 | Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery. ( Fluder, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1998) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 9.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "To determine the dose-response relationship of ondansetron in preventing postoperative nausea and vomiting (PONV) in women undergoing elective surgery." | 9.08 | A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. ( Chang, Y; Conant, JA; Connors, PM; Dershwitz, M; Rosow, CE, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 9.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 9.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following minor oral surgery was evaluated in a prospective randomized double-blind study." | 9.07 | Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study. ( Campbell, RC; Chow, J; Hui, E; Lueveswanij, S; Rodrigo, MR; Tong, CK, 1994) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 9.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Ondansetron in the prophylaxis of Cisplatin-induced emesis and nausea." | 9.07 | Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. ( Chakrapee-Sirisuk, S; Cheirsilpa, A; Chindavijak, K; Lousoontornsiri, W; Ratanatharathorn, V; Sinlarat, P; Srimuninimit, V, 1994) |
| "Oral ondansetron is an effective therapy for the prevention of emesis induced by TBI." | 9.07 | Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. ( Bryson, JC; Cirenza, E; Dubois, A; Foelber, R; Kunka, RL; Plagge, PB; Spitzer, TR; Stout, C; Wallerstadt, M, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 9.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "25 mg droperidol in preventing postoperative vomiting." | 9.07 | [Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol]. ( Alon, E; Atanassoff, PG; Biro, P; Lenzlinger, PM, 1994) |
| "Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting (PONV), but it has not been proved to be superior to established antiemetics for prophylaxis or therapy." | 9.07 | [Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients]. ( Heim, C; Listyo, R; Münzer, T, 1994) |
| "The purpose of this double-blind, randomized study was to compare the effectiveness of ondansetron plus saline versus ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting." | 9.07 | Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. ( Abdelhady, H; Karambelkar, DJ; McKenzie, R; Riley, TJ; Tantisira, B, 1994) |
| "This prospective, randomized, placebo-controlled, double-blinded study evaluated the antiemetic efficacy of ondansetron and metoclopramide in 90 ASA physical status I or II children, 2-17 yr of age, undergoing strabismus repair." | 9.07 | Ondansetron reduces the incidence and severity of poststrabismus repair vomiting in children. ( Corddry, DH; Kettrick, RG; Martin, TM; Rose, JB; Zagnoev, M, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 9.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 9.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "We performed a double-blind, randomized, placebo-controlled trial to investigate the efficacy and safety of ondansetron in preventing vomiting after tonsillectomy with or without adenoidectomy in children." | 9.07 | Ondansetron decreases emesis after tonsillectomy in children. ( Catanzaro, FA; Litman, RS; Wu, CL, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 9.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2)." | 9.07 | A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. ( Beck, TM; Bricker, LJ; Hainsworth, JD; Haley, B; Harker, WG; Harvey, WH; Hesketh, PJ; Kish, JA; Murphy, WK; Ryan, T, 1994) |
| "In two placebo-controlled, double-blind, multicentre studies, the efficacy and safety of single oral doses of ondansetron 4 mg, 8 mg and 16 mg were evaluated for the prevention of postoperative nausea and vomiting in female inpatients." | 9.07 | Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups. ( Cohen, LA; Rust, M, 1994) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 9.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 9.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 9.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 9.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy." | 9.07 | Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of ( Hoskins, P; Kaizer, L; Latreille, J; Levy, M; Lofters, W; Palmer, M; Pater, J; Warr, D; Yau, J; Zee, B, 1994) |
| "This prospective, randomized, double-blind study assessed whether the addition of dexamethasone to ondansetron leads to improved control of chemotherapy--induced emesis, both in patients undergoing their first course of highly emetogenic chemotherapy and in chemotherapy-pretreated patients refractory to standard anti-emetics." | 9.07 | Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). ( Aapro, MS; Bacchi, M; Buser, K; Joss, RA; Kirchner, V; Neuenschwander, H; Orth, B; Thürlimann, B, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 9.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which has shown activity in the prevention of emesis following cytotoxic and radiation therapy for cancer." | 9.07 | Ondansetron for efficient emesis control during total body irradiation. ( König, V; Riess, H; Schmid, H; Schmidt-Wolf, I; Schwella, N; Schwerdtfeger, R; Siegert, W, 1994) |
| "We studied the efficacy and safety of intravenous ondansetron 4 mg for the prevention of postoperative nausea and vomiting after minor gynaecological laparoscopic surgery in Oriental women." | 9.07 | Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. ( Chen, PP; Critchley, LA; Gin, TA; Ray, AK; Rowbottom, YM; Suen, TK, 1994) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 9.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "Vomiting was prevented in two thirds of patients treated with MDL plus ondansetron, a result similar to that observed in earlier trials of MDL alone." | 9.07 | The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. ( Baltzer, L; Kris, MG; Pisters, KM; Rigas, JR; Tyson, LB, 1994) |
| "Thirty-six consecutive patients, who were to be treated with cisplatin-based chemotherapy for testicular or bladder cancer, underwent a single-blind randomized study to compare the antiemetic therapies with dexamethasone (DEX)+ondansetron (OND) and DEX + alizapride (ALI)." | 9.07 | Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. ( Faustini, M; Mangiarotti, B; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R, 1993) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 9.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 9.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| "Ondansetron, a selective 5-HT3 antagonist, is known to be effective for preventing emesis induced by cisplatin and other antineoplastic agents." | 9.07 | Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. ( Bosi, A; Fanci, R; Guidi, S; Lombardini, L; Messori, A; Rossi-Ferrini, P; Saccardi, R; Vannucchi, AM, 1993) |
| "The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study." | 9.07 | The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. ( Cunningham, D; Davidson, N; Gore, M; Manchanda, M; Miocevich, M; Wells, N, 1993) |
| " Patients were stratified by gender and received, in a randomized, double-blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively." | 9.07 | Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. ( Apfelbaum, J; Claybon, L; DuPen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1993) |
| "Data from the 544 women showed that all doses of intravenous ondansetron tested (1, 4, and 8 mg) were significantly more effective (62%, 76%, and 77%, respectively) than placebo (46%) in reducing the incidence of emesis following surgery until 24 h after recovery room entry." | 9.07 | Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. ( Angel, J; Duncalf, D; Gratz, I; Joslyn, A; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T; Tolpin, E, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following major gynaecological surgery was evaluated in this multicentre, double-blind study." | 9.07 | The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. ( Conseiller, C; Dupeyron, JP; Gribomont, B; Hemmingsen, C; Kaplan, LA; Levarlet, M; Pedersen, FM; Schoeffler, P, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 9.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The efficacy of ondansetron, a selective 5-HT3 receptor antagonist, in preventing postoperative nausea and vomiting in surgical patients was studied." | 9.07 | Ondansetron is effective in decreasing postoperative nausea and vomiting. ( Dershwitz, M; Di Biase, PM; Joslyn, AF; Rosow, CE; Sanderson, PE, 1992) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 9.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 9.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 9.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Following a single intravenous dose given pre-chemotherapy, the efficacy and tolerability of oral ondansetron treatment given twice daily was compared with the established three times daily oral supplementary regimen in the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 9.07 | Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group. ( Bleiberg, H; Campora, E; Cunningham, D; Dicato, MA; Kaasa, S; Liebhard, A; Upadhyaya, BK; Vindevoghel, A; Warnier, P, 1992) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 9.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Forty-seven patients receiving non-cisplatin-containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron plus dexamethasone and tropisetron plus dexamethasone in the prophylaxis of acute vomiting was evaluated." | 9.07 | Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. ( Jantunen, IT; Johansson, RT; Kataja, VV, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 9.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis." | 9.07 | Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. ( Beck, TM; Gandara, DR; Hainsworth, JD; Hesketh, PJ; Kish, JA; Lester, EP; Madajewicz, S; Murphy, WK; Navari, RM; Pendergrass, K, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 9.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 9.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 9.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "The effect of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting was investigated in a randomized, double-blind, placebo-controlled study of 84 patients undergoing gynecologic operation and receiving the same general anesthetic." | 9.07 | Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. ( Leeser, J; Lip, H, 1991) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 9.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated patients." | 9.07 | Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. ( Amadori, D; Bella, MA; Cognetti, F; Cortesi, E; Donati, D; Favalli, G; Gramazio, V; Marangolo, M; Roila, F; Tonato, M, 1991) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 9.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 9.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| "Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis." | 9.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 9.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 9.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 9.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The efficacy of ondansetron was compared with metoclopramide in the prophylaxis of nausea and vomiting induced by cyclophosphamide greater than or equal to 500 mg/m2 in combination with doxorubicin greater than or equal to 40 mg/m2 or epirubicin greater than or equal to 40 mg/m2." | 9.06 | A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. ( Carruthers, L; Dicato, MA; Huys, JV; Kaasa, S; Kvaløy, S; Ries, F; Royer, E, 1990) |
| " The study was open, dose ranging, and noncomparative, and designed to evaluate safety and efficacy of ondansetron in preventing nausea and vomiting caused by cyclophosphamide intravenous (IV) 1,000 mg/m2 day 1, and cytarabine IV subcutaneously (SC) 75 mg/m2 on days 2 to 5." | 9.06 | Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. ( Carden, PA; Ekert, H; Mitchell, SL; Tiedemann, K; Waters, KD, 1990) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 9.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 9.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 9.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "Sixty five chemotherapy naive patients receiving cisplatin (50-120 mg/m2) containing chemotherapy participated in an evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and emesis." | 9.06 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. ( Bella, M; Bracarda, S; Cetto, G; Del Favero, A; Donati, D; Marangolo, M; Roila, F; Tonato, M, 1990) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 9.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 9.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 9.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 8.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "To systematically update evidence on the effects of ondansetron (5-HT3 serotonin antagonist) for vomiting in children with acute gastroenteritis." | 8.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 8.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "To investigate potential beneficial effects of ondansetron, compared with placebo or no intervention, in treating vomiting during acute gastroenteritis in children." | 8.84 | Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. ( Dylag, M; Gieruszczak-Białek, D; Szajewska, H, 2007) |
| "Granisetron (Kytril, Roche) is a 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin." | 8.82 | Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. ( Tan, M, 2003) |
| "Palonosetron (Aloxi) is a 5-HT(3)-receptor antagonist antiemetic indicated for the prevention of acute and delayed nausea and vomiting following moderately emetogenic chemotherapy and for acute nausea and vomiting following highly emetogenic chemotherapy." | 8.82 | Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. ( Grunberg, SM; Koeller, JM, 2003) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 8.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| "To assess the efficacy of ondansetron and the incidence of headache when used as prophylaxis for postoperative vomiting." | 8.80 | Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. ( Canosa, LG; Figueredo, ED, 1998) |
| "For the usual doses recommended for postoperative emesis, there was equivalent effectiveness of ondansetron whether administered as prophylaxis or as a treatment of established vomiting." | 8.80 | Prevention or treatment of postoperative vomiting using ondansetron? A mathematical assessment. ( Canosa, LG; Figueredo, E, 1999) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 8.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| "The clinical development of ondansetron for the prevention and treatment of postoperative nausea and vomiting has been progressing for 5 years, and continues as new directions of research are being addressed." | 8.79 | Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions. ( Joslyn, AF, 1994) |
| "Available clinical data on the use of oral ondansetron for the prevention of nausea and vomiting in patients undergoing cancer chemotherapy or surgery are reviewed." | 8.79 | Oral ondansetron for preventing nausea and vomiting. ( Cooke, CE; Mehra, IV, 1994) |
| "The efficacy and safety of the serotonin (5-HT3) receptor antagonists granisetron, ondansetron, and tropisetron in the control of acute and delayed emesis and emesis induced by repeat-cycle chemotherapy are summarized." | 8.79 | Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). ( Hickok, JT; Morrow, GR; Rosenthal, SN, 1995) |
| "To test the evidence for a dose-response with ondansetron for treatment of postoperative nausea and vomiting and to establish whether differences in efficacy between doses are of clinical relevance." | 8.79 | A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 8.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy." | 8.78 | Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. ( Markham, A; Sorkin, EM, 1993) |
| "Serotonin is a neurotransmitter involved in chemotherapy-induced emesis and ondansetron is a new drug endowed with selective antagonism against the 5HT3 receptors." | 8.78 | Cisplatinum based chemotherapy: role of the antiserotoninergic ondansetron in prevention of emesis. ( D'Antona, A; Locatelli, MC; Luporini, G, 1993) |
| " Metoclopramide is generally acknowledged to be the single most effective conventional drug for the prevention of acute cisplatin-induced emesis and, therefore, was considered an appropriate agent for inclusion in comparative trials with ondansetron." | 8.78 | Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. ( Hesketh, PJ, 1992) |
| " Ondansetron prevents emesis by blocking the 5-HT3 receptors associated with the vomiting reflex." | 8.78 | Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis. ( Dicato, MA; Freeman, AJ, 1992) |
| "An international clinical trial programme has been established to assess the efficacy and safety of ondansetron in the prevention and treatment of postoperative nausea and vomiting." | 8.78 | The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting. ( Haigh, CG; Hellstern, K; Inall, FC; Isal, JP; Joslyn, AF; Kanarek, BK; Kaplan, LA; Povey, PM, 1992) |
| "Ondansetron hydrochloride dihydrate is a 5-hydroxytryptamine (5-HT3) antagonist that was recently approved by the Food and Drug Administration for the treatment of chemotherapy-induced emesis." | 8.78 | Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. ( Burnette, PK; Perkins, J, 1992) |
| " Ondansetron, a specific 5-HT3 antagonist, has been fully evaluated in the clinic, both as an intravenous and oral presentation, and in open studies in patients receiving non-cisplatin chemotherapy regimens it was highly effective in controlling acute and delayed emesis -- more than 90% of patients had a complete or major response to treatment." | 8.77 | The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. ( Schmoll, HJ, 1989) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 8.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting." | 8.31 | Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department. ( Miroluz, D; Palnizky Soffer, G; Rimon, A; Schnapp, Z, 2023) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 8.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 8.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 8.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 8.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 8.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 8.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 8.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 8.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs." | 8.02 | The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome. ( Elliott, J; Foth, S; Kenward, H; Meller, S; Pelligand, L; Volk, HA, 2021) |
| "We determine whether an ondansetron prescription for pediatric patients with vomiting or gastroenteritis is associated with decreased return visits to the emergency department (ED), and whether alternate diagnoses are more frequent on return visits in patients prescribed ondansetron." | 7.96 | Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis. ( Benary, D; Higley, R; Lowe, D; Lozano, JM, 2020) |
| "We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration." | 7.91 | Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial. ( Ali, N; Bhutta, ZA; Dawoud, F; Freedman, SB; Soofi, SB; Willan, AR; Williamson-Urquhart, S; Xie, J, 2019) |
| "We have sought to determine the effect of a standardized dose of intravenous ondansetron on the QTc duration of children under 14years of age treated for gastroenteritis-associated vomiting in a pediatric ED." | 7.88 | Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. ( Alansari, K; Hoffman, RJ, 2018) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 7.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "This is a single-center prospective study enrolling children aged 3-8 years with gastroenteritis treated for persistent vomiting; patients received single dose of flavored intravenous ondansetron orally." | 7.83 | Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children. ( Al Ansari, K; Ibrahim, K, 2016) |
| "Ondansetron is often used in the emergency department (ED) to promote oral rehydration in children with acute gastroenteritis (AGE), yet medication solutions administered orally may be poorly tolerated in this population." | 7.83 | Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis. ( Chaulk, D; Johnson, DW; Kwong, S; Morrison, EL; Thompson, GC; Wobma, H, 2016) |
| "To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes)." | 7.81 | Emergency department ondansetron use in children with type 1 diabetes mellitus and vomiting. ( Freedman, SB; Leung, JS; Perlman, K; Rumantir, M, 2015) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 7.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| "The current Tactical Combat Casualty Care (TCCC) Guidelines recommend parenteral promethazine as the single agent for the treatment of opioid-induced nausea and/or vomiting and give a secondary indication of "synergistic analgesic effect." | 7.81 | Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care. ( Burrell, E; Butler, FK; Gross, K; Onifer, DJ; Otten, EJ; Patton, R; Russell, RJ; Stockinger, Z, 2015) |
| "The main objective of this study was to develop a microemulsion (ME) formulation for transdermal delivery of ondansetron for chemotherapy induced nausea and vomiting (CINV)." | 7.79 | Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. ( Ahmad, FJ; Al Abood, RM; Talegaonkar, S; Tariq, M, 2013) |
| "The use of ondansetron in children with vomiting after a head injury has not been well studied." | 7.79 | The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED. ( Hirsh, DA; Khan, NS; Simon, HK; Sturm, JJ, 2013) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 7.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "Emergency department use of ondansetron in children with gastroenteritis is increasing; however, its effect on clinical outcomes is unknown." | 7.78 | Time-series analysis of ondansetron use in pediatric gastroenteritis. ( Chan, KJ; Cho, D; Freedman, SB; Rumantir, M; Tung, C, 2012) |
| " The aim of this study is to develop and evaluate mucoadhesive ondansetron buccal films for the treatment of emesis using CS as a mucoadhesive polymer." | 7.78 | Development of chitosan-based ondansetron buccal delivery system for the treatment of emesis. ( Jee, JP; Kim, CK; Kim, HT; Park, DM; Song, YK, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 7.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| "In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use." | 7.78 | Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department. ( Armero, C; Carrión, T; Hervás, D; Hervás, JA; Utrera, JF, 2012) |
| "The objective of this study was to determine if overweight children are more likely than normal-weight children to require ondansetron when undergoing ketamine sedation in a pediatric emergency department." | 7.78 | Do children with high body mass indices have a higher incidence of emesis when undergoing ketamine sedation? ( Gerard, JM; Kinder, KL; Lehman-Huskamp, KL, 2012) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 7.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| "To document ondansetron-induced dystonia, hypoglycemia, and seizures in a child." | 7.77 | Ondansetron-induced dystonia, hypoglycemia, and seizures in a child. ( Manchanda, S; Mittal, S; Patel, A; Puliyel, JM, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 7.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 7.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| "A cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the US and Canada." | 7.76 | Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. ( Chan, KJ; Freedman, SB; Steiner, MJ, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin." | 7.75 | [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study]. ( Auger, A; Combes, JD; Favier, B; Galy, G; Labidi, SI; Latour, JF; Tissier, F, 2009) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 7.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 7.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 7.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "The 5-HT3 antagonist, ondansetron (OND), and the cannabinoid, delta9-tetrahydrocannabinol (delta9-THC), have been shown to interfere with emesis; however, their relative and/or combined effectiveness in suppressing vomiting produced by the chemotherapeutic agent, cisplatin, is unknown." | 7.72 | A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). ( Burton, P; Kwiatkowska, M; Mechoulam, R; Parker, LA, 2004) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 7.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "The cost efficacy of various ondansetron regimens for the control of emesis induced by noncisplatin, moderately emetogenic chemotherapy was examined from a hospital perspective." | 7.71 | Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. ( Lachaine, J; Laurier, C, 2002) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 7.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 7.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "To determine the incidence of nausea and vomiting and the antiemetic effect of ondansetron hydrochloride (OND) in patients with hepatocellular carcinoma treated with arterial chemo-embolization, we studied 59 patients with hepatocellular carcinoma who were treated with transcatheter arterial embolization (TAE) or lipiodolized transcatheter arterial infusion (L-TAI)." | 7.70 | Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride. ( Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H, 1999) |
| "The article reports a study comparing the cost-effectiveness of ondansetron tablets and prochlorperazine capsules in preventing nausea and vomiting after moderately emetogenic chemotherapy in an outpatient setting." | 7.70 | Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. ( Kwong, WJ; Parasuraman, TV, 1999) |
| "We investigated the emetic effects of cisplatin and methotrexate in dogs, the effects of ondansetron on cisplatin-induced vomiting, and the effects of ondansetron, dexamethasone and a combination of the two on the vomiting induced by methotrexate." | 7.70 | Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy. ( Fukui, H; Yamamoto, M, 1999) |
| "To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting." | 7.69 | Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. ( Aspinall, RL; Goodman, NW, 1995) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 7.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 7.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "The efficacy and safety of prophylactic intravenous ondansetron on prevention of postoperative nausea and vomiting were investigated in 65 ASA grades I-III patients undergoing elective abdominal surgery and receiving general anesthesia." | 7.69 | [Ondansetron on postoperative nausea and vomiting]. ( Guo, XY; Luo, AL; Ye, TH, 1994) |
| "To describe the efficacy of ondansetron for the treatment of poisoning-associated vomiting in two patients following drug intoxication." | 7.69 | Ondansetron for treating nausea and vomiting in the poisoned patient. ( Marx, CM; Reed, MD, 1994) |
| "The incidences of nausea and vomiting were significantly lower in the patients premedicated with ondansetron." | 7.69 | [Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery]. ( Bejarano-López, C; Bustos-Molina, F; Cid-Calzada, J; Cortés-Uribe, A; García-Cruz, JJ; Soro-Domingo, M, 1996) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 7.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 7.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| " 5 min prior to morphine while each ferret was maintained under isoflurane-O2 anesthesia." | 7.68 | The effects of different antiemetic agents on morphine-induced emesis in ferrets. ( Essien, E; Thut, PD; Wynn, RL, 1993) |
| "Ondansetron may be the preferred agent for controlling nausea and vomiting in patients with neurosurgical trauma." | 7.68 | Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. ( Deppe, SA; Kleinerman, KB; Sargent, AI, 1993) |
| " Ondansetron, an antagonist of 5-hydroxytryptamine (subtype 3) receptor is a new, very potent drug preventing vomiting and nausea induced by different factors (chemotherapy, radiotherapy, anaesthesia)." | 7.68 | Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. ( Beshari, SE; Kołecki, P; Wachowiak, J, 1993) |
| "We present a 17-year-old girl who developed persistent vomiting following acetaminophen overdose." | 7.68 | Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication. ( Deshpande, JK; Gregory, DF; Tobias, JD, 1992) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 7.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| " Ondansetron, a selective 5-HT3-receptor antagonist has shown efficacy in cisplatin-induced emesis." | 7.68 | Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. ( du Bois, A; Fenzl, E; Kommoss, FG; Meerpohl, HG; Pfleiderer, A; Vach, W, 1992) |
| "Previous studies of the mechanism of zacopride-induced emesis in ferrets have concluded that it is mediated predominantly by an antagonist effect on 5-HT3 receptors although the possibility of a contribution from an agonist effect at 5-HT4 receptors was not excluded." | 7.68 | Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. ( Andrews, PL; Bhandari, P, 1991) |
| "Twenty-four patients with severe post-chemotherapy emesis (greater than 15 emetic episodes) refractory to prior combination antiemetic therapy were treated with a selective 5-HT3 receptor antagonist ondansetron (GR38032F)." | 7.68 | Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). ( Ardizzoni, A; Campora, E; Oliva, C; Rosso, R; Vidili, G, 1991) |
| " Ondansetron is an investigational serotonin antagonist that has documented effectiveness for cancer chemotherapy-induced emesis." | 7.68 | Ondansetron: a new entity in emesis control. ( Graves, T, 1990) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 7.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 7.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 6.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 6.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| " Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy." | 6.84 | Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). ( Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K, 2017) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 6.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| "Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy." | 6.80 | Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara ( Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W, 2015) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 6.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| "Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control." | 6.77 | Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. ( Carrasco, MM; Cruz, FM; da Costa Miranda, M; da Cunha Vieira, M; de Afonseca, SO; de Iracema Gomes Cubero, D; de Souza Fêde, AB; del Giglio, A; Lera, AT; Lerner, T; Pinczowski, H; Schindler, F; Taranto, P, 2012) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 6.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "The meclizine group had lower VNRS scores in the PACU at 15 (P = ." | 6.73 | Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. ( Benfield, DA; Forrester, CM; Kelly, JA; Matern, CE; Pellegrini, JE, 2007) |
| "as prophylaxis in breast cancer patients regimens was studied." | 6.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "Nausea was assessed by means of a four-point ordinal scale at intervals over the 7 day period." | 6.70 | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. ( Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L, 2001) |
| "Ondansetron was given at a dose of 12 mg/day and TENS was applied by commercially available 'Relief Band'(Maven Labs, Inc." | 6.70 | Combination of transcutaneous electrical nerve stimulation and ondansetron in preventing cisplatin-induced emesis. ( Arik, AI; Erol, D; Ozgür Tan, M; Sandikçi, Z; Uygur, MC, 2001) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "Emesis is common in the postoperative period following epidural opioid and general anaesthesia." | 6.69 | A double blind comparison of droperidol and ondansetron for prevention of emesis in children undergoing orthopaedic surgery. ( Goodarzi, M, 1998) |
| "Sixty cancer patients took part in this randomized prospective study." | 6.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| " dosing regimen over a 24 h period, administered to patients prior to receiving cisplatin (50 mg/m2 or greater) chemotherapy." | 6.69 | A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. ( Goedhals, L; Graham, E; Joly, F; Krzakowski, M; Lees, J; McQuade, B; Pawlicki, M; Rapoport, B; Yelle, L, 1998) |
| "Ondansetron alone was not adequate to provide sustained control of CT-induced nausea and vomiting over the entire 5-day study period." | 6.69 | An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. ( Cohen, L; Davidson, T; Dix, SP; Joyce, R; Lynn, M; Miyahara, T; Osowski, CL; Sexauer, MC; Wingard, JR; Yeager, A, 1998) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days." | 6.69 | Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. ( Curtis, P; Davidson, N; Erikstein, B; L'Esperance, B; Miller, I; Paska, W; Rapoport, B; Ruff, P, 1999) |
| "Ondansetron 24 mg q." | 6.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "Ondansetron is an effective and well-tolerated antiemetic, which is used for the prevention of both chemotherapy and radiotherapy-induced emesis and nausea." | 6.69 | Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab ( Coster, B; Feyer, P; Franzén, L; Goedhals, L; Graham, E; Haigh, C; LeBourgeois, JP; Marzecki, Z; McKenna, CJ; Mitchell, T; Souhami, L; Stewart, A; Tønnessen, F; Wilkinson, JR, 1999) |
| "Ondansetron was extremely effective over this time in the control of emesis and nausea." | 6.68 | The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. ( Beck, TM, 1995) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 6.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "Metoclopramide was ineffective." | 6.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 6.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "A total of 259 chemotherapy-naive breast cancer patients treated with a 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen were randomly assigned to ondansetron (OND) 8 mg tablet or alizapride (ALI) 150 mg intravenous (i." | 6.68 | Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. ( Bonneterre, J; Clavel, M; d'Allens, H; Paillarse, JM, 1995) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 6.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| "Postoperative pain was treated with morphine, codeine and/or acetaminophen." | 6.68 | Oral ondansetron decreases vomiting after tonsillectomy in children. ( Baxter, MR; Gould, HM; Hall, LE; Komocar, L; MacNeill, HB; Roberts, DJ; Splinter, WM, 1995) |
| "We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving moderately emetogenic chemotherapy." | 6.68 | Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ( Beijnen, JH; de Boer-Dennert, M; de Wit, R; Schellens, JH; van Tellingen, O; Verweij, J, 1996) |
| " In addition, ondansetron had a similar dose-response curve in both menstruating and nonmenstruating women." | 6.68 | The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. ( Afshar, M; Allen, E; Buxbaum, J; Gratz, I; Joslyn, AF; Prilliman, B, 1996) |
| "Ondansetron was significantly more effective than droperidol in reducing emesis after discharge (P < 0." | 6.68 | Ondansetron decreases postoperative vomiting in pediatric patients undergoing tonsillectomy and adenoidectomy. ( Bower, C; Brown, RE; Kymer, PJ; Lawhorn, CD; Schmitz, ML; Shirey, R; Stoner, J; Vollers, JM, 1996) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 6.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Ondansetron is a serotonin (5HT) receptor antagonist at both peripheral and central 5-HT3 receptor sites with no known action on dopamine-mediated activity." | 6.68 | Droperidol/ondansetron combination controls nausea and vomiting after tubal banding. ( Hamilton, DL; McKenzie, R; Riley, TJ; Uy, NT, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 6.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Ondansetron was used as an antiemetic along with dexamethasone during 16 cycles of highly or moderately ematogenic chemotherapy." | 6.68 | Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. ( Jain, PK; Parikh, PM; Patel, RA; Shah, KC; Shah, SC; Shah, SR; Sheth, V, 1996) |
| "As ondansetron was clearly effective in patients receiving hemibody irradiation it seems it would be prudent to adopt it for use in such patients routinely." | 6.68 | Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. ( Kiltie, AE; Stewart, AL; Sykes, AJ, 1997) |
| "The metoclopramide dosage was 20 mg i." | 6.68 | Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. ( Advani, SH; Cooverji, ND; Dhar, AK; Gopal, R; Lal, HM, 1996) |
| "Nausea and emesis are significant side effects in patients undergoing stereotactic radiosurgery for brain lesions in the region of the chemoreceptor trigger zone (area postrema of the brain)." | 6.67 | The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone. ( Alexander, E; Bodis, S; Kooy, H; Loeffler, JS, 1994) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 6.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Oral ondansetron 8 mg was subsequently given in the evening of day 1, and then even 12 hours on days 2, 3 and 4." | 6.67 | Control of emesis by a low dose of ondansetron and dexamethasone. ( Bajetta, E; Biganzoli, L; Buzzoni, R; Di Bartolomeo, M; Di Leo, A; Zampino, MG, 1994) |
| "Ondansetron is a well tolerated, efficacious antiemetic which has a similar side effect profile to placebo." | 6.67 | Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting. ( Claybon, L, 1994) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy." | 6.67 | Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. ( Beck, TM; Chang, A; Ciociola, AA; Galvin, D; Hart, NE; Harvey, WH; Jones, SE; Tchekmedyian, NS, 1993) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 6.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 6.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 6.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 6.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 6.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron is a new 5-HT3-antagonist with antiemetic properties." | 6.67 | The effect of ondansetron on radiation-induced emesis and diarrhoea. ( Franzén, L; Henriksson, R; Israelsson, G; Lomberg, H; Zackrisson, B, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 6.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron was an effective antiemetic in 78% (14/18) and placebo was effective in 28% (5/18) of the patients." | 6.67 | Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. ( Afshar, M; Gratz, I; Larijani, GE; Minassian, S, 1991) |
| "Ondansetron was administered as an 8 mg loading dose (A: 4 mg i." | 6.67 | The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. ( de Mulder, PH; Lane-Allman, E; Seynaeve, C; van Liessum, PA; Verweij, J, 1991) |
| "Nausea and vomiting are two of the most distressing side effects of chemotherapy." | 6.44 | Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. ( Vrabel, M, 2007) |
| "Ondansetron is a serotonin receptor antagonist that is effective in preventing and treating PONV." | 6.39 | Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting. ( Charbonneau, J; Early, TE; Jenkins, P; McKnight, G, 1995) |
| "Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs." | 6.38 | Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. ( Goldspiel, BR; Kohler, DR, 1991) |
| "Postoperative nausea and vomiting (PONV) is still a common perioperative complication and ondansetron has proved to be an effective antiemetic substance in its prevention." | 6.18 | [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms]. ( Buhre, W; Kazmaier, S; Mühr, C; Neumann, P; Saur, P, 1996) |
| "A total of 1442 patients who had major gynaecological surgery were recruited into three multicentre studies using a standard general anaesthetic technique in order to assess the efficacy of various doses of orally administered ondansetron in the prevention of postoperative nausea and vomiting." | 6.17 | Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence. ( Dupeyron, JP; Durham, JM; Haigh, CG; Harmer, M; Kaplan, LA; Kenny, GN, 1993) |
| "Twenty patients receiving cisplatin (greater than or equal to 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5-HT3) antagonist, in controlling delayed emesis." | 6.17 | Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1992) |
| "Ondansetron is a 5-HT3 receptor antagonist which is effective and well tolerated as an antiemetic for emesis induced by cancer chemotherapy and radiation therapy, and in the prevention and treatment of postoperative nausea and vomiting." | 6.17 | Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ( Baber, N; Frazer, NM; Palmer, JL; Pritchard, JF, 1992) |
| "The chemistry, pharmacokinetics, adverse effects, stability, compatibility, and dosage of ondansetron hydrochloride are described, and clinical studies of the use of ondansetron for the prophylaxis of nausea and vomiting induced by antineoplastic therapy are reviewed." | 6.16 | Ondansetron--the first of a new class of antiemetic agents. ( Chaffee, BJ; Tankanow, RM, 1991) |
| "We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC)." | 5.69 | Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. ( Eom, YA; Jin, JY; Kang, JH; Kim, HK; Ko, YH; Park, SY; Sun, S; Woo, IS, 2023) |
| "Olanzapine significantly improved complete control of vomiting in the delayed phase." | 5.51 | Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial. ( Gupta, AK; Meena, JP; Moothedath, AW; Pandey, RM; Seth, R; Velpandian, T, 2022) |
| "The primary objective of this retrospective safety study was to determine the incidence of torsades de pointes (TdP) or death following perioperative administration of low-dose, 4 mg, ondansetron for postoperative nausea and vomiting." | 5.51 | The incidence of torsades de pointes with peri-operative low-dose ondansetron administration. ( Ackerman, MJ; Danke, H; Marienau, MS; Nuttall, GA; Oyen, LJ; Voogd, SC; Warner, PA, 2022) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 5.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 5.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 5.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "To compare effectiveness of maropitant and ondansetron in preventing preoperative vomiting and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate." | 5.41 | Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate. ( Burke, JE; Hess, RS; Silverstein, DC, 2021) |
| " PONV incidence, complete response, 80 mg aprepitant combined with dexamethasone and ondansetron, vomiting, nausea, and analgesic dose-response were the main outcomes measured." | 5.41 | The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. ( Chen, X; He, H; Hu, W; Liao, Y; Liu, W; Liu, Y; Pan, Z; Wang, X; Zheng, F; Zhong, H, 2023) |
| "To compare rates of complete response (no emesis, retching, or rescue antiemetics) in the late phase (days 4-7 post-chemotherapy) of cycle 1 between transdermal granisetron and oral ondansetron in cervical, endometrial, or vaginal cancer survivors undergoing chemoradiation at The University of Texas MD Anderson Cancer Center and LBJ Hospital in Houston, TX." | 5.41 | A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. ( Armbruster, SD; Coleman, RL; Eifel, PJ; Fellman, BM; Frumovitz, M; Jhingran, A; Klopp, AH; Ramondetta, LM, 2021) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 5.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| " Interestingly, none of the patients aged under 7 years, receiving divided dosing ondansetron, presented nausea symptoms compared with those receiving single daily dosing (p-value ." | 5.41 | Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. ( Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021) |
| "To determine the cost-effectiveness of adding oral ondansetron to care as usual (CAU) for children with acute gastroenteritis presenting to out-of-hours primary care (OOH-PC)." | 5.41 | Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Holtman, GA; Kollen, BJ; Vermeulen, KM; Weghorst, AA; Wolters, PI, 2021) |
| " In secondary care, ondansetron was found to be effective at reducing vomiting." | 5.41 | Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Fickweiler, F; Holtman, GA; Kollen, BJ; Russchen, HA; Verkade, HJ; Weghorst, AA, 2021) |
| " The combined treatment markedly and significantly decreased the mean number of emetic events recorded between 24 and 54 h after cisplatin dosing (-75%, P < 0." | 5.40 | Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron. ( Barrais, L; Castagné, V; Goineau, S; Guillaume, P, 2014) |
| "The thermosensitive-mucoadhesive ondansetron liquid suppository (tmOLS) was developed to enhance patient compliance and bioavailability in high-risk patients receiving highly emetogenic therapy and having difficulty in swallowing, The thermosensitive-mucoadhesive liquid suppository bases were formulated using poloxamers (P407 and P188) and hydroxypropylmethyl cellulose (HPMC)." | 5.39 | Design and evaluation of ondansetron liquid suppository for the treatment of emesis. ( Ban, E; Kim, CK, 2013) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 5.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "A generalized tonic-clonic seizure occurred in each patient--12, 15, and 22 min after injection." | 5.35 | Ondansetron and seizures. ( Acharya, JN; Rai, A; Selhorst, JB; Singh, NN, 2009) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC)." | 5.34 | The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Angspatt, P; Chenaksara, P; Parinyanitikun, N; Poovorawan, N; Sakdejayont, S; Sriuranpong, V; Sukprakun, S; Tanasanvimon, S; Thawinwisan, W; Vimolchalao, V; Vinayanuwatikun, C; Wongchanapai, P, 2020) |
| "This study was conducted to determine the effect of intramuscular ondansetron on ketamine-associated vomiting in children undergoing procedural sedation." | 5.34 | Does intramuscular ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomized, double blind, controlled study. ( Akbari, H; Davarani, SS; Hossein, F; Nejati, A; Talebian, MT, 2020) |
| "Oral ondansetron does not significantly reduce vomiting during or shortly after procedural sedation with combined intranasal fentanyl and inhaled nitrous oxide." | 5.34 | Oral Ondansetron to Reduce Vomiting in Children Receiving Intranasal Fentanyl and Inhaled Nitrous Oxide for Procedural Sedation and Analgesia: A Randomized Controlled Trial. ( Babl, FE; Davidson, A; Fauteux-Lamarre, E; Hopper, SM; Lee, KJ; Legge, D; McCarthy, M; Palmer, GM; Quinn, N, 2020) |
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 5.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| " In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit." | 5.34 | Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. ( Beer, D; Dixon, A; Finkelstein, Y; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Pechlivanoglou, P; Plint, AC; Williamson-Urquhart, S, 2020) |
| "To evaluate the incidence of tranexamic acid (TXA)-induced nausea and vomiting after the prophylactic use of 2 antiemetics, ondansetron and maropitant, compared with saline." | 5.34 | Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis. ( Bettschart-Wolfensberger, R; Hartnack, S; Kantyka, ME; Kutter, APN; Meira, C, 2020) |
| "The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo." | 5.34 | A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. ( Beer, D; Dixon, A; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Offringa, M; Pechlivanoglou, P; Plint, AC; Rios, JD; Williamson-Urquhart, S, 2020) |
| "Ondansetron was inactive to modify behavior, but CP-99,994 reduced spontaneous locomotor activity and lip licking by 48% (P<0." | 5.33 | Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. ( Kan, KK; Lai, HW; Lau, AH; Ngan, MP; Rudd, JA; Wai, MK; Yew, DT, 2005) |
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 5.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration." | 5.30 | Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. ( Avarello, J; Fathi, R; Hahn, B; House, SL; Kalfus, IN; Lovato, LM; Meltzer, AC; Miller, JB; Plasse, TF; Raday, G; Silverman, RA; Yan, EC, 2019) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay." | 5.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "induced emesis was investigated in the ferret during a 24 h period." | 5.30 | The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. ( Naylor, RJ; Rudd, JA, 1997) |
| "Lerisetron is a new 5-HT3 receptor antagonist chemically unrelated to other antagonists like Ondansetron." | 5.30 | Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. ( De Miguel, E; Gomez-de-Segura, IA; Grande, AG, 1998) |
| "Pretreatment with domperidone inhibited apomorphine-induced kaolin intake." | 5.29 | Pica in rats is analogous to emesis: an animal model in emesis research. ( Hasegawa, S; Matsunaga, T; Morita, M; Takeda, N, 1993) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 5.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| "Ondansetron 1 mg/kg was without effect to modify apomorphine-, morphine- or copper sulphate-induced emesis but the combination pretreatment of ondansetron 1 mg/kg with dexamethasone 2." | 5.29 | The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. ( Bunce, KT; Naylor, RJ; Rudd, JA, 1996) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 5.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| "Ondansetron was also given to 16 patients receiving cisplatin chemotherapy." | 5.28 | Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. ( Allan, SG; Dickson, D; Evans, BD; Forgeson, GV; Harvey, VJ; Humm, G; Langley, G; Mak, D; Mitchell, PL; Neave, L, 1992) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 5.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| " Complete response (CR; no vomiting and no rescue medication) rates in the acute, delayed, and overall phases (0-25, 25-120, and 0-120 h, respectively) were analyzed by chemotherapy type (carboplatin-based vs non-carboplatin-based), chemotherapy duration (single-day vs multiple-day), and baseline characteristics." | 5.27 | Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. ( Beckford-Brathwaite, E; Camacho, E; Green, SA; Jordan, K; Khanani, S; Noga, SJ; Pong, A; Rapoport, BL; Weinstein, C, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 5.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 5.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC)." | 5.24 | Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study. ( Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A, 2017) |
| "Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV)." | 5.24 | Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. ( Abbas, N; Abdel-Malek, R; Fawzy, R; Ismail, M; Safwat, E; Salem, DS; Shohdy, KS, 2017) |
| "Ginger (500 mg) twice daily was safe, but conferred no additional benefit in terms of reducing nausea severity in breast cancer patients receiving AC and ondansetron and dexamethasone for CINV prophylaxis." | 5.24 | Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. ( Akewanlop, C; Chantharasamee, J; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Soparattanapaisarn, N; Srimuninnimit, V; Techawathanawanna, S; Thamlikitkul, L, 2017) |
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 5.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 5.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "The aim of the study was to evaluate the efficiencies of selected anti-emetic drugs (metoclopramide, ondansetron and maropitant) in preventing vomiting in the treatment of canine parvoviral enteritis." | 5.24 | Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs. ( Keser, GO; Yalcin, E, 2017) |
| "To describe the use of ketamine in an adult patient in aborting a cyclic vomiting syndrome (CVS) episode." | 5.22 | Ketamine in Refractory Cyclic Vomiting Syndrome: A Case Report and Review of Literature. ( Cheung, F; Doherty, SM; Tatara, AW, 2022) |
| "Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control." | 5.22 | Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. ( Bouganim, N; Clemons, M; Dranitsaris, G; Mazzarello, S; Smith, S; Vandermeer, L, 2016) |
| "To evaluate the role of oral ondansetron in facilitating successful rehydration of under-5-year-old children suffering from acute diarrhea with vomiting and some dehydration." | 5.22 | Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial. ( Batra, P; Bhattacharya, SK; Danewa, AS; Gupta, P; Shah, D, 2016) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 5.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 5.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV)." | 5.22 | APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. ( Agajanian, R; Cooper, W; Dakhil, C; Gabrail, NY; Klepper, MJ; Mosier, MC; Payne, JY; Schnadig, ID; Schwartzberg, LS; Smith, RE; Taylor, C; Vacirca, JL; Wilks, ST, 2016) |
| "To compare the efficacy between acupuncture and ondansetron in the prevention of delayed chemotherapy induced nausea and vomiting (CINV)." | 5.20 | Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. ( Akkayagorn, L; Manchana, T; Rithirangsriroj, K, 2015) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 5.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "Aprepitant, a neurokinin-1 receptor antagonist, in combination with 5 HT-3 antagonist and dexamethasone is recommended in adults receiving moderately and highly emetogenic chemotherapy to reduce chemotherapy-induced vomiting (CIV)." | 5.20 | Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. ( Bakhshi, S; Batra, A; Biswas, B; Dhawan, D; Paul, R; Sreenivas, V, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 5.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 5.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 5.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| "Regardless of age, gender, or region, the aprepitant regimen provided better control for the no-vomiting and complete-response (no vomiting, no rescue therapy) endpoints." | 5.19 | Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. ( Rapoport, BL, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 5.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " Pre-treatment with ondansetron 4 mg IV was compared against placebo on nausea and vomiting following the standard (20." | 5.17 | Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP). ( Bateman, DN; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, S; Sandilands, EA; Thanacoody, HK; Thomas, SH; Webb, DJ, 2013) |
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 5.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| "To estimate whether the addition of metoclopramide or its combination with ondansetron to a prophylactic phenylephrine infusion provides improved intraoperative nausea and vomiting prophylaxis compared with phenylephrine infusion alone." | 5.17 | Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. ( Allen, TK; George, RB; Habib, AS; Ituk, US; McKeen, DM; Megalla, SA; White, WD, 2013) |
| " The objective of this study was to establish the overall complete response (CR; no emesis or use of rescue medication 0-120 h after chemotherapy) with either ondansetron- or palonosetron-containing antiemetic regimens in patients receiving highly emetogenic chemotherapy (HEC)." | 5.17 | Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. ( Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R, 2013) |
| "Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1." | 5.16 | Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ( Dube, P; Hesketh, PJ; Kopp, M; Lane, S; Levin, J; Makhson, A; Moiseyenko, V; Rosati, G; Russo, M; Wright, O, 2012) |
| "To observe the therapeutic efficacy of Hewei Zhiou Recipe (HZR) combined ondansetron hydrochloride (OH) in treating vomiting in children patients with solid tumor." | 5.16 | [Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride]. ( Liu, ZM; Shi, X; Zhu, XD, 2012) |
| " Aprepitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting, is an inhibitor and inducer of CYP3A4." | 5.16 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. ( Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y, 2012) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 5.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| " For HEC, aprepitant reduced the risk of first emesis by 38-77% vs." | 5.15 | Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). ( Carides, AD; Hesketh, PJ; Street, JC; Warr, DG, 2011) |
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 5.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| "Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours)." | 5.15 | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. ( Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A, 2011) |
| "To determine the effect of ondansetron on the incidence of vomiting in cats pre-medicated with dexmedetomidine and buprenorphine." | 5.15 | A randomized, blinded, controlled trial of the antiemetic effect of ondansetron on dexmedetomidine-induced emesis in cats. ( Basher, KL; Erb, HN; Kirch, P; Ludders, JW; Martin-Flores, M; Santos, LC, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 5.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 5.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "Tramadol, a central analgesic acting on serotonin neurotransmission, is often co-used with ondansetron, a 5-HT(3) antagonist, for the management of postoperative pain to decrease nausea and vomiting." | 5.15 | Co-administration of ondansetron decreases the analgesic efficacy of tramadol in humans. ( Assunção, J; Fontes-Ribeiro, C; Oliveira, F; Pereira, F; Vale, C, 2011) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 5.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 5.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 5.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis." | 5.14 | Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. ( Sertdemir, Y; Yildizdas, RD; Yilmaz, HL, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with ondansetron/dexamethasone (ond/dex) for the prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera ( Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J, 2009) |
| "The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy." | 5.14 | Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. ( Blackburn, LM; Gridelli, C; Haiderali, AM; Lykopoulos, K; Russo, MW, 2010) |
| " The neurokinin-1 antagonist casopitant or its placebo was administered cyclically with ondansetron and dexamethasone in two randomized chemotherapy-induced nausea and vomiting clinical trials in nearly 3000 subjects." | 5.14 | The evaluation of drug rechallenge: the casopitant Phase III program. ( Abissi, CJ; Hunt, CM; Papay, JI; Rich, DS; Russo, MW, 2010) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 5.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "Palonosetron and ondansetron are two selective 5-hydroxytryptamine (5-HT3) receptor antagonists that have shown remarkable efficacy in controlling nausea and vomiting following administration of moderately emetic anticancer chemotherapy." | 5.14 | Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. ( Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S, 2010) |
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 5.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 5.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 5.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "We hypothesize that ondansetron will facilitate oral rehydration therapy in children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy." | 5.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea." | 5.13 | Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. ( Braude, D; Crandall, C, 2008) |
| " We evaluated the effects of oral ondansetron disintegrating tablets (ODT) on the incidence of at-home emesis in children undergoing tonsillectomy with and without adenoidectomy and with and without bilateral myringotomy and tube insertion." | 5.13 | The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery. ( Boretsky, KR; Davis, PJ; Fedel, GM; Fertal, KM; Gurnaney, H; Hoffmann, PC; Ingram, MD; Woelfel, SK; Young, MC, 2008) |
| "We investigate the effect of ondansetron on the incidence of vomiting in children who receive intravenous (IV) ketamine for procedural sedation and analgesia in the emergency department (ED)." | 5.13 | Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. ( Bajaj, L; Langston, WT; Roback, MG; Wathen, JE, 2008) |
| "In the present phase II randomized study, two different schedules of ondansetron were investigated as rescue antiemetic treatment for delayed emesis related to moderately emetogenic chemotherapy (MEC)." | 5.13 | Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. ( Bria, E; Carbone, I; Ciccarese, M; Cognetti, F; Fabi, A; Giannarelli, D; Metro, G; Nuzzo, CM; Russillo, M; Savarese, A; Sperduti, I, 2008) |
| "To compare the efficacy of prophylactic ondansetron and tropisetron for postoperative nausea and vomiting (PONV)." | 5.12 | Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: A meta-analysis of randomized controlled trials. ( Chen, Y; Song, X; Wang, J; Wang, N; Wang, R, 2021) |
| "5 mg, nausea and vomiting were relieved at one hour in 74% and 68%, respectively, compared with 59% for intravenous ondansetron 4 mg." | 5.12 | No more than necessary: safety and efficacy of low-dose promethazine. ( Caldwell, JB; Moser, JD; Rhule, FJ, 2006) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 5.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| "In children with gastroenteritis and dehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department." | 5.12 | Oral ondansetron for gastroenteritis in a pediatric emergency department. ( Adler, M; Freedman, SB; Powell, EC; Seshadri, R, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 5.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "This pivotal phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)." | 5.12 | A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F, 2006) |
| "To evaluate the effectiveness of prophylactic dexamethasone for the control of radiation induced emesis (RIE) when added to ondansetron during days 1 to 5 of fractionated radiotherapy." | 5.12 | 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). ( Ackerman, I; Brundage, M; Chabot, P; Ding, K; Fortin, A; Fyles, A; McKenzie, M; Nabid, A; Pater, J; Paul, N; Souhami, L; Whitehead, M; Wilke, D; Wilson, D; Wong, RK, 2006) |
| "In children with dehydration secondary to vomiting from acute viral gastritis, ondansetron with intravenous rehydration improves tolerance of oral fluids after two hours and reduces the hospital admission rate when compared with intravenous rehydration with or without dexamethasone." | 5.12 | Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. ( Brown, KM; Brown, LH; Reilly, TH; Secreti, L; Stork, CM, 2006) |
| " Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss." | 5.12 | Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. ( Ai, B; Dong, M; Han, X; He, X; Huang, D; Liu, P; Shi, Y; Yang, S; Zhang, C; Zhou, S, 2007) |
| "We compared the efficacy of inhaled isopropyl alcohol (IPA) with ondansetron for the control of postoperative nausea and vomiting (PONV) during a 24-hour period in 100 ASA class I-III women undergoing laparoscopic surgery." | 5.12 | A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. ( Cotton, JW; Hood, RR; Pellegrini, JE; Rowell, LR, 2007) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 5.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "To evaluate the antiemetic effect of a single dose of ondansetron and dexamethasone as a prophylaxis for chemotherapy induced acute nausea and emesis and factors associated with the control of acute nausea and emesis." | 5.12 | Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. ( Manusirivithaya, S; Pradermdee, P; Sukwattana, P; Tangjitgamol, S; Thavaramara, T, 2006) |
| "All consecutive chemotherapy-naive patients enrolled onto study were randomly assigned to receive for the prevention of acute emesis, during the first 24 hours, one of the following dexamethasone regimens, in combination with ondansetron 8 mg intravenously (i." | 5.11 | Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. ( , 2004) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 5.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "This study in volunteers has shown that betamethasone does not prevent nausea and vomiting induced by oral intake of ipecacuanha syrup." | 5.11 | Betamethasone does not prevent nausea and vomiting induced by ipecacuanha. ( Axelsson, P; Thörn, SE; Wattwil, M, 2004) |
| "5-HT3 receptor antagonists, including granisetron and ondansetron, are widely used in the prophylactic treatment of chemotherapy-induced nausea and vomiting." | 5.11 | The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. ( Buyukavci, M; Ceviz, N; Olgun, H, 2005) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 5.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 5.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "The current analysis of > 1000 patients from 2 large randomized trials showed that in the subpopulation at increased risk of chemotherapy-induced nausea and vomiting due to concomitant emetogenic chemotherapy, the addition of aprepitant to standard antiemetics improved protection to an even greater extent than in the general study population." | 5.11 | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize ( Carides, AD; de Wit, R; Evans, JK; Gralla, RJ; Guoguang-Ma, J; Herrstedt, J; Horgan, KJ; Ianus, J, 2005) |
| " Overall nausea and vomiting were significantly lower in the ondansetron prophylaxis group than in the group without prophylaxis (52." | 5.11 | Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis. ( Baublys, A; Ivaskevicius, J; Kontrimaviciute, E, 2005) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 5.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "Although the L-758,298 and dexamethasone combination reduced acute (Day 1) emesis compared with historic rates, dual therapy with ondansetron and dexamethasone was superior in controlling acute emesis." | 5.10 | Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. ( Brestan, E; Bui, B; Carides, AD; De Smet, M; Decramer, ML; Eldridge, K; Evans, JK; Garin, AM; Gertz, BJ; Lichinitser, MR; Michiels, N; Navari, RM; Reinhardt, RR; Riviere, A; Thant, M; Van Belle, S, 2002) |
| "To study the enhancement by dexamethasone of the effect of ondansetron and tropiesetron against postoperative nausea and vomiting (PONV) in patients receiving patient-controlled analgesia (PCA) and observe the effect of dexamethasone on wound healing." | 5.10 | [Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia]. ( Liu, HF; Lu, ZH; Sheng, PT; Wang, C; Wang, LY; Xiong, LZ; Xu, N; Yang, XY, 2002) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 5.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| "In this study, the efficacy and safety of intravenous administration of droperidol followed by oral use of dimenhydrinate did not differ from that of intravenous followed by oral use of ondansetron in children undergoing strabismus surgery." | 5.10 | Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery. ( Bussières, JF; Caron, E; Jacob, JL; Lebel, D; Lortie, L; Mathews, S; Milot, J; Moride, Y, 2003) |
| "To study if acupuncture, combined with ondansetron treatment, reduces nausea and vomiting associated with cyclophosphamide infusion in patients with rheumatic diseases." | 5.10 | Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. ( Josefson, A; Kreuter, M, 2003) |
| " In the present study, the Functional Living Index-Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant)." | 5.10 | Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. ( Cai, B; Carides, AD; Chawla, SP; Elmer, M; Grunberg, SM; Horgan, K; Martin, AR; Pearson, JD; Schmidt, C, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 5.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 5.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 5.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 5.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "Antiemetic treatment with tropisetron or ondansetron could be improved by adjustment for the CYP2D6 genotype; approximately 50 subjects would have to be genotyped to protect one patient from severe emesis." | 5.10 | Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. ( Bauer, S; Brockmöller, J; Kaiser, R; Papies, A; Possinger, K; Roots, I; Schelenz, C; Sezer, O; Tremblay, PB, 2002) |
| "Although combination antiemetics prevent vomiting during the initial 24 h after high-dose (> or =100 mg/m2) cisplatin, many patients experience delayed emesis 24-120 h afterwards despite receiving prophylactic dexamethasone and metoclopramide during this time." | 5.09 | Oral cisapride for the control of delayed vomiting following high-dose cisplatin. ( Baltzer, L; Grant, SC; Hinckley, L; Kris, MG; Miller, VA; Pisters, KM; Pizzo, BA, 1999) |
| " If postoperative nausea or vomiting persisted after three sequences, intravenous ondansetron was administered as rescue therapy." | 5.09 | An alternative method to alleviate postoperative nausea and vomiting in children. ( Hofstadter, MB; Kain, ZN; Wang, SM, 1999) |
| "This randomized, double-masked, placebo-controlled, multicenter trial was conducted in 9 countries to assess the safety and efficacy of 2 doses of intravenous ondansetron (8 and 16 mg) for the control of opioid-induced nausea and vomiting." | 5.09 | Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. ( Allegra, J; Ames, M; Creed, MR; Ducharme, J; Ferrer-Brechner, T; Foster, E; Grafstein, E; Larsen, LS; Montgomery, R; Noll, D; Ortenwall, P; Patel, V; Ramalanjaona, G; Schreck, D; Shurman, J; Sussman, G, 1999) |
| "The purpose of the present study was to examine whether its is possible to successfully replace ondansetron (OND) with metoclopramide (MCP) in patients exposed to moderately emetogenic chemotherapy who did not experience severe nausea and vomiting while undergoing OND treatment during their first chemotherapy cycle." | 5.09 | Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy. ( Athanasiou, E; Dimitrakopoulos, A; Katsikas, M; Koufos, C; Linardaki, G; Tsavaris, NB, 1999) |
| "A double-blind randomized comparison (protocol S3AB4003, Glaxo Wellcome, Great Britain) carried out in a group of 52 children showed that the 5-HT3-receptor antagonist ondansetron (in syrup) effectively prevented vomiting, nausea and loss of appetite caused in combination chemotherapy with highly- or moderately emetogenic cytostatic drugs in 92." | 5.09 | [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. ( Gershanovich, ML; Kolygin, BA; Punanov, IuA; Safonova, SA, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 5.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "We aimed to evaluate the antiemetic efficacy, safety, and clinical utility of prophylactic ondansetron administered at the end of the surgery for the prevention of postoperative nausea and vomiting (PONV) in a homogenous population of 54 women undergoing modified radical mastectomy (MRM)." | 5.09 | The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. ( Kannan, TR; Kathirvel, S; Mohan, V; Sadhasivam, S; Saxena, A; Trikha, A, 1999) |
| "To assess the efficacy and safety of intravenous ondansetron (4 mg) for the prevention of nausea and vomiting after middle ear surgery under local anesthesia." | 5.09 | Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia. ( Ku, PK; Lo, P; Tong, MC; van Hasselt, CA, 2000) |
| "The purpose of this study was to compare the antiemetic efficacy of three 5-HT3 antagonists (granisetron, ondansetron, tropisetron) plus dexamethasone for the prevention of acute emesis induced by high-dose cisplatin chemotherapy." | 5.09 | Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. ( Chan, R; Chua, DT; Foo, YC; Kwok, CC; Kwong, DL; Sham, JS; Yue, A, 2000) |
| "The efficacy of an intravenous 5-HT3 antagonist (granisetron) and four oral 5-HT3 antagonists (granisetron, ondansetron, tropisetron and ramosetron) on chemotherapy-induced emesis were investigated in 21 gynecologic cancer patients (63 courses)." | 5.09 | [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]. ( Akutagawa, N; Ishioka, S; Ito, E; Kiya, T; Kudo, R; Sagae, S; Saito, T; Sugimura, M; Umemura, K, 2000) |
| " All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy (acute emesis)." | 5.09 | Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. ( , 2000) |
| "The purpose of this study was to develop a cost-effective prophylactic antiemetic regimen for the prevention of carboplatin-induced emesis." | 5.09 | The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 2000) |
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 5.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 5.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 5.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| " dexamethasone had comparable antiemetic efficacy for the prevention of nausea in the first 24-hour period after initiation of chemotherapy compared with intravenous ondansetron plus i." | 5.09 | Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. ( Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tzeng, WF; Wang, WS; Yen, CC, 2000) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| " There was a statistically significant decrease in the chance of vomiting with increasing dose of ondansetron (P=0." | 5.09 | A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children. ( Booker, PD; Bowhay, AR; May, HA; Rudnicka, AR, 2001) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 5.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| " Ondansetron was given either before or after cisplatin to control nausea and vomiting." | 5.09 | Cisplatin-induced vomiting depends on circadian timing. ( Fujimura, A; Kobayashi, E; Kobayashi, M; To, H; Tokue, A, 2001) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 5.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "A prospective double-blind study was conducted to compare the anti-emetic efficacy of ondansetron and droperidol in preventing postoperative emesis following strabismus surgery." | 5.08 | A double-blind randomized prospective study comparing ondansetron with droperidol in the prevention of emesis following strabismus surgery. ( Davis, A; Krige, S; Moyes, D, 1995) |
| " In a double-blind manner, the effects of ondansetron, droperidol, and placebo on the incidence of emesis, postanesthesia care unit stay, and hospital discharge time were evaluated in children undergoing dental surgery." | 5.08 | Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery. ( Davis, PJ; Hoffmann, P; Landsman, I; Maloney, K; McGowan, FX, 1995) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 5.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "A single IV dose of either 8, 24, or 32 mg of ondansetron combined with a single 20-mg IV dose of dexamethasone resulted in good control of acute emesis across a wide spectrum of chemotherapy regimens." | 5.08 | Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. ( Beck, T; Cohen, JR; Griffen, D; Hainsworth, JD; Harker, WG; Hesketh, PJ; Kessler, JF; Kris, MG; Lester, E; Uhlenhopp, M, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To compare ondansetron and domperidone for treatment of delayed nausea/vomiting (DN/V) following highly emetogenic chemotherapy, after attaining total suppression of emesis on the day of chemotherapy by mean of ondansetron (combined with dexamethasone in the case of cisplatin-treated patients)." | 5.08 | Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. ( Borm, JJ; Esseboom, EU; Rojer, RA; Statius van Eps, LW, 1995) |
| "Ondansetron and droperidol are both effective in the prevention of postoperative nausea and vomiting (PONV)." | 5.08 | Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery. ( Altrock, K; Diefenbach, C; Grond, S; Lehmann, KA; Lynch, J, 1995) |
| "Ondansetron has had a major impact on the prevention of emesis in patients receiving chemotherapy." | 5.08 | A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. ( Dranitsaris, G; Puodziunas, A; Warr, D, 1995) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 5.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To investigate the efficacy and safety of oral ondansetron in the control of cisplatin-induced delayed emesis in patients who do not require rescue antiemetic therapy for acute emesis." | 5.08 | Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. ( Anderson, N; Beck, TM; Caldwell, KC; Chang, AY; Garewal, H; Greenberg, B; Madajewicz, S; Navari, RM; Tchekmedyian, NS; Whaley, W, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 5.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "To compare the effectiveness of ondansetron with droperidol in preventing postoperative emesis in children after strabismus repair." | 5.08 | Prevention of emesis after strabismus repair in children: a prospective, double-blinded, randomized comparison of droperidol versus ondansetron. ( Griswold, JD; Lee, A; Litman, RS; Marshall, C; Voisine, R; Wu, CL, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 5.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 5.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " Effective prophylaxis for postoperative nausea and vomiting can be achieved in adults with lower doses of ondansetron, a 5-hydroxytryptamine subtype 3 receptor antagonist, compared with chemotherapy-induced emesis." | 5.08 | The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. ( Bras, PJ; Cieslak, GD; Pennant, JH; Watcha, MF, 1995) |
| "In a randomised, placebo-controlled trial we have compared the efficacy of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia after orthopaedic surgery." | 5.08 | Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. ( Alexander, R; Jones, RM; Lovell, AT; Seingry, D, 1995) |
| "Ondansetron 8mg and granisetron 3 mg, both combined with dexamethasone, showed similar efficacy and tolerability in the prevention of cisplatin-induced emesis." | 5.08 | Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. ( , 1995) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 5.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "We performed a prospective, single arm, observational study examining the effectiveness of the 5HT3 receptor antagonist ondansetron in the management if nausea and vomiting associated with acetaminophen poisoning." | 5.08 | The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. ( Chen, R; Clark, RF; Harchelroad, F; Johnson, CL; Williams, SR, 1996) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 5.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 5.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "The aim of this study was to compare the efficacy and safety of ondansetron plus droperidol with each drug alone or placebo in the prevention of postoperative nausea and vomiting (PONV)." | 5.08 | Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. ( Carrascosa, F; García-Pedrajas, F; Iribarren, MJ; Lopez, L; Pueyo, FJ; Saez, A, 1996) |
| " Patients received one of four regimens for the prevention of postoperative nausea and vomiting (PONV): ondansetron 4 mg (n = 25), dexamethasone 8 mg (n = 25), ondansetron with dexamethasone (4 mg and 8 mg, respectively, n = 25) or placebo (saline, n = 25) There were no differences in background factors or factors related to operation and anaesthesia, morphine consumption, pain or side effects between groups." | 5.08 | Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. ( Busto, N; Carrascosa, F; López-Olaondo, L; Monedero, P; Pueyo, FJ; Sáez, A, 1996) |
| "Two large randomized, double-blind, placebo-controlled studies with an appropriate study design have been conducted to fully evaluate the efficacy of ondansetron in the control of cisplatin-induced delayed emesis." | 5.08 | 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. ( Anderson, E; Freeman, A; Ossi, M, 1996) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 5.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "Both intravenous ondansetron (OND) and droperidol (DROP) have been observed to reduce vomiting after tonsillectomy in children." | 5.08 | Ondansetron is a better prophylactic antiemetic than droperidol for tonsillectomy in children. ( Baxter, MR; Gould, HM; Hall, LE; MacNeill, HB; Rhine, EJ; Roberts, DW; Splinter, WM, 1995) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 5.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| " This randomized, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of ondansetron in the control of established postoperative emesis in outpatients aged 2-12 yr." | 5.08 | Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group. ( Creed, M; Ginsberg, B; Grunwald, Z; Kaye, R; Khalil, S; Lawhorn, CD; Otto, A; Prillaman, BA; Rodarte, A; Weinstein, M; Weldon, BC; Wheeler, M, 1996) |
| "To compare the incidence of vomiting following codeine or ketorolac for tonsillectomy in children." | 5.08 | Preoperative ketorolac increases bleeding after tonsillectomy in children. ( MacNeill, HB; Reid, CW; Rhine, EJ; Roberts, DW; Splinter, WM, 1996) |
| "The efficacy of ondansetron 4 mg and 8 mg was compared with placebo in the reduction of postoperative nausea, retching and vomiting (PONV) after middle ear surgery during general anaesthesia, in 75 patients, in a double-blind and randomized study." | 5.08 | Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. ( Honkavaara, P, 1996) |
| "This study has compared the incidences of nausea, vomiting and headache after ondansetron 0." | 5.08 | Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. ( van den Berg, AA, 1996) |
| "The new antiemetic ondansetron is effective for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), but has been subject to limited comparative evaluation in surgical inpatients." | 5.08 | Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. ( Evans, SF; Paech, MJ; Pavy, TJ, 1995) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 5.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 5.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "67% of patients given ondansetron had complete control of emesis compared with 45% of patients with placebo (P < 0." | 5.08 | A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. ( Franzén, L; Hagberg, H; Henriksson, R; Jakobsson, M; Lomberg, H; Nyman, J; Nyth, AL; Sorbe, B, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 5.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "The efficacy of ondansetron and droperidol were evaluated for prophylactic treatment of nausea and vomiting in cesarean section patients under epidural anesthesia." | 5.08 | Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. ( Moore, CH; Pan, PH, 1996) |
| "This study determined the overall incidence of postoperative nausea and vomiting (PONV) in 38 patients undergoing laparoscopic gynaecological procedures who received a standardized propofol/isoflurane anaesthetic but no preoperative antiemetic." | 5.08 | A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy. ( Watts, SA, 1996) |
| "To compare the antimetic efficacy of prophylactic ondansetron, metoclopramide, and placebo for prevention of postoperative vomiting in pediatric tonsillectomy or adenotonsillectomy patients." | 5.08 | Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. ( Bohnsack, LE; Bostrom, BC; Seay, RE; Stene, FN; Young, LA, 1996) |
| "Propofol administered to induce and maintain anesthesia is more effective than ondansetron (with thiopental-isoflurane anesthesia) in preventing postoperative vomiting and is associated with fewer requests for rescue antiemetic and sedation in the early phase of recovery." | 5.08 | Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. ( Gan, TJ; Ginsberg, B; Glass, PS; Grant, AP, 1996) |
| "To determine (1) the efficacy and safety of ondansetron in the prevention of postoperative nausea and vomiting (PONV) in male outpatients; (2) prognostic factors for PONV in male outpatients; and (3) patients' perceptions of the debilitating effects of PONV in the ambulatory surgery setting." | 5.08 | Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group. ( Cox, F; Joslyn, AF; Khalil, SN; Kovac, AL; Pearman, MH; Prillaman, BA; Scuderi, PE, 1996) |
| "Efficiency of ondansetron, a selective 5-HT3 receptor antagonist, in prevention of postoperative nausea and vomiting in 40 ASA I-II patients who will undergo emergency intraabdominal operations is studied in a randomized double-blind and placebo controlled study." | 5.08 | Prophylactic administration of ondansetron in emergency intraabdominal operations. ( Aktürk, G; Albayrak, D; Kalaç, N; Lüleci, N; Ulusoy, HO, 1996) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 5.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| "A randomized, double-blind, placebo-controlled study was designed to compare the relative efficacy of prophylactic ondansetron, 4 mg intravenously (IV), when administered before induction of anesthesia or at the end of surgery to an outpatient population at high risk of developing postoperative nausea and vomiting (PONV)." | 5.08 | The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. ( Klein, KW; Sun, R; White, PF, 1997) |
| "In a prospective, randomised, double-blind trial, we assessed the relative efficacy of prophylactic ondansetron and metoclopramide administration in the reduction of postoperative nausea and vomiting in 60 patients undergoing routine major neurosurgical procedures." | 5.08 | A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures. ( Barsoum, LZ; Jones, NC; Pugh, SC, 1996) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 5.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "The hypothesis that the addition of dexamethasone to the propofolondansetron combination would significantly reduce postoperative nausea and vomiting (PONV) was not confirmed." | 5.08 | Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. ( Hamilton, DL; McKenzie, R; Riley, TJ; Tantisira, B, 1997) |
| "Efficiency of ondansetron, a selective 5- HT3 receptor antagonist, in prevention of postoperative nausea and vomiting in 40 ASA I-II patients to undergo emergency intraabdominal operations is studied in a randomized, double-blind and placebo controlled study." | 5.08 | Prophylactic administration of ondansetron in emergency intraabdominal operations. ( Aktürk, G; Albayrak, D; Kalaç, N; Lüleci, N; Ulusoy, HO, 1997) |
| "To assess the efficacy of 4 mg of intravenous ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV) in cholecystectomy, a type of surgery that is highly emetic." | 5.08 | [Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy]. ( Cabrera, JC; Castaño, J; Castillo, J; Escolano, F; Matute, E; Santiveri, X, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 5.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "Twenty-nine patients with gynecologic malignancies were treated with a fixed low dose of intravenous ondansetron (8 mg) plus dexamethasone (20 mg) in an effort to develop an effective and less expensive antiemetic regimen for the control of carboplatin-induced emesis." | 5.08 | Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 5.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "This randomized, double-blind study assessed the impact of two different doses of intraoperative ondansetron on vomiting following tonsillectomy in 240 preadolescent children in a day care surgical setting." | 5.08 | Prophylactic antiemetics in children undergoing tonsillectomy: high-dose vs low-dose ondansetron. ( Rhine, EJ; Splinter, WM, 1997) |
| "To compare the efficacy in the treatment of post-operative nausea and/or vomiting (PONV), 75 patients undergoing gynaecological procedures under general anaesthesia using N2O/enflurane who suffered from PONV in the first hour after surgery were randomly allocated to three groups containing 25 patients each to receive either alizapride 100 mg, droperidol 1 mg or ondansetron 8 mg (i." | 5.08 | Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea. ( Bovill, JG; de Bont, LE; el-Mofty, M; Samhan, YM; Stienstra, R, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 5.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| " Experimental investigations show that orally it is rapidly absorbed (about 90 min), is highly bioavailable (greater than 90%), has a long half-life (about 12 h) and is more potent (about 10 times) in animal models than ondansetron, currently standard therapy for the prophylactic control of chemotherapy induced nausea and vomiting." | 5.08 | Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. ( Egerer, G; Goldschmidt, H; Kempe, R; Salwender, H; Voigt, T, 1997) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 5.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 5.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 5.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "In this study the antiemetic effects of droperidol, ondansetron and their combination were evaluated in 160 ASA Grade I and II children undergoing surgery for strabismus, who were randomly assigned to one of four groups: Group D received droperidol 75 micrograms kg-1, group O ondansetron 0." | 5.08 | Ondansetron, droperidol and their combination for the prevention of post-operative vomiting in children. ( Braun, U; Klockgether-Radke, A; Mühlendyck, H; Neumann, P; Neumann, S, 1997) |
| "To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to evaluate the efficacy when dexamethasone is added to either drug in the first 24 hours; and to extend these comparisons over 7 days in patients receiving moderately emetogenic chemotherapy." | 5.08 | Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. ( Chin, C; Dempsey, E; Guevin, RM; Hainsworth, J; Hoskins, P; Krook, JE; Lofters, WS; Moquin, JP; Navari, R; Palmer, M; Pater, JL; Verma, S; Walde, D; Wilson, K; Zee, B, 1997) |
| "Intravenous dolasetron mesilate has shown efficacy in the prevention of postoperative nausea and vomiting (PONV) when administered as a single dose prior to emergence from anesthesia." | 5.08 | Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. ( Brown, R; Clergue, F; Feiss, P; Hahne, W; Korttila, K; Leeser, J; Nave, S; Olthoff, D; Payeur-Michel, C; Wessel, P, 1997) |
| "To compare the prophylactic administration of ondansetron with droperidol or placebo to determine its effectiveness in reducing postoperative nausea and vomiting after middle ear procedures." | 5.08 | Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. ( Fluter, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1997) |
| " The purpose of this study was to compare the efficacy of ondansetron, a highly selective 5-hydroxytryptamine subtype-3 receptor antagonist, with that of metoclopramide for the prevention of postoperative emesis in patients undergoing cataract surgery." | 5.08 | Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. ( Ascaso, FJ; Ayala, I; Carbonell, P; Castro, FJ; Palomar, A, 1997) |
| "1 mg/kg to 4 mg intravenously) compared with placebo in the prevention of postoperative vomiting in 429 ASA status I-III children 1-12 yr old undergoing outpatient surgery under nitrous oxide- and halothane-based general anesthesia." | 5.08 | Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. ( Cohen, IT; Colingo, K; Creed, MR; Davis, PJ; Donlon, JV; Ferrari, LR; Haberkern, CM; Hannallah, RS; McGowan, FX; Orr, RJ; Parasuraman, TV; Patel, RI; Prillaman, BA; Rimar, S, 1997) |
| "To investigate the incidence of postoperative nausea and vomiting (PONV) depending on the administration time of ondansetron." | 5.08 | [Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients]. ( Kainzwaldner, A; Ploner, F, 1997) |
| "To compare the efficacy of ondansetron, droperidol, or metoclopramide with placebo in preventing postoperative vomiting following strabismus surgery." | 5.08 | A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children. ( Elliott, WG; James, RL; Mims, G; Scuderi, PE; Weaver, RG; Weeks, DB, 1997) |
| "To compare the efficacy of two antiemetic regimens, ondansetron alone versus perphenazine with diphenhydramine, on emesis control in children undergoing conditioning therapy for bone marrow transplantation (BMT)." | 5.08 | Controlling conditioning-related emesis in children undergoing bone marrow transplantation. ( Kuhlman, C; Mehta, NH; Parsons, SK; Reed, CM; Weinstein, HJ, 1997) |
| " Combination of corticosteroids with ondansetron enables greater control of emesis than that obtained with ondansetron alone, but some patients still experience symptoms." | 5.08 | The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. ( d'Allens, H; Depierre, A; Giovannini, M; Hédouin, M; Kaluzinski, L; Lebeau, B; Rivière, A; Votan, B, 1997) |
| "Patient functional status after administration of either granisetron or ondansetron to prevent acute chemotherapy-induced nausea and vomiting (CINV) was studied." | 5.08 | Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. ( Bernstein, G; Colgan, K; Dempsey, CL; Farley, PA; Kulis-Robitaille, C; Shillington, AA, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 5.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "The proportion of patients with nausea was 48%, 50% and 67% in the ondansetron, droperidol and placebo groups, respectively; with a significant difference when both ondansetron (P=0." | 5.08 | Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. ( Alahuhta, S; Koivuranta, M; Läärä, E; Ranta, P; Ravaska, P, 1997) |
| "To establish a dose-response relationship for ondansetron, and to evaluate any effects of oral premedication with metoclopramide in pediatric patients undergoing tonsillectomy and adenoidectomy and strabismus surgery." | 5.08 | Ondansetron dose response curve in high-risk pediatric patients. ( Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997) |
| "Low-dose ondansetron plus dexamethasone is an effective prophylactic antiemetic combination for children undergoing strabismus surgery." | 5.08 | Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron. ( Rhine, EJ; Splinter, WM, 1998) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 5.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 5.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| " bolus dose of ondansetron 4 mg were evaluated in the prevention of postoperative nausea and vomiting (PONV), which remains one of the most unpleasant side effects experienced by patients postoperatively." | 5.08 | Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis. ( De Guchteneere, E; Hendrickx, P; Levarlet, M; Moens, P, 1997) |
| "To investigate the hypothesis that the combination of ondansetron and droperidol would be more effective than droperidol alone in reducing nausea and vomiting." | 5.08 | Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy. ( Hamilton, DL; McKenzie, R; Riley, TJ; Trantisira, BR, 1998) |
| "Children (3-16 yr) undergoing elective strabismus surgery as inpatients were randomly allocated to four anaesthetic techniques: (A) thiopentone induction and isoflurane maintenance; (B) as (A) plus ondansetron 5 mg x m(-2) i." | 5.08 | Oculocardiac reflex and postoperative vomiting in paediatric strabismus surgery. A randomised controlled trial comparing four anaesthetic techniques. ( Fuchs-Buder, T; Rifat, K; Sansonetti, A; Tramèr, MR, 1998) |
| "05 mg kg(-1) +droperidol 20 microg kg(-1) was given as prophylaxis for postoperative pain and emesis, respectively." | 5.08 | Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy. ( Aasbø, V; Buanes, T; Grøgaard, B; Mjåland, O; Raeder, JC, 1998) |
| "More than 2000 patients at high risk of postoperative nausea and vomiting were given either placebo, ondansetron 4 mg, or droperidol 0." | 5.08 | A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. ( Creed, MR; Duncan, B; Fortney, JT; Gan, TJ; Glass, PS; Graczyk, S; Khalil, S; McKenzie, R; Melson, T; Moote, C; Parasuraman, TV; Parrillo, S; Wermeling, D; Wetchler, B, 1998) |
| "We have compared the effects of ondansetron and perphenazine on vomiting after tonsillectomy in 216 healthy children, aged 2-12 yr." | 5.08 | Prophylaxis for vomiting by children after tonsillectomy: ondansetron compared with perphenazine. ( Rhine, EJ; Splinter, WM, 1998) |
| "This study compares the preoperative administration of ondansetron with that of droperidol or saline solution for the prevention of nausea and vomiting in otologic surgery patients." | 5.08 | Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery. ( Fluder, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1998) |
| "A double-blind randomized crossover trial was performed to compare the antiemetic efficacy of two 5-HT3 receptor antagonists, granisetron and ondansetron, in Chinese patients receiving adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) for breast cancer." | 5.08 | Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. ( Chow, LW; Poon, RT, 1998) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 5.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "To determine the dose-response relationship of ondansetron in preventing postoperative nausea and vomiting (PONV) in women undergoing elective surgery." | 5.08 | A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. ( Chang, Y; Conant, JA; Connors, PM; Dershwitz, M; Rosow, CE, 1998) |
| "To compare the prophylactic administration of ondansetron plus droperidol, droperidol plus metoclopramide, and perphenazine to determine effects on postoperative nausea, vomiting, and sedation after laparoscopic cholecystectomy." | 5.08 | Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide. ( Freiberger, D; Gosnell, JL; Steinbrook, RA, 1998) |
| " The present study was aimed at determining (1) if pressure pain detection thresholds (PDT) varied dynamically with the primary disease symptoms of binge eating and vomiting and (2) if the elevation in PDT was effected by treatment with ondansetron (ONDAN), a 5-HT3 receptor antagonist." | 5.08 | Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. ( Eckert, ED; Faris, PL; Goodale, RL; Hartman, BK; Hofbauer, RD; Howard, LA; Meller, WH; Oakman, SA; Stevens, ER; Won Kim, S, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 5.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 5.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "The aim of this study was to determine the mechanism of action of radiation-induced emesis by determining the incidence of radiation-induced emesis following hemibody irradiation; the effects of specific antiemetics especially ondansetron, a 5-hydroxytryptamine receptor antagonist, and to determine the relationship between radiation-induced emesis and serotonin (5-hydroxytryptamine) through its active metabolite, 5-hydroxyindoleacetic acid (5-HIAA)." | 5.07 | On the mechanism of radiation-induced emesis: the role of serotonin. ( Anderson, RF; Hoffman, LG; Ornitz, RD; Scarantino, CW, 1994) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following minor oral surgery was evaluated in a prospective randomized double-blind study." | 5.07 | Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study. ( Campbell, RC; Chow, J; Hui, E; Lueveswanij, S; Rodrigo, MR; Tong, CK, 1994) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 5.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Ondansetron in the prophylaxis of Cisplatin-induced emesis and nausea." | 5.07 | Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. ( Chakrapee-Sirisuk, S; Cheirsilpa, A; Chindavijak, K; Lousoontornsiri, W; Ratanatharathorn, V; Sinlarat, P; Srimuninimit, V, 1994) |
| " Acetaminophen and meperidine were given for postoperative pain." | 5.07 | Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. ( Furst, SR; Rodarte, A, 1994) |
| "Oral ondansetron is an effective therapy for the prevention of emesis induced by TBI." | 5.07 | Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. ( Bryson, JC; Cirenza, E; Dubois, A; Foelber, R; Kunka, RL; Plagge, PB; Spitzer, TR; Stout, C; Wallerstadt, M, 1994) |
| "The purpose of our study was to evaluate the effectiveness of alprazolam (APZ) as an adjuvant drug to ondansentron against cisplatin-induced emesis." | 5.07 | Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy. ( Bacoyiannis, C; Charalambidis, G; Karabelis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 5.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "25 mg droperidol in preventing postoperative vomiting." | 5.07 | [Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol]. ( Alon, E; Atanassoff, PG; Biro, P; Lenzlinger, PM, 1994) |
| "Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting (PONV), but it has not been proved to be superior to established antiemetics for prophylaxis or therapy." | 5.07 | [Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients]. ( Heim, C; Listyo, R; Münzer, T, 1994) |
| "The purpose of this double-blind, randomized study was to compare the effectiveness of ondansetron plus saline versus ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting." | 5.07 | Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. ( Abdelhady, H; Karambelkar, DJ; McKenzie, R; Riley, TJ; Tantisira, B, 1994) |
| " dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i." | 5.07 | Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. ( , 1994) |
| "This prospective, randomized, placebo-controlled, double-blinded study evaluated the antiemetic efficacy of ondansetron and metoclopramide in 90 ASA physical status I or II children, 2-17 yr of age, undergoing strabismus repair." | 5.07 | Ondansetron reduces the incidence and severity of poststrabismus repair vomiting in children. ( Corddry, DH; Kettrick, RG; Martin, TM; Rose, JB; Zagnoev, M, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 5.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 5.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "We performed a double-blind, randomized, placebo-controlled trial to investigate the efficacy and safety of ondansetron in preventing vomiting after tonsillectomy with or without adenoidectomy in children." | 5.07 | Ondansetron decreases emesis after tonsillectomy in children. ( Catanzaro, FA; Litman, RS; Wu, CL, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 5.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2)." | 5.07 | A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. ( Beck, TM; Bricker, LJ; Hainsworth, JD; Haley, B; Harker, WG; Harvey, WH; Hesketh, PJ; Kish, JA; Murphy, WK; Ryan, T, 1994) |
| "In two placebo-controlled, double-blind, multicentre studies, the efficacy and safety of single oral doses of ondansetron 4 mg, 8 mg and 16 mg were evaluated for the prevention of postoperative nausea and vomiting in female inpatients." | 5.07 | Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups. ( Cohen, LA; Rust, M, 1994) |
| "Ondansetron, a selective 5-HT3 antagonist, has been shown to be effective in preventing chemotherapy-induced nausea and vomiting." | 5.07 | Use of oral and intravenous ondansetron in patients treated with cisplatin. ( Ang, PT; Au, E; Khoo, KS; Soh, LT, 1993) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 5.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 5.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 5.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 5.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy." | 5.07 | Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of ( Hoskins, P; Kaizer, L; Latreille, J; Levy, M; Lofters, W; Palmer, M; Pater, J; Warr, D; Yau, J; Zee, B, 1994) |
| "This prospective, randomized, double-blind study assessed whether the addition of dexamethasone to ondansetron leads to improved control of chemotherapy--induced emesis, both in patients undergoing their first course of highly emetogenic chemotherapy and in chemotherapy-pretreated patients refractory to standard anti-emetics." | 5.07 | Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). ( Aapro, MS; Bacchi, M; Buser, K; Joss, RA; Kirchner, V; Neuenschwander, H; Orth, B; Thürlimann, B, 1994) |
| "Ondansetron controls cisplatin-induced emesis when given in three 0." | 5.07 | Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2. ( Baltzer, L; Clark, RA; Kris, MG; Pisters, KM; Rigas, JR; Tyson, LB, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 5.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which has shown activity in the prevention of emesis following cytotoxic and radiation therapy for cancer." | 5.07 | Ondansetron for efficient emesis control during total body irradiation. ( König, V; Riess, H; Schmid, H; Schmidt-Wolf, I; Schwella, N; Schwerdtfeger, R; Siegert, W, 1994) |
| "We studied the efficacy and safety of intravenous ondansetron 4 mg for the prevention of postoperative nausea and vomiting after minor gynaecological laparoscopic surgery in Oriental women." | 5.07 | Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. ( Chen, PP; Critchley, LA; Gin, TA; Ray, AK; Rowbottom, YM; Suen, TK, 1994) |
| "Ondansetron plus dexamethasone was significantly more efficacious and better tolerated than metoclopramide plus dexamethasone and diphenhydramine during three cycles of chemotherapy and, in contrast to the metoclopramide regimen, the efficacy of ondansetron plus dexamethasone, at least for vomiting, is maintained in subsequent cycles." | 5.07 | Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research. ( , 1993) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 5.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "Vomiting was prevented in two thirds of patients treated with MDL plus ondansetron, a result similar to that observed in earlier trials of MDL alone." | 5.07 | The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. ( Baltzer, L; Kris, MG; Pisters, KM; Rigas, JR; Tyson, LB, 1994) |
| "Thirty-six consecutive patients, who were to be treated with cisplatin-based chemotherapy for testicular or bladder cancer, underwent a single-blind randomized study to compare the antiemetic therapies with dexamethasone (DEX)+ondansetron (OND) and DEX + alizapride (ALI)." | 5.07 | Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. ( Faustini, M; Mangiarotti, B; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R, 1993) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 5.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 5.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| "Ondansetron, a selective 5-HT3 antagonist, is known to be effective for preventing emesis induced by cisplatin and other antineoplastic agents." | 5.07 | Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. ( Bosi, A; Fanci, R; Guidi, S; Lombardini, L; Messori, A; Rossi-Ferrini, P; Saccardi, R; Vannucchi, AM, 1993) |
| "166 patients receiving moderately emetogenic chemotherapy were entered into a randomised prospective study in which the efficacy of single dose ondansetron 8 mg, tropisetron 5 mg and granisetron 3 mg in the prophylaxis of acute vomiting was evaluated." | 5.07 | 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. ( Flander, MK; Jantunen, IT; Kataja, VV; Muhonen, TT; Teerenhovi, L, 1993) |
| "The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study." | 5.07 | The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. ( Cunningham, D; Davidson, N; Gore, M; Manchanda, M; Miocevich, M; Wells, N, 1993) |
| " Patients were stratified by gender and received, in a randomized, double-blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively." | 5.07 | Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. ( Apfelbaum, J; Claybon, L; DuPen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1993) |
| "Data from the 544 women showed that all doses of intravenous ondansetron tested (1, 4, and 8 mg) were significantly more effective (62%, 76%, and 77%, respectively) than placebo (46%) in reducing the incidence of emesis following surgery until 24 h after recovery room entry." | 5.07 | Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. ( Angel, J; Duncalf, D; Gratz, I; Joslyn, A; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T; Tolpin, E, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following major gynaecological surgery was evaluated in this multicentre, double-blind study." | 5.07 | The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. ( Conseiller, C; Dupeyron, JP; Gribomont, B; Hemmingsen, C; Kaplan, LA; Levarlet, M; Pedersen, FM; Schoeffler, P, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 5.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The efficacy of ondansetron, a selective 5-HT3 receptor antagonist, in preventing postoperative nausea and vomiting in surgical patients was studied." | 5.07 | Ondansetron is effective in decreasing postoperative nausea and vomiting. ( Dershwitz, M; Di Biase, PM; Joslyn, AF; Rosow, CE; Sanderson, PE, 1992) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 5.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 5.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs." | 5.07 | [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 5.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Following a single intravenous dose given pre-chemotherapy, the efficacy and tolerability of oral ondansetron treatment given twice daily was compared with the established three times daily oral supplementary regimen in the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 5.07 | Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group. ( Bleiberg, H; Campora, E; Cunningham, D; Dicato, MA; Kaasa, S; Liebhard, A; Upadhyaya, BK; Vindevoghel, A; Warnier, P, 1992) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 5.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "In order to make an objective evaluation of anti-emetic effect, safety and usefulness of ondansetron injection in nausea and vomiting associated with cancer chemotherapy, we carried out a double-blind placebo controlled comparative study in patients receiving high-single dose (50 mg/m2 or more) of cisplatin." | 5.07 | [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron, a selective 5-HT3 receptor antagonist, has already been reported to have a marked effect to alleviate or prevent nausea and vomiting associated with cancer chemotherapy, after its intravenous administration." | 5.07 | [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Forty-seven patients receiving non-cisplatin-containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron plus dexamethasone and tropisetron plus dexamethasone in the prophylaxis of acute vomiting was evaluated." | 5.07 | Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. ( Jantunen, IT; Johansson, RT; Kataja, VV, 1992) |
| "The efficacy and safety of prophylactic intravenous ondansetron in preventing postoperative nausea and vomiting was investigated in a randomized, stratified, double-blind, placebo-controlled, dose-comparison study of 580 ASA physical class I and II female outpatients undergoing gynaecological surgery and receiving general anaesthesia." | 5.07 | Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. ( Angel, J; Duncalf, D; Fagraeus, I; Gratz, I; Joslyn, AF; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 5.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis." | 5.07 | Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. ( Beck, TM; Gandara, DR; Hainsworth, JD; Hesketh, PJ; Kish, JA; Lester, EP; Madajewicz, S; Murphy, WK; Navari, RM; Pendergrass, K, 1992) |
| " Costs, effects and cost-effectiveness of ondansetron in the prophylaxis of acute nausea and vomiting induced by chemotherapy are assessed relative to antiemetic therapy with metoclopramide." | 5.07 | Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. ( Buxton, MJ; O'Brien, BJ, 1992) |
| "In a phase II study including 80 patients treated with highly emetic drugs such as cisplatin, carboplatin or cyclophosphamide > 600 mg/day) we confirmed the potential of ondansetron to prevent cancer chemotherapy- related acute nausea and vomiting." | 5.07 | The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). ( Lelli, G; Martoni, A; Pannuti, F; Piana, E; Tanneberger, S, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 5.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 5.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| "Ondansetron, a serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving high-dose cisplatin is poorly controlled by ondansetron alone." | 5.07 | Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. ( Bagshawe, KD; Begent, RH; Howells, N; McQuade, B; Newlands, ES; Rustin, GJ; Smith, DB, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 5.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "The effect of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting was investigated in a randomized, double-blind, placebo-controlled study of 84 patients undergoing gynecologic operation and receiving the same general anesthetic." | 5.07 | Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. ( Leeser, J; Lip, H, 1991) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 5.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated patients." | 5.07 | Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. ( Amadori, D; Bella, MA; Cognetti, F; Cortesi, E; Donati, D; Favalli, G; Gramazio, V; Marangolo, M; Roila, F; Tonato, M, 1991) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 5.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "The safety and efficacy of ondansetron were evaluated for the treatment of postoperative nausea and vomiting after laparoscopic surgical procedures." | 5.07 | Antiemetic efficacy of ondansetron after outpatient laparoscopy. ( Bodner, M; White, PF, 1991) |
| "Ondansetron as a single agent has been shown to be superior to metoclopramide in the control of acute nausea and vomiting induced by high-dose cisplatin, complete or major control (0-2 emetic episodes) being achieved in 65-75% of patients." | 5.07 | Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research. ( Tonato, M, 1991) |
| " dose prechemotherapy, was compared with the established three times a day oral supplement regimen for the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 5.07 | Oral treatment with ondansetron in an outpatient setting. ( Dicato, MA, 1991) |
| "Ondansetron, a new 5-HT3 receptor antagonist, has been compared with high-dose metoclopramide in the control of acute emesis (24 h) induced by cisplatin (greater than or equal to 100 mg/m2)." | 5.07 | Progress in the control of acute and delayed emesis induced by cisplatin. ( Gandara, DR, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 5.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| "Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis." | 5.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 5.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 5.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 5.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| " The study was open, dose ranging, and noncomparative, and designed to evaluate safety and efficacy of ondansetron in preventing nausea and vomiting caused by cyclophosphamide intravenous (IV) 1,000 mg/m2 day 1, and cytarabine IV subcutaneously (SC) 75 mg/m2 on days 2 to 5." | 5.06 | Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. ( Carden, PA; Ekert, H; Mitchell, SL; Tiedemann, K; Waters, KD, 1990) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 5.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 5.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles." | 5.06 | [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron]. ( Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 5.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "Sixty five chemotherapy naive patients receiving cisplatin (50-120 mg/m2) containing chemotherapy participated in an evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and emesis." | 5.06 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. ( Bella, M; Bracarda, S; Cetto, G; Del Favero, A; Donati, D; Marangolo, M; Roila, F; Tonato, M, 1990) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 5.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| " Ondansetron revealed the largest effect in comparison to placebo for cessation of vomiting (odds ratio = 0." | 5.05 | Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. ( Acosta-Reyes, J; Florez, ID; Niño-Serna, LF; Veroniki, AA, 2020) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 5.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 5.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| "Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration." | 4.98 | Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management. ( Agostoni, C; Bianchetti, MG; Canziani, BC; Fossali, EF; Lava, SAG; Milani, GP; Uestuener, P, 2018) |
| "Compatibility of ondansetron offers a broad number of options to be used to avoid nausea and vomiting symptoms in patients with other concomitant medication." | 4.95 | Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review. ( Estan-Cerezo, G; Jiménez-Pulido, I; Matoses Chirivella, C; Navarro-Ruiz, A; Rodríguez Lucena, FJ; Soriano-Irigaray, L, 2017) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 4.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "To systematically update evidence on the effects of ondansetron (5-HT3 serotonin antagonist) for vomiting in children with acute gastroenteritis." | 4.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| " In postoperative nausea and vomiting (PONV), two randomized controlled trials found treatment with haloperidol comparable to ondansetron." | 4.89 | Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. ( Bennett, MI; Blenkinsopp, A; McLean, SL, 2013) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 4.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "Oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission." | 4.87 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Carter, B; Fedorowicz, Z; Jagannath, VA, 2011) |
| " Ondansetron (orally or intravenously) may be effective in decreasing the rate of vomiting, improving the success rate of oral hydration, preventing the need for i." | 4.86 | The management of children with gastroenteritis and dehydration in the emergency department. ( Barata, IA; Brown, KM; Colletti, JE; Ishimine, P; Sharieff, GQ, 2010) |
| "Based on the safety and efficacy of ondansetron, it may be used as a first-line agent for relief of nausea or vomiting for most patient populations in the ED." | 4.86 | Antiemetic therapy for nausea and vomiting in the emergency department. ( Amini, R; Hays, DP; Patanwala, AE; Rosen, P, 2010) |
| "Ondansetron and granisetron appear to be equivalent drugs for the prevention of acute and delayed emesis following the use of highly emetogenic chemotherapy." | 4.86 | Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. ( Billio, A; Clarke, MJ; Morello, E, 2010) |
| "The small number of included trials provided some limited evidence favouring the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.85 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Al-Hashimi, H; Alhashimi, D; Fedorowicz, Z, 2009) |
| " Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV)." | 4.84 | A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. ( Arnold, D; Grothey, A; Hinke, A; Jordan, K; Schmoll, HJ; Voigt, W; Wolf, HH, 2007) |
| "To investigate potential beneficial effects of ondansetron, compared with placebo or no intervention, in treating vomiting during acute gastroenteritis in children." | 4.84 | Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. ( Dylag, M; Gieruszczak-Białek, D; Szajewska, H, 2007) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "Granisetron (Kytril, Roche) is a 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin." | 4.82 | Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. ( Tan, M, 2003) |
| "Palonosetron (Aloxi) is a 5-HT(3)-receptor antagonist antiemetic indicated for the prevention of acute and delayed nausea and vomiting following moderately emetogenic chemotherapy and for acute nausea and vomiting following highly emetogenic chemotherapy." | 4.82 | Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. ( Grunberg, SM; Koeller, JM, 2003) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 4.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| "Ondansetron is a selective 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonist that has been introduced to clinical practice as an antiemetic for cancer treatment-induced and anesthesia-related nausea and vomiting." | 4.81 | Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. ( Ponnudurai, R; Schaefer, R; Ye, JH, 2001) |
| "To assess the efficacy of ondansetron and the incidence of headache when used as prophylaxis for postoperative vomiting." | 4.80 | Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. ( Canosa, LG; Figueredo, ED, 1998) |
| "For the usual doses recommended for postoperative emesis, there was equivalent effectiveness of ondansetron whether administered as prophylaxis or as a treatment of established vomiting." | 4.80 | Prevention or treatment of postoperative vomiting using ondansetron? A mathematical assessment. ( Canosa, LG; Figueredo, E, 1999) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 4.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| " doses of ondansetron for the prevention of acute nausea and emesis due to cisplatin." | 4.79 | Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. ( Perez, EA, 1995) |
| "Ondansetron is effective in the control of nausea and vomiting occurring 24-48 hours after highly emetogenic chemotherapy and after radiotherapy." | 4.79 | The clinical use of ondansetron. New South Wales Therapeutic Assessment Group. ( Currow, DC; Noble, PD; Stuart-Harris, RC, 1995) |
| "The clinical development of ondansetron for the prevention and treatment of postoperative nausea and vomiting has been progressing for 5 years, and continues as new directions of research are being addressed." | 4.79 | Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions. ( Joslyn, AF, 1994) |
| "Available clinical data on the use of oral ondansetron for the prevention of nausea and vomiting in patients undergoing cancer chemotherapy or surgery are reviewed." | 4.79 | Oral ondansetron for preventing nausea and vomiting. ( Cooke, CE; Mehra, IV, 1994) |
| "Ondansetron is a new selective serotonin-3-receptor antagonist which has proved to be effective in chemotherapy-induced nausea and vomiting." | 4.79 | [Ondansetron--a new anesthesia relevant antiemetic?]. ( Bach, A; Böhrer, H; Martin, E, 1994) |
| "The efficacy and safety of the serotonin (5-HT3) receptor antagonists granisetron, ondansetron, and tropisetron in the control of acute and delayed emesis and emesis induced by repeat-cycle chemotherapy are summarized." | 4.79 | Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). ( Hickok, JT; Morrow, GR; Rosenthal, SN, 1995) |
| "The use of ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia and surgery." | 4.79 | Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. ( Markham, A; Wilde, MI, 1996) |
| "To test the evidence for a dose-response with ondansetron for treatment of postoperative nausea and vomiting and to establish whether differences in efficacy between doses are of clinical relevance." | 4.79 | A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "In the past few years important progress in the prevention of chemotherapy-induced nausea and vomiting has been made mainly thanks to the introduction of the 5-HT3 receptor antagonists in clinical practice (ondansetron, granisetron, tropisetron)." | 4.79 | [Recent improvements in antiemetic therapy]. ( Basurto, C; Ciccarese, G; Palladino, MA; Roila, F, 1997) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 4.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy." | 4.78 | Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. ( Markham, A; Sorkin, EM, 1993) |
| "This paper described an outline of clinically applications of 5-HT3 receptor antagonists, mainly on ondansetron, which control nausea and vomiting associated with cancer chemotherapy." | 4.78 | [An outline of 5-HT3 receptor antagonists (2)--In clinical applications]. ( Ohta, J; Taguchi, T; Tsukagoshi, S, 1993) |
| "Serotonin is a neurotransmitter involved in chemotherapy-induced emesis and ondansetron is a new drug endowed with selective antagonism against the 5HT3 receptors." | 4.78 | Cisplatinum based chemotherapy: role of the antiserotoninergic ondansetron in prevention of emesis. ( D'Antona, A; Locatelli, MC; Luporini, G, 1993) |
| "Ondansetron is the first selective antagonist of the 5-hydroxytryptamine receptors (type 3) marketed for the prevention of emesis induced by antineoplastic agents." | 4.78 | Ondansetron. ( Ballatori, E; Basurto, C; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1993) |
| "Ondansetron hydrochloride is a new serotonin receptor antagonist that is effective in preventing emesis associated with cancer chemotherapy." | 4.78 | Ondansetron: a novel antiemetic agent. ( Dukes, GE; Figg, WD; Graham, CL; Hak, LJ, 1993) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| "Phase II trials of ondansetron were undertaken to assess the ability of this agent to control nausea and vomiting caused by specific chemotherapeutic agents, to establish the optimal number of doses and the most appropriate schedule of administration, to see if control could be improved by the use of continuous infusion, and to ascertain if the degree of efficacy and safety of ondansetron would warrant further investigations." | 4.78 | Phase II trials of ondansetron with high-dose cisplatin. ( Kris, MG, 1992) |
| " Metoclopramide is generally acknowledged to be the single most effective conventional drug for the prevention of acute cisplatin-induced emesis and, therefore, was considered an appropriate agent for inclusion in comparative trials with ondansetron." | 4.78 | Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. ( Hesketh, PJ, 1992) |
| " Ondansetron, currently the only serotonin antagonist with Food and Drug Administration approval for treatment of chemotherapy-induced emesis, demonstrates the efficacy and potential advantages of this class of antiemetics." | 4.78 | Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment. ( Graves, T, 1992) |
| "Ondansetron, a potent and highly selective 5-HT3 receptor antagonist, prevents emesis following chemotherapy by antagonising the action of 5-hydroxytryptamine (5-HT) at 5-HT3 receptors on vagal afferent neurons that innervate the gastrointestinal tract and 5-HT3 receptors in the central vomiting system." | 4.78 | Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. ( Freeman, AJ; Tyers, MB, 1992) |
| " Ondansetron prevents emesis by blocking the 5-HT3 receptors associated with the vomiting reflex." | 4.78 | Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis. ( Dicato, MA; Freeman, AJ, 1992) |
| "An international clinical trial programme has been established to assess the efficacy and safety of ondansetron in the prevention and treatment of postoperative nausea and vomiting." | 4.78 | The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting. ( Haigh, CG; Hellstern, K; Inall, FC; Isal, JP; Joslyn, AF; Kanarek, BK; Kaplan, LA; Povey, PM, 1992) |
| "Ondansetron hydrochloride dihydrate is a 5-hydroxytryptamine (5-HT3) antagonist that was recently approved by the Food and Drug Administration for the treatment of chemotherapy-induced emesis." | 4.78 | Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. ( Burnette, PK; Perkins, J, 1992) |
| "Ondansetron (GR 38032F), a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, is a highly effective and safe drug for the prophylaxis and treatment of emesis induced by various chemotherapy regimens in cancer patients." | 4.78 | Closing remarks. Ondansetron: effects on gastrointestinal motility. ( Lamers, CB, 1991) |
| " Ondansetron, a specific 5-HT3 antagonist, has been fully evaluated in the clinic, both as an intravenous and oral presentation, and in open studies in patients receiving non-cisplatin chemotherapy regimens it was highly effective in controlling acute and delayed emesis -- more than 90% of patients had a complete or major response to treatment." | 4.77 | The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. ( Schmoll, HJ, 1989) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 4.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "We evaluated the characteristics and sought risk factors for hospitalization in children who return to the emergency department within 7 days of discharge after oral or intravenous ondansetron treatment for vomiting." | 4.31 | Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department. ( Miroluz, D; Palnizky Soffer, G; Rimon, A; Schnapp, Z, 2023) |
| "Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery." | 4.31 | Embryo-fetal safety evaluation of ondansetron in rats. ( Arena, AC; da Silva Moreira, S; de Matos Manoel, B; Jorge, BC; Perdão, CB; Reis, ACC; Stein, J, 2023) |
| " Ondansetron, which is widely used in treatment of nausea and vomiting symptoms in head injuries, was issued a safety warning from the U." | 4.31 | Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma. ( Assaad, R; Pratt, RE; Qiao, H; Territo, HM; Wrotniak, BH, 2023) |
| " All patients were treated with a standardized postoperative protocol consisting of scheduled ondansetron, along with promethazine and scopolamine for breakthrough nausea and vomiting episodes." | 4.12 | Predictors of Postoperative Nausea and Vomiting After Endoscopic Skull Base Surgery. ( Abiri, A; Birkenbeuel, JL; Bitner, BF; Boladian, LA; Brown, NJ; Chen, JW; Golshani, K; Goshtasbi, K; Hsu, FPK; Hsu, Z; Kuan, EC; Lee, A; Nguyen, ES; Warner, DC, 2022) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 4.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 4.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| " Patients' demographics and postoperative pain, satisfaction, and nausea-vomiting scores and tramadol/ondansetron doses were evaluated." | 4.12 | Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy? ( Akkaya, T; Ozciftci, S; Sahiner, IT; Sahiner, Y, 2022) |
| "Rheumatoid arthritis, Methotrexate, Ondansetron, Nausea, Arthritis juvenile." | 4.12 | Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis. ( Fida, S; Kakalia, S; Khan, HA; Kitchlew, R; Saif, S; Siddique, M, 2022) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 4.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 4.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 4.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 4.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 4.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 4.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs." | 4.02 | The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome. ( Elliott, J; Foth, S; Kenward, H; Meller, S; Pelligand, L; Volk, HA, 2021) |
| "We determine whether an ondansetron prescription for pediatric patients with vomiting or gastroenteritis is associated with decreased return visits to the emergency department (ED), and whether alternate diagnoses are more frequent on return visits in patients prescribed ondansetron." | 3.96 | Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis. ( Benary, D; Higley, R; Lowe, D; Lozano, JM, 2020) |
| "Ondansetron has been shown to decrease admission rate and the need for intravenous fluids among pediatric emergency department (ED) patients with acute gastroenteritis, but there is limited evidence regarding its use after ED discharge." | 3.96 | Ondansetron Prescription for Home Use in a Pediatric Emergency Department. ( Furnival, RA; Gray, JM; Hendrickson, MA; Lunos, SA; Maewal, JD, 2020) |
| "In children presenting to the ED with an acute concussion, ondansetron use was associated with a higher risk of persistent post-concussion symptoms at 1 month." | 3.91 | Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy. ( Beauchamp, MH; Boutis, K; Dubrovsky, AS; Freedman, SB; Gagnon, I; Gravel, J; Momoli, F; Tang, K; Zemek, R, 2019) |
| " Our anesthetic protocol for strabismus surgery included postoperative nausea and vomiting prevention using dexamethasone and ondansetron." | 3.91 | Prospective evaluation of anesthetic protocols during pediatric ophthalmic surgery. ( Couret, C; Ducloyer, JB; Le Meur, G; Lebranchu, P; Lejus-Bourdeau, C; Magne, C; Weber, M, 2019) |
| "We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration." | 3.91 | Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial. ( Ali, N; Bhutta, ZA; Dawoud, F; Freedman, SB; Soofi, SB; Willan, AR; Williamson-Urquhart, S; Xie, J, 2019) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| "We have sought to determine the effect of a standardized dose of intravenous ondansetron on the QTc duration of children under 14years of age treated for gastroenteritis-associated vomiting in a pediatric ED." | 3.88 | Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. ( Alansari, K; Hoffman, RJ, 2018) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 3.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| "This was an observational study looking at patients aged 6 months to 18 years receiving intravenous ondansetron for nausea, vomiting, or the inability to take fluids in the emergency department." | 3.88 | Effect of Intravenous Ondansetron on the QT Interval of Patients' Electrocardiograms. ( Clark, JM; Jacobs, T; Krammes, SK; Lutes, RE, 2018) |
| "This study aimed to identify if prophylactic ondansetron administered with intravenous (IV) opioids prevents opioid-induced nausea or vomiting." | 3.85 | Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study. ( Culver, MA; Edwards, CJ; Jarrell, DH; Richards, EC, 2017) |
| "Background Two pivotal Phase III trials compared the efficacy of palonosetron, ondansetron and granisetron, combined with dexamethasone, for the prevention of nausea and vomiting following highly emetogenic chemotherapy." | 3.85 | Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients. ( Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B, 2017) |
| "This is a single-center prospective study enrolling children aged 3-8 years with gastroenteritis treated for persistent vomiting; patients received single dose of flavored intravenous ondansetron orally." | 3.83 | Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children. ( Al Ansari, K; Ibrahim, K, 2016) |
| "Ondansetron is often used in the emergency department (ED) to promote oral rehydration in children with acute gastroenteritis (AGE), yet medication solutions administered orally may be poorly tolerated in this population." | 3.83 | Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis. ( Chaulk, D; Johnson, DW; Kwong, S; Morrison, EL; Thompson, GC; Wobma, H, 2016) |
| " The following items: name of the anesthetist, duration of anesthesia, duration of monitoring, ventilatory status upon arrival in postoperative care unit, pain scores, nausea and vomiting scores, pain medication (morphine) and anti nausea and vomiting drug consumption (ondansetron) were extracted and analysed in order to determine exhaustivity (percentage of missing data) and accuracy of the database." | 3.81 | The use of a clinical database in an anesthesia unit: focus on its limits. ( Bourgain, JL; Eghiaian, A; Guye, ML; Motamed, C; Weil, G, 2015) |
| "To assess the hypothesis that ondansetron administration to children with type 1 diabetes mellitus (T1DM) presenting for emergency department (ED) care with intercurrent illness and vomiting improves clinical outcomes by reducing hospitalization rates (primary), length of ED stay, intravenous fluid (IVF) administration, and revisits (secondary outcomes)." | 3.81 | Emergency department ondansetron use in children with type 1 diabetes mellitus and vomiting. ( Freedman, SB; Leung, JS; Perlman, K; Rumantir, M, 2015) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 3.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| "The current Tactical Combat Casualty Care (TCCC) Guidelines recommend parenteral promethazine as the single agent for the treatment of opioid-induced nausea and/or vomiting and give a secondary indication of "synergistic analgesic effect." | 3.81 | Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care. ( Burrell, E; Butler, FK; Gross, K; Onifer, DJ; Otten, EJ; Patton, R; Russell, RJ; Stockinger, Z, 2015) |
| "During observation period,compared with model group,the frequency cisplatin induced retching and vomiting was significantly reduced by Ju-Pi-Tang in high- and mid-dose groups, during the 0-24 h acute period, the number of retching of Ju-Pi-Tang in high-dose group was decreased more than aprepitant group, during the 24-72 h delayed period, the number of both retching and vomiting was decreased more than ondansetron group, after 72 h of cisplatin administration, compared with model group, the grey levels of c-fos and substance P expression in distal ileum and brain tissues of Ju-Pi-Tang groups were higher significantly." | 3.81 | [Effect of Ju-Pi-Tang on Cisplatin-induced Emetic Model in Minks]. ( Liu, RR; Liu, ZT; Yang, YL; Yang, ZH; Yue, W, 2015) |
| "The exposed group (n = 143) was comprised of children whose mothers received promethazine or ondansetron during pregnancy." | 3.80 | Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. ( Dajani, NK; Eswaran, H; Larrimer, MB; Newport, DJ; Siegel, ER; Stowe, ZN, 2014) |
| "Ondansetron, selective serotonin (5-HT3) receptor blocker, is used in treating chemotherapy induced nausea and vomiting in cancer patients." | 3.79 | Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats. ( Chhalotiya, UK; Choudhary, DR; Kundawala, AJ; Patel, HV; Patel, VA, 2013) |
| "The main objective of this study was to develop a microemulsion (ME) formulation for transdermal delivery of ondansetron for chemotherapy induced nausea and vomiting (CINV)." | 3.79 | Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. ( Ahmad, FJ; Al Abood, RM; Talegaonkar, S; Tariq, M, 2013) |
| "The use of ondansetron in children with vomiting after a head injury has not been well studied." | 3.79 | The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED. ( Hirsh, DA; Khan, NS; Simon, HK; Sturm, JJ, 2013) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 3.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "Emergency department use of ondansetron in children with gastroenteritis is increasing; however, its effect on clinical outcomes is unknown." | 3.78 | Time-series analysis of ondansetron use in pediatric gastroenteritis. ( Chan, KJ; Cho, D; Freedman, SB; Rumantir, M; Tung, C, 2012) |
| " The aim of this study is to develop and evaluate mucoadhesive ondansetron buccal films for the treatment of emesis using CS as a mucoadhesive polymer." | 3.78 | Development of chitosan-based ondansetron buccal delivery system for the treatment of emesis. ( Jee, JP; Kim, CK; Kim, HT; Park, DM; Song, YK, 2012) |
| "Ondansetron is widely used in the pediatric emergency department (PED) for vomiting and acute gastroenteritis (GE)." | 3.78 | Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis. ( Hirsh, DA; Pierzchala, A; Simon, HK; Sturm, JJ, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 3.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| "In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use." | 3.78 | Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department. ( Armero, C; Carrión, T; Hervás, D; Hervás, JA; Utrera, JF, 2012) |
| "The objective of this study was to determine if overweight children are more likely than normal-weight children to require ondansetron when undergoing ketamine sedation in a pediatric emergency department." | 3.78 | Do children with high body mass indices have a higher incidence of emesis when undergoing ketamine sedation? ( Gerard, JM; Kinder, KL; Lehman-Huskamp, KL, 2012) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 3.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| "To document ondansetron-induced dystonia, hypoglycemia, and seizures in a child." | 3.77 | Ondansetron-induced dystonia, hypoglycemia, and seizures in a child. ( Manchanda, S; Mittal, S; Patel, A; Puliyel, JM, 2011) |
| "We examined treatment outcomes in women with severe nausea and vomiting of pregnancy (NVP) receiving outpatient nursing support and either subcutaneous metoclopramide or subcutaneous ondansetron via a microinfusion pump." | 3.77 | Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. ( Desch, C; Fox, NS; Istwan, N; Klauser, CK; Palmer, B; Rebarber, A; Rhea, D; Saltzman, D, 2011) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 3.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "We evaluate the effect of ondansetron use in cases of suspected gastroenteritis on the proportion of hospital admissions and return visits and assess whether children who receive ondansetron on their initial visit to the pediatric emergency department (ED) for suspected gastroenteritis return with an alternative diagnosis more frequently than those who did not receive ondansetron." | 3.76 | Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? ( Hirsh, DA; Massey, R; Schweickert, A; Simon, HK; Sturm, JJ, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 3.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| "A cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the US and Canada." | 3.76 | Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. ( Chan, KJ; Freedman, SB; Steiner, MJ, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin." | 3.75 | [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study]. ( Auger, A; Combes, JD; Favier, B; Galy, G; Labidi, SI; Latour, JF; Tissier, F, 2009) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 3.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| " Dolasetron ( n=157), granisetron ( n=81), and ondansetron ( n=131) achieved complete control of vomiting in 89." | 3.74 | Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? ( Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A, 2007) |
| "In highly emetogenic chemotherapy, the recommended dose of the serotonin-receptor antagonist ondansetron (5 mg/m(2) q8h) may be insufficient to prevent chemotherapy-induced nausea and vomiting." | 3.74 | Safety of ondansetron loading doses in children with cancer. ( Ammann, RA; Hasler, SB; Hirt, A; Leibundgut, KK; Ridolfi Luethy, A, 2008) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 3.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| " In contrast to control anti-emetic experiments using the 5-HT3 receptor antagonist ondansetron, SB-222200 was found to have no effects on cisplatin-induced vomiting or on the associated reductions in feeding and drinking behaviors at any dose tested." | 3.73 | Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. ( King, AG; Sanger, GJ, 2005) |
| " The current experiments evaluated the potential of the antiemetic agents, ondansetron (OND) and delta-9-tetrahydrocannabinol (THC), to interfere with lithium chloride (LiCl)-induced taste avoidance in the house musk shrew, Suncus murinus, an insectivore that, unlike rats, is capable of vomiting." | 3.73 | Ondansetron and Delta-9-tetrahydrocannabinol interfere with the establishment of lithium-induced conditioned taste avoidance in the house musk shrew (Suncus murinus). ( Kwiatkowska, M; Parker, LA, 2005) |
| " However, retching and vomiting were significantly inhibited by pretreatment with ondansetron and metoclopramide in cisplatin and copper sulfate groups (P=0." | 3.73 | Value of mink vomit model in study of anti-emetic drugs. ( Liu, ZT; Wang, L; Yang, ZH; Yue, W; Zhang, F, 2006) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 3.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| " Cisplatin, apomorphine, copper sulfate and X-radiation were used to establish vomiting model." | 3.72 | [A new vomiting animal model--mink]. ( Fang, X; Liu, YX; Minami, M; Wang, L; Yue, W; Zhang, F, 2003) |
| "The 5-HT3 antagonist, ondansetron (OND), and the cannabinoid, delta9-tetrahydrocannabinol (delta9-THC), have been shown to interfere with emesis; however, their relative and/or combined effectiveness in suppressing vomiting produced by the chemotherapeutic agent, cisplatin, is unknown." | 3.72 | A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). ( Burton, P; Kwiatkowska, M; Mechoulam, R; Parker, LA, 2004) |
| " ondansetron, which resolved the vomiting, one dose of activated charcoal, and intravenous fluids." | 3.72 | A rare ingestion of the Black Locust tree. ( Hui, A; Marraffa, JM; Stork, CM, 2004) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 3.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "The cost efficacy of various ondansetron regimens for the control of emesis induced by noncisplatin, moderately emetogenic chemotherapy was examined from a hospital perspective." | 3.71 | Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. ( Lachaine, J; Laurier, C, 2002) |
| "The purpose of this study was to investigate the feasibility of transdermal drug delivery of ondansetron, an antagonist of the 5-HT3 receptor, used for the treatment of chemotherapy-induced emesis." | 3.71 | Novel approach to improve permeation of ondansetron across shed snake skin as a model membrane. ( Rytting, JH; Takahashi, K, 2001) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 3.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "In the large majority of patients, serotonin-receptor antagonist antiemetic therapy, administered in combination with dexamethasone, is highly effective over multiple courses in preventing significant carboplatin-induced nausea and vomiting." | 3.71 | Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy. ( Kulp, B; Markman, M; Markman, MR; Peterson, G, 2002) |
| "Patients presenting with acetaminophen toxicity and vomiting are often treated with antiemetics so that orally administered N-acetylcysteine can be retained." | 3.70 | Use of ondansetron and other antiemetics in the management of toxic acetaminophen ingestions. ( Scharman, EJ, 1998) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 3.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "The effects of a NK1 antagonist, GR205171, and a 5-HT3 antagonist, ondansetron, in a novel model of post-anaesthesia-induced emesis in Suncus murinus is described." | 3.70 | Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus. ( Gardner, C; Perren, M, 1998) |
| "To determine the incidence of nausea and vomiting and the antiemetic effect of ondansetron hydrochloride (OND) in patients with hepatocellular carcinoma treated with arterial chemo-embolization, we studied 59 patients with hepatocellular carcinoma who were treated with transcatheter arterial embolization (TAE) or lipiodolized transcatheter arterial infusion (L-TAI)." | 3.70 | Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride. ( Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H, 1999) |
| "We demonstrated that both eusatron and ondansetron effectively abolished the emesis normally induced by 2-Gy doses of either 60Co gamma or neutron:gamma, mixed-field irradiation, the latter with a neutron-to-total dose ratio (Dn/Dt) of 0." | 3.70 | 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. ( King, GL; Rabin, BM; Weatherspoon, JK, 1999) |
| "The article reports a study comparing the cost-effectiveness of ondansetron tablets and prochlorperazine capsules in preventing nausea and vomiting after moderately emetogenic chemotherapy in an outpatient setting." | 3.70 | Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. ( Kwong, WJ; Parasuraman, TV, 1999) |
| "We investigated the emetic effects of cisplatin and methotrexate in dogs, the effects of ondansetron on cisplatin-induced vomiting, and the effects of ondansetron, dexamethasone and a combination of the two on the vomiting induced by methotrexate." | 3.70 | Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy. ( Fukui, H; Yamamoto, M, 1999) |
| "To evaluate the effect of ondansetron availability on the costs of managing nausea and vomiting." | 3.70 | Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. ( Coyle, D; Dahrouge, S; Evans, WK; Stewart, DJ, 1999) |
| " Intravenous ondansetron 8 mg and dexamethasone 20 mg served as an alternative regimen in patients <30 years old with a history of extrapyramidal manifestations or emesis in previous cycles." | 3.70 | Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy. ( Catalán Arlandis, JL; Jiménez Torres, NV, 2000) |
| "To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting." | 3.69 | Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. ( Aspinall, RL; Goodman, NW, 1995) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 3.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "Selective 5-HT3 receptor antagonists such as ondansetron are potent antiemetics for chemotherapy-induced emesis." | 3.69 | Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy. ( Kurtin, P; Ninane, J; Ozkaynak, MF; Siegel, SE, 1995) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 3.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "The efficacy and safety of prophylactic intravenous ondansetron on prevention of postoperative nausea and vomiting were investigated in 65 ASA grades I-III patients undergoing elective abdominal surgery and receiving general anesthesia." | 3.69 | [Ondansetron on postoperative nausea and vomiting]. ( Guo, XY; Luo, AL; Ye, TH, 1994) |
| " Ondansetron was used to treat chemotherapy-induced emesis in 88 percent of the patients and 12 percent received it for various other indications." | 3.69 | Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients. ( McQueen, KD; Milton, JD, 1994) |
| "To describe the efficacy of ondansetron for the treatment of poisoning-associated vomiting in two patients following drug intoxication." | 3.69 | Ondansetron for treating nausea and vomiting in the poisoned patient. ( Marx, CM; Reed, MD, 1994) |
| "The incidences of nausea and vomiting were significantly lower in the patients premedicated with ondansetron." | 3.69 | [Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery]. ( Bejarano-López, C; Bustos-Molina, F; Cid-Calzada, J; Cortés-Uribe, A; García-Cruz, JJ; Soro-Domingo, M, 1996) |
| " were hundreds of times more potent than 1 (ondansetron) and 2 (granisetron) in their inhibitory effects on cisplatin-induced emesis in ferrets and restraint stress-induced increases in fecal pellet output in rats." | 3.69 | Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives. ( Furuya, T; Kurihara, H; Miyata, K; Ohta, M; Suzuki, T; Tokunaga, T; Yanagisawa, I, 1996) |
| "Prochlorperazine is a centrally acting dopamine receptor antagonist that is most commonly used for the treatment of nausea and vomiting." | 3.69 | Tardive dyskinesia as a result of long-term prochlorperazine use. ( Alberts, VA; Catalano, G; Poole, MA, 1996) |
| " Patients, who did not receive ondansetron (n = 37) showed a nausea and emesis rate of 73%." | 3.69 | [Acute tolerance in hyperfractionated accelerated whole-body irradiation]. ( Latz, D; Schraube, P; Wannenmacher, M, 1996) |
| "Systematic search for published full reports of randomised controlled trials investigating ondansetron's effect on postoperative emesis." | 3.69 | Impact of covert duplicate publication on meta-analysis: a case study. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used." | 3.69 | Acute severe depression following peri-operative ondansetron. ( Blaine, EM, 1997) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 3.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "The potency of Ondansetron (Zofran, Glaxo), a highly specific 5HT3 antagonist in preventing the very unfavorable complication during introducing anesthesia, i." | 3.68 | Evaluation of ondansetron as a drug for premedication. ( Kamenova, E, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 3.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| " 5 min prior to morphine while each ferret was maintained under isoflurane-O2 anesthesia." | 3.68 | The effects of different antiemetic agents on morphine-induced emesis in ferrets. ( Essien, E; Thut, PD; Wynn, RL, 1993) |
| "Ondansetron may be the preferred agent for controlling nausea and vomiting in patients with neurosurgical trauma." | 3.68 | Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. ( Deppe, SA; Kleinerman, KB; Sargent, AI, 1993) |
| " Ondansetron, an antagonist of 5-hydroxytryptamine (subtype 3) receptor is a new, very potent drug preventing vomiting and nausea induced by different factors (chemotherapy, radiotherapy, anaesthesia)." | 3.68 | Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. ( Beshari, SE; Kołecki, P; Wachowiak, J, 1993) |
| " The emesis induced by both morphine and morphine 6-glucuronide was abolished by the preadministration of naloxone (0." | 3.68 | Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret. ( Andrews, PL; Bingham, S; Joel, SP; Patel, N; Slevin, ML; Thompson, PI, 1992) |
| "The study examined the budgetary implications of using 5-hydroxytryptamine3 receptor antagonists (5-HT3RA), granisetron or ondansetron, in the management of chemotherapy-induced emesis (CIE)." | 3.68 | The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. ( Bosanquet, N; Jones, AL; Lee, GJ, 1992) |
| "The excitatory amino acid (EAA) receptor antagonists, 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo(f)quinoxaline (NBQX) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), which preferentially block non-N-methyl-D-aspartate (non-NMDA) subtypes of EAA receptors, effectively inhibit cisplatin-induced emesis in ferrets." | 3.68 | Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. ( Fink-Jensen, A; Hansen, JB; Honoré, T; Jacobsen, P; Judge, ME; Olney, J; Turski, L, 1992) |
| "We present a 17-year-old girl who developed persistent vomiting following acetaminophen overdose." | 3.68 | Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication. ( Deshpande, JK; Gregory, DF; Tobias, JD, 1992) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 3.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| " Furthermore, the 5HT3 antagonist ondansetron prevented emesis at doses as high as 75% of the MTD." | 3.68 | Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents. ( Beningo, KA; Elliott, WL; Heffner, TG; Leopold, WR; Sebolt-Leopold, JS; Stier, MA; Suto, MJ; Vincent, PW; Wiley, JN, 1992) |
| " Ondansetron, a selective 5-HT3-receptor antagonist has shown efficacy in cisplatin-induced emesis." | 3.68 | Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. ( du Bois, A; Fenzl, E; Kommoss, FG; Meerpohl, HG; Pfleiderer, A; Vach, W, 1992) |
| "Previous studies of the mechanism of zacopride-induced emesis in ferrets have concluded that it is mediated predominantly by an antagonist effect on 5-HT3 receptors although the possibility of a contribution from an agonist effect at 5-HT4 receptors was not excluded." | 3.68 | Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. ( Andrews, PL; Bhandari, P, 1991) |
| "In summary, ondansetron has proved to be a highly effective anti-emetric and is superior to metoclopramide in the treatment of acute emesis." | 3.68 | Introduction: the clinical challenge. ( Schmoll, HJ, 1991) |
| "The antiemetic activity of DAU 6215, a novel antagonist of 5-HT3 receptors, was investigated in animal models of cytotoxic treatment-evoked emesis and compared with the antiemetic activity of ondansetron and metoclopramide." | 3.68 | Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. ( Algate, DR; Bonali, P; Donetti, A; Micheletti, R; Montagna, E; Nicola, M; Rimoldi, EM; Sagrada, A; Schiantarelli, P; Turconi, M, 1991) |
| "Twenty-four patients with severe post-chemotherapy emesis (greater than 15 emetic episodes) refractory to prior combination antiemetic therapy were treated with a selective 5-HT3 receptor antagonist ondansetron (GR38032F)." | 3.68 | Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). ( Ardizzoni, A; Campora, E; Oliva, C; Rosso, R; Vidili, G, 1991) |
| " Ondansetron is an investigational serotonin antagonist that has documented effectiveness for cancer chemotherapy-induced emesis." | 3.68 | Ondansetron: a new entity in emesis control. ( Graves, T, 1990) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 3.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Nausea and vomiting is a common ED chief complaint." | 3.01 | Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis. ( Lee, SY; Tamale, JR, 2023) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 3.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 2.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| "The effect against nausea is of particular interest." | 2.87 | Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. ( Christensen, TB; Daugaard, G; Fox, GM; Herrstedt, J; Holmskov, K; Molassiotis, A; Summers, Y; Taylor, PD, 2018) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 2.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| " Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy." | 2.84 | Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). ( Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K, 2017) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 2.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| "Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy." | 2.80 | Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara ( Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W, 2015) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 2.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| "Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control." | 2.77 | Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. ( Carrasco, MM; Cruz, FM; da Costa Miranda, M; da Cunha Vieira, M; de Afonseca, SO; de Iracema Gomes Cubero, D; de Souza Fêde, AB; del Giglio, A; Lera, AT; Lerner, T; Pinczowski, H; Schindler, F; Taranto, P, 2012) |
| "Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone." | 2.77 | Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. ( Akewanlop, C; Ithimakin, S; Keerativitayanan, N; Laocharoenkeat, A; Nimmannit, A; Runglodvatana, K; Soparattanapaisarn, N; Srimuninnimit, V, 2012) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 2.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "Pretreatment with ondansetron or metoclopramide does not reduce oral contrast solution ingestion time." | 2.74 | Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy. ( Bamber, D; Chohan, J; Garra, G; Singer, AJ; Thode, HC; Troxell, R, 2009) |
| "Nausea and vomiting are important symptoms observed in cancer patients." | 2.74 | Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. ( de Camargo, B; del Giglio, A; Lajolo, PP, 2009) |
| "Ondansetron exposure was equivalent in regimens B and C." | 2.74 | Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. ( Adams, L; Blum, R; Johnson, B; Lates, C; Lebowitz, P; Lu, E; Zhang, K, 2009) |
| "The meclizine group had lower VNRS scores in the PACU at 15 (P = ." | 2.73 | Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. ( Benfield, DA; Forrester, CM; Kelly, JA; Matern, CE; Pellegrini, JE, 2007) |
| "Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy)." | 2.71 | [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs]. ( Liu, DW; Liu, YY; Shan, XJ; Xie, XD; Zheng, ZD, 2003) |
| "as prophylaxis in breast cancer patients regimens was studied." | 2.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "Patients with cancer (N = 216) treated with chemotherapeutic regimens composed of highly or moderately emetogenic agents were examined for their antiemetic responses to tropisetron, ondansetron, or granisetron." | 2.71 | Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. ( Abali, H; Aynacioglu, AS; Babaoglu, MO; Bayar, B; Bozkurt, A; Celik, I; Kerb, R, 2005) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "Ondansetron was administered as 8 mg bid, metopimazine as 30 mg qid, and prednisolone as 50 mg qd." | 2.70 | Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. ( Dombernowsky, P; Handberg, J; Herrstedt, J; Kjaer, M; Sigsgaard, T, 2001) |
| "Nausea was assessed by means of a four-point ordinal scale at intervals over the 7 day period." | 2.70 | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. ( Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L, 2001) |
| "Ondansetron was given at a dose of 12 mg/day and TENS was applied by commercially available 'Relief Band'(Maven Labs, Inc." | 2.70 | Combination of transcutaneous electrical nerve stimulation and ondansetron in preventing cisplatin-induced emesis. ( Arik, AI; Erol, D; Ozgür Tan, M; Sandikçi, Z; Uygur, MC, 2001) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "The reduction in the frequency of posttreatment vomiting supports research findings of efficacy." | 2.69 | Progress in reducing anticipatory nausea and vomiting: a study of community practice. ( Burish, T; Flynn, PJ; Hynes, HE; Morrow, GR; Pierce, HI; Roscoe, JA, 1998) |
| "Emesis is common in the postoperative period following epidural opioid and general anaesthesia." | 2.69 | A double blind comparison of droperidol and ondansetron for prevention of emesis in children undergoing orthopaedic surgery. ( Goodarzi, M, 1998) |
| "Sixty cancer patients took part in this randomized prospective study." | 2.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| "Ondansetron 8 mg was added to dexamethasone and was administered i." | 2.69 | Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. ( , 1998) |
| " dosing regimen over a 24 h period, administered to patients prior to receiving cisplatin (50 mg/m2 or greater) chemotherapy." | 2.69 | A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. ( Goedhals, L; Graham, E; Joly, F; Krzakowski, M; Lees, J; McQuade, B; Pawlicki, M; Rapoport, B; Yelle, L, 1998) |
| "Ondansetron alone was not adequate to provide sustained control of CT-induced nausea and vomiting over the entire 5-day study period." | 2.69 | An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. ( Cohen, L; Davidson, T; Dix, SP; Joyce, R; Lynn, M; Miyahara, T; Osowski, CL; Sexauer, MC; Wingard, JR; Yeager, A, 1998) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days." | 2.69 | Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. ( Curtis, P; Davidson, N; Erikstein, B; L'Esperance, B; Miller, I; Paska, W; Rapoport, B; Ruff, P, 1999) |
| "Ondansetron 24 mg q." | 2.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "In patients with cancer (n = 16), baseline blood dialysate 5-HIAA concentrations averaged 2." | 2.69 | Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. ( Castejon, AM; Cubeddu, LX; Hernandez, L; Paez, X, 1999) |
| "Ondansetron is an effective and well-tolerated antiemetic, which is used for the prevention of both chemotherapy and radiotherapy-induced emesis and nausea." | 2.69 | Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab ( Coster, B; Feyer, P; Franzén, L; Goedhals, L; Graham, E; Haigh, C; LeBourgeois, JP; Marzecki, Z; McKenna, CJ; Mitchell, T; Souhami, L; Stewart, A; Tønnessen, F; Wilkinson, JR, 1999) |
| "Perceived nausea was evaluated using a nausea scoring system, and no differences were apparent between the granisetron and ondansetron groups; however, reported nausea was significantly higher in females (p<0." | 2.69 | A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. ( Burns, L; DeFor, TE; Larson, H; Orchard, PJ; Ramsay, NK; Rogosheske, J; Rydholm, N; Weisdorf, D, 1999) |
| " Serial plasma and pleural or ascitic fluid samples were collected during each dosing and analyzed by high-performance liquid chromatography for both the intact lactone form of topotecan and its ring-opened carboxylate form." | 2.69 | Topotecan lacks third space sequestration. ( de Jonge, MJ; Gelderblom, H; Loos, WJ; Sparreboom, A; Verweij, J, 2000) |
| "Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days." | 2.69 | Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000) |
| "Ondansetron was extremely effective over this time in the control of emesis and nausea." | 2.68 | The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. ( Beck, TM, 1995) |
| "Ondansetron appears to be a safe and efficacious antiemetic during conditioning for BMT." | 2.68 | Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. ( Agura, ED; Brown, MC; Donaldson, G; Schaffer, R; Shen, DD, 1995) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 2.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "Metoclopramide was ineffective." | 2.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 2.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "A total of 259 chemotherapy-naive breast cancer patients treated with a 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen were randomly assigned to ondansetron (OND) 8 mg tablet or alizapride (ALI) 150 mg intravenous (i." | 2.68 | Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. ( Bonneterre, J; Clavel, M; d'Allens, H; Paillarse, JM, 1995) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 2.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| "Postoperative pain was treated with morphine, codeine and/or acetaminophen." | 2.68 | Oral ondansetron decreases vomiting after tonsillectomy in children. ( Baxter, MR; Gould, HM; Hall, LE; Komocar, L; MacNeill, HB; Roberts, DJ; Splinter, WM, 1995) |
| "Nausea was absent or mild in 79% of patients on day 1, 45% on day 2 and 41% on day 3." | 2.68 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. ( Barbounis, V; Efremidis, AP; Hatzichristou, H; Koumakis, G; Tsousis, S; Vassilomanolakis, M, 1995) |
| " In conclusion, ondansetron given prior to anaesthesia in a dosage of 4 mg did not prevent postoperative nausea and vomiting after laparoscopic cholecystectomy." | 2.68 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial. ( Koivuranta, MK; Läärä, E; Ryhänen, PT, 1996) |
| "We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving moderately emetogenic chemotherapy." | 2.68 | Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. ( Beijnen, JH; de Boer-Dennert, M; de Wit, R; Schellens, JH; van Tellingen, O; Verweij, J, 1996) |
| " In addition, ondansetron had a similar dose-response curve in both menstruating and nonmenstruating women." | 2.68 | The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. ( Afshar, M; Allen, E; Buxbaum, J; Gratz, I; Joslyn, AF; Prilliman, B, 1996) |
| "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P." | 2.68 | Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. ( Ionta, MT; Massidda, B, 1996) |
| "Ondansetron was significantly more effective than droperidol in reducing emesis after discharge (P < 0." | 2.68 | Ondansetron decreases postoperative vomiting in pediatric patients undergoing tonsillectomy and adenoidectomy. ( Bower, C; Brown, RE; Kymer, PJ; Lawhorn, CD; Schmitz, ML; Shirey, R; Stoner, J; Vollers, JM, 1996) |
| "Metoclopramide was ineffective." | 2.68 | Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. ( Attia, M; Channa, AB; el Bakry, AK; el Gammal, K; el Gammal, M; Elhattab, YS; Jaroudi, R; Khoshim, MH; Naguib, M; Saddique, A, 1996) |
| "We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course." | 2.68 | Impact of tumour burden on chemotherapy-induced nausea and vomiting. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1996) |
| "Headache was frequent in the control (69%), i." | 2.68 | The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison. ( van den Berg, AA, 1996) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 2.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Ondansetron is a serotonin (5HT) receptor antagonist at both peripheral and central 5-HT3 receptor sites with no known action on dopamine-mediated activity." | 2.68 | Droperidol/ondansetron combination controls nausea and vomiting after tubal banding. ( Hamilton, DL; McKenzie, R; Riley, TJ; Uy, NT, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 2.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Ondansetron was used as an antiemetic along with dexamethasone during 16 cycles of highly or moderately ematogenic chemotherapy." | 2.68 | Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. ( Jain, PK; Parikh, PM; Patel, RA; Shah, KC; Shah, SC; Shah, SR; Sheth, V, 1996) |
| "Nausea was measured at three intervals: at admission to the postanesthesia care unit (PACU), 1 h after admission to the PACU, and on Postoperative Day 1." | 2.68 | A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. ( Alberts, MS; Sniadach, MS, 1997) |
| "As ondansetron was clearly effective in patients receiving hemibody irradiation it seems it would be prudent to adopt it for use in such patients routinely." | 2.68 | Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. ( Kiltie, AE; Stewart, AL; Sykes, AJ, 1997) |
| "The metoclopramide dosage was 20 mg i." | 2.68 | Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. ( Advani, SH; Cooverji, ND; Dhar, AK; Gopal, R; Lal, HM, 1996) |
| "Emesis is one of the most disturbing side-effects of platinum therapy." | 2.67 | Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. ( du Bois, A; Karck, U; Madjar, H; Meerpohl, HG; Prömpeler, H; Thomssen, C; Vach, W, 1994) |
| "Nausea and emesis are significant side effects in patients undergoing stereotactic radiosurgery for brain lesions in the region of the chemoreceptor trigger zone (area postrema of the brain)." | 2.67 | The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone. ( Alexander, E; Bodis, S; Kooy, H; Loeffler, JS, 1994) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 2.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Oral ondansetron 8 mg was subsequently given in the evening of day 1, and then even 12 hours on days 2, 3 and 4." | 2.67 | Control of emesis by a low dose of ondansetron and dexamethasone. ( Bajetta, E; Biganzoli, L; Buzzoni, R; Di Bartolomeo, M; Di Leo, A; Zampino, MG, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Ondansetron is a well tolerated, efficacious antiemetic which has a similar side effect profile to placebo." | 2.67 | Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting. ( Claybon, L, 1994) |
| "ondansetron was superior to metoclopramide in preventing nausea and vomiting after general anaesthesia for day-case gynaecological laparoscopic surgery." | 2.67 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. ( Norton, AC; Raphael, JH, 1993) |
| "Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on." | 2.67 | Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. ( de Boer-Dennert, M; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1993) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy." | 2.67 | Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. ( Beck, TM; Chang, A; Ciociola, AA; Galvin, D; Hart, NE; Harvey, WH; Jones, SE; Tchekmedyian, NS, 1993) |
| "Ondansetron use was concurrently monitored in adult inpatients for four months." | 2.67 | Multicenter evaluation of ondansetron use in hospitalized oncology patients. ( Emhart, GC; Jessen, LM; Long, KS; Patel, HS; Peters, MD; Reitz, JA, 1993) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 2.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 2.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 2.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 2.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 2.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron hydrochloride is a selective serotonin subtype 3 (5HT3) receptor antagonist that has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy." | 2.67 | Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. ( Einhorn, L; House, K; Nagy, C; Sledge, GW, 1992) |
| "Ondansetron is a new 5-HT3-antagonist with antiemetic properties." | 2.67 | The effect of ondansetron on radiation-induced emesis and diarrhoea. ( Franzén, L; Henriksson, R; Israelsson, G; Lomberg, H; Zackrisson, B, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 2.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron appears to be a safe and effective antiemetic when administered during a multiple-day cisplatin-containing chemotherapy regimen." | 2.67 | Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. ( Bryson, JC; Finn, AL; Hainsworth, JD; Khojasteh, A; Omura, GA, 1991) |
| "Ondansetron was an effective antiemetic in 78% (14/18) and placebo was effective in 28% (5/18) of the patients." | 2.67 | Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. ( Afshar, M; Gratz, I; Larijani, GE; Minassian, S, 1991) |
| "Ondansetron was administered as an 8 mg loading dose (A: 4 mg i." | 2.67 | The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. ( de Mulder, PH; Lane-Allman, E; Seynaeve, C; van Liessum, PA; Verweij, J, 1991) |
| "Ondansetron was given as 4 mg oral +4 mg iv 30 minutes prior to carboplatin followed by 8 mg oral tds for 5 days." | 2.67 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group. ( Howells, N; Lambert, HE; McQuade, B; Rustin, GJ; Smith, DB, 1991) |
| "The pharmacological treatment of vomiting in children remains a challenge for the pediatrician because several antiemetics are prescribed as "off-label," outside their authorized drug label." | 2.61 | Antiemetic Drug Use in Children: What the Clinician Needs to Know. ( Dipasquale, V; Romano, C; Scarpignato, C, 2019) |
| "Acute gastroenteritis is defined as a diarrheal disease of rapid onset, with or without nausea, vomiting, fever, or abdominal pain." | 2.61 | Gastroenteritis in Children. ( Brown, E; Hartman, S; Loomis, E; Russell, HA, 2019) |
| "Bone cancer was the most incident (≥50%) neoplasm, followed by rhabdomyosarcoma and Hodgkin's lymphoma." | 2.55 | Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. ( D'Athayde Rodrigues, F; Ferreira, MAP; Moreira, LB; Okumura, LM, 2017) |
| "Nausea and vomiting is a common and distressing presenting complaint in emergency departments (ED)." | 2.52 | Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. ( Egerton-Warburton, D; Furyk, JS; Meek, RA, 2015) |
| "The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron." | 2.50 | 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. ( Brygger, L; Herrstedt, J, 2014) |
| "Nausea and vomiting are two of the most distressing side effects of chemotherapy." | 2.44 | Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. ( Vrabel, M, 2007) |
| "Emesis is not only unpleasant, but negatively impacts on global quality of life." | 2.43 | Update on anti-emetics for chemotherapy-induced emesis. ( Olver, IN, 2005) |
| "Emesis is an instinctive defense reaction caused by the somato-autonomic nerve reflex, which is integrated in the medulla oblongata." | 2.42 | [Serotonin and anticancer drug-induced emesis]. ( Endo, T; Hamaue, N; Hirafuji, M; Minami, M, 2004) |
| "Ondansetron is a serotonin receptor antagonist that is effective in preventing and treating PONV." | 2.39 | Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting. ( Charbonneau, J; Early, TE; Jenkins, P; McKnight, G, 1995) |
| "Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups." | 2.38 | [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology]. ( Borsi, J; Csáki, C; Ferencz, T; Koós, R; Schuler, D, 1993) |
| "Ondansetron (ODS) is a new carbazole which exerts selective and potent antagonism on serotoninergic neurotransmission at serotonin 3 (5-HT3) receptors." | 2.38 | [Clinical pharmacology of ondansetron]. ( Robak, T, 1993) |
| "Ondansetron (GR 38032) has potent and highly selective antagonist properties at the 5-hydroxytryptamine (5-HT, serotonin) 5-HT3 receptor." | 2.38 | Pharmacology and preclinical antiemetic properties of ondansetron. ( Tyers, MB, 1992) |
| "Ondansetron is a highly potent and selective antagonist at 5-HT3 receptors." | 2.38 | Pharmacology of ondansetron. ( Naylor, RJ; Rudd, JA, 1992) |
| " In adult patients receiving single-day chemotherapy, the incidence of adverse events was 45% with IV ondansetron (n = 317) and 59% with metoclopramide (n = 279)." | 2.38 | Clinical safety of ondansetron. ( Bryson, JC, 1992) |
| "Ondansetron (GR 38032F) is a highly selective 5-HT3 receptor antagonist, one of a new class of compounds which may have several therapeutic applications." | 2.38 | Ondansetron. Therapeutic use as an antiemetic. ( Heel, RC; Milne, RJ, 1991) |
| "Ondansetron was effective in children receiving a wide variety of chemotherapy regimens." | 2.38 | The role of ondansetron in paediatric patients: a review of three studies. ( Stevens, RF, 1991) |
| "Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs." | 2.38 | Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. ( Goldspiel, BR; Kohler, DR, 1991) |
| "Ondansetron is a specific antagonist of 5-HT3 serotonin receptors." | 2.38 | [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ( Aubert, B; Bons, J; d'Allens, H; Pappo, M, 1991) |
| "Ondansetron failure was determined by review of the medical records and by patient-reported outcomes (PROs)." | 1.72 | Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. ( Davenport, L; Dome, JS; Gai, J; Gross, AM; Hinds, PS; Jacobs, SS; Mowbray, C; Postell, E; van den Anker, JN, 2022) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 1.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| " For the duration of 4 months, weight, body mass index, and the occurrence of adverse events was documented." | 1.48 | The safety and efficacy of the procedureless intragastric balloon. ( Al Haddad, E; Al Kendari, M; Al-Subaie, S; Almulla, A; Alsabah, S; Ekrouf, S, 2018) |
| "Nausea is a common symptom in patients taken care of by the ambulance service." | 1.43 | Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study. ( Hjelte Judell, O; Lindström, V; Vicente, V; Westerlund, A, 2016) |
| "Nausea and vomiting are common, but prevalence of antiemetic use in ED patients is unknown." | 1.43 | Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective. ( Garra, G; Singer, AJ; Thode, HC, 2016) |
| " Together with these new biomarkers of hepatotoxicity, a 12-hour acetylcysteine protocol offers clinicians and patients the possibility for better targeting of therapy, fewer adverse effects, a simpler dosing regimen, and shorter hospital stay." | 1.42 | Changing the Management of Paracetamol Poisoning. ( Bateman, DN, 2015) |
| "Pretreatment with ondansetron, a serotonin 5-HT3 receptor antagonist, which is used to treat nausea in patients in chemo- or radiation therapy, attenuated hypothermia by ~30%." | 1.40 | Thermoregulatory correlates of nausea in rats and musk shrews. ( Cerri, M; Corrigan, JJ; Del Vecchio, F; Dragic, AS; Kamphee, A; Nalivaiko, E; Ngampramuan, S; Romanovsky, AA; Rudd, JA, 2014) |
| " The combined treatment markedly and significantly decreased the mean number of emetic events recorded between 24 and 54 h after cisplatin dosing (-75%, P < 0." | 1.40 | Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron. ( Barrais, L; Castagné, V; Goineau, S; Guillaume, P, 2014) |
| "The thermosensitive-mucoadhesive ondansetron liquid suppository (tmOLS) was developed to enhance patient compliance and bioavailability in high-risk patients receiving highly emetogenic therapy and having difficulty in swallowing, The thermosensitive-mucoadhesive liquid suppository bases were formulated using poloxamers (P407 and P188) and hydroxypropylmethyl cellulose (HPMC)." | 1.39 | Design and evaluation of ondansetron liquid suppository for the treatment of emesis. ( Ban, E; Kim, CK, 2013) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| "Vomiting is a protective reflex that results in forceful ejection of stomach contents up to and out of the mouth." | 1.39 | Management of a child with vomiting. ( Bansal, A; Jayashree, M; Shah, R; Singhi, SC, 2013) |
| "Whereas nausea and emesis are burdensome side effects that lead to poor treatment compliance especially in chemotherapy, it is difficult to predict the emetic potential of agents in rats and mice because rodents do not vomit." | 1.38 | Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats. ( Ando, K; Takagi, K; Tsubone, H, 2012) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 1.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "Nausea and emesis are often observed as side effects with many medicines and may lead to poor treatment compliance." | 1.37 | Solid gastric emptying mediated by the serotonin (5-HT)3 receptor in mice is a simple marker to predict emesis. ( Ando, K; Takagi, K, 2011) |
| "For moderate dehydration, eight CPGs advocated nasogastric (NG) rehydration in preference to intravenous (IV) rehydration." | 1.35 | Emergency department management of gastro-enteritis in Australia and New Zealand. ( Babl, FE; Borland, M; Schutz, J; Sheriff, N, 2008) |
| "A generalized tonic-clonic seizure occurred in each patient--12, 15, and 22 min after injection." | 1.35 | Ondansetron and seizures. ( Acharya, JN; Rai, A; Selhorst, JB; Singh, NN, 2009) |
| "Women with breast cancer without previous chemotherapy were eligible for this prospective study." | 1.35 | Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. ( Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S, 2008) |
| " Emetic episodes, doses of rescue medications to treat breakthrough nausea or vomiting, and occurrence of adverse events were recorded." | 1.34 | Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. ( Cartwright, J; Frangoul, H; Ho, RH; Jones, E; Koyama, T; Kuttesch, J; Shankar, S; Whitlock, JA, 2007) |
| "Ondansetron was inactive to modify behavior, but CP-99,994 reduced spontaneous locomotor activity and lip licking by 48% (P<0." | 1.33 | Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. ( Kan, KK; Lai, HW; Lau, AH; Ngan, MP; Rudd, JA; Wai, MK; Yew, DT, 2005) |
| "Pre-treatment with methysergide (a 5-HT(1/2/7) receptor antagonist, 1." | 1.33 | The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus. ( Javid, FA; Naylor, RJ, 2006) |
| "We included 242 cancer patients on their first day of chemotherapy." | 1.32 | Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. ( Brockmoller, J; Kaiser, R; Possinger, K; Roots, I; Rosler, N; Schelenz, C; Sezer, O; Tremblay, PB, 2003) |
| "Six children developed severe daily migraine-type headaches during cancer treatment." | 1.31 | Migraine-type headaches in children receiving chemotherapy and ondansetron. ( Khan, RB, 2002) |
| "To introduce a computerized data collection system used for an outcomes-based approach to antiemetic therapy in children, and to present data collected with this system in support of a new antiemetic dosing regimen." | 1.31 | Computerized system for outcomes-based antiemetic therapy in children. ( Adams, VR; Holdsworth, MT; Raisch, DW; Winter, SS; Wood, JG, 2000) |
| "induced emesis was investigated in the ferret during a 24 h period." | 1.30 | The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. ( Naylor, RJ; Rudd, JA, 1997) |
| "Lerisetron is a new 5-HT3 receptor antagonist chemically unrelated to other antagonists like Ondansetron." | 1.30 | Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. ( De Miguel, E; Gomez-de-Segura, IA; Grande, AG, 1998) |
| " Emesis induced by RS14203 exhibited a dose-response relationship but no such relationship was seen for R-rolipram or CT-2450." | 1.30 | Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. ( Choudhury, I; Robichaud, A; Rodger, IW; Tattersall, FD, 1999) |
| " After a 4- to 5-day recovery, piglets were hydrated, then dosed with cisplatin (5." | 1.29 | The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. ( Blower, P; Grélot, L; Milano, S; Romain, D, 1995) |
| "It is the purpose of this article to discuss ondansetron hydrochloride (Zofran Glaxo, Research Triangle Park, NJ) and its mechanisms of action, indications for use, dosage and administration, side effects, and nursing implications." | 1.29 | Practical points in the use of ondansetron. ( Litwack, K, 1994) |
| "Domperidone did not inhibit these cytotoxic agents-induced emeses." | 1.29 | The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. ( Fukuda, T; Haga, K; Inaba, K; Morimoto, Y; Setoguchi, M; Shoji, H, 1993) |
| " The dosage protocols with which it has usually been employed establish an i." | 1.29 | Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer. ( Cagnazzo, G; Marinaccio, M; Miniello, G; Pinto, V, 1993) |
| "Pretreatment with domperidone inhibited apomorphine-induced kaolin intake." | 1.29 | Pica in rats is analogous to emesis: an animal model in emesis research. ( Hasegawa, S; Matsunaga, T; Morita, M; Takeda, N, 1993) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 1.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| " Criteria for dosage and administration were met by 76% of the inpatient orders and 83% of the outpatient orders." | 1.29 | Ondansetron use in a major university teaching hospital. ( Chapman, SM; Pruemer, JM, 1993) |
| "Ondansetron 1 mg/kg was without effect to modify apomorphine-, morphine- or copper sulphate-induced emesis but the combination pretreatment of ondansetron 1 mg/kg with dexamethasone 2." | 1.29 | The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. ( Bunce, KT; Naylor, RJ; Rudd, JA, 1996) |
| "The treatment of cancer patients has improved over the few past years." | 1.29 | [Future trends in chemotherapy and impact on the management of emesis]. ( Catimel, G; Droz, JP, 1995) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "A group of 90 breast cancer patients undergoing chemotherapy were assessed prospectively to estimate the prevalence of acute (post-treatment) and anticipatory emesis in the 1990s." | 1.29 | Acute and anticipatory emesis in breast cancer patients. ( Casado, A; Diaz-Rubio, E; Fernández-Marcos, A; López Martin, JA; Martín, M; Rodriguez-Lescure, A; Sanchez, JJ, 1996) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| " Our data suggest that in comparison to ondansetron, granisetron is a more potent, longer acting and pharmacologically "cleaner" compound with a more conventional dose-response profile." | 1.28 | Are all 5-HT3 receptor antagonists the same? ( Andrews, PL; Bhandari, P; Bingham, S; Blower, PR; Davey, PT; Marr, HE, 1992) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 1.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| "Ondansetron was also given to 16 patients receiving cisplatin chemotherapy." | 1.28 | Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. ( Allan, SG; Dickson, D; Evans, BD; Forgeson, GV; Harvey, VJ; Humm, G; Langley, G; Mak, D; Mitchell, PL; Neave, L, 1992) |
| "Ondansetron is a selective 5-HT3 antagonist and has clear anti-emetic capabilities." | 1.28 | Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist. ( Cornish, J; Hewitt, M; Oakhill, A; Pamphilon, D, 1991) |
| "Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting." | 1.28 | Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan. ( Butcher, ME; Gore, ME; McElwain, TJ; Selby, PJ; Viner, CV; Wootton, CM; Zulian, GB, 1990) |
| "Ondansetron was well tolerated, with no significant drug-related adverse events." | 1.28 | [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs]. ( Sampi, K; Taguchi, T, 1990) |
| "A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting." | 1.28 | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Bons, J; Brion, N; Droz, JP; Marty, M; Paule, B; Pouillart, P, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (1.42) | 18.7374 |
| 1990's | 600 (56.93) | 18.2507 |
| 2000's | 169 (16.03) | 29.6817 |
| 2010's | 195 (18.50) | 24.3611 |
| 2020's | 75 (7.12) | 2.80 |
| Authors | Studies |
|---|---|
| Youssefyeh, RD | 3 |
| Campbell, HF | 2 |
| Klein, S | 2 |
| Airey, JE | 3 |
| Darkes, P | 1 |
| Powers, M | 2 |
| Schnapper, M | 2 |
| Neuenschwander, K | 1 |
| Fitzpatrick, LR | 2 |
| Pendley, CE | 2 |
| Woodward, R | 1 |
| Rodriguez, W | 1 |
| Golec, S | 1 |
| Studt, W | 1 |
| Clark, RD | 1 |
| Miller, AB | 1 |
| Berger, J | 1 |
| Repke, DB | 1 |
| Weinhardt, KK | 1 |
| Kowalczyk, BA | 1 |
| Eglen, RM | 2 |
| Bonhaus, DW | 1 |
| Lee, CH | 2 |
| Michel, AD | 1 |
| Hayashi, H | 1 |
| Miwa, Y | 1 |
| Ichikawa, S | 1 |
| Yoda, N | 1 |
| Miki, I | 1 |
| Ishii, A | 2 |
| Kono, M | 1 |
| Yasuzawa, T | 1 |
| Suzuki, F | 1 |
| Gill, PJ | 1 |
| Thomas, E | 1 |
| Van den Bruel, A | 1 |
| Barzegar-Fallah, A | 1 |
| Alimoradi, H | 1 |
| Dunlop, JL | 1 |
| Torbati, E | 1 |
| Baird, SK | 1 |
| Edwards, A | 1 |
| Teusink-Cross, A | 1 |
| Martin, LJ | 1 |
| Prows, CA | 1 |
| Mehta, PA | 1 |
| Ramsey, LB | 1 |
| Birkenbeuel, JL | 1 |
| Warner, DC | 1 |
| Abiri, A | 1 |
| Brown, NJ | 1 |
| Nguyen, ES | 1 |
| Lee, A | 2 |
| Goshtasbi, K | 1 |
| Boladian, LA | 1 |
| Hsu, Z | 1 |
| Bitner, BF | 1 |
| Golshani, K | 1 |
| Chen, JW | 1 |
| Hsu, FPK | 1 |
| Kuan, EC | 1 |
| Coulm, B | 1 |
| Yang, H | 1 |
| Jeon, W | 1 |
| Ko, Y | 1 |
| Jeong, S | 1 |
| Lee, J | 1 |
| Robson, S | 1 |
| McParlin, C | 2 |
| Mossop, H | 1 |
| Lie, M | 1 |
| Fernandez-Garcia, C | 1 |
| Howel, D | 1 |
| Graham, R | 1 |
| Ternent, L | 1 |
| Steel, A | 1 |
| Goudie, N | 1 |
| Nadeem, A | 1 |
| Phillipson, J | 1 |
| Shehmar, M | 1 |
| Simpson, N | 1 |
| Tuffnell, D | 1 |
| Campbell, I | 1 |
| Williams, R | 1 |
| O'Hara, ME | 1 |
| McColl, E | 1 |
| Nelson-Piercy, C | 2 |
| Kamiya, T | 1 |
| Sakurai, M | 1 |
| Kikuchi, T | 1 |
| Okayama, M | 1 |
| Mizuno, K | 1 |
| Tanigawa, T | 1 |
| Koda, Y | 1 |
| Kato, J | 1 |
| Mori, T | 1 |
| Tubog, TD | 1 |
| Bramble, RS | 1 |
| Burke, JE | 1 |
| Hess, RS | 1 |
| Silverstein, DC | 1 |
| Jacobs, SS | 1 |
| Dome, JS | 1 |
| Gai, J | 1 |
| Gross, AM | 1 |
| Postell, E | 1 |
| Hinds, PS | 1 |
| Davenport, L | 1 |
| van den Anker, JN | 1 |
| Mowbray, C | 1 |
| Moothedath, AW | 1 |
| Meena, JP | 1 |
| Gupta, AK | 1 |
| Velpandian, T | 1 |
| Pandey, RM | 1 |
| Seth, R | 1 |
| Nuttall, GA | 1 |
| Voogd, SC | 1 |
| Danke, H | 1 |
| Warner, PA | 1 |
| Oyen, LJ | 1 |
| Marienau, MS | 1 |
| Ackerman, MJ | 1 |
| Sun, S | 1 |
| Ko, YH | 2 |
| Jin, JY | 1 |
| Woo, IS | 1 |
| Park, SY | 1 |
| Eom, YA | 1 |
| Kang, JH | 2 |
| Kim, HK | 1 |
| Slattery, J | 1 |
| Quinten, C | 1 |
| Candore, G | 1 |
| Pinheiro, L | 1 |
| Flynn, R | 1 |
| Kurz, X | 1 |
| Nordeng, H | 1 |
| Wichers, IM | 1 |
| Ozciftci, S | 1 |
| Sahiner, Y | 1 |
| Sahiner, IT | 1 |
| Akkaya, T | 1 |
| Henze, L | 1 |
| Foth, S | 2 |
| Meller, S | 2 |
| Twele, F | 1 |
| Charalambous, M | 1 |
| Kenward, H | 2 |
| Elliott, J | 2 |
| Pelligand, L | 2 |
| Volk, HA | 2 |
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
| Saif, S | 1 |
| Kakalia, S | 1 |
| Kitchlew, R | 1 |
| Khan, HA | 1 |
| Fida, S | 1 |
| Siddique, M | 1 |
| Mansour, M | 2 |
| Nasr, M | 2 |
| Ahmed-Farid, OAH | 2 |
| Ahmed, RF | 2 |
| Akashi, M | 1 |
| Palnizky Soffer, G | 1 |
| Schnapp, Z | 1 |
| Miroluz, D | 1 |
| Rimon, A | 1 |
| Reis, ACC | 1 |
| Jorge, BC | 1 |
| da Silva Moreira, S | 1 |
| Stein, J | 1 |
| Perdão, CB | 1 |
| de Matos Manoel, B | 1 |
| Arena, AC | 1 |
| Assaad, R | 1 |
| Pratt, RE | 1 |
| Wrotniak, BH | 1 |
| Qiao, H | 1 |
| Territo, HM | 1 |
| Lee, SY | 1 |
| Tamale, JR | 1 |
| Cinar, E | 1 |
| Sanci, E | 1 |
| Utku, HS | 1 |
| Ozbek, AE | 1 |
| Liu, Y | 2 |
| Chen, X | 1 |
| Wang, X | 3 |
| Zhong, H | 1 |
| He, H | 2 |
| Liao, Y | 1 |
| Pan, Z | 1 |
| Hu, W | 1 |
| Liu, W | 1 |
| Zheng, F | 1 |
| França de Moraes, GH | 1 |
| Lima, LC | 1 |
| Couceiro, TCM | 1 |
| Lins, MM | 1 |
| Cumino, DO | 1 |
| Simões, LABM | 1 |
| Mello, MJG | 1 |
| Scheier, E | 1 |
| Balla, U | 1 |
| Patel, MP | 2 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 1 |
| Healy, P | 1 |
| Herndon, JE | 2 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 2 |
| Barney, EZ | 1 |
| Fuller, ME | 1 |
| Habib, AS | 2 |
| Tienchaiananda, P | 1 |
| Nipondhkit, W | 1 |
| Maneenil, K | 1 |
| Sa-Nguansai, S | 1 |
| Payapwattanawong, S | 1 |
| Laohavinij, S | 1 |
| Maneechavakajorn, J | 1 |
| Silverman, RA | 1 |
| House, SL | 1 |
| Meltzer, AC | 1 |
| Hahn, B | 1 |
| Lovato, LM | 1 |
| Avarello, J | 1 |
| Miller, JB | 1 |
| Kalfus, IN | 1 |
| Fathi, R | 1 |
| Raday, G | 1 |
| Plasse, TF | 1 |
| Yan, EC | 1 |
| Navari, RM | 4 |
| Willier, S | 1 |
| Cabanillas Stanchi, KM | 1 |
| von Have, M | 1 |
| Binder, V | 1 |
| Blaeschke, F | 1 |
| Feucht, J | 1 |
| Feuchtinger, T | 1 |
| Döring, M | 1 |
| Vimolchalao, V | 1 |
| Sakdejayont, S | 1 |
| Wongchanapai, P | 1 |
| Sukprakun, S | 1 |
| Angspatt, P | 1 |
| Thawinwisan, W | 1 |
| Chenaksara, P | 1 |
| Sriuranpong, V | 1 |
| Vinayanuwatikun, C | 1 |
| Parinyanitikun, N | 1 |
| Poovorawan, N | 1 |
| Tanasanvimon, S | 1 |
| Nejati, A | 1 |
| Davarani, SS | 1 |
| Talebian, MT | 1 |
| Hossein, F | 1 |
| Akbari, H | 1 |
| Momper, JD | 1 |
| Heinrichs, MT | 1 |
| Krudys, K | 1 |
| Griebel, D | 1 |
| Kumar, S | 2 |
| Kim, I | 1 |
| Mehrotra, N | 1 |
| Mulberg, AE | 1 |
| Garimella, N | 1 |
| Nelson, R | 1 |
| Reaman, G | 1 |
| Sinha, V | 1 |
| Yao, L | 1 |
| Zineh, I | 1 |
| Burckart, G | 1 |
| Sachs, H | 1 |
| Mulugeta, Y | 1 |
| Yeo, W | 2 |
| Lau, TK | 1 |
| Li, L | 1 |
| Lai, KT | 1 |
| Pang, E | 1 |
| Cheung, M | 1 |
| Chan, VT | 1 |
| Wong, A | 2 |
| Soo, WM | 1 |
| Yeung, VT | 1 |
| Tse, T | 1 |
| Lam, DC | 1 |
| Yeung, EW | 1 |
| Ng, KP | 1 |
| Tang, NL | 1 |
| Tong, M | 1 |
| Suen, JJ | 2 |
| Mo, FK | 2 |
| Fauteux-Lamarre, E | 1 |
| McCarthy, M | 1 |
| Quinn, N | 1 |
| Davidson, A | 1 |
| Legge, D | 1 |
| Lee, KJ | 1 |
| Palmer, GM | 1 |
| Babl, FE | 2 |
| Hopper, SM | 1 |
| Ithimakin, S | 3 |
| Theeratrakul, P | 1 |
| Laocharoenkiat, A | 1 |
| Nimmannit, A | 2 |
| Akewanlop, C | 3 |
| Soparattanapaisarn, N | 3 |
| Techawattanawanna, S | 1 |
| Korphaisarn, K | 2 |
| Danchaivijitr, P | 2 |
| Niño-Serna, LF | 1 |
| Acosta-Reyes, J | 1 |
| Veroniki, AA | 1 |
| Florez, ID | 1 |
| Rowland, KD | 1 |
| Fuehrer, J | 1 |
| Motov, SM | 1 |
| Vilke, G | 1 |
| Rosenbaum, SB | 1 |
| Quenzer, F | 1 |
| Armbruster, SD | 1 |
| Fellman, BM | 1 |
| Jhingran, A | 1 |
| Eifel, PJ | 1 |
| Klopp, AH | 1 |
| Coleman, RL | 1 |
| Ramondetta, LM | 1 |
| Frumovitz, M | 1 |
| Fugetto, F | 1 |
| Filice, E | 1 |
| Biagi, C | 1 |
| Pierantoni, L | 1 |
| Gori, D | 1 |
| Lanari, M | 1 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Freedman, SB | 11 |
| Williamson-Urquhart, S | 3 |
| Heath, A | 2 |
| Pechlivanoglou, P | 2 |
| Hopkin, G | 2 |
| Gouin, S | 3 |
| Plint, AC | 2 |
| Dixon, A | 2 |
| Beer, D | 2 |
| Joubert, G | 2 |
| McCabe, C | 2 |
| Finkelstein, Y | 3 |
| Klassen, TP | 2 |
| Benary, D | 1 |
| Lozano, JM | 1 |
| Higley, R | 1 |
| Lowe, D | 1 |
| Huybrechts, KF | 2 |
| Hernández-Díaz, S | 3 |
| Bateman, BT | 2 |
| Wu, HL | 1 |
| Zhan, X | 1 |
| Kantyka, ME | 1 |
| Meira, C | 1 |
| Bettschart-Wolfensberger, R | 1 |
| Hartnack, S | 1 |
| Kutter, APN | 1 |
| Vasquez-Camargo, A | 1 |
| Gamble, J | 1 |
| Fedoruk, KA | 1 |
| Lim, HJJ | 1 |
| Mondal, PK | 1 |
| Martinez, J | 1 |
| Miller, GG | 1 |
| Rios, JD | 1 |
| Offringa, M | 1 |
| Suarez, EA | 2 |
| Boggess, K | 2 |
| Engel, SM | 2 |
| Stürmer, T | 2 |
| Lund, JL | 2 |
| Jonsson Funk, M | 1 |
| Ben-Yakov, M | 1 |
| Bhatt, M | 1 |
| Funk, MJ | 1 |
| Ruberto, AJ | 2 |
| Sivilotti, MLA | 2 |
| Forrester, S | 1 |
| Hall, AK | 2 |
| Crawford, FM | 2 |
| Day, AG | 1 |
| Afzal, A | 1 |
| Khan, A | 2 |
| Farooqi, R | 1 |
| Khan, BT | 1 |
| Ara, I | 1 |
| Sakran, R | 1 |
| Shechtman, S | 2 |
| Arnon, J | 1 |
| Diav-Citrin, O | 2 |
| Damkier, P | 1 |
| Kaplan, YC | 1 |
| Cassina, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Gray, JM | 2 |
| Hendrickson, MA | 2 |
| Leonard, SA | 1 |
| Miceli Sopo, S | 1 |
| Baker, MG | 1 |
| Fiocchi, A | 1 |
| Wood, RA | 1 |
| Nowak-Węgrzyn, A | 1 |
| Ruktrirong, J | 1 |
| Traivaree, C | 1 |
| Monsereenusorn, C | 1 |
| Photia, A | 1 |
| Lertvivatpong, N | 1 |
| Rujkijyanont, P | 1 |
| Mukhopadhyay, S | 1 |
| Dutta, P | 1 |
| Banerjee, S | 1 |
| Bhattacharya, B | 1 |
| Biswas, S | 1 |
| M Navari, R | 1 |
| Cheung, F | 1 |
| Doherty, SM | 1 |
| Tatara, AW | 1 |
| Moussa, G | 1 |
| Genest, M | 1 |
| Villeneuve, E | 1 |
| Wang, JJ | 1 |
| Goda, M | 1 |
| Kanda, M | 1 |
| Yoshioka, T | 1 |
| Yoshida, A | 1 |
| Murai, Y | 1 |
| Zamami, Y | 1 |
| Aizawa, F | 1 |
| Niimura, T | 1 |
| Hamano, H | 1 |
| Okada, N | 1 |
| Yagi, K | 1 |
| Chuma, M | 1 |
| Izawa-Ishizawa, Y | 1 |
| Ishizawa, K | 1 |
| Weghorst, AA | 2 |
| Holtman, GA | 2 |
| Bonvanie, IJ | 2 |
| Wolters, PI | 1 |
| Kollen, BJ | 2 |
| Vermeulen, KM | 1 |
| Berger, MY | 2 |
| Wang, R | 1 |
| Song, X | 2 |
| Chen, Y | 2 |
| Wang, N | 1 |
| Wang, J | 1 |
| Sutherland, H | 1 |
| Miller, M | 1 |
| Tomanec, A | 1 |
| Xu, KT | 1 |
| Barton, T | 1 |
| Richman, P | 1 |
| Powell, EC | 3 |
| Roskind, CG | 1 |
| Schnadower, D | 1 |
| Olsen, CS | 1 |
| Casper, TC | 1 |
| Tarr, PI | 1 |
| O'Connell, KJ | 1 |
| Levine, AC | 1 |
| Poonai, N | 1 |
| Schuh, S | 1 |
| Rogers, AJ | 1 |
| Bhatt, SR | 1 |
| Mahajan, P | 1 |
| Vance, C | 1 |
| Hurley, K | 1 |
| Farion, KJ | 1 |
| Sapien, RE | 1 |
| Russchen, HA | 1 |
| Fickweiler, F | 1 |
| Verkade, HJ | 1 |
| Richards, JR | 1 |
| Gordon, BK | 1 |
| Danielson, AR | 1 |
| Moulin, AK | 1 |
| Bernhardt, MB | 1 |
| Cerit, Z | 1 |
| Kovács, G | 2 |
| Wachtel, A | 1 |
| Basharova, E | 1 |
| Spinelli, T | 2 |
| Nicolas, P | 2 |
| Kabickova, E | 2 |
| Herrstedt, J | 10 |
| Summers, Y | 1 |
| Daugaard, G | 1 |
| Christensen, TB | 1 |
| Holmskov, K | 1 |
| Taylor, PD | 1 |
| Fox, GM | 1 |
| Molassiotis, A | 2 |
| Abdel-Malek, R | 1 |
| Abbas, N | 1 |
| Shohdy, KS | 1 |
| Ismail, M | 1 |
| Fawzy, R | 1 |
| Salem, DS | 1 |
| Safwat, E | 1 |
| Estan-Cerezo, G | 1 |
| Jiménez-Pulido, I | 1 |
| Rodríguez Lucena, FJ | 1 |
| Matoses Chirivella, C | 1 |
| Soriano-Irigaray, L | 1 |
| Navarro-Ruiz, A | 1 |
| Zhou, C | 1 |
| Zhu, Y | 3 |
| Bao, Z | 1 |
| Liu, Q | 1 |
| Tan, J | 1 |
| Wang, S | 1 |
| Liang, X | 1 |
| Li, CC | 1 |
| Zhang, J | 1 |
| Zhao, Z | 1 |
| Kong, XR | 1 |
| Deng, X | 1 |
| Peng, L | 1 |
| Yang, C | 1 |
| Canziani, BC | 1 |
| Uestuener, P | 1 |
| Fossali, EF | 1 |
| Lava, SAG | 1 |
| Bianchetti, MG | 1 |
| Agostoni, C | 1 |
| Milani, GP | 1 |
| Culver, MA | 1 |
| Richards, EC | 1 |
| Jarrell, DH | 1 |
| Edwards, CJ | 1 |
| Karabulut, B | 1 |
| Hoffman, RJ | 1 |
| Alansari, K | 1 |
| Green-Hopkins, I | 1 |
| Monuteaux, MC | 1 |
| Lee, LK | 1 |
| Nigrovic, LE | 2 |
| Mannix, R | 1 |
| Schutzman, SA | 1 |
| Maewal, JD | 1 |
| Lunos, SA | 1 |
| Furnival, RA | 1 |
| Alsabah, S | 1 |
| Al Haddad, E | 1 |
| Ekrouf, S | 1 |
| Almulla, A | 1 |
| Al-Subaie, S | 1 |
| Al Kendari, M | 1 |
| Bergemalm, J | 1 |
| Ludvigsson, JF | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Koneru, S | 1 |
| Vishwakarma, G | 1 |
| Weinstein, C | 1 |
| Jordan, K | 5 |
| Green, SA | 1 |
| Camacho, E | 1 |
| Khanani, S | 1 |
| Beckford-Brathwaite, E | 1 |
| Pong, A | 2 |
| Noga, SJ | 1 |
| Rapoport, BL | 3 |
| Gravel, J | 1 |
| Boutis, K | 1 |
| Tang, K | 1 |
| Beauchamp, MH | 1 |
| Dubrovsky, AS | 1 |
| Gagnon, I | 1 |
| Momoli, F | 1 |
| Zemek, R | 1 |
| Kang, HJ | 1 |
| Loftus, S | 1 |
| DiCristina, C | 1 |
| Green, S | 1 |
| Zwaan, CM | 1 |
| Clemmons, AB | 1 |
| Orr, J | 1 |
| Andrick, B | 1 |
| Gandhi, A | 1 |
| Sportes, C | 1 |
| DeRemer, D | 1 |
| Steurer, J | 1 |
| Ye, Z | 1 |
| Xue, A | 1 |
| Huang, Y | 1 |
| Wu, Q | 1 |
| LaPorte, J | 1 |
| Leone, K | 1 |
| Zhang, X | 1 |
| Holland, K | 1 |
| Morris, L | 1 |
| Bashey, A | 1 |
| Solh, M | 1 |
| Solomon, S | 1 |
| Lindblad, AJ | 1 |
| Ting, R | 1 |
| Harris, K | 1 |
| Wang, W | 1 |
| Lou, G | 1 |
| Zhang, Y | 2 |
| Carroll, C | 1 |
| Clinton, F | 1 |
| Smith, A | 2 |
| Fox, A | 1 |
| Capra, M | 1 |
| Pears, J | 1 |
| Owens, C | 1 |
| Osman, AAM | 1 |
| Elhassan, MMA | 1 |
| AbdElrahim, BHA | 1 |
| Ahmed, FHA | 1 |
| Yousif, JBH | 1 |
| Ahmed, MAM | 1 |
| Abdelhafeez, RHA | 1 |
| Ahmed, UMY | 1 |
| Ducloyer, JB | 1 |
| Couret, C | 1 |
| Magne, C | 1 |
| Lejus-Bourdeau, C | 1 |
| Weber, M | 1 |
| Le Meur, G | 1 |
| Lebranchu, P | 1 |
| Soofi, SB | 1 |
| Willan, AR | 1 |
| Ali, N | 1 |
| Xie, J | 1 |
| Dawoud, F | 1 |
| Bhutta, ZA | 1 |
| Rees, CA | 1 |
| Romano, C | 1 |
| Dipasquale, V | 1 |
| Scarpignato, C | 1 |
| Haas, DM | 1 |
| Straub, L | 1 |
| Gray, KJ | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Mogun, H | 1 |
| Ali, S | 1 |
| Hartman, S | 1 |
| Brown, E | 1 |
| Loomis, E | 1 |
| Russell, HA | 1 |
| Dalrymple, RA | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Chaudhary, NK | 1 |
| John, RR | 1 |
| Boddu, D | 1 |
| Mahasampath, G | 1 |
| Nesadeepam, N | 1 |
| Mathew, LG | 1 |
| McKenzie, E | 1 |
| Chan, D | 1 |
| Parsafar, S | 1 |
| Razvi, Y | 1 |
| McFarlane, T | 1 |
| Rico, V | 1 |
| Pasetka, M | 2 |
| DeAngelis, C | 3 |
| Chow, E | 3 |
| Rang, NN | 1 |
| Chanh, TQ | 1 |
| My, PT | 1 |
| Tien, TTM | 1 |
| Rotella, JA | 1 |
| Hase, T | 1 |
| Hashimoto, T | 1 |
| Saito, H | 1 |
| Uchida, Y | 1 |
| Kato, R | 2 |
| Tsuruga, K | 1 |
| Takita, K | 1 |
| Morimoto, Y | 3 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Ban, E | 1 |
| Kim, CK | 2 |
| Thanacoody, HK | 3 |
| Gray, A | 2 |
| Dear, JW | 3 |
| Coyle, J | 2 |
| Sandilands, EA | 2 |
| Webb, DJ | 2 |
| Lewis, S | 1 |
| Eddleston, M | 3 |
| Thomas, SH | 3 |
| Bateman, DN | 4 |
| Eisenberg, S | 1 |
| Wickline, M | 1 |
| Linenberger, M | 1 |
| Gooley, T | 1 |
| Holmberg, L | 1 |
| McLean, SL | 1 |
| Blenkinsopp, A | 1 |
| Bennett, MI | 1 |
| George, RB | 1 |
| McKeen, DM | 1 |
| White, WD | 1 |
| Ituk, US | 1 |
| Megalla, SA | 1 |
| Allen, TK | 1 |
| Ngampramuan, S | 2 |
| Baumert, M | 1 |
| Czippelova, B | 1 |
| Nalivaiko, E | 2 |
| Wenzell, CM | 1 |
| Berger, MJ | 1 |
| Blazer, MA | 1 |
| Crawford, BS | 1 |
| Griffith, NL | 1 |
| Wesolowski, R | 1 |
| Lustberg, MB | 1 |
| Phillips, GS | 1 |
| Ramaswamy, B | 1 |
| Mrozek, E | 1 |
| Flynn, JM | 1 |
| Shapiro, CL | 1 |
| Layman, RM | 1 |
| Choudhary, DR | 1 |
| Patel, VA | 1 |
| Chhalotiya, UK | 1 |
| Patel, HV | 1 |
| Kundawala, AJ | 1 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Lawler, M | 1 |
| Schwartzberg, L | 2 |
| Barbour, SY | 1 |
| Morrow, GR | 3 |
| Ballinari, G | 1 |
| Thorn, MD | 1 |
| Cox, D | 1 |
| Hays, HL | 1 |
| Jolliff, HA | 1 |
| Casavant, MJ | 1 |
| Park, K | 1 |
| Antoine, DJ | 1 |
| Pirmohamed, M | 1 |
| Cooper, JG | 1 |
| Rodriguez, A | 1 |
| Butcher, I | 1 |
| Lewis, SC | 1 |
| Vliegenthart, AD | 1 |
| Veiraiah, A | 1 |
| Billio, A | 2 |
| Morello, E | 2 |
| Clarke, MJ | 2 |
| Cotton, PJ | 1 |
| Noaman, SQ | 1 |
| Bodge, M | 1 |
| Shillingburg, A | 1 |
| Paul, S | 1 |
| Biondo, L | 1 |
| Larrimer, MB | 1 |
| Dajani, NK | 1 |
| Siegel, ER | 1 |
| Eswaran, H | 1 |
| Newport, DJ | 1 |
| Stowe, ZN | 1 |
| Lee, JS | 4 |
| Jeon, WC | 1 |
| Park, EJ | 1 |
| Min, YG | 1 |
| Kim, GW | 1 |
| Jung, YS | 1 |
| Choi, SC | 1 |
| Chan, SW | 2 |
| Lu, Z | 1 |
| Lin, G | 2 |
| Yew, DT | 3 |
| Yeung, CK | 1 |
| Rudd, JA | 12 |
| Cerri, M | 1 |
| Del Vecchio, F | 1 |
| Corrigan, JJ | 1 |
| Kamphee, A | 1 |
| Dragic, AS | 1 |
| Romanovsky, AA | 1 |
| Goineau, S | 1 |
| Guillaume, P | 1 |
| Barrais, L | 1 |
| Castagné, V | 1 |
| Kessler, B | 1 |
| Hoffman, R | 1 |
| Egerton-Warburton, D | 2 |
| Meek, R | 2 |
| Mee, MJ | 1 |
| Braitberg, G | 1 |
| Weil, G | 1 |
| Motamed, C | 1 |
| Eghiaian, A | 1 |
| Guye, ML | 1 |
| Bourgain, JL | 1 |
| Yin, JY | 1 |
| Xu, YJ | 1 |
| Li, X | 1 |
| Liu, ZG | 1 |
| Zhou, F | 1 |
| Zhai, M | 1 |
| Li, Y | 2 |
| Li, XP | 1 |
| Wang, Y | 2 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Furyk, JS | 2 |
| McKenzie, S | 1 |
| Brygger, L | 1 |
| Oliveira, LG | 1 |
| Capp, SM | 1 |
| You, WB | 1 |
| Riffenburgh, RH | 1 |
| Carstairs, SD | 1 |
| Rithirangsriroj, K | 1 |
| Manchana, T | 1 |
| Akkayagorn, L | 1 |
| Leung, JS | 1 |
| Perlman, K | 1 |
| Rumantir, M | 2 |
| Pitts, SR | 1 |
| Wang, L | 3 |
| Wang, H | 2 |
| Zhang, H | 2 |
| Badar, T | 1 |
| Cortes, J | 1 |
| Borthakur, G | 2 |
| O'Brien, S | 2 |
| Wierda, W | 1 |
| Garcia-Manero, G | 1 |
| Ferrajoli, A | 1 |
| Kadia, T | 1 |
| Poku, R | 1 |
| Kantarjian, H | 2 |
| Mattiuzzi, G | 1 |
| Bakhshi, S | 2 |
| Batra, A | 1 |
| Biswas, B | 1 |
| Dhawan, D | 1 |
| Paul, R | 1 |
| Sreenivas, V | 1 |
| Lalani, N | 1 |
| Gaco, D | 1 |
| Rapoport, B | 4 |
| Chua, D | 2 |
| Poma, A | 1 |
| Arora, S | 2 |
| Fein, LE | 1 |
| Jahn, F | 1 |
| Riesner, A | 1 |
| Jahn, P | 1 |
| Sieker, F | 1 |
| Vordermark, D | 1 |
| Kitamura, H | 1 |
| Takahashi, A | 1 |
| Hotta, H | 1 |
| Kunishima, Y | 1 |
| Takei, F | 1 |
| Horita, H | 1 |
| Masumori, N | 1 |
| Onifer, DJ | 1 |
| Butler, FK | 1 |
| Gross, K | 1 |
| Otten, EJ | 1 |
| Patton, R | 1 |
| Russell, RJ | 1 |
| Stockinger, Z | 1 |
| Burrell, E | 1 |
| Dranitsaris, G | 3 |
| Mazzarello, S | 2 |
| Smith, S | 2 |
| Vandermeer, L | 2 |
| Bouganim, N | 2 |
| Clemons, M | 2 |
| Meek, RA | 1 |
| Liu, RR | 1 |
| Yang, ZH | 2 |
| Yang, YL | 1 |
| Liu, ZT | 2 |
| Yue, W | 4 |
| Mills, JR | 1 |
| Greene, DN | 1 |
| Bainton, J | 1 |
| Lorey, TS | 1 |
| Baumann, NA | 1 |
| Kim, HJ | 2 |
| Shin, SW | 1 |
| Song, EK | 1 |
| Lee, NR | 1 |
| Kim, JS | 1 |
| Ahn, JS | 1 |
| Yun, HJ | 1 |
| Cho, YH | 1 |
| Park, KU | 1 |
| Kim, SY | 1 |
| Jang, JS | 2 |
| Kim, SW | 3 |
| Lee, HW | 1 |
| Lee, SR | 1 |
| Kim, YS | 1 |
| Lee, SN | 1 |
| Segal, R | 1 |
| Dent, S | 1 |
| Gertler, S | 1 |
| Wheatley-Price, P | 1 |
| Danewa, AS | 1 |
| Shah, D | 1 |
| Batra, P | 1 |
| Bhattacharya, SK | 1 |
| Gupta, P | 1 |
| Okumura, LM | 2 |
| Wachtel, AE | 1 |
| Basharova, EV | 1 |
| Chiu, N | 1 |
| Chiu, L | 1 |
| Popovic, M | 1 |
| Lutz, S | 1 |
| Zhang, N | 1 |
| Marta, GN | 1 |
| Mendez, LC | 1 |
| Lechner, B | 1 |
| Pulenzas, N | 1 |
| Milakovic, M | 1 |
| Chow, R | 1 |
| Chasen, M | 1 |
| Powers, D | 1 |
| Navari, R | 6 |
| Schnadig, I | 1 |
| Mathew, JL | 1 |
| Kumar, P | 1 |
| Deswal, S | 1 |
| Ibrahim, K | 1 |
| Al Ansari, K | 1 |
| Schnadig, ID | 1 |
| Agajanian, R | 1 |
| Dakhil, C | 1 |
| Gabrail, NY | 1 |
| Smith, RE | 1 |
| Taylor, C | 1 |
| Wilks, ST | 1 |
| Schwartzberg, LS | 1 |
| Cooper, W | 1 |
| Mosier, MC | 1 |
| Payne, JY | 1 |
| Klepper, MJ | 1 |
| Vacirca, JL | 1 |
| Shi, Q | 1 |
| Li, W | 1 |
| Li, H | 1 |
| Le, Q | 1 |
| Liu, S | 1 |
| Zong, S | 1 |
| Zheng, L | 1 |
| Hou, F | 1 |
| Westerlund, A | 1 |
| Vicente, V | 1 |
| Hjelte Judell, O | 1 |
| Lindström, V | 1 |
| Freedman, S | 2 |
| Simino, GP | 1 |
| Marra, LP | 1 |
| Andrade, EI | 1 |
| Acúrcio, Fde A | 1 |
| Reis, IA | 1 |
| De Araújo, VE | 1 |
| Cherchiglia, ML | 1 |
| Singer, AJ | 2 |
| Garra, G | 2 |
| Thode, HC | 2 |
| Suzuki, S | 1 |
| Karayama, M | 1 |
| Inui, N | 1 |
| Kuroishi, S | 1 |
| Fujisawa, T | 1 |
| Enomoto, N | 1 |
| Nakamura, Y | 1 |
| Yokomura, K | 1 |
| Toyoshima, M | 1 |
| Imokawa, S | 1 |
| Asada, K | 1 |
| Masuda, M | 1 |
| Yamada, T | 1 |
| Watanabe, H | 1 |
| Hayakawa, H | 1 |
| Suda, T | 1 |
| Du, Q | 1 |
| Zhai, Q | 1 |
| Zhu, B | 1 |
| Xu, XL | 1 |
| Yu, B | 1 |
| Krammes, SK | 1 |
| Jacobs, T | 1 |
| Clark, JM | 1 |
| Lutes, RE | 1 |
| Tomasik, E | 1 |
| Ziółkowska, E | 1 |
| Kołodziej, M | 1 |
| Szajewska, H | 2 |
| Wilbur, MB | 1 |
| Birrer, MJ | 1 |
| Spriggs, DR | 1 |
| Song, Z | 1 |
| Zhao, K | 1 |
| Zhang, M | 1 |
| Yang, F | 1 |
| Thompson, GC | 1 |
| Morrison, EL | 1 |
| Chaulk, D | 1 |
| Wobma, H | 1 |
| Kwong, S | 1 |
| Johnson, DW | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Thamlikitkul, L | 1 |
| Srimuninnimit, V | 2 |
| Techawathanawanna, S | 1 |
| Chantharasamee, J | 1 |
| Nakagaki, M | 1 |
| Barras, M | 1 |
| Curley, C | 1 |
| Butler, JP | 1 |
| Kennedy, GA | 1 |
| Bourdon, F | 1 |
| Lecoeur, M | 1 |
| Leconte, L | 1 |
| Ultré, V | 1 |
| Kouach, M | 1 |
| Odou, P | 1 |
| Vaccher, C | 1 |
| Foulon, C | 1 |
| Kim, JE | 1 |
| Kim, JW | 1 |
| Sung, YL | 1 |
| Cho, CH | 1 |
| Lee, MA | 1 |
| Kim, DJ | 1 |
| Ahn, MJ | 2 |
| Lee, KY | 1 |
| Sym, SJ | 1 |
| Lim, MC | 1 |
| Jung, H | 1 |
| Cho, EK | 1 |
| Min, KW | 1 |
| D'Athayde Rodrigues, F | 1 |
| Ferreira, MAP | 1 |
| Moreira, LB | 1 |
| Moeen, SM | 1 |
| Marchetti, F | 2 |
| Bonati, M | 2 |
| Maestro, A | 2 |
| Zanon, D | 2 |
| Rovere, F | 2 |
| Arrighini, A | 2 |
| Barbi, E | 1 |
| Bertolani, P | 2 |
| Biban, P | 2 |
| Da Dalt, L | 2 |
| Guala, A | 2 |
| Mazzoni, E | 1 |
| Pazzaglia, A | 2 |
| Perri, PF | 1 |
| Reale, A | 2 |
| Renna, S | 2 |
| Urbino, AF | 2 |
| Valletta, E | 2 |
| Vitale, A | 2 |
| Zangardi, T | 2 |
| Clavenna, A | 2 |
| Ronfani, L | 2 |
| Ades, S | 1 |
| Halyard, M | 1 |
| Wilson, K | 3 |
| Ashikaga, T | 1 |
| Heimann, R | 1 |
| Blackstock, W | 1 |
| Yalcin, E | 1 |
| Keser, GO | 1 |
| Schutz, J | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Bamber, D | 1 |
| Chohan, J | 1 |
| Troxell, R | 1 |
| Krobbuaban, B | 1 |
| Pitakpol, S | 1 |
| Diregpoke, S | 1 |
| Gore, L | 1 |
| Chawla, S | 2 |
| Petrilli, A | 1 |
| Hemenway, M | 1 |
| Schissel, D | 1 |
| Chua, V | 1 |
| Carides, AD | 10 |
| Taylor, A | 4 |
| Devandry, S | 2 |
| Valentine, J | 1 |
| Evans, JK | 6 |
| Oxenius, B | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Tóth, J | 1 |
| Szántó, J | 1 |
| Lajolo, PP | 2 |
| de Camargo, B | 1 |
| del Giglio, A | 4 |
| Johnson, B | 1 |
| Adams, L | 1 |
| Lu, E | 1 |
| Zhang, K | 1 |
| Lebowitz, P | 1 |
| Lates, C | 1 |
| Blum, R | 1 |
| Galy, G | 1 |
| Labidi, SI | 1 |
| Tissier, F | 1 |
| Combes, JD | 1 |
| Auger, A | 1 |
| Favier, B | 1 |
| Latour, JF | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Colletti, JE | 1 |
| Brown, KM | 2 |
| Sharieff, GQ | 1 |
| Barata, IA | 1 |
| Ishimine, P | 1 |
| Yamamoto, K | 2 |
| Asano, K | 1 |
| Yamatodani, A | 2 |
| Alhashimi, D | 4 |
| Al-Hashimi, H | 1 |
| Fedorowicz, Z | 5 |
| Du Bois, A | 6 |
| Singh, NN | 1 |
| Rai, A | 1 |
| Selhorst, JB | 1 |
| Acharya, JN | 1 |
| Roila, F | 14 |
| Rolski, J | 1 |
| Ramlau, R | 1 |
| Dediu, M | 1 |
| Russo, MW | 4 |
| Bandekar, RR | 2 |
| Grunberg, SM | 14 |
| Boice, JA | 2 |
| Brown, C | 1 |
| Hardwick, JS | 2 |
| Carides, A | 2 |
| Webb, T | 1 |
| Schmoll, HJ | 4 |
| Ng, WL | 1 |
| Della-Fiorentina, SA | 1 |
| Yilmaz, HL | 1 |
| Yildizdas, RD | 1 |
| Sertdemir, Y | 1 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Van Belle, S | 5 |
| Levin, J | 3 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Arpornwirat, W | 1 |
| Albert, I | 1 |
| Hansen, VL | 1 |
| Rzepecki, P | 2 |
| Pielichowski, W | 2 |
| Oborska, S | 2 |
| Barzal, J | 2 |
| Mlot, B | 2 |
| Gridelli, C | 2 |
| Haiderali, AM | 1 |
| Blackburn, LM | 1 |
| Lykopoulos, K | 1 |
| Ayuhara, H | 1 |
| Takayanagi, R | 1 |
| Okuyama, K | 1 |
| Yoshimoto, K | 1 |
| Ozeki, T | 1 |
| Yokoyama, H | 1 |
| Yamada, Y | 1 |
| Patanwala, AE | 1 |
| Amini, R | 1 |
| Hays, DP | 1 |
| Rosen, P | 1 |
| Sturm, JJ | 3 |
| Hirsh, DA | 3 |
| Schweickert, A | 1 |
| Massey, R | 1 |
| Simon, HK | 3 |
| Lee, CY | 1 |
| Ratnapalan, S | 1 |
| Thompson, M | 1 |
| Nathan, PC | 2 |
| Closs, J | 1 |
| French, A | 1 |
| Punnett, A | 1 |
| Garcia-Bournissen, F | 1 |
| Ito, S | 1 |
| Koren, G | 3 |
| Qian, Q | 1 |
| Chen, W | 1 |
| Yang, Z | 1 |
| Liu, Z | 1 |
| Qian, W | 1 |
| Trepanier, L | 1 |
| Gener, B | 1 |
| Burns, JM | 1 |
| Griffin, S | 1 |
| Boyer, EW | 1 |
| Yeh, YC | 1 |
| McDonnell, A | 1 |
| Klinger, E | 1 |
| Fowler, B | 1 |
| Matta, L | 1 |
| Voit, D | 1 |
| Reddy, P | 1 |
| Warr, DG | 4 |
| Street, JC | 2 |
| Brearley, SG | 1 |
| Stamataki, Z | 1 |
| Dong, X | 1 |
| Huang, J | 1 |
| Cao, R | 1 |
| Liu, L | 1 |
| Hesketh, PJ | 17 |
| Pillai, AK | 1 |
| Sharma, KK | 1 |
| Gupta, YK | 2 |
| Demir, HA | 1 |
| Batu, ED | 1 |
| Yalçın, B | 1 |
| Civelek, E | 1 |
| Saçkesen, C | 1 |
| Büyükpamukçu, M | 1 |
| Hunt, CM | 1 |
| Papay, JI | 1 |
| Rich, DS | 1 |
| Abissi, CJ | 1 |
| Steiner, MJ | 1 |
| Chan, KJ | 2 |
| Howard, S | 1 |
| Nava-Ocampo, AA | 1 |
| Kaushal, J | 1 |
| Gupta, MC | 1 |
| Kaushal, V | 1 |
| Bhutani, G | 1 |
| Dhankar, R | 1 |
| Atri, R | 1 |
| Verma, S | 3 |
| Patel, A | 1 |
| Mittal, S | 1 |
| Manchanda, S | 1 |
| Puliyel, JM | 1 |
| Mattiuzzi, GN | 1 |
| Cortes, JE | 1 |
| Blamble, DA | 1 |
| Bekele, BN | 1 |
| Xiao, L | 1 |
| Cabanillas, M | 1 |
| Ando, K | 2 |
| Takagi, K | 2 |
| Di Pietro, P | 1 |
| Mannelli, F | 1 |
| Messi, G | 1 |
| Perri, F | 1 |
| Tondelli, MT | 1 |
| Grunberg, S | 1 |
| Maru, A | 1 |
| Dinis, J | 1 |
| Beckford, E | 1 |
| Cruz, FM | 1 |
| de Iracema Gomes Cubero, D | 1 |
| Taranto, P | 1 |
| Lerner, T | 1 |
| Lera, AT | 1 |
| da Costa Miranda, M | 1 |
| da Cunha Vieira, M | 1 |
| de Souza Fêde, AB | 1 |
| Schindler, F | 1 |
| Carrasco, MM | 1 |
| de Afonseca, SO | 1 |
| Pinczowski, H | 1 |
| Runglodvatana, K | 1 |
| Keerativitayanan, N | 1 |
| Laocharoenkeat, A | 1 |
| Benner, JP | 1 |
| Ferguson, JD | 1 |
| Judkins, AE | 1 |
| O'Connor, RE | 1 |
| Brady, WJ | 1 |
| Santos, LC | 1 |
| Ludders, JW | 1 |
| Erb, HN | 1 |
| Martin-Flores, M | 1 |
| Basher, KL | 1 |
| Kirch, P | 1 |
| Klauser, CK | 1 |
| Fox, NS | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Rebarber, A | 1 |
| Desch, C | 1 |
| Palmer, B | 1 |
| Saltzman, D | 1 |
| Ebrahim Soltani, AR | 1 |
| Mohammadinasab, H | 1 |
| Goudarzi, M | 1 |
| Arbabi, S | 1 |
| Mohammadinasab, A | 1 |
| Mohammadinasab, F | 1 |
| Samimi, M | 1 |
| Feinberg, B | 1 |
| Gilmore, J | 1 |
| Haislip, S | 1 |
| Jackson, J | 1 |
| Jain, G | 1 |
| Balu, S | 1 |
| Buchner, D | 1 |
| Robb, PJ | 1 |
| Ewah, BN | 1 |
| Al-Ansari, K | 1 |
| Alomary, S | 1 |
| Abdulateef, H | 1 |
| Alshawagfa, M | 1 |
| Kamal, K | 1 |
| Wright, O | 1 |
| Rosati, G | 1 |
| Russo, M | 1 |
| Lane, S | 1 |
| Moiseyenko, V | 1 |
| Dube, P | 1 |
| Kopp, M | 1 |
| Makhson, A | 1 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 2 |
| Guchelaar, HJ | 1 |
| Dennis, K | 1 |
| Nguyen, J | 1 |
| Presutti, R | 1 |
| Tsao, M | 1 |
| Danjoux, C | 1 |
| Barnes, E | 1 |
| Sahgal, A | 1 |
| Holden, L | 1 |
| Jon, F | 1 |
| Wong, S | 1 |
| Jagannath, VA | 1 |
| Carter, B | 1 |
| Hayashi, T | 1 |
| Ikesue, H | 1 |
| Esaki, T | 1 |
| Fukazawa, M | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Tomizawa, T | 1 |
| Oishi, R | 1 |
| Vale, C | 1 |
| Oliveira, F | 1 |
| Assunção, J | 1 |
| Fontes-Ribeiro, C | 1 |
| Pereira, F | 1 |
| Gawronski, K | 1 |
| Wasko-Grabowska, A | 1 |
| Siddique, R | 1 |
| Hafiz, MG | 1 |
| Rokeya, B | 1 |
| Jamal, CY | 1 |
| Islam, A | 1 |
| Anderka, M | 1 |
| Mitchell, AA | 1 |
| Louik, C | 1 |
| Werler, MM | 1 |
| Rasmussen, SA | 1 |
| Tung, C | 1 |
| Cho, D | 1 |
| Park, DM | 1 |
| Song, YK | 1 |
| Jee, JP | 1 |
| Kim, HT | 1 |
| Pierzchala, A | 1 |
| Gupta, V | 1 |
| Bala, M | 1 |
| Prasad, J | 1 |
| Singh, S | 1 |
| Gupta, M | 1 |
| Allan, GM | 1 |
| Wilson, E | 1 |
| Ivers, N | 1 |
| Reichmann, JP | 1 |
| Kirkbride, MS | 1 |
| Tsubone, H | 1 |
| Al Abood, RM | 1 |
| Talegaonkar, S | 1 |
| Tariq, M | 1 |
| Ahmad, FJ | 1 |
| Shi, X | 1 |
| Liu, ZM | 1 |
| Zhu, XD | 1 |
| Cayley, WE | 1 |
| Khan, NS | 1 |
| Zhang, D | 1 |
| Mita, M | 1 |
| Shapiro, GI | 1 |
| Poon, J | 1 |
| Small, K | 1 |
| Tzontcheva, A | 1 |
| Kantesaria, B | 1 |
| Bannerji, R | 1 |
| Statkevich, P | 1 |
| Hervás, D | 1 |
| Armero, C | 1 |
| Carrión, T | 1 |
| Utrera, JF | 1 |
| Hervás, JA | 1 |
| Kinder, KL | 1 |
| Lehman-Huskamp, KL | 1 |
| Gerard, JM | 1 |
| Gomez, DR | 1 |
| Liao, KP | 1 |
| Giordano, S | 1 |
| Nguyen, H | 1 |
| Smith, BD | 1 |
| Elting, LS | 3 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Singhi, SC | 1 |
| Shah, R | 1 |
| Bansal, A | 1 |
| Jayashree, M | 1 |
| Lichinitser, MR | 1 |
| Garin, AM | 1 |
| Decramer, ML | 2 |
| Riviere, A | 2 |
| Thant, M | 1 |
| Brestan, E | 1 |
| Bui, B | 1 |
| Eldridge, K | 2 |
| De Smet, M | 2 |
| Michiels, N | 1 |
| Reinhardt, RR | 2 |
| Gertz, BJ | 2 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Park, JS | 1 |
| Markman, M | 6 |
| Leman, P | 1 |
| Lachaine, J | 2 |
| Laurier, C | 2 |
| Wang, C | 1 |
| Xu, N | 1 |
| Xiong, LZ | 1 |
| Liu, HF | 1 |
| Yang, XY | 1 |
| Lu, ZH | 1 |
| Sheng, PT | 1 |
| Wang, LY | 1 |
| Zhang, P | 3 |
| Feng, F | 1 |
| He, Y | 1 |
| Zhou, M | 1 |
| Cheng, G | 1 |
| Liaw, CC | 4 |
| Chang, HK | 4 |
| Liau, CT | 2 |
| Huang, JS | 4 |
| Lin, YC | 2 |
| Chen, JS | 1 |
| Khan, RB | 1 |
| Spirko, BA | 1 |
| Chawla, SP | 3 |
| Gralla, RJ | 9 |
| Rittenberg, C | 2 |
| Elmer, ME | 2 |
| Schmidt, C | 2 |
| Horgan, KJ | 5 |
| Caron, E | 1 |
| Bussières, JF | 1 |
| Lebel, D | 1 |
| Mathews, S | 1 |
| Milot, J | 1 |
| Jacob, JL | 1 |
| Moride, Y | 1 |
| Lortie, L | 1 |
| Aapro, M | 4 |
| Tattersall, FD | 2 |
| Naylor, RJ | 7 |
| Hargreaves, R | 1 |
| Tremblay, PB | 2 |
| Kaiser, R | 2 |
| Sezer, O | 2 |
| Rosler, N | 1 |
| Schelenz, C | 2 |
| Possinger, K | 2 |
| Roots, I | 2 |
| Brockmoller, J | 2 |
| Josefson, A | 1 |
| Kreuter, M | 1 |
| Zhang, F | 2 |
| Fang, X | 1 |
| Liu, YX | 1 |
| Minami, M | 2 |
| Martin, AR | 1 |
| Pearson, JD | 1 |
| Horgan, K | 1 |
| Elmer, M | 1 |
| Cai, B | 1 |
| Sam, TS | 2 |
| Cheng, JT | 1 |
| Johnston, KD | 1 |
| Kan, KK | 2 |
| Ngan, MP | 3 |
| Wai, MK | 3 |
| Yeung, JH | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| Xie, XD | 1 |
| Zheng, ZD | 1 |
| Liu, DW | 1 |
| Liu, YY | 1 |
| Shan, XJ | 1 |
| Tan, M | 1 |
| Gralla, R | 2 |
| Lichinitser, M | 1 |
| Van Der Vegt, S | 1 |
| Sleeboom, H | 1 |
| Mezger, J | 1 |
| Peschel, C | 1 |
| Tonini, G | 1 |
| Labianca, R | 1 |
| Macciocchi, A | 2 |
| de Wit, R | 5 |
| Ianus, J | 2 |
| Beck, K | 1 |
| Reines, S | 1 |
| Gershanovich, ML | 2 |
| Beresneva, IA | 1 |
| Makhnova, EV | 1 |
| Koeller, JM | 1 |
| Kwiatkowska, M | 2 |
| Parker, LA | 2 |
| Burton, P | 1 |
| Mechoulam, R | 1 |
| Bhatia, A | 3 |
| Tripathi, KD | 2 |
| Sharma, M | 2 |
| Hui, A | 1 |
| Marraffa, JM | 1 |
| Stork, CM | 2 |
| Dempsey, CL | 2 |
| Coop, AJ | 1 |
| Shillington, A | 1 |
| Farley, PA | 2 |
| Eberhardt, DR | 1 |
| O'Briant, S | 1 |
| Hariharan, SL | 1 |
| Pohlgeers, AP | 1 |
| Reeves, SD | 1 |
| Endo, T | 1 |
| Hamaue, N | 1 |
| Hirafuji, M | 1 |
| Einarson, A | 1 |
| Maltepe, C | 1 |
| Navioz, Y | 1 |
| Kennedy, D | 1 |
| Tan, MP | 1 |
| Goldsmith, B | 1 |
| Walsh, T | 1 |
| Morris, AK | 1 |
| Holle, LM | 1 |
| Callander, N | 1 |
| Bradshaw, P | 1 |
| Valley, AW | 1 |
| Clark, G | 1 |
| Freytes, CO | 1 |
| Axelsson, P | 1 |
| Thörn, SE | 1 |
| Wattwil, M | 1 |
| Lau, AH | 2 |
| Lai, HW | 1 |
| Dua, N | 1 |
| Bhatnagar, S | 1 |
| Mishra, S | 1 |
| Singhal, AK | 1 |
| Cheng, FH | 1 |
| Andrews, PL | 6 |
| Moreaux, B | 1 |
| Wan, C | 1 |
| King, AG | 1 |
| Sanger, GJ | 1 |
| Buyukavci, M | 1 |
| Olgun, H | 1 |
| Ceviz, N | 1 |
| Corapçioglu, F | 1 |
| Sarper, N | 1 |
| Muss, HB | 1 |
| Eisenberg, PD | 1 |
| Raftopoulos, H | 1 |
| Gabriel, M | 1 |
| Rodgers, A | 1 |
| Bohidar, N | 1 |
| Klinger, G | 1 |
| Hustad, CM | 1 |
| Skobieranda, F | 1 |
| Lindley, C | 3 |
| Goodin, S | 1 |
| McCune, J | 1 |
| Kane, M | 1 |
| Amamoo, MA | 1 |
| Shord, S | 1 |
| Pham, T | 1 |
| Yowell, S | 1 |
| Laliberte, K | 1 |
| Schell, M | 1 |
| Bernard, S | 2 |
| Socinski, MA | 1 |
| Guoguang-Ma, J | 1 |
| Kontrimaviciute, E | 1 |
| Baublys, A | 1 |
| Ivaskevicius, J | 1 |
| Tomlinson, G | 1 |
| Dupuis, LL | 1 |
| Greenberg, ML | 1 |
| Ota, S | 1 |
| Bartels, U | 1 |
| Feldman, BM | 1 |
| Rubenstein, EB | 3 |
| Olver, IN | 2 |
| Jones, E | 2 |
| Koyama, T | 1 |
| Ho, RH | 1 |
| Kuttesch, J | 1 |
| Shankar, S | 1 |
| Whitlock, JA | 1 |
| Cartwright, J | 1 |
| Frangoul, H | 1 |
| Bloch, J | 1 |
| Rixe, O | 1 |
| Meric, JB | 1 |
| Delgado, A | 2 |
| Khayat, D | 3 |
| Babaoglu, MO | 1 |
| Bayar, B | 1 |
| Aynacioglu, AS | 1 |
| Kerb, R | 1 |
| Abali, H | 1 |
| Celik, I | 1 |
| Bozkurt, A | 1 |
| Moser, JD | 1 |
| Caldwell, JB | 1 |
| Rhule, FJ | 1 |
| Khamales, S | 1 |
| Bethune-Volters, A | 1 |
| Chidiac, J | 1 |
| Bensaoula, O | 1 |
| Di Palma, M | 1 |
| Adler, M | 4 |
| Seshadri, R | 2 |
| Leksowski, K | 1 |
| Peryga, P | 1 |
| Szyca, R | 1 |
| Aapro, MS | 7 |
| Manikhas, GM | 1 |
| Olivares, G | 1 |
| Suarez, T | 1 |
| Tjulandin, SA | 1 |
| Bertoli, LF | 1 |
| Yunus, F | 1 |
| Morrica, B | 1 |
| Lordick, F | 2 |
| Wong, RK | 1 |
| Paul, N | 1 |
| Ding, K | 1 |
| Whitehead, M | 1 |
| Brundage, M | 1 |
| Fyles, A | 1 |
| Wilke, D | 1 |
| Nabid, A | 1 |
| Fortin, A | 1 |
| Wilson, D | 1 |
| McKenzie, M | 1 |
| Ackerman, I | 1 |
| Souhami, L | 2 |
| Chabot, P | 1 |
| Pater, J | 2 |
| Alhashimi, H | 3 |
| Reilly, TH | 1 |
| Secreti, L | 1 |
| Brown, LH | 1 |
| Hamadani, M | 2 |
| Awab, A | 1 |
| Chaudhary, L | 2 |
| Tfayli, A | 2 |
| Ehlken, B | 1 |
| Ihbe-Heffinger, A | 1 |
| Berger, K | 1 |
| Krobot, KJ | 1 |
| Pellissier, J | 1 |
| Davies, G | 1 |
| Deuson, R | 1 |
| Javid, FA | 1 |
| Shi, Y | 1 |
| He, X | 1 |
| Yang, S | 1 |
| Ai, B | 1 |
| Zhang, C | 1 |
| Huang, D | 1 |
| Dong, M | 1 |
| Liu, P | 1 |
| Zhou, S | 1 |
| Han, X | 1 |
| Hinke, A | 1 |
| Grothey, A | 1 |
| Voigt, W | 1 |
| Arnold, D | 1 |
| Wolf, HH | 1 |
| McNulty, R | 1 |
| Gieruszczak-Białek, D | 1 |
| Dylag, M | 1 |
| Mehta, S | 1 |
| Goldman, RD | 1 |
| Cotton, JW | 1 |
| Rowell, LR | 1 |
| Hood, RR | 1 |
| Pellegrini, JE | 2 |
| Forrester, CM | 1 |
| Benfield, DA | 1 |
| Matern, CE | 1 |
| Kelly, JA | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 1 |
| Hashimoto, R | 1 |
| Ueda, T | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Meiri, E | 1 |
| Jhangiani, H | 1 |
| Vredenburgh, JJ | 1 |
| Barbato, LM | 1 |
| Carter, FJ | 1 |
| Yang, HM | 1 |
| Baranowski, V | 1 |
| Hernández García, D | 1 |
| Lara Vila, I | 1 |
| Caba Barrientos, F | 1 |
| Ramos Curado, P | 1 |
| Núñez García, A | 1 |
| Echevarría Moreno, M | 1 |
| Powell, E | 1 |
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
| Pradermdee, P | 1 |
| Manusirivithaya, S | 2 |
| Tangjitgamol, S | 1 |
| Thavaramara, T | 1 |
| Sukwattana, P | 1 |
| Wilkes, G | 1 |
| Awan, FT | 1 |
| Khan, JK | 1 |
| Kojouri, K | 1 |
| Ozer, H | 1 |
| Hasler, SB | 1 |
| Hirt, A | 1 |
| Ridolfi Luethy, A | 1 |
| Leibundgut, KK | 1 |
| Ammann, RA | 1 |
| Roslund, G | 1 |
| Hepps, TS | 1 |
| McQuillen, KK | 1 |
| Vrabel, M | 1 |
| Braude, D | 1 |
| Crandall, C | 1 |
| Ho, WM | 1 |
| Chan, SL | 1 |
| Lau, W | 1 |
| Koh, J | 1 |
| Yeung, WK | 1 |
| Kwan, WH | 1 |
| Lee, KK | 1 |
| Mok, TS | 1 |
| Poon, AN | 1 |
| Lam, KC | 1 |
| Hui, EK | 1 |
| Zee, B | 4 |
| Davis, PJ | 3 |
| Fertal, KM | 1 |
| Boretsky, KR | 1 |
| Fedel, GM | 1 |
| Ingram, MD | 1 |
| Woelfel, SK | 1 |
| Hoffmann, PC | 1 |
| Gurnaney, H | 1 |
| Young, MC | 1 |
| Langston, WT | 1 |
| Wathen, JE | 1 |
| Roback, MG | 1 |
| Bajaj, L | 1 |
| Fasching, PA | 1 |
| Kollmannsberger, B | 1 |
| Strissel, PL | 1 |
| Niesler, B | 1 |
| Engel, J | 1 |
| Kreis, H | 1 |
| Lux, MP | 1 |
| Weihbrecht, S | 1 |
| Lausen, B | 1 |
| Bani, MR | 1 |
| Beckmann, MW | 1 |
| Strick, R | 1 |
| Fabi, A | 1 |
| Ciccarese, M | 1 |
| Metro, G | 1 |
| Savarese, A | 1 |
| Giannarelli, D | 1 |
| Nuzzo, CM | 1 |
| Russillo, M | 1 |
| Sperduti, I | 1 |
| Carbone, I | 1 |
| Bria, E | 1 |
| Cognetti, F | 3 |
| Davis, A | 1 |
| Krige, S | 1 |
| Moyes, D | 1 |
| Campbell, RC | 2 |
| Rodrigo, MR | 2 |
| McGowan, FX | 2 |
| Landsman, I | 1 |
| Maloney, K | 1 |
| Hoffmann, P | 1 |
| Campora, E | 5 |
| Chiara, S | 1 |
| Aschele, C | 1 |
| Rose, JB | 5 |
| McCloskey, JJ | 1 |
| Dick, GS | 1 |
| Meller, ST | 2 |
| Pinkerton, CR | 2 |
| Freeman, AJ | 3 |
| Bountra, C | 1 |
| Dale, TJ | 1 |
| Gardner, CJ | 1 |
| Twissell, DJ | 1 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Scarantino, CW | 2 |
| Ornitz, RD | 2 |
| Hoffman, LG | 2 |
| Anderson, RF | 2 |
| Beck, TM | 7 |
| Alfieri, AB | 1 |
| Cubeddu, LX | 8 |
| Parasuraman, TV | 5 |
| Osterhaus, JT | 1 |
| Aspinall, RL | 1 |
| Goodman, NW | 1 |
| Agura, ED | 1 |
| Brown, MC | 1 |
| Schaffer, R | 1 |
| Donaldson, G | 1 |
| Shen, DD | 1 |
| Zeng, W | 2 |
| Zhou, J | 2 |
| Desilva, PH | 1 |
| Darvish, AH | 1 |
| McDonald, SM | 1 |
| Cronin, MK | 1 |
| Clark, K | 1 |
| Walton, SC | 1 |
| Koenig, TJ | 1 |
| Dłuzniewska, A | 1 |
| Balwierz, W | 1 |
| Armata, J | 1 |
| Eliasińska, A | 1 |
| Chow, J | 2 |
| Tong, CK | 1 |
| Hui, E | 1 |
| Lueveswanij, S | 1 |
| Beck, T | 1 |
| Uhlenhopp, M | 1 |
| Kris, MG | 12 |
| Hainsworth, JD | 5 |
| Harker, WG | 2 |
| Cohen, JR | 1 |
| Lester, E | 2 |
| Kessler, JF | 1 |
| Griffen, D | 1 |
| Milano, S | 1 |
| Blower, P | 3 |
| Romain, D | 1 |
| Grélot, L | 1 |
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Esseboom, EU | 1 |
| Rojer, RA | 1 |
| Borm, JJ | 1 |
| Statius van Eps, LW | 1 |
| Grond, S | 1 |
| Lynch, J | 1 |
| Diefenbach, C | 1 |
| Altrock, K | 1 |
| Lehmann, KA | 1 |
| Noble, A | 1 |
| Bremer, K | 1 |
| Goedhals, L | 4 |
| Cupissol, D | 2 |
| Dilly, SG | 1 |
| Warr, D | 3 |
| Puodziunas, A | 1 |
| Huang, X | 1 |
| Guo, N | 1 |
| Fan, Y | 1 |
| Madajewicz, S | 2 |
| Anderson, N | 1 |
| Tchekmedyian, NS | 2 |
| Whaley, W | 1 |
| Garewal, H | 1 |
| Chang, AY | 1 |
| Greenberg, B | 1 |
| Caldwell, KC | 1 |
| Markham, A | 2 |
| Sorkin, EM | 1 |
| Matera, MG | 1 |
| Di Tullio, M | 1 |
| Lucarelli, C | 1 |
| Casale, F | 1 |
| Calabria, C | 1 |
| Lampa, E | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| Clavel, M | 1 |
| Bonneterre, J | 9 |
| d'Allens, H | 3 |
| Paillarse, JM | 3 |
| Lee, CW | 1 |
| Suh, CW | 1 |
| Lee, KH | 2 |
| Cho, GY | 1 |
| Kim, SH | 2 |
| Lévy, E | 1 |
| Votan, B | 4 |
| Perez, EA | 7 |
| Gin, T | 3 |
| Holdsworth, MT | 2 |
| Raisch, DW | 2 |
| Duncan, MH | 1 |
| Chavez, CM | 1 |
| Leasure, MM | 1 |
| Gelman, S | 1 |
| Khalil, S | 3 |
| Andrews, PA | 1 |
| Quan, V | 1 |
| Ogg, CS | 1 |
| Gandara, D | 3 |
| Hesketh, P | 4 |
| Hall, S | 1 |
| Mailliard, J | 1 |
| Ritter, H | 1 |
| Friedman, C | 2 |
| Fitts, D | 1 |
| Martin, TM | 3 |
| Hebbar, M | 1 |
| Hecquet, B | 3 |
| Vanlemmens, L | 1 |
| Lecomte, S | 1 |
| Pion, JM | 2 |
| Adenis, A | 3 |
| Marty, M | 4 |
| Kleisbauer, JP | 1 |
| Fournel, P | 1 |
| Vergnenegre, A | 1 |
| Carles, P | 1 |
| Loria-Kanza, Y | 1 |
| Simonetta, C | 1 |
| de Bruijn, KM | 1 |
| Alvarez, O | 1 |
| Freeman, A | 2 |
| Bedros, A | 1 |
| Call, SK | 1 |
| Volsch, J | 1 |
| Kalbermatter, O | 1 |
| Halverson, J | 1 |
| Convy, L | 1 |
| Cook, L | 1 |
| Mick, K | 1 |
| Ninane, J | 2 |
| Ozkaynak, MF | 1 |
| Kurtin, P | 1 |
| Siegel, SE | 1 |
| Litman, RS | 2 |
| Wu, CL | 2 |
| Griswold, JD | 1 |
| Voisine, R | 1 |
| Marshall, C | 1 |
| Smith, WL | 2 |
| Johnson, LG | 1 |
| Clark, R | 1 |
| Whiting, RL | 1 |
| Hegde, SS | 1 |
| Priestley, GS | 1 |
| Seavell, CR | 1 |
| Rust, M | 3 |
| Splinter, WM | 7 |
| Baxter, MR | 2 |
| Gould, HM | 2 |
| Hall, LE | 2 |
| MacNeill, HB | 3 |
| Roberts, DJ | 2 |
| Komocar, L | 1 |
| Paxton, LD | 1 |
| McKay, AC | 1 |
| Mirakhur, RK | 1 |
| Johnson, N | 1 |
| Bosanquet, N | 2 |
| Litwack, K | 1 |
| Borgeat, A | 1 |
| Wilder-Smith, O | 1 |
| Forni, M | 1 |
| Suter, PM | 1 |
| Seliuzhitskiĭ, IV | 1 |
| Eliseev, SN | 1 |
| Ivanov, AI | 1 |
| Watcha, MF | 2 |
| Bras, PJ | 1 |
| Cieslak, GD | 1 |
| Pennant, JH | 1 |
| Forster, ER | 1 |
| Palmer, JL | 2 |
| Guo, XY | 1 |
| Ye, TH | 1 |
| Luo, AL | 1 |
| Cheirsilpa, A | 1 |
| Ratanatharathorn, V | 1 |
| Sinlarat, P | 1 |
| Chindavijak, K | 1 |
| Lousoontornsiri, W | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Srimuninimit, V | 1 |
| Currow, DC | 1 |
| Noble, PD | 1 |
| Stuart-Harris, RC | 1 |
| de Boer, M | 1 |
| Stoter, G | 3 |
| Verweij, J | 9 |
| Chevalier-Evain, V | 1 |
| Joslyn, AF | 6 |
| Vach, W | 4 |
| Thomssen, C | 2 |
| Karck, U | 1 |
| Madjar, H | 1 |
| Prömpeler, H | 1 |
| Meerpohl, HG | 3 |
| Mughal, TI | 1 |
| van den Berg, AA | 4 |
| Bodis, S | 1 |
| Alexander, E | 1 |
| Kooy, H | 1 |
| Loeffler, JS | 1 |
| Fisher, DM | 2 |
| Furst, SR | 2 |
| Rodarte, A | 2 |
| Ummenhofer, W | 1 |
| Frei, FJ | 1 |
| Urwyler, A | 1 |
| Kern, C | 1 |
| Drewe, J | 1 |
| Spitzer, TR | 1 |
| Bryson, JC | 4 |
| Cirenza, E | 1 |
| Foelber, R | 1 |
| Wallerstadt, M | 1 |
| Stout, C | 1 |
| Kunka, RL | 1 |
| Plagge, PB | 2 |
| Dubois, A | 1 |
| Czeglédi, F | 1 |
| Baki, M | 1 |
| Tsavaris, N | 3 |
| Charalambidis, G | 1 |
| Pagou, M | 1 |
| Karabelis, A | 1 |
| Mylonakis, N | 2 |
| Bacoyiannis, C | 2 |
| Kosmidis, P | 2 |
| Giudici, S | 1 |
| Merlini, L | 1 |
| Rubagotti, A | 1 |
| Rosso, R | 3 |
| Alon, E | 3 |
| Biro, P | 2 |
| Lenzlinger, PM | 1 |
| Atanassoff, PG | 1 |
| Heim, C | 1 |
| Münzer, T | 1 |
| Listyo, R | 1 |
| Khalil, SN | 2 |
| Kataria, B | 1 |
| Pearson, K | 1 |
| Conahan, T | 1 |
| Kallar, S | 1 |
| Zahl, K | 1 |
| Gillies, B | 1 |
| Campbell, C | 1 |
| Brahen, N | 1 |
| Gilmour, I | 1 |
| McKenzie, R | 7 |
| Tantisira, B | 2 |
| Karambelkar, DJ | 1 |
| Riley, TJ | 4 |
| Abdelhady, H | 1 |
| Perry, MR | 1 |
| Rhee, J | 1 |
| Tonato, M | 8 |
| Del Favero, A | 8 |
| Pisters, KM | 5 |
| Hinkley, L | 1 |
| Cooke, CE | 1 |
| Mehra, IV | 1 |
| Di Bartolomeo, M | 1 |
| Bajetta, E | 1 |
| Biganzoli, L | 1 |
| Di Leo, A | 1 |
| Buzzoni, R | 1 |
| Zampino, MG | 1 |
| Lewis, MA | 1 |
| Fishman, DA | 1 |
| Bleiberg, H | 3 |
| Autier, P | 1 |
| Michaux, D | 1 |
| Ballatori, E | 5 |
| Wilson, BA | 1 |
| Goldspiel, BR | 2 |
| Kohler, DR | 2 |
| Corddry, DH | 2 |
| Zagnoev, M | 1 |
| Kettrick, RG | 1 |
| Calamandrei, M | 1 |
| Andreuccetti, T | 1 |
| Crescioli, M | 1 |
| Messeri, A | 1 |
| Sarti, A | 1 |
| Sestini, G | 1 |
| Busoni, P | 1 |
| Gebbia, V | 2 |
| Cannata, G | 2 |
| Testa, A | 2 |
| Curto, G | 1 |
| Valenza, R | 1 |
| Cipolla, C | 1 |
| Latteri, MA | 1 |
| Gebbia, N | 2 |
| Katsikas, M | 2 |
| Lioni, A | 1 |
| Zbrozek, AS | 2 |
| Cantor, SB | 1 |
| Cardenas, MP | 1 |
| Hill, DP | 1 |
| Minton, N | 1 |
| Swift, R | 1 |
| Lawlor, C | 1 |
| Mant, T | 1 |
| Henry, J | 1 |
| Haga, K | 1 |
| Inaba, K | 1 |
| Shoji, H | 1 |
| Fukuda, T | 1 |
| Setoguchi, M | 1 |
| Catanzaro, FA | 1 |
| Malins, AF | 1 |
| Field, JM | 1 |
| Nesling, PM | 1 |
| Cooper, GM | 1 |
| Claussen, DW | 1 |
| Harvey, WH | 5 |
| Ryan, T | 2 |
| Bricker, LJ | 1 |
| Kish, JA | 2 |
| Murphy, WK | 3 |
| Haley, B | 1 |
| Schwarz, LR | 1 |
| Higa, GM | 1 |
| McQueen, KD | 1 |
| Milton, JD | 1 |
| Pearman, MH | 2 |
| Cohen, LA | 3 |
| Claybon, L | 3 |
| Khoo, KS | 1 |
| Ang, PT | 2 |
| Soh, LT | 1 |
| Au, E | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Zoubek, A | 1 |
| Kronberger, M | 1 |
| Puschmann, A | 1 |
| Gadner, H | 1 |
| Ribiero, MM | 1 |
| de Faria, L | 1 |
| dos Reis, F | 1 |
| Fráguas, A | 1 |
| de Matos, E | 1 |
| Uva, S | 1 |
| Ribeiro, I | 1 |
| Brandão, A | 1 |
| Ribeiro, M | 1 |
| Batarda, M | 1 |
| Marschner, N | 3 |
| Pendergrass, K | 3 |
| York, M | 2 |
| Burton, G | 1 |
| Meshad, M | 2 |
| Galvin, D | 2 |
| Ciociola, AA | 2 |
| Suh, C | 1 |
| Choi, SS | 1 |
| Böhrer, H | 1 |
| Bach, A | 1 |
| Martin, E | 1 |
| Kaizer, L | 1 |
| Hoskins, P | 3 |
| Latreille, J | 2 |
| Lofters, W | 1 |
| Yau, J | 1 |
| Palmer, M | 3 |
| Levy, M | 1 |
| Joss, RA | 2 |
| Bacchi, M | 1 |
| Buser, K | 2 |
| Kirchner, V | 1 |
| Neuenschwander, H | 1 |
| Orth, B | 1 |
| Thürlimann, B | 1 |
| Tyson, LB | 6 |
| Baltzer, L | 4 |
| Rigas, JR | 2 |
| Clark, RA | 4 |
| Reed, MD | 2 |
| Marx, CM | 1 |
| Gan, TJ | 4 |
| Collis, R | 1 |
| Hetreed, M | 1 |
| Kamenova, E | 1 |
| Schwella, N | 1 |
| König, V | 1 |
| Schwerdtfeger, R | 1 |
| Schmidt-Wolf, I | 1 |
| Schmid, H | 1 |
| Riess, H | 1 |
| Siegert, W | 1 |
| Suen, TK | 1 |
| Gin, TA | 1 |
| Chen, PP | 2 |
| Rowbottom, YM | 1 |
| Critchley, LA | 1 |
| Ray, AK | 1 |
| Daly, D | 1 |
| Taylor, JN | 1 |
| Sargent, AI | 2 |
| Deppe, SA | 2 |
| Chan, FA | 1 |
| Zeng, WY | 2 |
| Wynn, RL | 2 |
| Essien, E | 1 |
| Thut, PD | 1 |
| Hindle, AT | 1 |
| Roberts, JR | 1 |
| Carney, S | 1 |
| Boyle, SM | 1 |
| Lee, DC | 1 |
| Fox, SM | 1 |
| Einhorn, LH | 2 |
| Cox, E | 1 |
| Powell, N | 1 |
| Abdy, A | 1 |
| Hindle, A | 1 |
| Tsukagoshi, S | 12 |
| Ohta, J | 11 |
| Taguchi, T | 13 |
| Haigh, CG | 2 |
| Kaplan, LA | 3 |
| Durham, JM | 1 |
| Dupeyron, JP | 2 |
| Harmer, M | 1 |
| Kenny, GN | 3 |
| Raphael, JH | 1 |
| Norton, AC | 1 |
| Helmers, JH | 2 |
| Briggs, L | 1 |
| Abrahamsson, J | 1 |
| Soni, J | 1 |
| Moodley, J | 1 |
| Forrler, M | 1 |
| Hellstern, K | 2 |
| Priestman, TJ | 3 |
| Roberts, JT | 4 |
| Upadhyaya, BK | 4 |
| Davidson, HI | 1 |
| Lane, M | 1 |
| Lester, EP | 3 |
| Sridhar, KS | 1 |
| Mortimer, J | 1 |
| Murphy, W | 1 |
| Sanderson, PE | 3 |
| Csáki, C | 1 |
| Ferencz, T | 1 |
| Koós, R | 1 |
| Schuler, D | 1 |
| Borsi, J | 1 |
| Nicolai, N | 1 |
| Mangiarotti, B | 1 |
| Salvioni, R | 1 |
| Piva, L | 1 |
| Faustini, M | 1 |
| Pizzocaro, G | 1 |
| Philpot, CR | 1 |
| Pinto, V | 1 |
| Marinaccio, M | 1 |
| Miniello, G | 1 |
| Cagnazzo, G | 1 |
| Kleinerman, KB | 1 |
| Sage, TA | 1 |
| Jones, WN | 1 |
| Clark, RF | 2 |
| Mansi, JL | 1 |
| Evans, TR | 1 |
| Oakley, C | 1 |
| Wastnage, R | 1 |
| Dalgleish, A | 1 |
| Buser, KS | 1 |
| Piquet, D | 1 |
| Cavalli, F | 1 |
| Haefliger, JM | 1 |
| Jungi, WF | 1 |
| Bauer, J | 1 |
| Obrist, R | 1 |
| Brunner, KW | 1 |
| Norum, J | 1 |
| Jantunen, IT | 3 |
| Flander, MK | 2 |
| Heikkinen, MI | 1 |
| Kuoppala, TA | 1 |
| Teerenhovi, L | 2 |
| Kataja, VV | 3 |
| Bosi, A | 1 |
| Guidi, S | 1 |
| Messori, A | 1 |
| Saccardi, R | 1 |
| Lombardini, L | 1 |
| Vannucchi, AM | 1 |
| Fanci, R | 1 |
| Rossi-Ferrini, P | 1 |
| Locatelli, MC | 1 |
| D'Antona, A | 1 |
| Luporini, G | 1 |
| Robak, T | 1 |
| Kołecki, P | 1 |
| Wachowiak, J | 1 |
| Beshari, SE | 1 |
| Muhonen, TT | 1 |
| Cunningham, D | 7 |
| Gore, M | 1 |
| Davidson, N | 2 |
| Miocevich, M | 1 |
| Manchanda, M | 1 |
| Wells, N | 1 |
| Planting, AS | 1 |
| van der Burg, ME | 1 |
| de Boer-Dennert, M | 2 |
| Takeda, N | 2 |
| Hasegawa, S | 1 |
| Morita, M | 1 |
| Matsunaga, T | 1 |
| Garcia-del-Muro, X | 1 |
| Cardenal, F | 1 |
| Ferrer, P | 1 |
| Mahaney, FX | 1 |
| Hahne, WF | 1 |
| Scuderi, P | 2 |
| Wetchler, B | 3 |
| Sung, YF | 2 |
| Mingus, M | 2 |
| DuPen, S | 1 |
| Leslie, J | 2 |
| Talke, P | 2 |
| Apfelbaum, J | 2 |
| Sharifi-Azad, S | 2 |
| Kovac, A | 2 |
| O'Connor, T | 2 |
| Duncalf, D | 2 |
| Angel, J | 2 |
| Gratz, I | 4 |
| Tolpin, E | 1 |
| McLeskey, C | 2 |
| Joslyn, A | 1 |
| Hewitt, M | 3 |
| McQuade, B | 7 |
| Stevens, R | 1 |
| Bhandari, P | 3 |
| Basurto, C | 2 |
| Bracarda, S | 2 |
| Sassi, M | 1 |
| Lupattelli, M | 1 |
| Picciafuoco, M | 1 |
| Gandara, DR | 7 |
| Monaghan, GG | 2 |
| Braken, JB | 1 |
| Raemaekers, JM | 1 |
| Koopmans, PP | 1 |
| de Pauw, BE | 2 |
| Incoronato, P | 1 |
| Airoma, G | 1 |
| Pepe, R | 1 |
| Arpinelli, F | 1 |
| Bianco, AR | 1 |
| Jones, SE | 1 |
| Chang, A | 2 |
| Hart, NE | 1 |
| Citron, ML | 1 |
| Woodward, M | 1 |
| Gora, ML | 1 |
| Sigsgaard, T | 3 |
| Boesgaard, M | 1 |
| Jensen, TP | 1 |
| Dombernowsky, P | 4 |
| Levitt, M | 1 |
| Yelle, L | 2 |
| Rayner, HL | 1 |
| Lofters, WS | 3 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Maisano, R | 1 |
| Toscano, G | 1 |
| Adamo, V | 1 |
| Altavilla, G | 1 |
| Caristi, N | 1 |
| Chiofalo, G | 1 |
| Gnani, A | 1 |
| Scimone, A | 1 |
| Conseiller, C | 2 |
| Levarlet, M | 2 |
| Hemmingsen, C | 1 |
| Schoeffler, P | 1 |
| Pedersen, FM | 1 |
| Gribomont, B | 1 |
| Chapman, SM | 1 |
| Pruemer, JM | 1 |
| Marsden, SC | 1 |
| Figg, WD | 1 |
| Graham, CL | 1 |
| Hak, LJ | 1 |
| Dukes, GE | 1 |
| Peters, MD | 1 |
| Long, KS | 1 |
| Patel, HS | 1 |
| Reitz, JA | 1 |
| Jessen, LM | 1 |
| Emhart, GC | 1 |
| Barbounis, V | 1 |
| Koumakis, G | 1 |
| Vassilomanolakis, M | 1 |
| Hatzichristou, H | 1 |
| Tsousis, S | 1 |
| Efremidis, AP | 1 |
| Berard, CM | 1 |
| Mahoney, CD | 1 |
| Paxton, D | 1 |
| Taylor, RH | 1 |
| Gallagher, TM | 1 |
| Crean, PM | 1 |
| Alexander, R | 2 |
| Lovell, AT | 1 |
| Seingry, D | 1 |
| Jones, RM | 1 |
| Palmer, JB | 1 |
| Gibbs, TG | 1 |
| Taylor, CM | 1 |
| Harada, H | 1 |
| Morie, T | 1 |
| Hirokawa, Y | 1 |
| Terauchi, H | 1 |
| Fujiwara, I | 1 |
| Yoshida, N | 1 |
| Kato, S | 1 |
| al-Moundhri, M | 1 |
| Ezzie, J | 1 |
| Ward, R | 1 |
| Henry, DW | 1 |
| Marshall, JL | 1 |
| Nazzaro, D | 1 |
| Fox, JL | 1 |
| Leff, RD | 1 |
| Mantovani, G | 1 |
| Macciò, A | 1 |
| Bianchi, A | 1 |
| Curreli, L | 1 |
| Ghiani, M | 1 |
| Proto, E | 1 |
| Santona, MC | 1 |
| Domínguez-Ortega, L | 1 |
| Cubedo-Cervera, R | 1 |
| Cortés-Funés, H | 2 |
| Díaz-Gállego, E | 1 |
| Chen, R | 1 |
| Williams, SR | 1 |
| Johnson, CL | 1 |
| Harchelroad, F | 1 |
| Eriksson, H | 1 |
| Korttila, K | 2 |
| Brenn, BR | 1 |
| Thomas, PC | 1 |
| Hickok, JT | 1 |
| Rosenthal, SN | 1 |
| Fedele, P | 1 |
| Spina, M | 1 |
| Valentini, M | 1 |
| Collini, D | 1 |
| Lucia, C | 1 |
| Manicone, M | 1 |
| Tirelli, U | 1 |
| Early, TE | 1 |
| Charbonneau, J | 1 |
| McKnight, G | 1 |
| Jenkins, P | 1 |
| Thavaraj, V | 1 |
| Arya, LS | 1 |
| Jørgensen, M | 1 |
| Victor, MA | 1 |
| Martin, M | 2 |
| Depierre, A | 3 |
| Meden, H | 1 |
| Meissner, O | 1 |
| Conrad, A | 1 |
| Kuhn, W | 1 |
| Pueyo, FJ | 2 |
| Carrascosa, F | 2 |
| Lopez, L | 1 |
| Iribarren, MJ | 1 |
| García-Pedrajas, F | 1 |
| Saez, A | 2 |
| Macario, A | 1 |
| Ronquillo, RB | 1 |
| Brose, WG | 1 |
| Gaeta, RR | 1 |
| Koivuranta, MK | 1 |
| Läärä, E | 2 |
| Ryhänen, PT | 1 |
| Harousseau, JL | 2 |
| Kurylak, A | 1 |
| Kurylak, D | 1 |
| Masłowska, E | 1 |
| Gałaj, A | 1 |
| Zawadzka, I | 1 |
| López-Olaondo, L | 1 |
| Monedero, P | 1 |
| Busto, N | 1 |
| Bunce, KT | 1 |
| Beijnen, JH | 1 |
| van Tellingen, O | 1 |
| Schellens, JH | 2 |
| Soukop, M | 2 |
| Ossi, M | 1 |
| Anderson, E | 1 |
| Peralta, M | 1 |
| Lettow, L | 1 |
| Cronin, M | 1 |
| Tang, J | 1 |
| White, PF | 3 |
| Sullivan, LJ | 1 |
| Soriano, SG | 1 |
| McDermott, JS | 1 |
| Adelson, PD | 1 |
| Rockoff, MA | 1 |
| Martoni, A | 2 |
| Angelelli, B | 1 |
| Guaraldi, M | 1 |
| Strocchi, E | 1 |
| Pannuti, F | 2 |
| Rhine, EJ | 6 |
| Roberts, DW | 2 |
| Grote, T | 1 |
| Hainsworth, J | 5 |
| Kris, M | 1 |
| Anthony, L | 1 |
| Khojasteh, A | 5 |
| Tapazoglou, E | 3 |
| Benedict, C | 1 |
| Hahne, W | 2 |
| Tezcan, C | 1 |
| Ates, Y | 1 |
| Dönmez, A | 1 |
| Ozatamer, O | 1 |
| Weldon, BC | 1 |
| Weinstein, M | 1 |
| Grunwald, Z | 1 |
| Ginsberg, B | 2 |
| Kaye, R | 1 |
| Otto, A | 1 |
| Wheeler, M | 1 |
| Lawhorn, CD | 4 |
| Prillaman, BA | 3 |
| Creed, M | 2 |
| Thwaites, R | 1 |
| Paska, W | 4 |
| Catimel, G | 1 |
| Droz, JP | 3 |
| Güller, R | 1 |
| Reichlin, B | 1 |
| Jost, G | 1 |
| Barrenetxea, G | 1 |
| Schneider, J | 1 |
| Centeno, MM | 1 |
| Romero, H | 1 |
| de la Rica, M | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Perevodchikova, NI | 1 |
| Volkova, MA | 1 |
| Gorbunova, VA | 1 |
| Manziuk, LV | 1 |
| Marenich, AF | 1 |
| Smirnova, NB | 1 |
| Reid, CW | 1 |
| Honkavaara, P | 1 |
| Allen, E | 1 |
| Afshar, M | 2 |
| Buxbaum, J | 1 |
| Prilliman, B | 1 |
| Paech, MJ | 1 |
| Pavy, TJ | 1 |
| Evans, SF | 1 |
| Wrench, IJ | 1 |
| Ward, JE | 1 |
| Walder, AD | 1 |
| Hobbs, GJ | 1 |
| Massidda, B | 1 |
| Ionta, MT | 1 |
| Gibbs, SJ | 1 |
| Cassoni, AM | 1 |
| Bustos-Molina, F | 1 |
| García-Cruz, JJ | 1 |
| Cid-Calzada, J | 1 |
| Soro-Domingo, M | 1 |
| Bejarano-López, C | 1 |
| Cortés-Uribe, A | 1 |
| Kacker, V | 1 |
| Bower, C | 1 |
| Brown, RE | 1 |
| Schmitz, ML | 1 |
| Kymer, PJ | 2 |
| Stoner, J | 1 |
| Vollers, JM | 1 |
| Shirey, R | 2 |
| Naguib, M | 1 |
| el Bakry, AK | 1 |
| Khoshim, MH | 1 |
| Channa, AB | 1 |
| el Gammal, M | 1 |
| el Gammal, K | 1 |
| Elhattab, YS | 1 |
| Attia, M | 1 |
| Jaroudi, R | 1 |
| Saddique, A | 1 |
| Cramer-Giraud, U | 1 |
| Glaubitz, M | 1 |
| Fiola, M | 1 |
| Ohta, M | 1 |
| Suzuki, T | 1 |
| Furuya, T | 1 |
| Kurihara, H | 1 |
| Tokunaga, T | 1 |
| Miyata, K | 1 |
| Yanagisawa, I | 1 |
| Lekprasert, V | 1 |
| Meesangnil, S | 1 |
| Pausawasdi, S | 1 |
| Pongravee, V | 1 |
| Hursti, TJ | 2 |
| Avall-Lundqvist, E | 2 |
| Börjeson, S | 2 |
| Fredrikson, M | 3 |
| Fürst, CJ | 3 |
| Steineck, G | 3 |
| Peterson, C | 3 |
| Rodrigo, C | 1 |
| Campbell, R | 1 |
| Tong, A | 1 |
| Alberts, VA | 1 |
| Catalano, G | 1 |
| Poole, MA | 1 |
| Bosnjak, SM | 2 |
| Neskovic-Konstantinovic, ZB | 2 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 2 |
| Franzén, L | 3 |
| Nyman, J | 1 |
| Hagberg, H | 1 |
| Jakobsson, M | 1 |
| Sorbe, B | 1 |
| Nyth, AL | 1 |
| Lomberg, H | 3 |
| Henriksson, R | 2 |
| Davies, PR | 1 |
| Warwick, P | 1 |
| O'Connor, M | 1 |
| Fernández-Marcos, A | 1 |
| Sanchez, JJ | 1 |
| Rodriguez-Lescure, A | 1 |
| Casado, A | 1 |
| López Martin, JA | 1 |
| Diaz-Rubio, E | 2 |
| Holy, R | 1 |
| Kriesinger-Schröder, H | 1 |
| Chui, PT | 1 |
| Pan, PH | 1 |
| Moore, CH | 1 |
| Steinbrook, RA | 2 |
| Freiberger, D | 2 |
| Gosnell, JL | 2 |
| Brooks, DC | 1 |
| Nakamura, M | 1 |
| Tamura, T | 1 |
| Kunii, T | 1 |
| Shimizu, K | 1 |
| Miyauchi, Y | 1 |
| Watts, SA | 1 |
| Stene, FN | 1 |
| Seay, RE | 1 |
| Young, LA | 1 |
| Bohnsack, LE | 1 |
| Bostrom, BC | 1 |
| Fauser, AA | 1 |
| Duclos, B | 1 |
| Chemaissani, A | 1 |
| Conte, PF | 1 |
| Dressler, H | 1 |
| Grant, AP | 1 |
| Glass, PS | 2 |
| Venkatraman, E | 1 |
| Homesley, HD | 1 |
| Polati, E | 2 |
| Finco, G | 2 |
| Bartoloni, A | 1 |
| Gottin, L | 2 |
| Pinaroli, AM | 2 |
| Zanoni, L | 1 |
| Mazzetti, C | 1 |
| Fontanive, P | 1 |
| Jordan, CC | 1 |
| Uy, NT | 1 |
| Hamilton, DL | 3 |
| Kovac, AL | 1 |
| Scuderi, PE | 2 |
| Cox, F | 1 |
| Brock, P | 1 |
| Brichard, B | 1 |
| Rechnitzer, C | 1 |
| Langeveld, NE | 1 |
| Lanning, M | 1 |
| Söderhäll, S | 1 |
| Laurent, C | 1 |
| Latz, D | 1 |
| Schraube, P | 1 |
| Wannenmacher, M | 1 |
| Ulusoy, HO | 2 |
| Aktürk, G | 2 |
| Lüleci, N | 2 |
| Kalaç, N | 2 |
| Albayrak, D | 2 |
| Olver, I | 1 |
| Seitz, JF | 1 |
| Stewart, DJ | 2 |
| McRae, J | 1 |
| Wilkinson, JR | 2 |
| Sánchez-Peña, J | 1 |
| Luis-Navarro, J | 1 |
| Pérez-Torres, C | 1 |
| Gutiérrez-Crespo, A | 1 |
| Bello, R | 1 |
| Suan, CB | 1 |
| García del Valle, S | 1 |
| González, A | 1 |
| Vidal, M | 1 |
| Sun, R | 1 |
| Klein, KW | 1 |
| Pugh, SC | 1 |
| Jones, NC | 1 |
| Barsoum, LZ | 1 |
| Morton, NS | 1 |
| Camu, F | 2 |
| Dorman, T | 1 |
| Knudsen, KE | 1 |
| Kvalsvik, O | 1 |
| Nellgard, P | 1 |
| Saint-Maurice, CP | 1 |
| Wilhelm, W | 1 |
| Trujillo, LM | 1 |
| Talmaciu, I | 1 |
| Gonzalez, V | 1 |
| Guariguata, J | 1 |
| Seijas, J | 1 |
| Miller, IA | 1 |
| Saur, P | 1 |
| Mühr, C | 1 |
| Kazmaier, S | 1 |
| Neumann, P | 2 |
| Buhre, W | 1 |
| Mansfield, M | 1 |
| Russell, D | 2 |
| Kinsella, J | 1 |
| Parikh, PM | 1 |
| Shah, SR | 1 |
| Shah, SC | 1 |
| Sheth, V | 1 |
| Patel, RA | 1 |
| Shah, KC | 1 |
| Jain, PK | 1 |
| Fry, RA | 1 |
| Walker, MA | 1 |
| Rung, GW | 1 |
| Hord, A | 1 |
| Patel, C | 1 |
| Kallgren, M | 1 |
| Koppel, J | 1 |
| Benedetti, C | 1 |
| Asgharian, A | 1 |
| Bryson, J | 1 |
| Bliss, A | 1 |
| Lewis, IH | 1 |
| Kobayashi, F | 1 |
| Yamanouchi, T | 1 |
| Shimizu, T | 1 |
| Sato, H | 1 |
| Adachi, I | 1 |
| Sakamoto, T | 1 |
| Fujimaki, M | 1 |
| Horikoshi, I | 1 |
| Pitkänen, MT | 1 |
| Numminen, MK | 1 |
| Tuominen, MK | 1 |
| Rosenberg, PH | 1 |
| Pater, JL | 2 |
| Dempsey, E | 2 |
| Walde, D | 2 |
| Moquin, JP | 2 |
| Guevin, RM | 2 |
| Krook, JE | 2 |
| Chin, C | 2 |
| Tavorath, R | 1 |
| Wilde, MI | 1 |
| Tramèr, MR | 6 |
| Moore, RA | 5 |
| Reynolds, DJ | 5 |
| McQuay, HJ | 5 |
| Sundström, GM | 1 |
| Wahlin, A | 1 |
| Cabrera, JC | 1 |
| Matute, E | 1 |
| Escolano, F | 1 |
| Castillo, J | 1 |
| Santiveri, X | 1 |
| Castaño, J | 1 |
| Lawhorn, S | 1 |
| Davison, C | 1 |
| Gabriel, CM | 1 |
| Minor, JR | 1 |
| Vogel, S | 1 |
| Piscitelli, SC | 1 |
| Shende, D | 1 |
| Mandal, NG | 1 |
| Kennedy, A | 2 |
| Webster, K | 2 |
| Peterson, G | 3 |
| Kulp, B | 3 |
| Belinson, J | 2 |
| Mjahed, K | 1 |
| el Harrar, N | 1 |
| Idali, B | 1 |
| Laouissi, F | 1 |
| Benaguida, M | 1 |
| Amraoui, A | 1 |
| Benline, TA | 1 |
| French, J | 1 |
| Handberg, J | 2 |
| Schousboe, BM | 1 |
| Hansen, M | 1 |
| Stienstra, R | 1 |
| Samhan, YM | 1 |
| el-Mofty, M | 1 |
| de Bont, LE | 1 |
| Bovill, JG | 1 |
| Arango, HA | 1 |
| Kalter, CS | 1 |
| Decesare, SL | 1 |
| Fiorica, JV | 1 |
| Lyman, GH | 1 |
| Spellacy, WN | 1 |
| Ariyoshi, Y | 11 |
| Nukariya, N | 3 |
| Akasaka, Y | 11 |
| Suminaga, M | 9 |
| Ota, J | 1 |
| Ikeda, M | 12 |
| Goldschmidt, H | 1 |
| Salwender, H | 1 |
| Egerer, G | 1 |
| Kempe, R | 1 |
| Voigt, T | 1 |
| Palladino, MA | 1 |
| Ciccarese, G | 1 |
| Fennelly, M | 1 |
| Griffin, D | 1 |
| Wentz, A | 1 |
| Verlato, G | 1 |
| Mosaner, W | 1 |
| Grosso, S | 1 |
| Ischia, S | 1 |
| Klockgether-Radke, A | 1 |
| Neumann, S | 1 |
| Braun, U | 1 |
| Mühlendyck, H | 1 |
| Wong, RH | 1 |
| Lao, L | 1 |
| Berman, BM | 1 |
| Carter, AK | 1 |
| Clergue, F | 1 |
| Leeser, J | 2 |
| Feiss, P | 3 |
| Olthoff, D | 1 |
| Payeur-Michel, C | 1 |
| Wessel, P | 1 |
| Nave, S | 1 |
| Brown, R | 1 |
| Cieślińska, A | 1 |
| Pajak, K | 1 |
| Ziemba, AB | 1 |
| Filipczyk-Cisarz, E | 1 |
| Gajewska, A | 1 |
| Jellish, WS | 2 |
| Thalji, Z | 2 |
| Fluter, E | 1 |
| Leonetti, JP | 2 |
| Cunningham, RS | 1 |
| Ascaso, FJ | 1 |
| Ayala, I | 1 |
| Carbonell, P | 1 |
| Castro, FJ | 1 |
| Palomar, A | 1 |
| Saphir, A | 1 |
| Patel, RI | 1 |
| Orr, RJ | 1 |
| Ferrari, LR | 1 |
| Rimar, S | 1 |
| Hannallah, RS | 1 |
| Cohen, IT | 1 |
| Colingo, K | 1 |
| Donlon, JV | 1 |
| Haberkern, CM | 1 |
| Creed, MR | 3 |
| Ploner, F | 1 |
| Kainzwaldner, A | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Sniadach, MS | 1 |
| Alberts, MS | 1 |
| Blaine, EM | 1 |
| Coiffier, B | 1 |
| Misset, JL | 1 |
| Weaver, RG | 1 |
| James, RL | 1 |
| Mims, G | 1 |
| Elliott, WG | 1 |
| Weeks, DB | 1 |
| Mehta, NH | 1 |
| Reed, CM | 1 |
| Kuhlman, C | 1 |
| Weinstein, HJ | 1 |
| Parsons, SK | 1 |
| Koivuranta, M | 2 |
| Jokela, R | 1 |
| Kiviluoma, K | 1 |
| Alahuhta, S | 2 |
| Lebeau, B | 1 |
| Giovannini, M | 2 |
| Kaluzinski, L | 1 |
| Hédouin, M | 2 |
| Shillington, AA | 1 |
| Kulis-Robitaille, C | 1 |
| Colgan, K | 1 |
| Bernstein, G | 1 |
| Hoshino, K | 1 |
| Ono, K | 1 |
| Kimura, O | 1 |
| Kawaguchi, H | 1 |
| Fukui, H | 2 |
| Diemunsch, P | 1 |
| Clyti, N | 1 |
| Mamet, JP | 1 |
| Park, JO | 1 |
| Rha, SY | 1 |
| Yoo, NC | 1 |
| Kim, JH | 1 |
| Roh, JK | 1 |
| Min, JS | 1 |
| Kim, BS | 1 |
| Chung, HC | 1 |
| Moyle, JT | 1 |
| Sykes, AJ | 1 |
| Kiltie, AE | 1 |
| Stewart, AL | 1 |
| Fumoleau, P | 1 |
| Rolland, F | 1 |
| Ranta, P | 1 |
| Ravaska, P | 1 |
| García-Romero, J | 1 |
| Jiménez-Romero, M | 1 |
| Gil-Fernández, M | 1 |
| Bach-Styles, T | 1 |
| Martin-Sheridan, D | 1 |
| Hughes, C | 1 |
| Kaufman, S | 1 |
| Stewart, FC | 1 |
| Stoner, JM | 1 |
| Volpe, P | 1 |
| Roscoe, JA | 1 |
| Hynes, HE | 1 |
| Flynn, PJ | 1 |
| Pierce, HI | 1 |
| Burish, T | 1 |
| Monagle, J | 1 |
| Barnes, R | 1 |
| Goodchild, C | 1 |
| Sandbach, J | 1 |
| Reeves, J | 1 |
| Bushnell, W | 1 |
| Nolte, MJ | 1 |
| Berkery, R | 1 |
| Pizzo, B | 1 |
| Grossano, D | 1 |
| Lucarelli, CD | 1 |
| Shinohara, H | 1 |
| Yonekawa, H | 1 |
| Machimura, T | 1 |
| Furukawa, T | 1 |
| Nishihori, H | 1 |
| Kurihara, N | 1 |
| Urakami, H | 1 |
| Nemoto, Y | 1 |
| Morris, RW | 1 |
| Aune, H | 1 |
| Hanson, A | 1 |
| Hasselstrøm, L | 1 |
| Maltby, JR | 1 |
| Rocke, DA | 1 |
| Rozenberg, B | 1 |
| Thomas, A | 1 |
| Walker-Smith, JA | 1 |
| Moens, P | 1 |
| Hendrickx, P | 1 |
| De Guchteneere, E | 1 |
| Trantisira, BR | 1 |
| Sansonetti, A | 1 |
| Fuchs-Buder, T | 1 |
| Rifat, K | 1 |
| Raeder, JC | 1 |
| Mjåland, O | 1 |
| Aasbø, V | 1 |
| Grøgaard, B | 1 |
| Buanes, T | 1 |
| Fortney, JT | 1 |
| Graczyk, S | 1 |
| Melson, T | 1 |
| Parrillo, S | 1 |
| Moote, C | 1 |
| Wermeling, D | 1 |
| Duncan, B | 1 |
| Scharman, EJ | 1 |
| Figueredo, ED | 1 |
| Canosa, LG | 2 |
| Martin, C | 1 |
| Roman, V | 1 |
| Agay, D | 1 |
| Fatôme, M | 1 |
| Chan, MT | 1 |
| Harper, CM | 1 |
| Barker, JP | 1 |
| Fluder, E | 1 |
| Poon, RT | 1 |
| Chow, LW | 1 |
| Kalaycio, M | 1 |
| Mendez, Z | 1 |
| Pohlman, B | 1 |
| Overmoyer, B | 1 |
| Boparai, N | 1 |
| Bolwell, B | 1 |
| Dershwitz, M | 2 |
| Conant, JA | 1 |
| Chang, Y | 1 |
| Rosow, CE | 2 |
| Connors, PM | 1 |
| Goodarzi, M | 1 |
| Zeidman, A | 1 |
| Ben Dayan, D | 1 |
| Ben Zion, T | 1 |
| Kaufman, O | 1 |
| Cohen, AM | 1 |
| Mittelman, M | 1 |
| Huc, P | 1 |
| Block, S | 1 |
| Carlier, D | 1 |
| Darloy, F | 1 |
| Bonneterre, ME | 1 |
| Bleuse, JP | 1 |
| Fournier, C | 1 |
| Ross, AK | 1 |
| Ferrero-Conover, D | 1 |
| Krzakowski, M | 1 |
| Graham, E | 2 |
| Joly, F | 1 |
| Pawlicki, M | 1 |
| Lees, J | 1 |
| Mercadante, S | 1 |
| Sapio, M | 1 |
| Serretta, R | 1 |
| Faris, PL | 1 |
| Won Kim, S | 1 |
| Meller, WH | 1 |
| Goodale, RL | 1 |
| Hofbauer, RD | 1 |
| Oakman, SA | 1 |
| Howard, LA | 1 |
| Stevens, ER | 1 |
| Eckert, ED | 1 |
| Hartman, BK | 1 |
| Köseoglu, V | 1 |
| Kürekçi, AE | 1 |
| Sarici, U | 1 |
| Atay, AA | 1 |
| Ozcan, O | 1 |
| Sorici, U | 1 |
| Osowski, CL | 1 |
| Dix, SP | 1 |
| Lynn, M | 1 |
| Davidson, T | 1 |
| Cohen, L | 1 |
| Miyahara, T | 1 |
| Sexauer, MC | 1 |
| Joyce, R | 1 |
| Yeager, A | 1 |
| Wingard, JR | 1 |
| Tanimura, S | 1 |
| Banba, J | 1 |
| Tomoyasu, H | 1 |
| Masaki, M | 1 |
| Leong, SS | 1 |
| Teo, CP | 1 |
| Tao, M | 1 |
| Gardner, C | 1 |
| Perren, M | 1 |
| Pizzo, BA | 1 |
| Miller, VA | 1 |
| Grant, SC | 1 |
| Hinckley, L | 1 |
| Stoner, NS | 1 |
| Yalçin, S | 1 |
| Tekuzman, G | 1 |
| Baltali, E | 1 |
| Ozişik, Y | 1 |
| Barişta, I | 1 |
| Gomez-de-Segura, IA | 1 |
| Grande, AG | 1 |
| De Miguel, E | 1 |
| Bacić, A | 1 |
| Rumboldt, Z | 2 |
| Gluncić, I | 1 |
| Buklijas, J | 1 |
| Sohara, N | 1 |
| Takagi, H | 1 |
| Abe, T | 1 |
| Hashimoto, Y | 1 |
| Kojima, A | 1 |
| Takahashi, H | 1 |
| Nagamine, T | 1 |
| Mori, M | 1 |
| Shane, R | 1 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 1 |
| Milne, RJ | 3 |
| Gerbino, PP | 1 |
| Goldsmith, M | 1 |
| Kenney, JT | 1 |
| Nolte, J | 1 |
| Quan, W | 1 |
| Reich, PR | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Robichaud, A | 1 |
| Choudhury, I | 1 |
| Rodger, IW | 1 |
| Lubarsky, DA | 1 |
| Erikstein, B | 1 |
| L'Esperance, B | 1 |
| Ruff, P | 1 |
| Miller, I | 1 |
| Curtis, P | 3 |
| King, GL | 1 |
| Rabin, BM | 1 |
| Weatherspoon, JK | 1 |
| Kwong, WJ | 1 |
| Yamamoto, M | 1 |
| Figueredo, E | 1 |
| Wang, SM | 1 |
| Hofstadter, MB | 1 |
| Kain, ZN | 1 |
| Fennig, S | 2 |
| Dahrouge, S | 1 |
| Coyle, D | 1 |
| Evans, WK | 1 |
| Sussman, G | 1 |
| Shurman, J | 1 |
| Larsen, LS | 1 |
| Ferrer-Brechner, T | 1 |
| Noll, D | 1 |
| Allegra, J | 1 |
| Montgomery, R | 1 |
| Schreck, D | 1 |
| Grafstein, E | 1 |
| Ramalanjaona, G | 1 |
| Patel, V | 1 |
| Ducharme, J | 1 |
| Ortenwall, P | 1 |
| Foster, E | 1 |
| Ames, M | 2 |
| Ozaki, A | 1 |
| Sukamoto, T | 1 |
| Needles, B | 1 |
| Miranda, E | 1 |
| Garcia Rodriguez, FM | 1 |
| Diaz, LB | 1 |
| Spector, J | 1 |
| Craig, J | 1 |
| Cohen, G | 1 |
| Krasnow, S | 1 |
| Brogden, J | 1 |
| Tsavaris, NB | 1 |
| Koufos, C | 1 |
| Dimitrakopoulos, A | 2 |
| Athanasiou, E | 1 |
| Linardaki, G | 1 |
| Safonova, SA | 1 |
| Punanov, IuA | 1 |
| Kolygin, BA | 1 |
| Tiemeier, T | 1 |
| Solberg, LA | 1 |
| Castejon, AM | 1 |
| Paez, X | 1 |
| Hernandez, L | 1 |
| Chung, F | 1 |
| Lane, R | 1 |
| Spraggs, C | 1 |
| Jacka, M | 1 |
| Luttropp, HH | 1 |
| Alahuta, S | 1 |
| Rocherieux, S | 1 |
| Roy, M | 1 |
| Duvaldestin, P | 1 |
| Sadhasivam, S | 1 |
| Saxena, A | 1 |
| Kathirvel, S | 2 |
| Kannan, TR | 1 |
| Trikha, A | 1 |
| Mohan, V | 1 |
| LeBourgeois, JP | 1 |
| McKenna, CJ | 2 |
| Coster, B | 1 |
| Feyer, P | 1 |
| Marzecki, Z | 1 |
| Stewart, A | 1 |
| Tønnessen, F | 1 |
| Haigh, C | 2 |
| Mitchell, T | 2 |
| Orchard, PJ | 1 |
| Rogosheske, J | 1 |
| Burns, L | 1 |
| Rydholm, N | 1 |
| Larson, H | 1 |
| DeFor, TE | 1 |
| Ramsay, NK | 1 |
| Weisdorf, D | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Ku, PK | 1 |
| Tong, MC | 1 |
| Lo, P | 1 |
| van Hasselt, CA | 1 |
| Forni, C | 1 |
| Ferrari, S | 1 |
| Loro, L | 1 |
| Mazzei, T | 1 |
| Beghelli, C | 1 |
| Biolchini, A | 1 |
| Simoni, P | 1 |
| Tremosini, M | 1 |
| Strazzari, S | 1 |
| Puggioli, C | 1 |
| Bacci, G | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Kwong, DL | 1 |
| Kwok, CC | 1 |
| Yue, A | 1 |
| Foo, YC | 1 |
| Chan, R | 1 |
| Loos, WJ | 1 |
| de Jonge, MJ | 1 |
| Sparreboom, A | 2 |
| Ishioka, S | 1 |
| Sagae, S | 1 |
| Saito, T | 1 |
| Kiya, T | 1 |
| Sugimura, M | 1 |
| Akutagawa, N | 1 |
| Umemura, K | 1 |
| Ito, E | 1 |
| Kudo, R | 1 |
| Catalán Arlandis, JL | 1 |
| Jiménez Torres, NV | 1 |
| Wang, CH | 3 |
| Kao, CY | 2 |
| McClay, EF | 1 |
| McClay, ME | 1 |
| Monroe, L | 1 |
| Baron, PL | 1 |
| Cole, DJ | 1 |
| O'Brien, PH | 1 |
| Metcalf, JS | 1 |
| Maize, JC | 1 |
| Zittoun, R | 1 |
| Ouvry, J | 1 |
| Barrajon, E | 1 |
| de las Peñas, R | 1 |
| White, L | 1 |
| Daly, SA | 1 |
| Zhestkova, N | 1 |
| Leal, C | 1 |
| Breatnach, F | 1 |
| Smelhaus, V | 1 |
| Hung, IJ | 1 |
| Kowalczyk, J | 1 |
| Advani, SH | 1 |
| Gopal, R | 1 |
| Dhar, AK | 1 |
| Lal, HM | 1 |
| Cooverji, ND | 1 |
| Copur, MS | 1 |
| Ledakis, P | 1 |
| Norvell, M | 1 |
| Harmon, D | 1 |
| O'Brien, B | 1 |
| Adams, VR | 1 |
| Wood, JG | 1 |
| Winter, SS | 1 |
| Chiou, TJ | 1 |
| Tzeng, WF | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Fan, FS | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Slabý, J | 1 |
| Trnený, M | 1 |
| Procházka, B | 1 |
| Klener, P | 1 |
| Lacerda, JF | 1 |
| Martins, C | 1 |
| Carmo, JA | 1 |
| Lourenço, MF | 1 |
| Araújo Pereira, ME | 1 |
| Rodrigues, A | 1 |
| Juncal, C | 1 |
| Lacerda, JM | 1 |
| Soares, HP | 1 |
| Caparroz, C | 1 |
| Castro, PC | 1 |
| Bowhay, AR | 1 |
| May, HA | 1 |
| Rudnicka, AR | 1 |
| Booker, PD | 1 |
| Horikoshi, K | 1 |
| Yokoyama, T | 1 |
| Kishibayashi, N | 1 |
| Ohmori, K | 1 |
| Karasawa, A | 1 |
| Kjaer, M | 1 |
| Walker, PC | 1 |
| Biglin, KE | 1 |
| Constance, TD | 1 |
| Bhambhani, K | 1 |
| Sims-McCallum, R | 1 |
| Cocquyt, V | 1 |
| O'Brien, M | 1 |
| Borms, M | 1 |
| Verbeke, L | 1 |
| Van Aelst, F | 1 |
| Kosmas, CH | 1 |
| Vadiaka, M | 1 |
| Kontos, A | 1 |
| Katsorida, M | 1 |
| Zerai, A | 1 |
| Koufos, CH | 1 |
| Dash, HH | 1 |
| Subramaniam, B | 1 |
| Prakash, A | 1 |
| Shenoy, S | 1 |
| Takahashi, K | 1 |
| Rytting, JH | 1 |
| Ozgür Tan, M | 1 |
| Sandikçi, Z | 1 |
| Uygur, MC | 1 |
| Arik, AI | 1 |
| Erol, D | 1 |
| Roome, C | 1 |
| Thompson, J | 1 |
| Ye, JH | 1 |
| Ponnudurai, R | 1 |
| Schaefer, R | 1 |
| Yeh, KY | 1 |
| de Boer, AC | 1 |
| vd Linden, GH | 1 |
| Tsukada, H | 1 |
| Hirose, T | 1 |
| Yokoyama, A | 1 |
| Kurita, Y | 1 |
| Chareoniam, V | 1 |
| Isariyodom, P | 1 |
| Sungsab, D | 1 |
| Fox-Geiman, MP | 1 |
| Fisher, SG | 1 |
| Kiley, K | 1 |
| Fletcher-Gonzalez, D | 1 |
| Porter, N | 1 |
| Stiff, P | 1 |
| Kobayashi, M | 1 |
| To, H | 1 |
| Tokue, A | 1 |
| Fujimura, A | 1 |
| Kobayashi, E | 1 |
| Watters, J | 1 |
| Riley, M | 1 |
| Pedley, I | 1 |
| Whitehead, A | 1 |
| Overend, M | 1 |
| Goss, I | 1 |
| Allgar, V | 1 |
| Ljutić, D | 1 |
| Perković, D | 1 |
| Bagatin, J | 1 |
| Hozo, I | 1 |
| Pivac, N | 1 |
| Keefe, DL | 1 |
| Parker, RI | 1 |
| Prakash, D | 1 |
| Mahan, RA | 1 |
| Giugliano, DM | 1 |
| Atlas, MP | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Ramsook, C | 1 |
| Sahagun-Carreon, I | 1 |
| Kozinetz, CA | 1 |
| Moro-Sutherland, D | 1 |
| Reeves, JJ | 1 |
| Shannon, MW | 1 |
| Fleisher, GR | 1 |
| Bernstein, BJ | 1 |
| Ong, C | 1 |
| Markman, MR | 1 |
| Papies, A | 1 |
| Bauer, S | 1 |
| Matsunaga, S | 1 |
| Matsui, M | 1 |
| Lehoczky, O | 1 |
| Udvary, J | 1 |
| Pulay, T | 1 |
| Parr, MD | 1 |
| McIntyre, WJ | 1 |
| Henderson, LM | 1 |
| MacDonald, JS | 1 |
| Chandler, MH | 1 |
| Davey, PT | 1 |
| Bingham, S | 2 |
| Marr, HE | 1 |
| Blower, PR | 1 |
| Dilly, S | 1 |
| Thompson, PI | 1 |
| Patel, N | 1 |
| Joel, SP | 1 |
| Slevin, ML | 1 |
| Jones, AL | 2 |
| Lee, GJ | 1 |
| Rosenthal, SA | 1 |
| Marquez, CM | 1 |
| Hourigan, HP | 1 |
| Ryu, JK | 1 |
| Nicholson, S | 1 |
| Evans, C | 1 |
| Mansi, J | 1 |
| Fink-Jensen, A | 1 |
| Judge, ME | 1 |
| Hansen, JB | 1 |
| Jacobsen, P | 1 |
| Turski, L | 1 |
| Olney, J | 1 |
| Honoré, T | 1 |
| Kaye, SB | 2 |
| Diehl, V | 1 |
| Tobias, JD | 2 |
| Gregory, DF | 1 |
| Deshpande, JK | 1 |
| Di Biase, PM | 1 |
| Seynaeve, C | 5 |
| Schuller, J | 1 |
| Porteder, H | 1 |
| Sevelda, P | 1 |
| Christmann, D | 2 |
| Schmidt, M | 1 |
| Kitchener, H | 1 |
| Paes, D | 3 |
| Furue, H | 10 |
| Ota, K | 10 |
| Niitani, H | 10 |
| Tyers, MB | 2 |
| Fraschini, G | 2 |
| Stokes, C | 1 |
| Finn, AL | 5 |
| Graves, T | 2 |
| Legha, SS | 1 |
| Hodges, C | 1 |
| Ring, S | 1 |
| Himmelseher, S | 1 |
| Dicato, MA | 4 |
| Kaasa, S | 3 |
| Warnier, P | 1 |
| Vindevoghel, A | 1 |
| Liebhard, A | 1 |
| Johansson, RT | 1 |
| Sledge, GW | 1 |
| Einhorn, L | 1 |
| Nagy, C | 2 |
| House, K | 1 |
| Baber, N | 1 |
| Frazer, NM | 1 |
| Pritchard, JF | 1 |
| Lauwers, MH | 1 |
| Verbessem, D | 1 |
| Isal, JP | 1 |
| Inall, FC | 1 |
| Kanarek, BK | 1 |
| Povey, PM | 1 |
| Fagraeus, I | 1 |
| Du Pen, S | 1 |
| Clayborn, L | 1 |
| Sullivan, MJ | 1 |
| Abbott, GD | 1 |
| Robinson, BA | 1 |
| Buxton, MJ | 1 |
| O'Brien, BJ | 1 |
| Bouly, A | 1 |
| Nathan, N | 1 |
| Israelsson, G | 1 |
| Zackrisson, B | 1 |
| Beyer, JH | 1 |
| Räth, U | 1 |
| Souchon, R | 1 |
| Tanneberger, S | 1 |
| Lelli, G | 1 |
| Piana, E | 1 |
| Berry, WR | 1 |
| House, KW | 1 |
| Lee, JT | 1 |
| Meshad, MW | 1 |
| Grapski, R | 1 |
| Tiley, C | 1 |
| Powles, R | 1 |
| Catalano, J | 1 |
| Treleaven, J | 1 |
| Eshelby, J | 1 |
| Hewetson, M | 1 |
| Tait, D | 1 |
| Sebolt-Leopold, JS | 1 |
| Vincent, PW | 1 |
| Beningo, KA | 1 |
| Elliott, WL | 1 |
| Leopold, WR | 1 |
| Heffner, TG | 1 |
| Wiley, JN | 1 |
| Stier, MA | 1 |
| Suto, MJ | 1 |
| Sands, R | 1 |
| Marsh, M | 1 |
| Gill, A | 1 |
| Dundee, JW | 3 |
| McMillan, CM | 2 |
| Mitchell, PL | 2 |
| Evans, BD | 2 |
| Allan, SG | 2 |
| Forgeson, GV | 1 |
| Mak, D | 2 |
| Neave, L | 1 |
| Humm, G | 1 |
| Langley, G | 1 |
| Dickson, D | 1 |
| Harvey, VJ | 2 |
| Yang, J | 1 |
| Wright, PM | 1 |
| Brown, SG | 1 |
| Prentice, DA | 1 |
| Burnette, PK | 1 |
| Perkins, J | 1 |
| Kommoss, FG | 1 |
| Fenzl, E | 2 |
| Pfleiderer, A | 2 |
| Vohra, S | 1 |
| Juricic, J | 1 |
| Egan, AP | 1 |
| Taggart, JR | 1 |
| Bender, CM | 1 |
| de Mulder, PH | 5 |
| Jantunen, I | 1 |
| Johansson, R | 1 |
| Hill, AS | 1 |
| Hutcheon, AW | 1 |
| Cassidy, J | 1 |
| Sikora, K | 1 |
| Carney, DN | 1 |
| Smith, DB | 4 |
| Newlands, ES | 3 |
| Rustin, GJ | 4 |
| Begent, RH | 3 |
| Crawford, SM | 1 |
| Bagshawe, KD | 3 |
| Carruthers, L | 2 |
| Hoffmann, IS | 1 |
| Fuenmayor, NT | 2 |
| Lucraft, H | 1 |
| Collis, CH | 1 |
| Adams, M | 1 |
| Priestman, S | 1 |
| Heel, RC | 1 |
| Howells, N | 2 |
| Harvey, W | 1 |
| Kasimis, B | 1 |
| Oblon, D | 1 |
| Monaghan, G | 1 |
| Harker, G | 1 |
| Ersbøll, J | 1 |
| Lip, H | 2 |
| Ciociola, A | 1 |
| Esparza, L | 1 |
| Templeton, D | 1 |
| Holmes, FA | 1 |
| Walters, RS | 1 |
| Hortobagyi, GN | 1 |
| Chaffee, BJ | 1 |
| Tankanow, RM | 1 |
| Cortesi, E | 1 |
| Favalli, G | 1 |
| Marangolo, M | 3 |
| Amadori, D | 1 |
| Bella, MA | 1 |
| Gramazio, V | 1 |
| Donati, D | 2 |
| Neave, LM | 1 |
| Langley, GB | 1 |
| Dickson, DS | 1 |
| Sagar, SM | 1 |
| Bayliss, MA | 1 |
| Chong, SL | 1 |
| Retsas, S | 1 |
| Omura, GA | 1 |
| Kapur, PA | 1 |
| Larijani, GE | 1 |
| Minassian, S | 1 |
| Bodner, M | 1 |
| Cornish, J | 1 |
| Pamphilon, D | 1 |
| Oakhill, A | 1 |
| Stevens, RF | 1 |
| Johansson, S | 1 |
| Hursti, T | 1 |
| Betcher, DL | 1 |
| Burnham, N | 1 |
| McMillan, C | 1 |
| Abram, WP | 1 |
| Lane-Allman, E | 2 |
| van Liessum, PA | 3 |
| Sagrada, A | 1 |
| Turconi, M | 1 |
| Bonali, P | 1 |
| Schiantarelli, P | 1 |
| Micheletti, R | 1 |
| Montagna, E | 1 |
| Nicola, M | 1 |
| Algate, DR | 1 |
| Rimoldi, EM | 1 |
| Donetti, A | 1 |
| Layer, P | 1 |
| Marschner, NW | 2 |
| Nagel, GA | 2 |
| Upadhyaya, B | 1 |
| Vidili, G | 1 |
| Oliva, C | 2 |
| Ardizzoni, A | 1 |
| Mammoliti, S | 1 |
| Cetto, GL | 1 |
| Fosser, V | 1 |
| Erben, M | 1 |
| Smyth, JF | 1 |
| Coleman, RE | 1 |
| Nicolson, M | 1 |
| Gallmeier, WM | 1 |
| Leonard, RC | 1 |
| Cornbleet, MA | 1 |
| Bruntsch, U | 1 |
| Lamers, CB | 1 |
| Aubert, B | 1 |
| Bons, J | 4 |
| Pappo, M | 1 |
| Lambert, HE | 1 |
| Hawthorn, J | 3 |
| Pouillart, P | 2 |
| Scholl, S | 1 |
| Azab, M | 1 |
| Brion, N | 2 |
| Pujade-Lauraine, E | 2 |
| Paule, B | 2 |
| Spruyt, OW | 1 |
| Mellor, B | 1 |
| Viner, CV | 1 |
| Selby, PJ | 1 |
| Zulian, GB | 1 |
| Gore, ME | 1 |
| Butcher, ME | 2 |
| Wootton, CM | 1 |
| McElwain, TJ | 2 |
| Werner, K | 2 |
| Sampi, K | 1 |
| Chevallier, B | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Kvaløy, S | 1 |
| Ries, F | 1 |
| Huys, JV | 1 |
| Royer, E | 1 |
| Carden, PA | 1 |
| Mitchell, SL | 1 |
| Waters, KD | 1 |
| Tiedemann, K | 1 |
| Ekert, H | 1 |
| Beex, LV | 2 |
| Williams, D | 1 |
| Wootton, C | 1 |
| Sartiano, G | 1 |
| Finn, A | 1 |
| Hoffman, IS | 1 |
| Groshen, S | 1 |
| Robinson, DC | 1 |
| Stevenson, LL | 2 |
| Hait, WN | 1 |
| Jaenicke, F | 1 |
| Albrecht, U | 1 |
| Vermorken, JB | 1 |
| Mols-Jevdevic, S | 1 |
| Allman, EL | 1 |
| Beranek, P | 1 |
| Bella, M | 1 |
| Cetto, G | 1 |
| Wilhelm, C | 1 |
| Quaas, L | 1 |
| Barnickel, I | 1 |
| Serve, H | 1 |
| Perker, M | 1 |
| Ertl, A | 1 |
| Reichold, M | 1 |
| Fink, U | 1 |
| Berdel, WE | 1 |
| Lambert, RM | 1 |
| Martin, GE | 1 |
| Bostwick, JS | 1 |
| Gessner, GW | 1 |
| Pendleton, RG | 1 |
| Decktor, DL | 1 |
| Kidgell, AE | 1 |
| Brown, GW | 1 |
| Cohen, ML | 1 |
| Bloomquist, W | 1 |
| Gidda, JS | 1 |
| Lacefield, W | 1 |
| Sartiano, GP | 1 |
| White, DR | 1 |
| Chubb, JM | 1 |
| Green, JA | 1 |
| Watkin, SW | 1 |
| Hammond, P | 1 |
| Griggs, J | 1 |
| Challoner, T | 3 |
| Russell, CA | 1 |
| McDermed, JE | 1 |
| Smith, RN | 1 |
| Turner, A | 1 |
| Rosin, RD | 1 |
| Pople, A | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| de Haan, LD | 1 |
| Debruyne, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)[NCT02246439] | Phase 3 | 330 participants (Actual) | Interventional | 2014-12-08 | Completed | ||
| Multi-dose Oral Ondansetron For Pediatric Gastroenteritis: A Pragmatic Randomized Controlled Trial[NCT03851835] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2019-09-04 | Recruiting | ||
| Intravenous Dextrose Versus Ondansetron for Prevention of Postoperative Vomiting in Children: a Randomized Non-inferiority Trial[NCT01912807] | 300 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial[NCT03056482] | Phase 4 | 33 participants (Actual) | Interventional | 2017-05-21 | Completed | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention [NCT01594749] | Phase 3 | 1,015 participants (Actual) | Interventional | 2012-09-24 | Completed | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Ped[NCT01362530] | Phase 3 | 307 participants (Actual) | Interventional | 2011-09-13 | Completed | ||
| Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant[NCT04535141] | Phase 3 | 91 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Re[NCT02635984] | Phase 3 | 108 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in Emergency Departments in Pakistan[NCT01870635] | Phase 4 | 625 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning[NCT01050270] | Phase 4 | 222 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay[NCT02956616] | Phase 2 | 118 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section[NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial[NCT04252521] | 150 participants (Actual) | Interventional | 2019-07-03 | Completed | |||
| Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial[NCT02760069] | Phase 4 | 122 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetoge[NCT00337727] | Phase 3 | 848 participants (Actual) | Interventional | 2007-01-01 | Completed | ||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069] | 36 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Isopropyl Alcohol Inhalation as Anti-emetic Therapy in the Emergency Department[NCT04464915] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn (stopped due to Given the COVID-19 pandemic, there has been a temporary suspension of study activities, therefore the study has not yet been initiated.) | |||
| Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure During Congenital Pulmonary Stenosis Balloon Dilatation[NCT05582213] | 40 participants (Actual) | Interventional | 2022-10-01 | Completed | |||
| Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)[NCT03125811] | Early Phase 1 | 121 participants (Actual) | Interventional | 2017-07-17 | Completed | ||
| A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study[NCT01913990] | Phase 4 | 323 participants (Anticipated) | Interventional | 2011-09-30 | Active, not recruiting | ||
| A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC o[NCT01442376] | Phase 3 | 502 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexameth[NCT02106494] | Phase 3 | 942 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Evaluation of the Impact of the HLNatural, Inc. Immune Support Product in Reducing the Length of Cold Symptoms in Adults Suffering From the Common Cold[NCT04103099] | 200 participants (Actual) | Interventional | 2019-10-16 | Completed | |||
| A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R[NCT01636947] | Phase 4 | 494 participants (Actual) | Interventional | 2012-12-12 | Completed | ||
| Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen[NCT00970905] | Phase 2 | 52 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated W[NCT00080444] | Phase 3 | 50 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients[NCT01757210] | 20 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects[NCT00437229] | Phase 1 | 37 participants (Actual) | Interventional | 2007-02-19 | Completed | ||
| Prevelane and Short Term Outcome of Hypernatremic Dehydration in Children With Acute Gastroenteritis in Sohag University Hospital[NCT05440162] | 50 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for [NCT00104403] | Phase 2 | 722 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Study to Evaluate the Anti-Emetic Effect of Ginger Powder Vs Placebo as an Add-on Therapy in Children and Adolescents Receiving Chemotherapy : A Randomized Controlled Trial[NCT00940368] | Phase 3 | 60 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| Oral Glucose Intervention for Children With Gastroenteritis and Ketosis[NCT02729870] | 0 participants (Actual) | Observational | 2018-01-31 | Withdrawn (stopped due to lack of funding) | |||
| Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial[NCT01257672] | Phase 3 | 356 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin[NCT03237611] | Phase 2 | 15 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Expired IRB approval on 2/11/21) | ||
| Phase 2B Double Blind Placebo Controlled Crossover Study Evaluating the Efficacy of IV Fosaprepitant for Chemo Induced N/V With High Dose Interleukin 2 for Metastatic Melanoma and Metastatic Renal Cell Carcinoma[NCT01874119] | Phase 2 | 13 participants (Actual) | Interventional | 2013-09-30 | Terminated (stopped due to Enrollment issues) | ||
| A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Indu[NCT00619359] | Phase 3 | 2,322 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin C[NCT05244577] | Phase 3 | 75 participants (Anticipated) | Interventional | 2022-01-18 | Recruiting | ||
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study[NCT01052844] | Phase 3 | 80 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial[NCT01165866] | Phase 4 | 170 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.[NCT00601172] | Phase 3 | 710 participants (Actual) | Interventional | 2008-03-10 | Completed | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting[NCT02473887] | Phase 1 | 40 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies[NCT00871910] | Phase 1 | 81 participants (Actual) | Interventional | 2006-10-11 | Completed | ||
| Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310] | Phase 3 | 303 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to we terminated the study before enrolling 303/560 due to a slow accrual) | ||
| Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667] | 70 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Thoracicsurgery Patients: A Single-center, Randomized, Double-Blinded Clinical Study[NCT05881486] | 234 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | |||
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911] | Phase 3 | 120 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Observational Study of Delayed Nausea and Vomiting Following Administration of Carboplatin Containing Regimens for Treatment of Cancer[NCT00696280] | 106 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia[NCT02635828] | Phase 4 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study[NCT00869973] | Phase 3 | 580 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to We terminated the study after enrolling 580/900 patients due to a slow accrual) | ||
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients[NCT01414777] | Phase 2/Phase 3 | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With [NCT00092196] | Phase 3 | 820 participants (Actual) | Interventional | 2002-12-01 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Che[NCT00092183] | Phase 4 | 866 participants (Actual) | Interventional | 2002-10-10 | Completed | ||
| Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial[NCT02619201] | Phase 3 | 250 participants (Anticipated) | Interventional | 2015-11-30 | Not yet recruiting | ||
| Does Oral Propranolol Accelerate Labor Induction/Augmentation With Oxytocin in Nulliparous Women in Abakaliki?[NCT05251610] | 110 participants (Actual) | Interventional | 2020-11-02 | Completed | |||
| Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis[NCT00691275] | 0 participants (Actual) | Interventional | 2008-09-30 | Withdrawn | |||
| A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis[NCT00016380] | Phase 3 | 211 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Inhalation Intervention for Nausea in the Emergency Department[NCT02092441] | 80 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| A Randomized Controlled Trial of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department[NCT00429832] | Phase 4 | 120 participants | Interventional | 2003-10-31 | Completed | ||
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Preoperative Pregabalin to Prevent Postoperative Nausea & Vomiting in Laparoscopic Surgery.[NCT05529004] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| A Phase III, Randomized, Open-label, Active-controlled, Two-arm, Parallel-design, Interventional Clinical Trial Evaluating the Efficacy and Safety of Ondansetron 8 mg IV/ IM Injection Compared to Metoclopramide 10 mg in the Management of Nausea and Vomiti[NCT05876585] | Phase 3 | 126 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.[NCT00825071] | Phase 4 | 180 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Effect of Intravenous Granisetron on Incidence and Severity of Intrathecal Morphine Induced Pruritus in Elective Cesarean Section[NCT03483870] | Phase 2 | 80 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population[NCT01592708] | 233 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy[NCT01980160] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Did not receive IRB approval from our institution therefore the study was closed.) | |||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.[NCT01679093] | Phase 3 | 66 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients receiving parenteral hydration within 24 hours after the first dose of study medication. (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 34 |
| Placebo Oral Tablet | 32 |
Patients receiving rescue antiemetic therapy within 24 hours after the first dose of study medication. (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 48 |
| Placebo Oral Tablet | 43 |
Number of patients requiring hospitalization. 4 patients in the RHB-102 treatment group and 1 patient in the placebo treatment group were hospitalized due to lack of efficacy. The remaining patients hospitalized were admitted for reasons other than gastroenteritis. (NCT02246439)
Timeframe: Day 1 of Study - Day 5 of Study
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 11 |
| Placebo Oral Tablet | 3 |
Proportion of patients returning to emergency department for gastrointestinal symptoms within 4 days of initial discharge (NCT02246439)
Timeframe: Day 1 of Study - Day 5 of Study
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 4 |
| Placebo Oral Tablet | 4 |
Treatment success, as defined in the primary outcome, through 4 days following first dose of study medication. (NCT02246439)
Timeframe: 4 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 114 |
| Placebo Oral Tablet | 67 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (analyzed using logistic regression with treatment as a factor and baseline nausea severity as a continuous variable) (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 126 |
| Placebo Oral Tablet | 70 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (analyzed using logistic regression with treatment as a factor and baseline nausea severity as a continuous variable) (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 123 |
| Placebo Oral Tablet | 67 |
Examination of treatment success rates by age (<18 and ≥18 years). (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 5 | 62 |
| RHB-102 | 11 | 112 |
Severity of nausea was assessed using a 5-point Likert scale: 0=no nausea; 1=mild nausea; 2=moderate nausea; 3=severe nausea; 4=nausea as bad as can be. (NCT02246439)
Timeframe: Day 1 - Baseline through 5 Hours Post Dose
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Hour 1 Post Dose | Hour 2 Post Dose | Hour 3 Post Dose | Hour 4 Post Dose | Hour 5 Post Dose | |
| Placebo Oral Tablet | 2.6 | 1.3 | 0.9 | 0.8 | 0.6 | 0.2 |
| RHB-102 | 2.8 | 1.1 | 0.8 | 0.5 | 0.4 | 0.1 |
Time from first dose of study medication to discharge from ED, extended observation unit or hospital, whichever comes last, and when clinically appropriate. (NCT02246439)
Timeframe: Hours from first dose of study medication to discharge from ED, extended observation unit or hospital, whichever comes last
| Intervention | Hours (Median) | ||
|---|---|---|---|
| All ages | < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 4.3 | 4.8 | 4.2 |
| RHB-102 | 4.3 | 4.3 | 4.3 |
Time from first dose of study medication to resumption of normal activities (work/school/household). (NCT02246439)
Timeframe: Hours from first dose of study medication to resumption of normal activities
| Intervention | Hours (Median) | ||
|---|---|---|---|
| All ages | < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 3 | 4 | 3 |
| RHB-102 | 3 | 2 | 3 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All ages | <18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 70 | 5 | 65 |
| RHB-102 | 126 | 12 | 114 |
Proportion of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All ages | <18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 67 | 5 | 62 |
| RHB-102 | 123 | 11 | 112 |
Proportion of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| No nausea or mild nausea | Moderate nausea | Severe nausea | Nausea as bad as it could have been | |
| Placebo Oral Tablet | 13 | 24 | 22 | 11 |
| RHB-102 | 22 | 26 | 47 | 31 |
Measuring the blood glucose level is important to ensure that administration of IV Dextrose at the dose to be used in our protocol, did not cause hyperglycemia in the participants. This measurement was done while patients were still under general anesthetic during the procedure. (NCT01912807)
Timeframe: Intraoperatively
| Intervention | mmol/L (Median) |
|---|---|
| Dextrose (D5NS) - Intervention Group | 6.3 |
| Ondansetron - Control Group | 5.5 |
Data was recorder for number of patients with delays in discharge from PACU due to POV (NCT01912807)
Timeframe: Within 24 hours after the procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Dextrose (D5NS) - Intervention Group | 2 |
| Ondansetron - Control Group | 0 |
"Parents were informed during the consent process that postoperative 24 hour follow up was going to be done over the phone by the researcher.~The number of participants (parents / caregivers) who answered the call was recorded, and from those the number of patients who presented the secondary outcome." (NCT01912807)
Timeframe: 2 to 24 hr after procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Dextrose (D5NS) - Intervention Group | 15 |
| Ondansetron - Control Group | 9 |
"In the Post Anesthetic Care Unit (PACU) the proper data (intraoperative and recovery period) was recorded at immediate postoperative period, at 2 hours after the procedure and prior to discharge.~Parents were informed during the consent process that postoperative 24 hour follow up was going to be done over the phone by researcher." (NCT01912807)
Timeframe: 0 to 2 hr after the procedure (in PACU)
| Intervention | Participants (Count of Participants) |
|---|---|
| Dextrose (D5NS) - Intervention Group | 11 |
| Ondansetron - Control Group | 5 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 77.1 |
| Control Regimen | 66.9 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 24 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 93.2 |
| Control Regimen | 91.0 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 25 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 78.9 |
| Control Regimen | 68.5 |
The percentages of participants with infusion-site thrombophlebitis are presented. Thrombophlebitis was defined as a condition affecting a superficial vein used for an IV infusion, associated with red color, hardness upon palpation, and the presence of a tender cord and possible fever. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.6 |
| Control Regimen | 0.0 |
No Vomiting was defined as no emetic (vomiting) episodes, including no vomiting and no retching or dry heaves (attempts to vomit that are not productive of stomach contents), regardless of use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of participants (Number) |
|---|---|
| Fosaprepitant Regimen | 82.7 |
| Control Regimen | 72.9 |
The percentages of participants with severe infusion-site reactions, including severe site pain, or severe site redness (erythema) or severe site hardness (induration) are presented. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.0 |
| Control Regimen | 0.0 |
Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 24 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 66.4 |
| Control Regimen | 52.0 |
Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1. (NCT01362530)
Timeframe: 25 to 120 hours after the start of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 50.7 |
| Control Regimen | 26.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 40.1 |
| Control Regimen | 20.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 46.7 |
| Control Regimen | 21.3 |
"The total number of rescue medications needed for breakthrough chemotherapy-induced nausea and vomiting were calculated, starting from the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for CINV prophylaxis." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.47 |
| Olanzapine | 1.17 |
"The total number of rescue medications needed acute was calculated, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for chemotherapy-induced nausea and vomiting (CINV) prophylaxis." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.08 |
| Olanzapin | 0.10 |
"Starting with the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions. Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely in the first 24 hours following receipt of chemotherapy." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 44 | 1 |
| Usual Care | 43 | 3 |
The frequency of somnolence was determined as the number of patients who experienced somnolence based on Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The number of subjects has somnolence during the study period was counted. (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| subjects have somnolence | subjects do not have somnolence | |
| Olanzapine | 1 | 42 |
| Usual Care | 0 | 46 |
The number of emesis episodes in acute phase was defined as the number of subjects with no emesis, 1 emesis, and 2 or more emesis. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| No emesis episodes | 1 emesis episode | 2 or more emesis episodes | |
| Olanzapine | 36 | 6 | 3 |
| Usual Care | 32 | 9 | 5 |
: The number of subjects who did not experience emesis, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy. Met endpoint = 0 emesis. (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 45 | 0 |
| Usual Care | 45 | 1 |
"Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions, starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~The number of subjects who experienced never or rarely nausea were considered as met the endpoint while those who experienced occasionally, frequently or almost constantly were considered as not met the endpoint." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2-12).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 27 | 18 |
| Usual Care | 19 | 27 |
"To determine the number of subjects achieving minimal nausea was defined as the frequency of participants responded to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea question In the last 24 hours, how often did you have nausea? as rarely or less Starting with the first dose of chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~PRO-CTCAE of nausea scale includes categories: Never, Rarely, Occasionally, Frequently, Almost constantly To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely and the score reported for the Pro-CTCAE question for nausea severity cannot exceed mild" (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Olanzapine | 25 | 20 |
| Usual Care | 15 | 31 |
Prolongation of corrected QTc interval graded as defined in Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Corrected QTc was calculated using Fredericia's Formula. Corrected QT interval (QTc) = QT interval / (60/Heart rate)^0.33. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2- 12).
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | None | |
| Baseline Olanzapine | 4 | 0 | 0 | 0 | 0 | 41 |
| Baseline Usual Care | 3 | 0 | 0 | 0 | 0 | 43 |
| Olanzapine Post-chemo Day 1 | 3 | 0 | 0 | 0 | 0 | 42 |
| Olanzapine- End of Study | 3 | 0 | 1 | 0 | 0 | 41 |
| Usual Care End of Study | 3 | 0 | 1 | 0 | 0 | 42 |
| Usual Care Post-chemo Day 1 | 2 | 0 | 0 | 0 | 0 | 44 |
"The severity of nausea in the delayed phase was defined as the response of the subject to the PRO- CTCAE nausea question.~Starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy (PRO-CTCAE) Scale: Never, Rarely, Occasionally, Frequently, Almost constantly~o meet the endpoint, the subject could not have answered a score as higher than mild in the period of time starting 24 hours after the last dose of chemotherapy and continuing until the 5th day following receipt of chemotherapy ." (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 31 | 24 |
| Usual Care | 23 | 23 |
Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (< 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy. (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 13 |
| Triplet Therapy Plus Olanzapine | 28 |
Reported as acute [chemotherapy days]. All assessment with all VAS < 25 mm on days of chemotherapy (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 33 |
| Triplet Therapy Plus Olanzapine | 39 |
Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 16 |
| Triplet Therapy Plus Olanzapine | 34 |
(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after] (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 13 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 31 |
| Triplet Therapy Plus Olanzapine | 39 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 15 |
| Triplet Therapy Plus Olanzapine | 31 |
No nausea (all VAS <5 mm) in overall assessment period (days of chemotherapy plus five days after) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 18 |
Reported for overall phases [chemotherapy days plus 5 days after] where all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 14 |
| Triplet Therapy Plus Olanzapine | 30 |
Number of patients discharged on postoperative Day #2 (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Enhanced Recovery | 5 |
| Routine Perioperative Care | 2 |
Postoperative Length of Hospital Stay in Hours from time of surgery (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Hours (Median) |
|---|---|
| Enhanced Recovery | 73.58 |
| Routine Perioperative Care | 75.50 |
The amount of postoperative pain medication required for each patient in Morphine Milligram Equivalents (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Morphine Milligram Equivalents (Mean) |
|---|---|
| Enhanced Recovery | 117.16 |
| Routine Perioperative Care | 119.38 |
All patients will be queried regarding whether breastfeeding was initiated after cesarean birth and how soon after birth (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Breastfeeding | Bottlefeeding | Both Breastfeeding and Bottlefeeding | |
| Enhanced Recovery | 39 | 4 | 15 |
| Routine Perioperative Care | 29 | 2 | 29 |
Comparison of intraoperative nausea and vomiting between the 3 groups. (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants (Number) |
|---|---|
| Combination Group | 23 |
| Metoclopramide | 31 |
| Phenylephrine Infusion | 49 |
The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants with SBP< 20 % baseline (Number) |
|---|---|
| Combination Group | 16 |
| Metoclopramide | 19 |
| Phenylephrine Infusion | 16 |
(NCT01216410)
Timeframe: 0-24 hrs
| Intervention | participants (Number) |
|---|---|
| Combination Group | 95 |
| Metoclopramide | 93 |
| Phenylephrine Infusion | 97 |
1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted. (NCT01216410)
Timeframe: 24 h
| Intervention | participants (Number) |
|---|---|
| Combination Group | 94 |
| Metoclopramide | 85 |
| Phenylephrine Infusion | 87 |
(NCT01216410)
Timeframe: 0-2h, 2-6h, 6-24h
| Intervention | participants (Number) | ||
|---|---|---|---|
| 0-2 hrs PONV | 2-6 hrs PONV | 6-24 hrs PONV | |
| Combination Group | 20 | 28 | 22 |
| Metoclopramide | 33 | 35 | 26 |
| Phenylephrine Infusion | 39 | 41 | 22 |
Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea. (NCT02760069)
Timeframe: 30 minutes post intervention
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 23 |
| Inhaled ISO + Oral Placebo | 19 |
| Inhaled Placebo + Oral Ondansetron | 42 |
Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record. (NCT02760069)
Timeframe: Study duration (up to 5 hours post intervention)
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 11 |
| Inhaled ISO + Oral Placebo | 10 |
| Inhaled Placebo + Oral Ondansetron | 18 |
The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1. (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 292 |
| Standard Regimen | 229 |
"The number of patients who reported No Vomiting in the overall phase in Cycle~1" (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 324 |
| Standard Regimen | 252 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from >24 to 120 hours (delayed phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. (NCT01442376)
Timeframe: from >24 to 120 hours (delayed phase) after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 28.9 |
| Palonosetron 20 mcg/kg | 38.8 |
| Ondansetron | 28.4 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. Time 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy. (NCT01442376)
Timeframe: 0 to 24 hours after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 54.2 |
| Palonosetron 20 mcg/kg | 59.4 |
| Ondansetron | 58.6 |
To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 60.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 53.1 |
Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 64.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 56.6 |
To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 54.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 49.6 |
To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 58.4 |
| Ondansetron + Fosaprepitant + Dexamethasone | 52.9 |
To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 82.2 |
| Ondansetron + Fosaprepitant + Dexamethasone | 79.2 |
The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Number of Emetic Events (Number) |
|---|---|
| Aprepitant Regimen | 54 |
| Control Regimen | 68 |
"The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, No Impact on daily life was defined as an average item score of >6 on the 7-point scale; a total score >108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC." (NCT01636947)
Timeframe: Day 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.8 |
| Control Regimen | 73.8 |
"Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: How much nausea have you had over the last 24 hours? The left end of the scale (0 mm) was labeled no nausea, and the right end of the scale (100 mm) is labeled nausea as bad as it could be. In this study, No Significant Nausea was defined as a VAS nausea rating <25 mm." (NCT01636947)
Timeframe: Days 1 to Day 5
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.4 |
| Control Regimen | 72.4 |
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event. (NCT01636947)
Timeframe: Day 1 through Day 29 (Up to 28 days after first dose of study drug)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 56.2 |
| Control Regimen | 53.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC). (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 77.2 |
| Control Regimen | 72.0 |
The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1 to Day 5
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 84.8 | 98.7 | 84.8 |
| Control Regimen | 87.7 | 99.2 | 88.5 |
A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 73.4 | 95.8 | 74.3 |
| Control Regimen | 70.4 | 97.9 | 71.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1, Day 2 to Day 5
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 95.8 | 78.5 |
| Control Regimen | 98.8 | 72.4 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 11 | 10 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the first cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 9 | 9 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the second cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the second cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
No vomiting from the initiation of through 48 hours following the final dose of HD IL-2 (NCT01874119)
Timeframe: From the initiation of through 48 hours following the final dose of Interleukin-2
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosaprepitant | 1 |
| Placebo | 0 |
The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Delayed phase (25 to 120 hours following initiation of cisplatin).
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 822 |
| Aprepitant | 841 |
The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Overall (in the 120 hours following initiation of cisplatin chemotherapy).
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 795 |
| Aprepitant | 820 |
The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Overall (the 120 hours following initiation of cisplatin chemotherapy)
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 806 |
| Aprepitant | 844 |
The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h) (NCT01052844)
Timeframe: 5 days
| Intervention | participants (Number) |
|---|---|
| Control Group | 17 |
| Gabapentin | 26 |
Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy (NCT01052844)
Timeframe: 6 days
| Intervention | participants (Number) |
|---|---|
| Control Group | 21 |
| Gabapentin | 29 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. Percentage of participants who achieved a complete response in the acute phase of Cycle 1 are presented. (NCT00601172)
Timeframe: 0 to 24 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 96 |
| Casopitant 90 mg | 97 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. Percentage of participants who achieved a complete response in the delayed phase of Cycle 1 are presented. (NCT00601172)
Timeframe: 24 to 120 hours (delayed phase) in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 85 |
| Casopitant 90 mg | 86 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. The overall phase began at the start of the administration of the oxaliplatin infusion. Percentage of participants who achieved a complete response in the overall phase (0-120 hours) are presented. (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 85 |
| Casopitant 90 mg | 86 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. The overall phase began at the start of the administration of the oxaliplatin infusion. Percentage of participants who achieved a complete response in the overall phase of Cycle 2 are presented. (NCT00601172)
Timeframe: 0 to 120 hours in the second cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 84 |
| Casopitant 90 mg | 90 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. CL for casopitant is presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Liter/hour (Geometric Mean) |
|---|---|
| Casopitant 90 mg | 10.457 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. Vdss for casopitant is presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Liter (Geometric Mean) |
|---|---|
| Casopitant 90 mg | 126.776 |
Time to first rescue medication was defined as the length of time from initiation of oxaliplatin till the first reported use of a rescue medication. Participants withdrawing prematurely during the 120 hour assessment period without having received a rescue medication were assumed to have done so and the time of rescue medication was set to 0 hours. The first quartile for time to use of anti-emetic rescue medication was evaluated when 25th percentile of participants of MITT population reported use of anti-emetic rescue medication. Similarly, median and 75th percentile of participants of MITT population was planned to be reported. If, less than 25th percentile of participants reported use of anti-emetic rescue medication at the end of the 120 hour time period, then the observation was censored for the purpose of this analysis and in such case the data was planned to be reported as not evaluable (NA). (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Hours (Median) |
|---|---|
| Placebo | NA |
| Casopitant 90 mg | NA |
Time to first emetic event was defined as the length of time from initiation of oxaliplatin until the time of first emetic event. Participants withdrawing prematurely from the study without having experienced an emetic event were assumed to have done so and the time of emetic event was set to 0 hours. The first quartile for time to emetic event was evaluated when 25th percentile of participants of MITT population reported emetic event. Similarly, median and 75th percentile of participants of MITT population was planned to be reported. If, less than 25th percentile of participants reported emetic event at the end of the 120 hour time period, then the observation was censored for the purpose of this analysis and in such case the data was planned to be reported as not evaluable (NA). (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Hours (Median) |
|---|---|
| Placebo | NA |
| Casopitant 90 mg | NA |
Vital signs assessment included DBP and SBP. SBP and DBP were recorded at Screening, on Day 1 of each cycle immediately before start of the investigational product infusion, at the completion of the infusion, and immediately after the end of the oxaliplatin infusion, then again at each end of cycle visit. Mean SBP and DBP are presented. (NCT00601172)
Timeframe: Up to End of Cycle for 6 cycles, an average of 24 days per cycle
| Intervention | Millimeters of mercury (mmHg) (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBP: Cycle 1, post-oxaliplatin | DBP: Cycle 1, End of cycle | DBP: Cycle 2, post-oxaliplatin | DBP: Cycle 2, End of cycle | DBP: Cycle 3, post-oxaliplatin | DBP: Cycle 3, End of cycle | DBP: Cycle 4, post-oxaliplatin | DBP: Cycle 4, End of cycle | DBP: Cycle 5, post-oxaliplatin | DBP: Cycle 5, End of cycle | DBP: Cycle 6, post-oxaliplatin | DBP: Cycle 6, End of cycle | SBP: Cycle 1, post-oxaliplatin | SBP: Cycle 1, End of cycle | SBP: Cycle 2, post-oxaliplatin | SBP: Cycle 2, End of cycle | SBP: Cycle 3, post-oxaliplatin | SBP: Cycle 3, End of cycle | SBP: Cycle 4, post-oxaliplatin | SBP: Cycle 4, End of cycle | SBP: Cycle 5, post-oxaliplatin | SBP: Cycle 5, End of cycle | SBP: Cycle 6, post-oxaliplatin | SBP: Cycle 6, End of cycle | |
| Casopitant 90 mg | 76.5 | 76.5 | 76.8 | 77.1 | 76.6 | 77.2 | 76.9 | 76.4 | 77.7 | 77.7 | 77.6 | 77.5 | 126.8 | 126.7 | 129.3 | 127.8 | 128.7 | 127.7 | 129.0 | 128.3 | 129.7 | 128.8 | 131.5 | 129.1 |
| Placebo | 77.2 | 76.9 | 77.7 | 76.8 | 78.0 | 77.3 | 78.2 | 76.8 | 77.4 | 77.1 | 77.9 | 77.9 | 130.6 | 128.7 | 130.1 | 128.9 | 131.0 | 128.8 | 131.8 | 128.0 | 131.3 | 128.6 | 132.2 | 129.7 |
Vital sign included heart rate which was recorded at Screening, on Day 1 of each cycle immediately before start of the investigational product infusion, at the completion of the infusion, and immediately after the end of the oxaliplatin infusion, then again at each end of cycle visit. Mean heart rate is presented. (NCT00601172)
Timeframe: Up to End of Cycle for 6 cycles, an average of 24 days per cycle
| Intervention | Beats/minute (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, post-oxaliplatin | Cycle 1, End of cycle | Cycle 2, post-oxaliplatin | Cycle 2, End of cycle | Cycle 3, post-oxaliplatin | Cycle 3, End of cycle | Cycle 4, post-oxaliplatin | Cycle 4, End of cycle | Cycle 5, post-oxaliplatin | Cycle 5, End of cycle | Cycle 6, post-oxaliplatin | Cycle 6, End of cycle | |
| Casopitant 90 mg | 73.7 | 75.3 | 73.7 | 74.7 | 72.2 | 75.4 | 72.2 | 74.7 | 72.9 | 75.0 | 73.4 | 75.6 |
| Placebo | 73.1 | 75.1 | 73.0 | 74.8 | 73.2 | 74.9 | 72.6 | 75.0 | 72.8 | 74.7 | 73.5 | 74.7 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 millimeter (mm) (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 16.0 | 5.3 | 15.3 |
| Placebo | 13.5 | 4.3 | 13.0 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect. Any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product was recorded from the time a participant consents to participate in the study up to and including any follow-up contact. (NCT00601172)
Timeframe: Up to 35 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE | SAE | |
| Casopitant 90 mg | 171 | 26 |
| Placebo | 176 | 23 |
Grade shifts from Baseline were assessed as shift from any Grade to Grade 3 or Grade 4 in any cycle. Toxicities were graded according to the NCI-CTCAE, version 3.0. Grade refers to the severity of the toxicity. The NCI-CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE and Grade 5: Death related to AE. It was assessed on Baseline (Day 1), during Day 6-10 and end of cycle. Clinical chemistry parameters assessed were alanine amino transferase (ALT), aspartate amino transferase (AST), chloride, glucose, potassium, sodium and total bilirubin. Data has been presented for the number of participants with chemistry toxicity grade shifts from Baseline to toxicity grade 3 and 4 for all cycles in a consolidated format. (NCT00601172)
Timeframe: Up to Day 24
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: All cycles, Grade 0 to 3 | ALT: All cycles, Grade 2 to 3 | AST: All cycles, Grade 0 to 3 | High chloride: All cycles, Grade 1 to 3 | Low chloride: All cycles, Grade 0 to 3 | Hyperglycemia: Al cycles, Grade 0 to 3 | Hyperglycemia: All cycles, Grade 1 to 3 | Hyperglycemia: All cycles, Grade 2 to 3 | Hyperglycemia: All cycles, Grade 3 to 3 | Hypoglycemia: All cycles, Grade 0 to 4 | Hyperkalemia: All cycles, Grade 2 to 3 | Hyperkalemia: All cycles, Grade 4 to 3 | Hyperkalemia: All cycles, Grade 0 to 3 | Hyperkalemia: All cycles, Grade 0 to 4 | Hypokalemia: All cycles, Grade 0 to 3 | Hyponatremia: All cycles, Grade 1 to 3 | Total Bilirubin: All cycles, Grade 0 to 3 | Total Bilirubin: All cycles, Grade 0 to 4 | |
| Casopitant 90 mg | 2 | 0 | 1 | 0 | 1 | 3 | 2 | 5 | 3 | 1 | 0 | 0 | 2 | 2 | 8 | 8 | 1 | 0 |
| Placebo | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 9 | 3 | 1 | 1 | 1 | 0 | 0 | 6 | 6 | 1 | 1 |
Grade shifts from Baseline were assessed as shift from any Grade to Grade 3 or Grade 4 in any cycle. Toxicities were graded according to the National Cancer Institute common toxicity criteria for adverse events (NCI-CTCAE), version 3.0. Grade refers to the severity of the toxicity. The NCI-CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE and Grade 5: Death related to AE. It was assessed on Baseline (Day 1), during Day 6-10 and end of cycle. Hematology parameters assessed were hematocrit, hemoglobin, platelet count, total neutrophils and white blood cell count. Data has been presented for the number of participants with hematology toxicity grade shifts from Baseline to toxicity grade 3 and 4 for all cycles in a consolidated format. (NCT00601172)
Timeframe: Baseline (Day 1) to Day 24
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematocrit: All cycles, Grade 2 to Grade 3 | Hemoglobin: All cycles, Grade 1 to Grade 3 | Hemoglobin: All cycles, Grade 2 to Grade 3 | Hemoglobin: All cycles, Grade 3 to Grade 3 | Platelet count: All cycles, Grade 0 to 3 | Total Neutrophils: All cycles, Grade 0 to 3 | Total Neutrophils: All cycles, Grade 1 to 3 | Total Neutrophils: All cycles, Grade 2 to 3 | White Blood Cell count: All cycles, Grade 0 to 3 | White Blood Cell count: All cycles, Grade 1 to 3 | White Blood Cell count: All cycles, Grade 2 to 3 | |
| Casopitant 90 mg | 1 | 0 | 1 | 2 | 1 | 37 | 1 | 0 | 5 | 1 | 2 |
| Placebo | 0 | 2 | 3 | 0 | 1 | 24 | 0 | 1 | 10 | 0 | 1 |
Complete protection was defined as no vomiting/retching, no use of rescue medication and no significant nausea. Percentage of participants who achieved complete protection or complete responders with no significant nausea are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 74 | 93 | 74 |
| Placebo | 75 | 93 | 75 |
Total control was defined as no vomiting/retching, no use of rescue medication and no nausea. Percentage of participants who achieved total control or complete responders with no nausea are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 54 | 83 | 54 |
| Placebo | 61 | 88 | 61 |
Anti-emetic rescue medication was defined as medication that was administered specifically for the treatment of nausea and/or emesis during Days 1-6 of each cycle. The choice of rescue anti-emetic medication was left to the discretion of the investigator. Participants who required antiemetic rescue medication(s) during the 120-hour assessment period were considered treatment failures for that cycle. Percentage of participants who received rescue medication are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 8 | 1 | 8 |
| Placebo | 9 | 2 | 9 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. Percentage of participants who reported nausea, defined as a maximum score of >= 5 mm on the VAS are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 45 | 15 | 45 |
| Placebo | 37 | 12 | 37 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. Percentage of participants who reported significant nausea, defined as a maximum score >= 25 mm on the VAS are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 21 | 5 | 21 |
| Placebo | 19 | 4 | 19 |
Vomiting was defined as the forceful expulsion of gastrointestinal contents through the mouth or nose. Retching was defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit, that is not productive of gastrointestinal contents (also known as dry heaves). If a participant took rescue medication but there was no evidence of vomiting or retching, then the participant was considered as not having vomited. Percentage of participants who vomited and/or retched during the first 120 hours of the first cycle of chemotherapy are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 10 | 2 | 10 |
| Placebo | 11 | 3 | 11 |
FLIE questionnaire specifically addresses the impact of nausea and vomiting on daily activities (physical, social and emotional function, ability to enjoy meals). It consists of 18 items with questions divided into two domains: Nausea (questions 1-9) and Vomiting (questions 10-18). Each item is scored on a VAS with 7 hatch marks. The scale is anchored at 1 (Not at all) and 7 (A great deal). For questions 1,2,4,5,7,8-10,12-14,16 and 17 the final score was calculated by subtracting the initial score from 100 for questions 3,6,11,15 and 18 the final score was the one provided in the dataset. The score for the nausea domain: ([sum of nausea item scores] ÷ [Number of items answered] x 9) and for vomiting domain: ([sum of vomiting item scores] ÷ [Number of items answered] x 9). The total score was the sum of the nausea and vomiting domain scores. Higher scores indicate less impairment on daily life as a result of nausea or vomiting. (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Nausea impact | Vomiting impact | |
| Casopitant 90 mg | 23.7 | 11.5 |
| Placebo | 21.3 | 12.5 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the electronic case report form (eCRF). Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. AUC(0-∞), AUC(0-t), AUC(0-24) for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Hour*nanogram/milliliter (hr*ng/mL) (Geometric Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Casopitant: AUC(0-24) | Casopitant: AUC(0-inf) | Casopitant: AUC(0-t) | GSK525060: AUC(0-24) | GSK525060: AUC(0-t) | GSK517142: AUC(0-24) | GSK517142: AUC(0-t) | GSK631832: AUC(0-24) | GSK631832: AUC(0-t) | |
| Casopitant 90 mg | 6913.626 | 8607.049 | 7688.562 | 2247.290 | 2796.734 | 49.964 | 40.997 | 165.550 | 231.018 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the electronic case report form (eCRF). Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. (Cmax) for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Nanogram/milliliter (ng/mL) (Geometric Mean) | |||
|---|---|---|---|---|
| Casopitant | GSK525060 | GSK517142 | GSK631832 | |
| Casopitant 90 mg | 2078.776 | 143.038 | 3.426 | 9.853 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. Tmax and t1/2 for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Hour (Median) | ||||
|---|---|---|---|---|---|
| Casopitant: Tmax | Casopitant: t1/2 | GSK525060: Tmax | GSK517142: Tmax | GSK631832: Tmax | |
| Casopitant 90 mg | 0.520 | 12.347 | 3.580 | 1.500 | 5.500 |
Participants were asked to rate the level of nausea he/she experienced over the previous (24 hours for a period of 120 hours following the administration of MEC), by placing a vertical mark on a VAS. The severity of nausea and was calculated by using a 0 - 100 VAS where 0 = No Nausea and 100 = Nausea as bad as it can be. The categorical scale assessed the participants severity of his/her nausea using the following: mild: Queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit/throw up (but not vomiting), that has significant negative effect on the daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others) and severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities. Higher scores indicated worst outcome. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0-120 hours72379989 | 0-120 hours72379990 | 0-24 hours72379989 | 0-24 hours72379990 | 24-120 hours72379990 | 24-120 hours72379989 | |||||||||||||||||||
| Mild | Moderate | Severe | None | |||||||||||||||||||||
| Placebo | 218 | |||||||||||||||||||||||
| Placebo | 73 | |||||||||||||||||||||||
| Casopitant 90 mg | 97 | |||||||||||||||||||||||
| Placebo | 49 | |||||||||||||||||||||||
| Casopitant 90 mg | 54 | |||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||
| Casopitant 90 mg | 12 | |||||||||||||||||||||||
| Placebo | 313 | |||||||||||||||||||||||
| Casopitant 90 mg | 299 | |||||||||||||||||||||||
| Placebo | 23 | |||||||||||||||||||||||
| Casopitant 90 mg | 40 | |||||||||||||||||||||||
| Placebo | 13 | |||||||||||||||||||||||
| Casopitant 90 mg | 15 | |||||||||||||||||||||||
| Placebo | 3 | |||||||||||||||||||||||
| Casopitant 90 mg | 1 | |||||||||||||||||||||||
| Casopitant 90 mg | 192 | |||||||||||||||||||||||
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 15 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 17 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Aprepitant Regimen | 15 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）" (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 18 |
| Control Regimen | 15 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 7 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 6 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 41 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 35 |
| Control Regimen | 40 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 31 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 30 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery (NCT02635828)
Timeframe: 24 and 120 hours/discharge after end of surgery
| Intervention | participants (Number) |
|---|---|
| Triple Therapy PONV Prohylaxis | 0 |
The incidence of PONV (NCT02635828)
Timeframe: 24 hours after end of surgery
| Intervention | participants (Number) |
|---|---|
| Triple Therapy PONV Prohylaxis | 12 |
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
"Primary outcome is nausea and vomiting measured on a scale from 0 (no nausea) to 10 (worst nausea imaginable) Verbal Numerical Response Scale (VNRS) at 10 minutes post intervention." (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | VNRS (Median) |
|---|---|
| Alcohol Prep Pad Group | 3 |
| Normal Saline Prep Pad | 6 |
"Patient satisfaction of smelling prep pad to alleviate nausea on a scale from 1 (completely unsatisfied) to 5 (completely satisfied)" (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | 5 point Likert Scale (Median) |
|---|---|
| Alcohol Prep Pad Group | 4 |
| Normal Saline Prep Pad | 2 |
"Scale ranges from 0 (no pain) to 10 (worst pain imaginable)" (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | VNRS (Median) |
|---|---|
| Alcohol Prep Pad Group | 6 |
| Normal Saline Prep Pad | 6 |
Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge. (NCT01592708)
Timeframe: Anesthesia start time to placement of hospital discharge order - average 26 - 28 hours
| Intervention | hours (Median) |
|---|---|
| Intervention Cohort | 26.4 |
| Comparison Cohort | 28.2 |
To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital (NCT01592708)
Timeframe: 1 week from discharge from hospital
| Intervention | percentage of subjects with PDN (Number) |
|---|---|
| Intervention Cohort | 72 |
| Comparison Cohort | 60 |
(NCT01592708)
Timeframe: 1 week post discharge
| Intervention | percentage of subjects with PDV (Number) |
|---|---|
| Intervention Cohort | 22 |
| Comparison Cohort | 29 |
End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted. (NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with PON (Number) |
|---|---|
| Intervention Cohort | 24 |
| Comparison Cohort | 70 |
(NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with POV (Number) |
|---|---|
| Intervention Cohort | 11 |
| Comparison Cohort | 28 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
152 reviews available for ondansetron and Emesis
| Article | Year |
|---|---|
Ondansetron for Shivering after Spinal Anesthesia in Cesarean Delivery: A Systematic Review and Meta-analysis.
Topics: Anesthesia, Spinal; Cesarean Section; Double-Blind Method; Female; Humans; Ondansetron; Pregnancy; S | 2022 |
Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis.
Topics: 2-Propanol; Adult; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Vomiting | 2023 |
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis.
Topics: Antiemetics; Aprepitant; Dexamethasone; Humans; Morpholines; Ondansetron; Postoperative Nausea and V | 2023 |
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Dexamethasone; Diarrhea; Dimenhydrinate; Domper | 2020 |
Should Antiemetics be Given Prophylactically with Intravenous Opioids While Treating Acute Pain in the Emergency Department?: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee.
Topics: Acute Pain; Analgesics, Opioid; Antiemetics; Emergency Medicine; Emergency Service, Hospital; Humans | 2020 |
Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Drug Administration Schedule; Gastroenteritis; Humans | 2020 |
Contextualizing Potential Risks of Medications in Pregnancy for the Newborn-the Case of Ondansetron.
Topics: Antiemetics; Female; Humans; Infant, Newborn; Maternal Exposure; Ondansetron; Pregnancy; Pregnancy C | 2020 |
Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Dehydration; Developing Countries; | 2020 |
Management of acute food protein-induced enterocolitis syndrome emergencies at home and in a medical facility.
Topics: Adrenal Cortex Hormones; Allergens; Antiemetics; Dietary Proteins; Enterocolitis; Food Hypersensitiv | 2021 |
Ketamine in Refractory Cyclic Vomiting Syndrome: A Case Report and Review of Literature.
Topics: Adult; Analgesics; Anesthetics; Humans; Hypnotics and Sedatives; Ketamine; Lorazepam; Male; Ondanset | 2022 |
Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: A meta-analysis of randomized controlled trials.
Topics: Antiemetics; Double-Blind Method; Humans; Ondansetron; Postoperative Nausea and Vomiting; Randomized | 2021 |
Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review.
Topics: Antiemetics; Benzodiazepines; Cannabinoids; Clinical Trials as Topic; Humans; Ondansetron; Treatment | 2017 |
Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.
Topics: Antiemetics; Drug Combinations; Drug Stability; Humans; Infusions, Parenteral; Nausea; Ondansetron; | 2017 |
Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bradycardia; Cesarean Section; Female; H | 2018 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2018 |
Antiemetic Drug Use in Children: What the Clinician Needs to Know.
Topics: Antiemetics; Child; Humans; Ondansetron; Vomiting | 2019 |
Gastroenteritis in Children.
Topics: Adolescent; Antiemetics; Bicarbonates; Child; Child, Preschool; Dehydration; Fluid Therapy; Gastroen | 2019 |
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neopl | 2019 |
Liraglutide toxicity presenting to the emergency department: A case report and literature review.
Topics: Abdominal Pain; Adult; Anti-Obesity Agents; Antiemetics; Drug Overdose; Humans; Liraglutide; Male; O | 2019 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2013 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline | 2014 |
Ondansetron for gastroenteritis in children and adolescents.
Topics: Adolescent; Antiemetics; Child; Diarrhea; Gastroenteritis; Humans; Ondansetron; Vomiting | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Topics: Antiemetics; Bone Neoplasms; Dexamethasone; Humans; Methylprednisolone; Musculoskeletal Pain; Nausea | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2016 |
Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Neoplasms; Ondansetron; Quality of Life; Randomi | 2016 |
Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Antiemetics; Child; Child, Prescho | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; | 2017 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpho | 2008 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
The management of children with gastroenteritis and dehydration in the emergency department.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dehydration; Diarrhea; Emergency Service, Hospital | 2010 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Metoclopra | 2009 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Archimedes. Question 1. Does oral ondansetron reduce vomiting and the need for intravenous fluids and hospital admission in children presenting with vomiting secondary to gastroenteritis?
Topics: Administration, Oral; Antiemetics; Child, Preschool; Evidence-Based Medicine; Female; Gastroenteriti | 2010 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2011 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Progress in preventing chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Granisetron; Humans; Indoles; Nausea; Neurotransm | 2002 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Granisetron; Humans; Indoles; Nausea; | 2003 |
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quino | 2003 |
[Serotonin and anticancer drug-induced emesis].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Enterochromaffin Cells; Granisetron; Humans; | 2004 |
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Topics: Age Factors; Aged; Antiemetics; Drug Resistance; Granisetron; Humans; Nausea; Neoplasms; Ondansetron | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-R | 2005 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, | 2007 |
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Ondansetron; Quinolizines; Seroton | 2007 |
Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children.
Topics: Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Infant; Ondansetron; Randomized Contr | 2007 |
Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Granisetron; | 2007 |
Best evidence topic reports. Bet 2. Should ondansetron be used as the first-line anti-emetic in paracetamol overdose?
Topics: Acetaminophen; Adult; Antiemetics; Dose-Response Relationship, Drug; Drug Overdose; Evidence-Based M | 2008 |
The vomiting reflex and the role of 5-HT3 receptors.
Topics: Afferent Pathways; Animals; Antiemetics; Antineoplastic Agents; Brain Stem; Chemoreceptor Cells; Fer | 1993 |
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Humans; Nausea; Ond | 1993 |
[Efficacy of ondansetron in radiation-induced nausea and vomiting: review of the literature].
Topics: Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1994 |
Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Indoles; Ondansetron; Prognosis; | 1995 |
Recent advances in the understanding and management of postoperative nausea and vomiting.
Topics: Antiemetics; Child; Female; Humans; Male; Nausea; Ondansetron; Postoperative Complications; Serotoni | 1994 |
The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1995 |
Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions.
Topics: Adult; Aged; Analgesics, Opioid; Child; Drug Administration Schedule; Female; Humans; Nausea; Ondans | 1994 |
Are there differences among the serotonin antagonists?
Topics: Animals; Antiemetics; Cisplatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granise | 1994 |
Delayed emesis following anticancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dexamethasone; Huma | 1994 |
Oral ondansetron for preventing nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Nausea; Ondansetron; Vomiting | 1994 |
Cost-effectiveness analysis of antiemetic treatment.
Topics: Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Dexamethasone; Europe; European Union; | 1994 |
Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Neoplasms; Ondansetron | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Ev | 1993 |
Ondansetron in the treatment of nausea and vomiting. Introduction.
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Evaluation; Drug Therapy, Combinatio | 1993 |
[Ondansetron--a new anesthesia relevant antiemetic?].
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
[Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Neoplasms; | 1993 |
Cisplatinum based chemotherapy: role of the antiserotoninergic ondansetron in prevention of emesis.
Topics: Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Dru | 1993 |
[Clinical pharmacology of ondansetron].
Topics: Animals; Humans; Ondansetron; Vomiting | 1993 |
Review of experience with ondansetron and granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin A | 1993 |
The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action.
Topics: Animals; Antiemetics; Dogs; Ferrets; Humans; Metoclopramide; Ondansetron; Receptors, Serotonin; Sero | 1993 |
Ondansetron.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1993 |
Ondansetron for postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1993 |
Ondansetron: a novel antiemetic agent.
Topics: Antineoplastic Agents; Humans; Ondansetron; Vomiting | 1993 |
Assessing the comparative clinical value of tropisetron.
Topics: Antiemetics; Evaluation Studies as Topic; Humans; Indoles; Ondansetron; Randomized Controlled Trials | 1995 |
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Nausea; Ondansetron; Serotonin Ant | 1995 |
Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron.
Topics: Administration, Oral; Adult; Antiemetics; Child; Child, Preschool; Clinical Trials as Topic; Drug-Re | 1995 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1996 |
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granisetron; Humans; Indole | 1996 |
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Granisetron | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[A new antiemetic ramosetron hydrochloride].
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Granisetron; Guinea Pigs; Humans; Male; | 1997 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Topics: Animals; Antiemetics; Brain; Colonic Diseases, Functional; Digestive System; Drug Interactions; Drug | 1996 |
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting.
Topics: Antiemetics; Dose-Response Relationship, Drug; Humans; Nausea; Ondansetron; Postoperative Complicati | 1997 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Gra | 1994 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Nausea; Ondansetron; Serotonin Antagonists; | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis.
Topics: Administration, Oral; Adult; Antiemetics; Child; Female; Follow-Up Studies; Headache; Humans; Incide | 1998 |
When placebo controlled trials are essential and equivalence trials are inadequate.
Topics: Antiemetics; Control Groups; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; | 1998 |
Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.
Topics: Antiemetics; Granisetron; Humans; Nausea; Ondansetron; Radiotherapy; Randomized Controlled Trials as | 1998 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Prevention or treatment of postoperative vomiting using ondansetron? A mathematical assessment.
Topics: Antiemetics; Evaluation Studies as Topic; Humans; Mathematics; Odds Ratio; Ondansetron; Postoperativ | 1999 |
Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
Topics: Administration, Oral; Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 1999 |
Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
Topics: Administration, Oral; Antineoplastic Agents; Clinical Trials as Topic; Enterochromaffin Cells; Human | 2000 |
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Cross-Over Studies; Granisetron; Humans; Nausea; Neoplasms; Onda | 2000 |
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
Topics: Animals; Colonic Diseases, Functional; Humans; Ion Channels; Nausea; Ondansetron; Receptors, Seroton | 2001 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiog | 2002 |
Are granisetron and ondansetron equivalent in the clinic?
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Imidazoles; Indazoles; Nausea; O | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Pharmacology and preclinical antiemetic properties of ondansetron.
Topics: Animals; Antiemetics; Imidazoles; Ondansetron; Serotonin Antagonists; Vomiting | 1992 |
Phase I and other dose-ranging studies of ondansetron.
Topics: Antiemetics; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Imidazoles; Ondansetron; Ser | 1992 |
Phase II trials of ondansetron with high-dose cisplatin.
Topics: Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Imidazole | 1992 |
Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
Topics: Antiemetics; Cisplatin; Clinical Trials as Topic; Female; Humans; Imidazoles; Male; Metoclopramide; | 1992 |
Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Neoplasms; Ondansetron; Serotonin | 1992 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
Topics: Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists.
Topics: Antiemetics; Brain Stem; Digestive System; Humans; Imidazoles; Ondansetron; Serotonin; Serotonin Ant | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Neoplasms; Ondansetron; Radiotherapy; Vomiting | 1992 |
Incidence and aetiology of postoperative nausea and vomiting.
Topics: Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Pharmacology of ondansetron.
Topics: Animals; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
[5-HT3 antagonists in therapy of cystostatic drug-induced vomiting].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Neoplasms; Ondansetron; Vomiting | 1992 |
Mechanisms by which cancer chemotherapeutic drugs induce emesis.
Topics: Animals; Antineoplastic Agents; Chemoreceptor Cells; Humans; Models, Biological; Nausea; Ondansetron | 1992 |
Clinical safety of ondansetron.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Vomiting | 1992 |
Radiation-induced emesis: effects of ondansetron.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Imidazoles; Nausea; | 1992 |
Ondansetron to prevent chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Ondansetron; Vomiting | 1992 |
5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
Topics: Animals; Antiemetics; Granisetron; Humans; Imidazoles; Indazoles; Indoles; Ondansetron; Serotonin An | 1991 |
[Chemotherapy-induced emesis and serotonin antagonists].
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Ondansetron; Serotonin Antagonists | 1991 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
The role of ondansetron in paediatric patients: a review of three studies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Imidazoles; Nausea; | 1991 |
Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomi | 1991 |
Closing remarks. Ondansetron: effects on gastrointestinal motility.
Topics: Gastrointestinal Motility; Humans; Imidazoles; Ondansetron; Serotonin Antagonists; Vomiting | 1991 |
[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Rec | 1991 |
Ondansetron, a new antiemetic therapy for oncology. An overview.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Ondansetron; Vomiting | 1990 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Human | 1990 |
The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Imidazoles; Ondansetron; Seroto | 1989 |
Safety of ondansetron.
Topics: Animals; Antiemetics; Drug Evaluation; Humans; Imidazoles; Ondansetron; Serotonin Antagonists; Vomit | 1989 |
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; N | 1989 |
518 trials available for ondansetron and Emesis
| Article | Year |
|---|---|
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Glycopyrrolate; Hydromor | 2021 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Nausea; Neopl | 2022 |
The incidence of torsades de pointes with peri-operative low-dose ondansetron administration.
Topics: Antiemetics; DNA-Binding Proteins; Humans; Incidence; Ondansetron; Postoperative Nausea and Vomiting | 2022 |
Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Granisetron; Humans; Nausea; Ondansetron; Q | 2023 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2019 |
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Double-Blind Method; Female; Gastroenteritis; | 2019 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Humans; | 2020 |
Does intramuscular ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomized, double blind, controlled study.
Topics: Anesthetics, Dissociative; Antiemetics; Child; Child, Preschool; Closed Fracture Reduction; Consciou | 2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2020 |
Oral Ondansetron to Reduce Vomiting in Children Receiving Intranasal Fentanyl and Inhaled Nitrous Oxide for Procedural Sedation and Analgesia: A Randomized Controlled Trial.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Analgesics; Antiemetics; Child; Child, | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemopreventio | 2020 |
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Agents; Cancer Survivors; Endometrial | 2021 |
Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial.
Topics: Administration, Oral; Antiemetics; Canada; Child; Clinical Trials, Phase III as Topic; Cost-Benefit | 2020 |
Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis.
Topics: Animals; Antiemetics; Antifibrinolytic Agents; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind | 2020 |
Intravenous dextrose versus ondansetron for prevention of postoperative vomiting in children: a randomized non-inferiority trial.
Topics: Adult; Antiemetics; Child; Child, Preschool; Double-Blind Method; Glucose; Humans; Ondansetron; Post | 2020 |
A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan.
Topics: Administration, Oral; Antiemetics; Child; Clinical Trials, Phase III as Topic; Fluid Therapy; Gastro | 2020 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 2021 |
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Topics: Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relations | 2021 |
Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial.
Topics: Administration, Oral; Antiemetics; Child; Cost-Benefit Analysis; Gastroenteritis; Humans; Ondansetro | 2021 |
Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Double-Blind Method; Gastroenteritis; Hu | 2021 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, New | 2017 |
Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Amisulpride; Antiemetics; Cisplatin; Dopamine Antagonists; Female; Humans; Male; Middle | 2018 |
Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cis | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; | 2018 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophospham | 2018 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Do | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Emergency Service, Hospital; Fe | 2018 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Ce | 2019 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nause | 2019 |
Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial.
Topics: Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Drug Administration Sched | 2019 |
Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP).
Topics: Acetaminophen; Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Double-Blind Me | 2013 |
Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
Topics: Antiemetics; Blood Transfusion, Autologous; Cohort Studies; Cryoprotective Agents; Dimethyl Sulfoxid | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2013 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoqu | 2014 |
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.
Topics: Acetaminophen; Acetylcysteine; Adult; Aged; Alanine Transaminase; Antiemetics; Double-Blind Method; | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Ch | 2014 |
Does ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomised, open, controlled study.
Topics: Administration, Oral; Adolescent; Anesthetics, Dissociative; Antiemetics; Child; Child, Preschool; D | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepit | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Topics: Acupuncture Therapy; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross | 2015 |
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response R | 2015 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; C | 2015 |
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female | 2016 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexam | 2015 |
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiaze | 2016 |
Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial.
Topics: Administration, Oral; Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Fem | 2016 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2016 |
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Ov | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 2017 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2017 |
Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Domperidone; Double-Blind | 2016 |
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Topics: Abdomen; Aged; Antiemetics; Aprepitant; Dose Fractionation, Radiation; Female; Humans; Male; Middle | 2017 |
Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.
Topics: Animals; Antiemetics; Dog Diseases; Dogs; Female; Male; Metoclopramide; Ondansetron; Parvoviridae In | 2017 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; | 2009 |
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects | 2009 |
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2009 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Dru | 2010 |
Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study.
Topics: Administration, Oral; Child, Preschool; Double-Blind Method; Female; Fluid Therapy; Gastroenteritis; | 2010 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2009 |
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antin | 2010 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Ne | 2011 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2011 |
Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2011 |
The evaluation of drug rechallenge: the casopitant Phase III program.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, | 2010 |
Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study.
Topics: Child; Child, Preschool; Cohort Studies; Dehydration; Diarrhea; Dose-Response Relationship, Drug; Fe | 2010 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administr | 2010 |
Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Clinical Protocols; Dompe | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Ondansetron as an effective antiemetic in the rural, out-of-hospital setting.
Topics: Antiemetics; Emergency Medical Services; Female; Humans; Male; Nausea; Ondansetron; Rural Health Ser | 2011 |
A randomized, blinded, controlled trial of the antiemetic effect of ondansetron on dexmedetomidine-induced emesis in cats.
Topics: Analgesics, Opioid; Animals; Antiemetics; Buprenorphine; Cat Diseases; Cats; Dexmedetomidine; Drug A | 2011 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dopamine Antagonists; Double-Blind Method; Female; | 2011 |
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neop | 2012 |
Co-administration of ondansetron decreases the analgesic efficacy of tramadol in humans.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Double-Blin | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Topics: Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Double-Blind Method; Female; Granisetro | 2011 |
[Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drugs, Chinese | 2012 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepit | 2012 |
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; D | 2002 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
[Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia].
Topics: Analgesia, Patient-Controlled; Anti-Inflammatory Agents; Antiemetics; Dexamethasone; Drug Synergism; | 2002 |
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Digestive System; Doxorubici | 2002 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Doub | 2003 |
Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dimenhydrinate; Double-Blind Method; Dro | 2003 |
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Topics: Acupuncture Therapy; Adult; Aged; Antiemetics; Antirheumatic Agents; Combined Modality Therapy; Cycl | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplati | 2003 |
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Humans; Male; Met | 2003 |
Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:.
Topics: Aged; Anthracyclines; Antiemetics; Antineoplastic Agents; Carboplatin; Cyclophosphamide; Dexamethaso | 2004 |
Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cohort Studies; | 2004 |
Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Topics: Adult; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Topics: Antiemetics; Double-Blind Method; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Huma | 2004 |
Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
Topics: Adolescent; Adult; Antiemetics; Betamethasone; Cross-Over Studies; Double-Blind Method; Emetics; Fem | 2004 |
Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Topics: Adult; Aged; Analysis of Variance; Anesthesia, General; Breast Neoplasms; Chi-Square Distribution; D | 2004 |
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Adolescent; Antiemetics; Antimetabolites, Antineoplastic; Child; Child, Preschool; Electrocardiograp | 2005 |
A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cost- | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis.
Topics: Analgesia, Patient-Controlled; Anesthesia, Spinal; Antiemetics; Female; Hemodynamics; Humans; Hyster | 2005 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Fema | 2005 |
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporter | 2005 |
No more than necessary: safety and efficacy of low-dose promethazine.
Topics: Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle | 2006 |
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Sublingual; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blin | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
Topics: Antiemetics; Canada; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 2006 |
Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children.
Topics: Antiemetics; Child; Child, Preschool; Dehydration; Dexamethasone; Double-Blind Method; Emergency Ser | 2006 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home.
Topics: 2-Propanol; Adult; Antiemetics; Female; Humans; Laparoscopy; Nausea; Ondansetron; Postoperative Comp | 2007 |
Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population.
Topics: Adult; Drug Therapy, Combination; Elective Surgical Procedures; Female; Humans; Male; Meclizine; Mid | 2007 |
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2007 |
[Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analgesics, Opioid | 2007 |
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery.
Topics: Adenoidectomy; Administration, Oral; Antiemetics; Child; Double-Blind Method; Humans; Ondansetron; O | 2008 |
Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Anesthetics, Dissociative; Antiemetics; Chi-Square Distribution; Child; Child, Preschool | 2008 |
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dose-Respo | 2008 |
A double-blind randomized prospective study comparing ondansetron with droperidol in the prevention of emesis following strabismus surgery.
Topics: Adult; Anesthesia Recovery Period; Anesthesia, General; Antiemetics; Child; Dopamine Antagonists; Do | 1995 |
Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1995 |
Ondansetron for the control of dacarbazine-induced emesis.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Humans; Middle Aged; Nausea; Ondansetron; Vom | 1995 |
Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children.
Topics: Adolescent; Age Factors; Antiemetics; Blood Pressure; Body Weight; Child; Child, Preschool; Double-B | 1995 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
On the mechanism of radiation-induced emesis: the role of serotonin.
Topics: Dexamethasone; Drug Therapy, Combination; Female; Hemibody Irradiation; Humans; Hydroxyindoleacetic | 1994 |
The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron.
Topics: Antiemetics; Cyclophosphamide; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; Male; | 1995 |
Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Agents; Buspirone; Cisplatin; Double-Blind | 1995 |
Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
Topics: Aged; Aged, 80 and over; Antiemetics; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; | 1995 |
[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study.
Topics: Adolescent; Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intravenous; Bloo | 1994 |
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Topics: Adult; Aged; Chi-Square Distribution; Cisplatin; Domperidone; Double-Blind Method; Female; Humans; M | 1995 |
Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery.
Topics: Adult; Anesthesia; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; Isoflurane; M | 1995 |
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Granise | 1994 |
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost Control; Drug Costs; Dru | 1995 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
[The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Child; China; Cisplatin; Cross-Over Studies; Female; Humans; Male; Middle A | 1995 |
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Female; Humans | 1995 |
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Bl | 1995 |
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neo | 1995 |
Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cr | 1995 |
Prevention of emesis after strabismus repair in children: a prospective, double-blinded, randomized comparison of droperidol versus ondansetron.
Topics: Adolescent; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Child; Child, Preschool; Dou | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
Oral ondansetron decreases vomiting after tonsillectomy in children.
Topics: Administration, Oral; Adolescent; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesth | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia, General; Child; Child, Preschool; Dose-Response Relation | 1995 |
Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1994 |
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Cross-Over Studies; Drug Resistance; Female; Humans; Indoles; M | 1995 |
Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Female; Hu | 1994 |
Efficacy of Ondansetron and Lorazepam in controlling emesis associated with cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Lorazepam | 1994 |
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?
Topics: Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Humans; Neoplasms; Ondansetron; Vom | 1994 |
The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone.
Topics: Adult; Aged; Cerebral Ventricles; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Pilot Proj | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.
Topics: Anesthesia, General; Anesthesia, Inhalation; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
Topics: Administration, Oral; Adult; Biological Availability; Double-Blind Method; Female; Half-Life; Humans | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adult; Aged; Alprazolam; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 1994 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
[Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
Ondansetron prevents postoperative nausea and vomiting in women outpatients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Nausea; Ondansetron; Outp | 1994 |
Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Control of emesis by a low dose of ondansetron and dexamethasone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Adm | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Ondansetron reduces the incidence and severity of poststrabismus repair vomiting in children.
Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Ondansetron; Postope | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; | 1994 |
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Co | 1994 |
Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ipecac; Male; Naus | 1993 |
Ondansetron decreases emesis after tonsillectomy in children.
Topics: Child; Child, Preschool; Double-Blind Method; Humans; Ondansetron; Postoperative Complications; Tons | 1994 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combina | 1994 |
Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 1994 |
Use of oral and intravenous ondansetron in patients treated with cisplatin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Ma | 1993 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenh | 1994 |
Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Nausea; Neopla | 1993 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Hum | 1994 |
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind | 1994 |
Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedul | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Ondansetron for efficient emesis control during total body irradiation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Female; Humans; Male; Ondan | 1994 |
Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Double-Blind Method; Female; Follow-Up Studi | 1994 |
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Topics: Chlorpromazine; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; H | 1993 |
Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Diphenhydramin | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1994 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-B | 1993 |
Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; H | 1993 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1993 |
Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Chlorpromazine; Double-Blind Method; Female; Humans; | 1993 |
5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Ind | 1993 |
The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Drug Utilization Review; Female; Hospitals | 1993 |
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Topics: Adult; Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; | 1993 |
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetr | 1993 |
Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Male; Nausea; Ondansetro | 1993 |
Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Laparoscopy; Middl | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Female; Humans; Male; Middle Aged; O | 1993 |
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclophosphamide; Double-Blind Method; Female; | 1993 |
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Hum | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Belgium; Double-Blind Method; Drug Administration Sche | 1993 |
Multicenter evaluation of ondansetron use in hospitalized oncology patients.
Topics: Aged; Antineoplastic Agents; Drug Utilization; Female; Hospitalization; Humans; Male; Middle Aged; N | 1993 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
Postoperative emesis following otoplasty in children.
Topics: Adolescent; Anesthesia, General; Antiemetics; Child; Child, Preschool; Drinking; Droperidol; Ear, Ex | 1995 |
Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Antiemetics; Droperidol; | 1995 |
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1995 |
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Gr | 1996 |
Sleep protects against chemotherapy induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; | 1996 |
The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Humans; Injections, I | 1996 |
Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Analgesics; Anesthesia Recovery Period; Anestheti | 1996 |
Preoperative oral ondansetron for pediatric tonsillectomy.
Topics: Administration, Oral; Anesthesia, Inhalation; Anesthetics, Inhalation; Antiemetics; Child; Child, Pr | 1996 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bromazepam; Cisplatin; Cyclophosphamide | 1996 |
Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combination; Fe | 1996 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Dr | 1996 |
Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1996 |
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
Topics: Administration, Oral; Administration, Rectal; Adult; Aged; Antiemetics; Antineoplastic Combined Chem | 1996 |
Management of cyclophosphamide-induced emesis over repeat courses.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; | 1996 |
5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 1996 |
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures.
Topics: Activities of Daily Living; Adult; Ambulatory Surgical Procedures; Antiemetics; Anxiety; Conscious S | 1996 |
Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.
Topics: Adolescent; Antiemetics; Brain; Cerebellum; Child; Child, Preschool; Craniotomy; Double-Blind Method | 1996 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
Ondansetron is a better prophylactic antiemetic than droperidol for tonsillectomy in children.
Topics: Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Humans; Ondansetron; Postoper | 1995 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles | 1996 |
Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting.
Topics: Anesthesia; Double-Blind Method; Humans; Nausea; Ondansetron; Propofol; Prospective Studies; Vomitin | 1996 |
Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group.
Topics: Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1996 |
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1995 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Preoperative ketorolac increases bleeding after tonsillectomy in children.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Analysis of Variance; Anesthesia, Inhalation; Anesthet | 1996 |
Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Ear, Middle; Female; Human | 1996 |
The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Menstrual Cycle; Multicenter S | 1996 |
Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy.
Topics: Adenoidectomy; Adolescent; Adult; Aged; Antiemetics; Child; Child, Preschool; Double-Blind Method; F | 1996 |
Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol.
Topics: Abdomen; Antiemetics; Droperidol; Female; Humans; Injections, Intravenous; Intraoperative Period; Mi | 1995 |
The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Droperidol; Drug Therapy, Combination; Female; Hu | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benef | 1996 |
A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
Topics: Administration, Oral; Antiemetics; Bone Marrow Transplantation; Cost-Benefit Analysis; Drug Administ | 1996 |
Ondansetron decreases postoperative vomiting in pediatric patients undergoing tonsillectomy and adenoidectomy.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Ondansetron; Posto | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Posttonsillectomy vomiting. Ondansetron or metoclopramide during paediatric tonsillectomy: are two doses better than one?
Topics: Analysis of Variance; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Inhalation; Anes | 1996 |
Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Clinical Protocols; Cyclop | 1995 |
Efficacy of prophylactic ondansetron in Thai patients undergoing gastrointestinal tract surgery.
Topics: Adolescent; Adult; Aged; Antiemetics; Child; Double-Blind Method; Female; Gastrointestinal Diseases; | 1996 |
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |
The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, General; Antiemetics; Chi-Square Distribution; Cleft Pa | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.
Topics: Adolescent; Adult; Antiemetics; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Nause | 1996 |
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
Topics: Abdomen; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; N | 1996 |
Antiemetic efficacy of ondansetron with patient-controlled analgesia.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Female; Humans; Hysterectomy | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Child; Double-Blind Method; Fem | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis.
Topics: Adenoidectomy; Analgesics; Anesthesia, Inhalation; Anesthetics, Inhalation; Antiemetics; Child; Chil | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting.
Topics: Adult; Breast; Double-Blind Method; Female; Humans; Metabolic Clearance Rate; Middle Aged; Nausea; O | 1996 |
[Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients].
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Ondansetro | 1995 |
Droperidol/ondansetron combination controls nausea and vomiting after tubal banding.
Topics: Antiemetics; Dopamine Antagonists; Double-Blind Method; Droperidol; Drug Combinations; Female; Human | 1996 |
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; | 1996 |
Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Antiemetics; | 1996 |
An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, | 1996 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergencies; Female; Humans; Mal | 1996 |
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
[Activity of ondansetron on the systemic vascular resistance and venous capacitance during cardiopulmonary bypass].
Topics: Aged; Antiemetics; Blood Pressure; Blood Volume; Cardiopulmonary Bypass; Catecholamines; Extracorpor | 1996 |
The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Drug Administration S | 1997 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy.
Topics: Adenoidectomy; Anesthesia; Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Infant | 1997 |
Antiemetic activity of ondansetron in acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Diarrhea; Female; Fluid Therapy; Gastroenteriti | 1997 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antiemetics; Double-Blind Method; Female; Huma | 1997 |
Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, Intravenous; Anesthetics, Intravenous; Antiemetics; Dexamethaso | 1997 |
Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Rel | 1996 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Fema | 1997 |
Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 1997 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Antiemetics; Female; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomi | 1997 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protoco | 1997 |
[Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Middle | 1997 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Drug | 1997 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron.
Topics: Adolescent; Adult; Affect; Antiemetics; Cognition; Cross-Over Studies; Double-Blind Method; Drug Mon | 1997 |
Prophylactic antiemetics in children undergoing tonsillectomy: high-dose vs low-dose ondansetron.
Topics: Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Antiemetics; Child; | 1997 |
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Double-Blind Method; Drug T | 1997 |
Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Female; Genitalia, Female; Hu | 1997 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzimidazoles; Biological Availability; Bridged Bi | 1997 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Ondansetron, droperidol and their combination for the prevention of post-operative vomiting in children.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Drug Therapy, Com | 1997 |
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Do | 1997 |
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Mal | 1997 |
[Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1996 |
Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Ear, Middle; Female; Humans; Male; Middle Aged; | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients.
Topics: Anesthesia, General; Anesthetics, Inhalation; Antiemetics; Child; Child, Preschool; Double-Blind Met | 1997 |
[Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients].
Topics: Adult; Anesthesia; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Onda | 1997 |
Vomiting after strabismus surgery in children: ondansetron vs propofol.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Female; Health Care Costs; Humans; Male; Ondansetr | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy.
Topics: Adolescent; Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Health Care Costs; Humans; | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1997 |
Controlling conditioning-related emesis in children undergoing bone marrow transplantation.
Topics: Adolescent; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Cross-Over Studies; D | 1997 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combin | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Th | 1997 |
Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Mal | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Administration Schedule; | 1997 |
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
Topics: Adult; Antiemetics; Chlorpromazine; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 1997 |
Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Hu | 1997 |
Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Droperidol; Female; Hu | 1997 |
Comparison of ondansetron, metoclopramide, and placebo in the prevention of postoperative emesis in children undergoing ophthalmic surgery.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Eye Diseases; Humans; Infant; Metoclopramide; Onda | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron.
Topics: Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Health Care Costs; Humans; | 1998 |
Progress in reducing anticipatory nausea and vomiting: a study of community practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; | 1998 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1998 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1997 |
Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Female; Humans; Hysterectomy | 1998 |
Oculocardiac reflex and postoperative vomiting in paediatric strabismus surgery. A randomised controlled trial comparing four anaesthetic techniques.
Topics: Adolescent; Alfentanil; Analgesics, Opioid; Anesthesia, General; Anesthetics, Inhalation; Anesthetic | 1998 |
Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy.
Topics: Ambulatory Surgical Procedures; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthetics, D | 1998 |
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Intravenous; Anesthetics, Inhal | 1998 |
Prophylaxis for vomiting by children after tonsillectomy: ondansetron compared with perphenazine.
Topics: Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Antiemetics; Child; | 1998 |
Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery.
Topics: Adult; Antiemetics; Droperidol; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Otorhinolary | 1998 |
Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1998 |
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bre | 1998 |
A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1998 |
A double blind comparison of droperidol and ondansetron for prevention of emesis in children undergoing orthopaedic surgery.
Topics: Adolescent; Anesthesia, Epidural; Anesthesia, General; Antiemetics; Child; Child, Preschool; Double- | 1998 |
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Granisetron; Humans; Male; Midd | 1998 |
Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-R | 1998 |
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cross-Over Studies; C | 1998 |
A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds.
Topics: Adult; Bulimia; Feeding Behavior; Female; Humans; Middle Aged; Nociceptors; Ondansetron; Pain Thresh | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Bone Marrow Transplantation; Breast Neoplasms; Drug Admin | 1998 |
[Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Fe | 1998 |
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Topics: Abdominal Pain; Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisapride; Cisplatin | 1999 |
Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indoles; Male; Middle | 1999 |
The impact of the menstrual cycle and ondansetron on postoperative nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Female; Humans; Menstrual Cycle; Nausea; Ondansetron; Postoperative | 1998 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Alkylating | 1999 |
An alternative method to alleviate postoperative nausea and vomiting in children.
Topics: 2-Propanol; Administration, Inhalation; Adolescent; Antiemetics; Child; Double-Blind Method; Female; | 1999 |
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions | 1999 |
A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1999 |
Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Male; Methylprednisolone; Metoclopramide; Middle | 1999 |
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1999 |
Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Granisetron; Humans; Hydroxyindoleacetic Acid | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind M | 1999 |
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab
Topics: Administration, Oral; Adult; Antiemetics; Dose Fractionation, Radiation; Double-Blind Method; Female | 1999 |
A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Dexameth | 1999 |
Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Local; Antiemetics; Double-Blind Method; Female; Humans; Inject | 2000 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Dexamethasone; Femal | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2000 |
[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Topics: Administration, Oral; Antiemetics; Benzimidazoles; Carboplatin; Cisplatin; Cyclophosphamide; Doxorub | 2000 |
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combinat | 2000 |
Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cross-Over Studies; Dexamethason | 2000 |
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Antineopla | 2000 |
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 2000 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Cross-Over Studies; Drug Cos | 2000 |
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dexam | 2000 |
Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; C | 1996 |
Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinatio | 2000 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children.
Topics: Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Ondansetron; Postoperative Nausea | 2001 |
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Drug Therapy | 2001 |
Promoting the use of oral ondansetron in children receiving cancer chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Child; Clinical Protocols; Cost Control; C | 2001 |
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method | 2001 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy.
Topics: Adolescent; Adult; Aged; Analgesia; Anesthesia; Antiemetics; Brain Neoplasms; Craniotomy; Dexamethas | 2001 |
Combination of transcutaneous electrical nerve stimulation and ondansetron in preventing cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Humans; Male; | 2001 |
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Chi-Square Distribut | 2001 |
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Double-Blind Met | 2001 |
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Combined Modality | 2001 |
Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chi-Square Distribution; Cisplatin; Dexamethasone; | 2001 |
Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Topics: Administration, Oral; Antiemetics; Costs and Cost Analysis; Double-Blind Method; Female; Granisetron | 2001 |
Cisplatin-induced vomiting depends on circadian timing.
Topics: Acetylglucosaminidase; Adult; Aged; Antiemetics; Antineoplastic Agents; Blood Urea Nitrogen; Chronot | 2001 |
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2001 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Diarrhea; Double-Blind Method; Female; | 2002 |
Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Freeze D | 2002 |
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Clinical Protocols; De | 1992 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
Ondansetron is effective in decreasing postoperative nausea and vomiting.
Topics: Abdomen; Adult; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Injections, Intravenou | 1992 |
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Hum | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Hu | 1992 |
Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Antiemetics; Dilatation and Curettage; Double-B | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle A | 1992 |
Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1992 |
Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Child; Female; Headache; Humans; Injections | 1992 |
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Drug Administration Schedule; Female | 1992 |
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
Topics: Adult; Aged; Antineoplastic Agents; Costs and Cost Analysis; Double-Blind Method; Drug Industry; Fem | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
The effect of ondansetron on radiation-induced emesis and diarrhoea.
Topics: Abdominal Neoplasms; Adult; Aged; Diarrhea; Female; Humans; Male; Middle Aged; Ondansetron; Radiothe | 1992 |
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Nausea | 1992 |
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Topics: Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Neoplasm | 1992 |
Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Administration Sche | 1992 |
Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; | 1992 |
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Dexamethasone; Doubl | 1991 |
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; | 1990 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Drug Evaluation; Female; Humans; | 1991 |
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
Topics: Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Reduction of carboplatin induced emesis by ondansetron.
Topics: Antiemetics; Carboplatin; Dysgerminoma; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondan | 1991 |
Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male | 1991 |
Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle | 1991 |
Antiemetic efficacy of ondansetron after outpatient laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; | 1991 |
Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic C | 1991 |
Progress in the control of acute and delayed emesis induced by cisplatin.
Topics: Akathisia, Drug-Induced; Cisplatin; Dystonia; Humans; Imidazoles; Metoclopramide; Ondansetron; Serot | 1991 |
Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biperiden; Cisplatin; Dexa | 1991 |
Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
Topics: Antiemetics; Antineoplastic Agents; Electric Stimulation Therapy; Humans; Imidazoles; Nausea; Ondans | 1991 |
The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1991 |
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; | 1991 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Topics: Adult; Aged; Carboplatin; Epithelium; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; | 1991 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1990 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 1990 |
Ondansetron and cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Ethics, Medical; Humans; Imidazoles; Nausea; Ondansetron; Research Design; Vomiting | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dou | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; F | 1990 |
[Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response R | 1990 |
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; H | 1990 |
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.
Topics: Adult; Aged; Cisplatin; Drug Evaluation; Female; Humans; Imidazoles; Male; Middle Aged; Ondansetron; | 1989 |
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1989 |
New antiemetic effective for cisplatin-induced emesis.
Topics: Antiemetics; Cisplatin; Humans; Imidazoles; Multicenter Studies as Topic; Neoplasms; Ondansetron; Qu | 1989 |
394 other studies available for ondansetron and Emesis
| Article | Year |
|---|---|
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Topics: Animals; Antiemetics; Benzamides; Benzofurans; Binding, Competitive; Bridged Bicyclo Compounds; Brid | 1992 |
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
Topics: Amides; Animals; Antiemetics; Benzamides; Benzofurans; Bridged Bicyclo Compounds; Bridged Bicyclo Co | 1992 |
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
Topics: Animals; Cisplatin; Computer Simulation; Dogs; Ferrets; Isoquinolines; Male; Models, Molecular; Mole | 1993 |
5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
Topics: Animals; Antiemetics; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; | 1993 |
Managing paediatric gastroenteritis in primary care: is there a role for ondansetron?
Topics: Acute Disease; Child; Gastroenteritis; Humans; Ondansetron; Primary Health Care; Vomiting | 2021 |
Serotonin type-3 receptor antagonists selectively kill melanoma cells through classical apoptosis, microtubule depolymerisation, ERK activation, and NF-κB downregulation.
Topics: Antiemetics; Apoptosis; Down-Regulation; Humans; Melanoma; Molecular Docking Simulation; NF-kappa B; | 2023 |
Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cytochrome P-450 CYP | 2022 |
Predictors of Postoperative Nausea and Vomiting After Endoscopic Skull Base Surgery.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Ondansetron; Postoperative Nausea and Vomiting; Re | 2022 |
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study.
Topics: Antiemetics; Child; Child, Preschool; Electrocardiography; Gastroenteritis; Humans; Infant; Long QT | 2021 |
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Topics: Antiemetics; Female; Humans; Nausea; Neoplasms; Ondansetron; Pharmacogenetics; Vomiting | 2022 |
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Topics: Antiemetics; Female; Folic Acid; General Practice; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2022 |
[No place for ondansetron in young children with gastroenteritis and persistent vomiting].
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Diarrhea; Double-Blind Method; Drug-Rela | 2022 |
Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy?
Topics: Abdominal Muscles; Analgesia; Analgesics, Opioid; Cholecystectomy, Laparoscopic; Double-Blind Method | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Methotrexate; Nausea; Onda | 2022 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study.
Topics: Animals; Antiemetics; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Ondansetron; Rats; | 2023 |
Food Protein-induced Enterocolitis Syndrome.
Topics: Allergens; Dietary Proteins; Enterocolitis; Food Hypersensitivity; Humans; Ondansetron; Vomiting | 2023 |
Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department.
Topics: Antiemetics; Child; Emergency Service, Hospital; Humans; Ondansetron; Retrospective Studies; Vomitin | 2023 |
Embryo-fetal safety evaluation of ondansetron in rats.
Topics: Animals; Antiemetics; Embryo, Mammalian; Female; Nausea; Ondansetron; Pregnancy; Rats; Vomiting | 2023 |
Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma.
Topics: Adult; Antiemetics; Child; Craniocerebral Trauma; Electrocardiography; Humans; Long QT Syndrome; Nau | 2023 |
Ondansetron-induced oculogyric crisis in a pediatric patient: case report.
Topics: Antiemetics; Child; Eye Diseases; Humans; Ondansetron; Vomiting | 2023 |
Vomiting after intrathecal chemotherapy under anesthesia in pediatric patients with hematologic cancers: A cohort study.
Topics: Anesthesia; Antiemetics; Child; Cohort Studies; Double-Blind Method; Female; Hematologic Neoplasms; | 2024 |
Ovarian torsion identified on point-of-care ultrasound in the paediatric emergency department.
Topics: Abdominal Pain; Antiemetics; Child; Delayed Diagnosis; Female; Humans; Ondansetron; Ovary; Torsion, | 2019 |
Comparison of metoclopramide and promethazine for the treatment of postoperative nausea and vomiting in the post-anesthesia care unit: A retrospective database analysis.
Topics: Anesthesia; Antiemetics; Double-Blind Method; Humans; Metoclopramide; Ondansetron; Postoperative Nau | 2020 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug | 2020 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasi | 2019 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; C | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis.
Topics: Antiemetics; Child; Child, Preschool; Emergency Service, Hospital; Female; Gastroenteritis; Hospital | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Ondansetron use in early pregnancy and the risk of miscarriage.
Topics: Abortion, Spontaneous; Antiemetics; Female; Humans; Metoclopramide; Ondansetron; Pregnancy; Vomiting | 2021 |
Emergency procedural sedation in children.
Topics: Anesthetics, Dissociative; Antiemetics; Child; Contraindications, Drug; Emergency Service, Hospital; | 2020 |
Ondansetron use in early pregnancy and the risk of late pregnancy outcomes.
Topics: Antiemetics; Female; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnancy Outcome; Premature B | 2021 |
Effect of paroxetine on intestinal motility in the presence of ondansetron.
Topics: Animals; Antiemetics; Drug Interactions; Female; Gastrointestinal Motility; Ileum; Male; Muscle, Smo | 2020 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Ondansetron prescription for vomiting associated with 72-hour ED return reduction.
Topics: Antiemetics; Humans; Ondansetron; Prescriptions; Vomiting | 2021 |
Topics: Cannabis; Haloperidol; Humans; Ondansetron; Syndrome; Vomiting | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Antiemetics; Cannabis; Female; Haloperidol; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; | 2021 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Grani | 2021 |
The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Topics: Administration, Intravenous; Animals; Antiemetics; Dogs; Nausea; Ondansetron; Vestibular Diseases; V | 2021 |
QTc interval changes following low-dose ondansetron administration in the emergency department.
Topics: Antiemetics; Electrocardiography; Emergency Service, Hospital; Humans; Long QT Syndrome; Ondansetron | 2022 |
Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child, Preschool; Diarrhea; Emergency Service, Hos | 2022 |
Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Topics: Antiemetics; Child; Child, Preschool; Granisetron; Humans; Methotrexate; Nausea; Ondansetron; Precur | 2017 |
Arrhythmic Side of Ondansetron Alongside Antiemetic Effect.
Topics: Antiemetics; Double-Blind Method; Humans; Nausea; Ondansetron; Vomiting | 2017 |
Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Antibiotic Prophylaxis; Antiemetics; D | 2017 |
Comparison of Dexamethasone-Dimenhydrinate and Dexamethasone-Ondansetron in Prevention of Nausea and Vomiting in Postoperative Patients.
Topics: Antiemetics; Dexamethasone; Dimenhydrinate; Double-Blind Method; Drug Therapy, Combination; Humans; | 2018 |
Effect of intravenous ondansetron on QTc interval in children with gastroenteritis.
Topics: Administration, Intravenous; Adolescent; Antiemetics; Child; Child, Preschool; Electrocardiography; | 2018 |
Use of Ondansetron for Vomiting After Head Trauma: Does It Mask Clinically Significant Traumatic Brain Injury?
Topics: Adolescent; Antiemetics; Brain Injuries, Traumatic; Child; Child, Preschool; Craniocerebral Trauma; | 2020 |
Ondansetron Prescription for Home Use in a Pediatric Emergency Department.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Electronic Health Records; Emergency Service, Hosp | 2020 |
The safety and efficacy of the procedureless intragastric balloon.
Topics: Adult; Antiemetics; Body Mass Index; Drug Therapy, Combination; Female; Gastric Balloon; Humans; Kuw | 2018 |
Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy.
Topics: Adolescent; Antiemetics; Brain Concussion; Canada; Child; Child, Preschool; Cohort Studies; Emergenc | 2019 |
Children with cyclic vomiting syndrome: phenotypes, disease burden and mitochondrial DNA analysis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Cost of Illness; DNA, Mitochondrial; Female; Fluid | 2018 |
Inhaled isopropyl alcohol for nausea and vomiting in the emergency department.
Topics: 2-Propanol; Administration, Inhalation; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Pa | 2018 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dexamethasone; | 2018 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Prospective evaluation of anesthetic protocols during pediatric ophthalmic surgery.
Topics: Acetaminophen; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Intravenous; Anti-Anxiety Agen | 2019 |
Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial.
Topics: Administration, Oral; Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Eme | 2019 |
Oral Ondansetron to Reduce Intravenous Fluid Rehydration: Context Matters.
Topics: Antiemetics; Child; Diarrhea; Emergency Service, Hospital; Fluid Therapy; Humans; Ondansetron; Pakis | 2019 |
Helping Pregnant Women and Clinicians Understand the Risk of Ondansetron for Nausea and Vomiting During Pregnancy.
Topics: Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Risk; Vomiting | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: Adult; Antiemetics; Aromatherapy; Emergency Service, Hospital; Humans; Ondansetron; Vomiting | 2019 |
Inhaling isopropyl alcohol from alcohol wipes was amore effective antiemetic than oral ondansetron in nauseated adults.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiem | 2020 |
Isoflurane induces c-Fos expression in the area postrema of the rat.
Topics: Anesthetics, Inhalation; Animals; Area Postrema; Isoflurane; Male; Neurons; Ondansetron; Proto-Oncog | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Design and evaluation of ondansetron liquid suppository for the treatment of emesis.
Topics: Adhesiveness; Administration, Oral; Administration, Rectal; Animals; Antiemetics; Biological Availab | 2013 |
Ondansetron prevents changes in respiratory pattern provoked by LiCl: a new approach for studying pro-emetic states in rodents?
Topics: Animals; Emetics; Lithium Chloride; Male; Ondansetron; Rats; Rats, Wistar; Respiratory Rate; Vomitin | 2013 |
Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Area Under Curve; Chemistry, Phar | 2013 |
More than just a case study: an introduction to ondansetron for my son, "the dehydrated child".
Topics: Antiemetics; Dehydration; Fluid Therapy; Humans; Infant; Male; Ondansetron; Vomiting | 2013 |
A 34-year-old triathlete with hyperthermia.
Topics: Adenosine; Adult; Anti-Arrhythmia Agents; Antiemetics; Athletes; Doping in Sports; Electrocardiograp | 2013 |
Thyrotoxicosis after a massive levothyroxine ingestion in a 3-year-old patient.
Topics: Antiemetics; Child, Preschool; Combined Modality Therapy; Dehydration; Drug Overdose; Emergencies; E | 2013 |
Treatment of paracetamol overdose: room for improvement?
Topics: Acetaminophen; Acetylcysteine; Alanine Transaminase; Antiemetics; Female; Humans; Male; Ondansetron; | 2014 |
An audit of the use of ondansetron in general medical patients.
Topics: Antiemetics; Guideline Adherence; Humans; Medical Audit; Nausea; Ondansetron; Practice Guidelines as | 2013 |
Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes.
Topics: Adult; Antiemetics; Child Development; Female; Humans; Infant, Newborn; Longitudinal Studies; Male; | 2014 |
The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Brain; Exenatide; Glucagon-Like Peptide-1 Receptor; Male; Ondansetron; Peptide | 2014 |
Thermoregulatory correlates of nausea in rats and musk shrews.
Topics: Animals; Body Temperature Regulation; Feeding Behavior; Hypothermia; Male; Motion Sickness; Nausea; | 2014 |
Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.
Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Automation; Cisplatin; Drug Synergism; Ferr | 2014 |
Treatment of paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Alanine Transaminase; Antiemetics; Female; Humans; Male; Ondansetron; | 2014 |
Treatment of paracetamol overdose--authors' reply.
Topics: Acetaminophen; Acetylcysteine; Alanine Transaminase; Antiemetics; Female; Humans; Male; Ondansetron; | 2014 |
The use of a clinical database in an anesthesia unit: focus on its limits.
Topics: Anesthesia; Anesthesiology; Automation; Databases, Factual; Humans; Morphine; Ondansetron; Pain; Pai | 2015 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Emergency department ondansetron use in children with type 1 diabetes mellitus and vomiting.
Topics: Antiemetics; Child; Cohort Studies; Diabetes Mellitus, Type 1; Emergency Service, Hospital; Emergenc | 2015 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Is Ondansetron any use in gastroenteritis?
Topics: Antiemetics; Gastroenteritis; Humans; Ondansetron; Vomiting | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2015 |
Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care.
Topics: Analgesics, Opioid; Antiemetics; Emergency Service, Hospital; Humans; Military Medicine; Nausea; Off | 2015 |
Changing the Management of Paracetamol Poisoning.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Anaphylaxis; Antidotes; Antiemetics; Biomar | 2015 |
[Effect of Ju-Pi-Tang on Cisplatin-induced Emetic Model in Minks].
Topics: Animals; Antiemetics; Aprepitant; Brain; Cisplatin; Disease Models, Animal; Drugs, Chinese Herbal; I | 2015 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.
Topics: Antiemetics; Dexamethasone; Female; Humans; Male; Morpholines; Nausea; Neurokinin-1 Receptor Antagon | 2016 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Evidence-based Medicine Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Evidence-Based Medicine; Humans; Ondansetron; Vom | 2016 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Pediatric Gastroenterologists Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Gastroenterologists; Humans; Ondansetron; Vomitin | 2016 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Pediatricians Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Humans; Ondansetron; Pediatricians; Vomiting | 2016 |
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Child; Child, Preschool; Female; Gas | 2016 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Ondansetron enhances efficacy of oral rehydration.
Topics: Administration, Oral; Antiemetics; Double-Blind Method; Fluid Therapy; Humans; Ondansetron; Vomiting | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-B | 2017 |
Effect of Intravenous Ondansetron on the QT Interval of Patients' Electrocardiograms.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Electrocardiography; Female; Humans; Infant; Long | 2018 |
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Therapy, Combin | 2016 |
Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Emergency Service, Hospital; Female; Flu | 2016 |
Evaluation of Pentravan
Topics: Administration, Cutaneous; Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Chemistry, Pharm | 2016 |
Response to comment "Cox: alternative therapies and postoperative vomiting".
Topics: Antiemetics; Complementary Therapies; Humans; Ondansetron; Postoperative Nausea and Vomiting; Vomiti | 2016 |
Emergency department management of gastro-enteritis in Australia and New Zealand.
Topics: Acute Disease; Antiemetics; Australia; Data Collection; Dehydration; Diarrhea; Emergency Medicine; E | 2008 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; H | 2009 |
Involvement of hypothalamic glutamate in cisplatin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Antineoplastic Agents; Brain; Cisplatin; Female; Glutamic Acid; Hypothalamus; | 2009 |
Ondansetron and seizures.
Topics: Adult; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Female; Follow-Up Studies; Humans; | 2009 |
The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Incidence; | 2010 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compoun | 2009 |
Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?
Topics: Abdominal Pain; Adolescent; Antiemetics; Child; Child, Preschool; Confidence Intervals; Cross-Sectio | 2010 |
Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
Topics: Antiemetics; Antineoplastic Agents; Child; Facial Muscles; Humans; Male; Ondansetron; Rhabdomyosarco | 2010 |
Antiemetic effect of Xiao-Ban-Xia-Tang, a Chinese medicinal herb recipe, on cisplatin-induced acute and delayed emesis in minks.
Topics: Animals; Antiemetics; Area Postrema; China; Cisplatin; Drugs, Chinese Herbal; Ethnopharmacology; Ile | 2010 |
Administration of ondansetron is associated with lethal outcome.
Topics: Antiemetics; Child, Preschool; Diseases in Twins; Fatal Outcome; Genetic Predisposition to Disease; | 2010 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administra | 2011 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Female; Granisetron; Humans; Infan | 2010 |
Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.
Topics: Administration, Oral; Algorithms; Antiemetics; Canada; Child; Child, Preschool; Cost-Benefit Analysi | 2010 |
Ondansetron-induced dystonia, hypoglycemia, and seizures in a child.
Topics: Antiemetics; Child, Preschool; Dystonia; Humans; Hypoglycemia; Male; Ondansetron; Seizures; Serotoni | 2011 |
Solid gastric emptying mediated by the serotonin (5-HT)3 receptor in mice is a simple marker to predict emesis.
Topics: Animals; Antispermatogenic Agents; Apomorphine; Cisplatin; Copper Sulfate; Dose-Response Relationshi | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |
Post-operative nausea and vomiting following paediatric day-case tonsillectomy: audit of the Epsom protocol.
Topics: Adenoidectomy; Adolescent; Ambulatory Surgical Procedures; Analgesics; Anesthesia, General; Antiemet | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Bone Neoplasms; Female; Humans; Male; Middle Aged; Naus | 2012 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |
Time-series analysis of ondansetron use in pediatric gastroenteritis.
Topics: Antiemetics; Canada; Child; Child, Preschool; Dehydration; Female; Fluid Therapy; Gastroenteritis; H | 2012 |
Development of chitosan-based ondansetron buccal delivery system for the treatment of emesis.
Topics: Absorption; Adhesiveness; Administration, Buccal; Animals; Antiemetics; Biological Availability; Chi | 2012 |
Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Emergency Service, Hospital; Humans; Infant; Ondan | 2012 |
Leaves of Hippophae rhamnoides prevent taste aversion in gamma-irradiated rats.
Topics: Animals; Antiemetics; Antioxidants; Behavior, Animal; Conditioning, Classical; Corticosterone; Dieta | 2011 |
Can ondansetron help children with vomiting due to gastroenteritis?
Topics: Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Infant; Ondansetron; Treatment Outcom | 2012 |
Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats.
Topics: Anesthesia; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Ci | 2012 |
Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting.
Topics: Administration, Cutaneous; Animals; Antiemetics; Area Under Curve; Centrifugation; Chemistry, Pharma | 2013 |
Antiemetics for acute gastroenteritis-related vomiting in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Dimenhydrinate; Gastroenteritis; Humans; Metocloprami | 2012 |
The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED.
Topics: Antiemetics; Child; Craniocerebral Trauma; Cross-Sectional Studies; Emergency Service, Hospital; Fem | 2013 |
Motherisk update. Is ondansetron safe for use during pregnancy?
Topics: Antiemetics; Canada; Cleft Palate; Female; Fetus; Humans; Long QT Syndrome; Morning Sickness; Nausea | 2012 |
Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Costs and Cost Analysis; Emergency Service, Hospit | 2012 |
Do children with high body mass indices have a higher incidence of emesis when undergoing ketamine sedation?
Topics: Adolescent; Anesthetics, Dissociative; Antiemetics; Body Mass Index; Child; Child, Preschool; Emerge | 2012 |
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Guideline Adhere | 2013 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
In brief: intravenous ondanstron (Zofran) 32 mg withdrawn.
Topics: Antiemetics; Antineoplastic Agents; Humans; Long QT Syndrome; Nausea; Ondansetron; Product Recalls a | 2012 |
Management of a child with vomiting.
Topics: Algorithms; Antiemetics; Child; Clinical Protocols; Dehydration; Fluid Therapy; Humans; India; Ondan | 2013 |
Utility of ondansetron in children with vomiting.
Topics: Antiemetics; Child; Emergency Service, Hospital; Gastroenteritis; Humans; Ondansetron; Severity of I | 2002 |
Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Drug Administrat | 2002 |
Migraine-type headaches in children receiving chemotherapy and ondansetron.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Female; Humans; Male; Migraine Disorders; Nau | 2002 |
Antiemetic use for gastroenteritis in children.
Topics: Acute Disease; Administration, Oral; Age Factors; Antiemetics; Child; Diarrhea; Emergency Treatment; | 2003 |
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Gene Deletio | 2003 |
[A new vomiting animal model--mink].
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Male; Metoclop | 2003 |
Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Esophagus; Female; Granis | 2003 |
[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Topics: Administration, Sublingual; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2003 |
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Antineoplastic Agents; Cannabinoids; Cisplatin; Dose-Response Relationship, Dr | 2004 |
A rare ingestion of the Black Locust tree.
Topics: Antiemetics; Child; Humans; Male; Ondansetron; Palliative Care; Plant Bark; Plant Poisoning; Robinia | 2004 |
"Doctor, my child needs some medicine!".
Topics: Abdominal Pain; Adolescent; Analgesics; Anti-Bacterial Agents; Antiemetics; Child, Preschool; Dehydr | 2004 |
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
Topics: Adult; Analysis of Variance; Antiemetics; Female; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2004 |
Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret.
Topics: Animals; Antiemetics; Behavior, Animal; Cisplatin; Ferrets; Male; Ondansetron; Piperidines; Vomiting | 2005 |
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydra | 2005 |
Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret.
Topics: Animals; Antiemetics; Behavior, Animal; Carrier Proteins; Cell-Penetrating Peptides; Cisplatin; Dose | 2005 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indo | 2005 |
Ondansetron and Delta-9-tetrahydrocannabinol interfere with the establishment of lithium-induced conditioned taste avoidance in the house musk shrew (Suncus murinus).
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Dose- | 2005 |
Action of ondansetron and CP-99,994 on cisplatin-induced emesis and locomotor activity in Suncus murinus (house musk shrew).
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Cisplatin; Female; Motor Activity; Ondansetron; Pi | 2005 |
Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confusion; Dexamethasone; D | 2007 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; | 2005 |
Value of mink vomit model in study of anti-emetic drugs.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Enterochromaff | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compou | 2006 |
The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Female; Male; Methysergide; Motion; Ondansetron; Ph | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinucli | 2007 |
Ondansetron for acute gastroenteritis in children.
Topics: Acute Disease; Antiemetics; Child; Dehydration; Diarrhea; Fluid Therapy; Gastroenteritis; Humans; On | 2006 |
Preventing emesis in lung cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Lung Neoplasms; Ondansetron; Palonosetron | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
Re: selected summary of "antiemetics for acute gastroenteritis: a never ending story".
Topics: Acute Disease; Antiemetics; Fluid Therapy; Gastroenteritis; Humans; Ondansetron; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children.
Topics: Antiemetics; Child; Gastroenteritis; Humans; Ondansetron; Vomiting | 2007 |
Safety of ondansetron loading doses in children with cancer.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; | 2008 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin | 2008 |
Ondansetron and minor oral surgery.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Placebos; Postoperative Complications; Serotonin Antagonis | 1995 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials.
Topics: Anesthesia Department, Hospital; Controlled Clinical Trials as Topic; Data Collection; England; Heal | 1995 |
Effectiveness and economy of low-dose ondansetron.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Nausea; Ondansetron; Practice Guidelines as To | 1995 |
[Evaluation of +ondansetron (Zolfiran) in prevention of vomiting in children treated with cytostatics].
Topics: Adolescent; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; Humans | 1995 |
The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Topics: Animals; Cisplatin; Disease Models, Animal; Female; Granisetron; Male; Nausea; Ondansetron; Swine; T | 1995 |
[Quality of life in oncology. Importance of optimal control of nausea/vomiting induced by antineoplastic agents].
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Quality of Life; Vomiting | 1994 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Clinical Trials as Topic; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Vomi | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Humans; Nausea; Ondansetron; Vomiting | 1995 |
Ondansetron for symptomatic relief in terminal uraemia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Nausea; Ondansetron; Uremia; Vomiting | 1995 |
Ondansetron or metoclopramide in children undergoing tonsillectomy.
Topics: Child; Humans; Metoclopramide; Ondansetron; Tonsillectomy; Vomiting | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy.
Topics: Antineoplastic Agents; Child; Drug Utilization; Humans; Ondansetron; Reproducibility of Results; Sur | 1995 |
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
Topics: Administration, Oral; Animals; Bradycardia; Dogs; Dose-Response Relationship, Drug; Duodenum; Female | 1995 |
Ondansetron for the prevention of nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Administration Schedule; Granisetron; Humans; Ond | 1995 |
Practical points in the use of ondansetron.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast Neoplasms; Consc | 1994 |
[The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feeding an | 1994 |
Comment: Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Humans; Ipecac; Nausea; Ondansetron; Poisoning; Vomiting | 1994 |
[Ondansetron on postoperative nausea and vomiting].
Topics: Abdomen; Adult; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Pos | 1994 |
Re-examination of clinical aspects of pharmacoeconomic analysis.
Topics: Antineoplastic Agents; Economics, Pharmaceutical; Humans; Metoclopramide; Ondansetron; Pharmacology, | 1994 |
Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1994 |
Which routine antiemetic: ondansetron or prochlorperazine?
Topics: Humans; Ondansetron; Postoperative Complications; Prochlorperazine; Vomiting | 1994 |
Surrogate end points. Are they meaningful?
Topics: Antiemetics; Child; Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Topics: Antineoplastic Agents; Control Groups; Double-Blind Method; Drug and Narcotic Control; Ethics, Medic | 1994 |
Plasma levels of peptide YY correlate with cisplatin-induced emesis in dogs.
Topics: Animals; Cisplatin; Dogs; Drug Interactions; Drug Therapy, Combination; Female; Granisetron; Immunoe | 1994 |
Ondansetron for postoperative nausea and vomiting: decisions in the absence of comparative trials.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; United States; U | 1994 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
Zofran: first of a new class of antiemetics.
Topics: Humans; Nausea; Ondansetron; Vomiting | 1994 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Metocloprami | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
Topics: Administration, Oral; Animals; Antiemetics; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, He | 1993 |
Zofran (Ondansetron hydrochloride) injection.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Difficulties in assessing appropriate ondansetron use.
Topics: Antineoplastic Agents; Humans; Ondansetron; Vomiting | 1993 |
Difficulties in assessing appropriate ondansetron use.
Topics: Antineoplastic Agents; Humans; Ondansetron; Vomiting | 1993 |
Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients.
Topics: Child; Child, Preschool; Drug Utilization Review; Hospitals, Pediatric; Humans; Ondansetron; Practic | 1994 |
Oral ondansetron: a useful addition to the supportive care armamentarium?
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Acetaminophen; Adolescent; Charcoal; Colchicine; Drug Overdose; Female; Humans; Nausea; Ondansetron; | 1994 |
Evaluation of ondansetron as a drug for premedication.
Topics: Adult; Aged; Anesthesia; Bradycardia; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; | 1993 |
Ondansetron in theophylline overdose.
Topics: Adolescent; Drug Overdose; Female; Humans; Ondansetron; Theophylline; Vomiting | 1993 |
Seizure associated with ondansetron.
Topics: Adult; Gram-Negative Bacterial Infections; Humans; Male; Nausea; Ondansetron; Seizures; Shock, Septi | 1993 |
[Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combina | 1993 |
The effects of different antiemetic agents on morphine-induced emesis in ferrets.
Topics: Anesthesia; Animals; Antiemetics; Droperidol; Ferrets; Granisetron; Injections, Intravenous; Isoflur | 1993 |
Ondansetron and the prevention of postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Research Design; Vomiting | 1993 |
Ondansetron quells drug-resistant emesis in theophylline poisoning.
Topics: Adult; Drug Resistance; Humans; Infusions, Intravenous; Male; Ondansetron; Theophylline; Vomiting | 1993 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
Drugs for vomiting caused by cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Humans; Metoclopramide; Ondansetron; Vomiting | 1993 |
Stimulation of gastrointestinal motility by cisplatin in the ferret: activation of an intrinsic cholinergic mechanism dissociated from emesis.
Topics: Animals; Atropine; Cisplatin; Female; Ferrets; Gastrointestinal Motility; Male; Muscle Contraction; | 1993 |
Ondansetron by subcutaneous infusion.
Topics: Female; Humans; Infusion Pumps; Middle Aged; Nausea; Ondansetron; Vomiting | 1993 |
Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Female; Humans; Nause | 1993 |
Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports.
Topics: Accidental Falls; Adult; Craniocerebral Trauma; Epilepsy, Generalized; Humans; Intensive Care Units; | 1993 |
Ondansetron in the treatment of intractable nausea associated with theophylline toxicity.
Topics: Adult; Delayed-Action Preparations; Humans; Male; Nausea; Ondansetron; Poisoning; Theophylline; Vomi | 1993 |
Should we be using 5-HT3 antagonists as first line antiemetic therapy in cisplatin-based chemotherapy?
Topics: Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Ondansetron; Serotonin Antagonists; Vom | 1993 |
[On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
Topics: Administration, Oral; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Nausea; No | 1993 |
Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Female; Hum | 1993 |
'... setron': are 5-HT3 receptor antagonists different?
Topics: Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indoles; Male; Ondansetron; Recepto | 1993 |
Antiemetic effects of ondansetron and metopimazine.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Isonipecotic Acids; Nausea; Ondansetron; Vomiting | 1993 |
Pica in rats is analogous to emesis: an animal model in emesis research.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper; Copper Sulfate; Disease Models, Animal; Domper | 1993 |
Extrapyramidal reaction associated with ondansetron.
Topics: Aged; Basal Ganglia Diseases; Female; Humans; Nasopharyngeal Neoplasms; Ondansetron; Vomiting | 1993 |
Ondansetron leads antiemetic research.
Topics: Antineoplastic Agents; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1993 |
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1993 |
Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Nausea; Ondansetr | 1993 |
Placebos and principles: a trial of ondansetron.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Control Groups; Ethics, Medical; Humans; Nausea; No | 1993 |
Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Evaluation; Female; Humans; Male; Middle Aged; Nausea; O | 1993 |
Ondansetron use in a major university teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Drug Utilization; Female; Hospital Bed Capacity, 500 and over; Hospi | 1993 |
Use of ondansetron (Zofran)
Topics: Adult; Female; Humans; Middle Aged; Nausea; Ondansetron; Terminal Care; Vomiting | 1993 |
Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Antineoplastic Agents; Cost Savings; Humans; Nausea; Ondansetron; Pr | 1995 |
Placebo controlled trials of ondansetron for postoperative nausea and vomiting.
Topics: Antiemetics; Controlled Clinical Trials as Topic; Humans; Nausea; Ondansetron; Placebos; Postoperati | 1996 |
Development of potent serotonin-3 (5-HT3) receptor antagonists. II. Structrue-activity relationships of N-(1-benzyl-4-methylhexahydro-1H-1,4- diazepin-6-yl)carboxamides.
Topics: Animals; Bradycardia; Granisetron; Injections, Intravenous; Magnetic Resonance Spectroscopy; Male; M | 1995 |
Rectal administration of ondansetron in uncontrolled emesis induced by chemotherapy.
Topics: Administration, Rectal; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1995 |
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Drug Stability; Humans; Infusions, Intravenous; Ondan | 1995 |
Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis?
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Confounding Factors, Epidemiolo | 1996 |
Improved outcome with chronic subcutaneous infusion of odansetron for intractable nausea and vomiting.
Topics: Administration, Cutaneous; Adult; Antiemetics; Female; Humans; Nausea; Ondansetron; Vomiting | 1996 |
[Estimation of effectiveness of antiemetic treatment with Zofran given in one dose to children with neoplasms].
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Ondansetr | 1995 |
The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret.
Topics: Animals; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Female; Ferrets; Male; | 1996 |
An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.
Topics: Animals; Antiemetics; Cisplatin; Dexamethasone; Drug Synergism; Ferrets; Male; Ondansetron; Vomiting | 1996 |
Re: 'Cost-effectiveness of 5-hydroxytryptamin3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'.
Topics: Cost-Benefit Analysis; Granisetron; Nausea; Ondansetron; Salvage Therapy; Serotonin Antagonists; Vom | 1996 |
[Future trends in chemotherapy and impact on the management of emesis].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Phenomena; Drug Administr | 1995 |
[The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; In | 1996 |
[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery].
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Child; Female; Humans; Male; M | 1996 |
An experimental model to study intracranial hypertension-induced vomiting in conscious dogs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Disease Models | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives.
Topics: Animals; Benzimidazoles; Cisplatin; Crystallography, X-Ray; Defecation; Ferrets; Guinea Pigs; In Vit | 1996 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Hum | 1996 |
Radiotherapy and drugs: 'setrons' once again.
Topics: Abdomen; Abdominal Neoplasms; Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1996 |
Acute and anticipatory emesis in breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; | 1996 |
The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.
Topics: Animals; Antineoplastic Agents; Cisplatin; Ferrets; Male; Neurokinin-1 Receptor Antagonists; Ondanse | 1996 |
Use of dexamethasone with 5-HT3-receptor antagonists.
Topics: Antiemetics; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Ondansetron; Serotonin A | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
[Acute tolerance in hyperfractionated accelerated whole-body irradiation].
Topics: Adult; Antiemetics; Bone Marrow Transplantation; Drug Evaluation; Female; Humans; Male; Nausea; Onda | 1996 |
Always more "setrons": how many do we need?
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indoles; Nausea; Ondansetron; S | 1997 |
[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery].
Topics: Ambulatory Surgical Procedures; Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complication | 1996 |
Can vomiting after squint surgery be prevented?
Topics: Adult; Antiemetics; Child, Preschool; Female; Humans; Male; Metoclopramide; Ondansetron; Postoperati | 1997 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret.
Topics: Animals; Antiemetics; Antineoplastic Agents; Behavior, Animal; Cisplatin; Dexamethasone; Ferrets; Ma | 1997 |
Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Topics: Adult; Antiemetics; Antihypertensive Agents; Epoprostenol; Female; Humans; Hypertension, Pulmonary; | 1997 |
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans; | 1997 |
The control of delayed nausea.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Ethics, Medical; Humans; Ondansetron; | 1997 |
Biphasic emetic response of cyclophosphamide in the ferret.
Topics: Animals; Antiemetics; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dose-Response Relationshi | 1997 |
Fighting nausea in the '90s: more and better anti-emetics can help.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Granis | 1997 |
Impact of covert duplicate publication on meta-analysis: a case study.
Topics: Antiemetics; Duplicate Publications as Topic; Humans; Meta-Analysis as Topic; Ondansetron; Postopera | 1997 |
Acute severe depression following peri-operative ondansetron.
Topics: Adult; Depressive Disorder; Female; Humans; Nausea; Ondansetron; Premedication; Serotonin Antagonist | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
The "big little problem" of postoperative nausea and vomiting: do we know the answer yet?
Topics: Antiemetics; Humans; Meta-Analysis as Topic; Nausea; Ondansetron; Outcome Assessment, Health Care; P | 1997 |
[Ondansetron is not a panacea].
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Humans; Ondansetron; Vomiting | 1997 |
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Utilization; Female; Granisetron; Guideline | 1998 |
Cyclical vomiting syndrome.
Topics: Antiemetics; Child; Female; Humans; Ondansetron; Periodicity; Syndrome; Vomiting | 1998 |
Use of ondansetron and other antiemetics in the management of toxic acetaminophen ingestions.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Analgesics, Non-Narcotic; Antidotes; Antiemetics; | 1998 |
Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
Topics: Animals; Antiemetics; Gamma Rays; Granisetron; Macaca fascicularis; Male; Nausea; Neutrons; Ondanset | 1998 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Antiemetics; Droperidol; Drug Therapy, Combination; Humans; Nausea; Ondansetron; Postoperative Compl | 1998 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Anaphylactoid reaction due to the administration of ondansetron in a pediatric neurosurgical patient.
Topics: Anaphylaxis; Antiemetics; Child; Cranial Fossa, Posterior; Drug Hypersensitivity; Female; Humans; In | 1998 |
Ondansetron in nausea and vomiting induced by spinal morphine.
Topics: Analgesics, Opioid; Antiemetics; Female; Humans; Injections, Spinal; Middle Aged; Morphine; Nausea; | 1998 |
Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 1998 |
Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus.
Topics: Anesthesia; Animals; Halothane; Humans; Male; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron | 1998 |
Antiemetic effects of Lerisetron in radiation-induced emesis in the dog.
Topics: Animals; Antiemetics; Benzimidazoles; Cobalt Radioisotopes; Dogs; Drug Administration Schedule; Onda | 1998 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Car | 1999 |
Development and implementation of practice guidelines (Part 1).
Topics: Acquired Immunodeficiency Syndrome; Colony-Stimulating Factors; Drug Utilization; Hospital Bed Capac | 1994 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Evaluation of the pharmacoeconomic literature.
Topics: Asthma; Bronchodilator Agents; Child; Cisplatin; Economics, Pharmaceutical; Forecasting; Humans; Ond | 1994 |
Is ondansetron cost effective?
Topics: Antiemetics; Cost-Benefit Analysis; Humans; Length of Stay; Nausea; Ondansetron; Retrospective Studi | 1994 |
Antiemetic therapy in managed care oncology: roundtable discussion.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Managed Care Programs; Medicare; Ondansetro | 1996 |
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret.
Topics: Animals; Antiemetics; Dose-Response Relationship, Drug; Emetics; Ferrets; Indoles; Molecular Structu | 1999 |
Cost effectiveness ratio: an often misunderstood term.
Topics: Cost-Benefit Analysis; Droperidol; Health Care Costs; Humans; Nausea; Ondansetron; Postoperative Com | 1999 |
5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Ferrets; Gamma | 1999 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Ana | 1999 |
Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Disease Models, Animal; Dogs; | 1999 |
Cyclic vomiting syndrome: role of a psychiatric inpatient unit in a general children's hospital.
Topics: Antiemetics; Child, Preschool; Combined Modality Therapy; Family Therapy; Female; Hospitals, Pediatr | 1999 |
Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Canada; Drug Costs; Female; Health Care Costs; Humans; Male; Mid | 1999 |
Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist.
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Topics: Acute Disease; Age Factors; Antiemetics; Antineoplastic Agents; Body Weights and Measures; Chlorprom | 2000 |
Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combinati | 2000 |
Prevention of delayed emesis caused by chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Area Under Curve; Biological Availability; | 2000 |
Prevention of delayed emesis caused by chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Confounding Factors, Epidemiologic; Dexamethasone; Drug Therapy, | 2000 |
Computerized system for outcomes-based antiemetic therapy in children.
Topics: Antiemetics; Child; Cost-Benefit Analysis; Female; Humans; Male; Nausea; Odds Ratio; Ondansetron; Ti | 2000 |
Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Indoles; Male; Ondansetron; Rec | 2001 |
Novel approach to improve permeation of ondansetron across shed snake skin as a model membrane.
Topics: Administration, Cutaneous; Animals; Ethanol; Humans; Models, Animal; Molting; Oleic Acid; Ondansetro | 2001 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
Efficacy of a single 8-mg i.v. dose of ondansetron hydrochloride for preventing chemotherapy-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Humans; Injections, Intr | 2002 |
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2002 |
Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Topics: Afferent Pathways; Antiemetics; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cross-Ov | 2002 |
Pica in mice as a new model for the study of emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carmine; Cisplatin; Disease Models, Animal; Eating; Fec | 2002 |
Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Male; Middle Aged; Nausea; | 1992 |
Are all 5-HT3 receptor antagonists the same?
Topics: Animals; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Ferrets; Granisetron; Imidazoles; | 1992 |
Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Emetics; Ferrets; Granisetron; Imidazol | 1992 |
The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indazoles; Models, Theoretical; | 1992 |
Ondansetron for patients given abdominal radiotherapy.
Topics: Abdominal Neoplasms; Aged; Antiemetics; Child; Female; Humans; Imidazoles; Nausea; Ondansetron; Radi | 1992 |
Ondansetron in intractable nausea and vomiting.
Topics: Adult; Antiemetics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Imidazoles; Nausea; Ondansetro | 1992 |
Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Benzamides; Bridged Bicyclo Compounds; Bridged Bicycl | 1992 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin | 1992 |
Ondansetron in postoperative nausea and vomiting. Proceedings of a symposium. London, 28 February 1992.
Topics: Humans; Nausea; Ondansetron; Postoperative Care; Surgical Procedures, Operative; Vomiting | 1992 |
Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Female; Humans; Infusions, Intravenous; Ipecac; Ondansetr | 1992 |
Serotonin-Mediated Emesis: The Role of Ondansetron. Proceedings of a symposium. Fort Lauderdale, Florida, April 24-26, 1992.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dac | 1992 |
Ondansetron as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Ondansetron; Vomiting | 1992 |
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
Topics: Child; Child, Preschool; Humans; Lymphoma, T-Cell; Nausea; Ondansetron; Precursor Cell Lymphoblastic | 1992 |
Ondansetron: indications and applications in the paediatric intensive care unit.
Topics: Adolescent; Child; Child, Preschool; Critical Care; Female; Humans; Male; Nausea; Ondansetron; Vomit | 1992 |
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Injections, Intravenous; Male | 1992 |
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
Topics: Animals; Antiemetics; Dogs; Drug Evaluation; Imidazoles; Mice; Misonidazole; Nitroimidazoles; Ondans | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Ondansetron in the control of refractory emesis following radiotherapy.
Topics: Adult; Antiemetics; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Radiotherapy; Seroto | 1992 |
Antiemetic or antinauseant effect of ondansetron?
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1992 |
Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Imidazoles; Male; Nausea; Ondansetron; Severity | 1992 |
Ondansetron in the treatment of theophylline overdose.
Topics: Adolescent; Antiemetics; Drug Overdose; Humans; Imidazoles; Male; Ondansetron; Theophylline; Vomitin | 1992 |
Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1992 |
High-dose and long-term use of ondansetron.
Topics: Antiemetics; Dexamethasone; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; Time Facto | 1992 |
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.
Topics: Analysis of Variance; Animals; Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo C | 1991 |
A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dose-Response Rel | 1990 |
Ondansetron vs dexamethasone for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dexamethasone; Hu | 1991 |
Publication of unethical studies on the treatment of chemotherapy-induced emesis.
Topics: Antiemetics; Clinical Trials as Topic; Cyclophosphamide; Ethics, Medical; Humans; Imidazoles; Ondans | 1991 |
[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Topics: Antiemetics; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Nausea; Neoplasms | 1991 |
Ondansetron to prevent vomiting after cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Humans; Imidazoles; On | 1991 |
Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Imida | 1991 |
The big "little problem".
Topics: Anesthetics; Antiemetics; Causality; Humans; Imidazoles; Nausea; Ondansetron; Postoperative Complica | 1991 |
Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Dose-Response Re | 1991 |
Introduction: the clinical challenge.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Odansetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
Topics: Animals; Antiemetics; Benzimidazoles; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocy | 1991 |
[Serotonin as mediator in vomiting reflex: effect of a serotonin3 receptor antagonist in chemotherapy-induced vomiting].
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Ondansetron; Reflex; Serotonin Antagonists; | 1991 |
Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Middle Aged; Ondansetron; Serot | 1991 |
[New, in Austria registered specialty drugs. Zofran (Ondansetron, Glaxo)].
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Austria; Dose-Response Relationsh | 1991 |
Serotonin antagonists: a new class of antiemetic agents.
Topics: Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Granise | 1991 |
Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret.
Topics: Animals; Cyclophosphamide; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Female; Ferrets | 1990 |
Making chemotherapy easier.
Topics: Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; | 1990 |
Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1990 |
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Topics: Administration, Oral; Antiemetics; Drug Administration Schedule; Drug Evaluation; Female; Humans; Im | 1990 |
Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Ondan | 1990 |
[Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Female; Humans; Imidazoles; Male; Middle | 1990 |
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imidazoles; | 1990 |
Correlation of anti-emetic efficacy and plasma levels of ondansetron.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotoni | 1990 |
Ondansetron: a new entity in emesis control.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1990 |
RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Benzofurans; Bridged Bicyclo Comp | 1990 |
Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
Topics: Animals; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Bridged-Rin | 1989 |
GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetro | 1989 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1989 |
GR38032F.
Topics: Cisplatin; Humans; Imidazoles; Ondansetron; Serotonin Antagonists; Vomiting | 1989 |
Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1989 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |
5-HT3 receptor antagonists: a new class of antiemetics.
Topics: Antiemetics; Humans; Imidazoles; Indoles; Ondansetron; Receptors, Serotonin; Serotonin Antagonists; | 1987 |
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1988 |